vaso10q-sept2015.htm

0001201800-15-000027.txt : 20151113 0001201800-15-000027.hdr.sgml : 20151113 20151113160224 ACCESSION NUMBER: 0001201800-15-000027 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151113 DATE AS OF CHANGE: 20151113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VASOMEDICAL, INC CENTRAL INDEX KEY: 0000839087 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112871434 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-18105 FILM NUMBER: 151229120 BUSINESS ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 BUSINESS PHONE: 516-997-4600 MAIL ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 FORMER COMPANY: FORMER CONFORMED NAME: VASOMEDICAL INC DATE OF NAME CHANGE: 19950517 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /DE/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /NY/ DATE OF NAME CHANGE: 19920506 10-Q 1 vaso10q-sept2015.htm vaso10q-sept2015.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2015

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _______________ to ______________

Commission File Number: 0-18105

VASOMEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware	11-2871434
(State or other jurisdiction of	(IRS Employer Identification Number)
incorporation or organization)

137 Commercial Street, Suite 200, Plainview, New York 11803

(Address of principal executive offices)

Registrant’s Telephone Number

(516) 997-4600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x Noo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.

Large Accelerated Filer o

Accelerated Filer o

Non-Accelerated Filer o

Smaller Reporting Company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Number of Shares Outstanding of Common Stock, $.001 Par Value, at November 8, 2015 – 158,412,283

Page 1

Vasomedical, Inc. and Subsidiaries

INDEX

PART I – FINANCIAL INFORMATION	3

ITEM 1 - FINANCIAL STATEMENTS	3

CONDENSED CONSOLIDATED BALANCE SHEETS as of September 30, 2015 (unaudited) and December 31, 2014	3

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) for the Three and Nine Months Ended September 30, 2015 and 2014	4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY for the Nine Months Ended September 30, 2015 (unaudited) and the Year Ended December 31, 2014	5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) for the Nine Months Ended September 30, 2015 and 2014	6

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)	7

ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	18

ITEM 4 - CONTROLS AND PROCEDURES	23

PART II - OTHER INFORMATION	25

ITEM 6 – EXHIBITS	25

Page 2

PART I – FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

Vasomedical, Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

	September 30, 2015			December 31, 2014
ASSETS	(unaudited)
CURRENT ASSETS
Cash and cash equivalents	$	1,928		$	9,128
Short-term investments		109			111
Accounts and other receivables, net of an allowance for doubtful
accounts and commission adjustments of $4,265 at September 30,
2015 and $4,571 at December 31, 2014		8,732			15,273
Receivables due from related parties		106			21
Inventories, net		1,950			1,898
Deferred commission expense		2,583			2,200
Prepaid expenses and other current assets		515			363
Total current assets		15,923			28,994

PROPERTY AND EQUIPMENT, net of accumulated depreciation of
$2,745 at September 30, 2015 and $1,397 at December 31, 2014		2,928			266
GOODWILL		22,582			3,288
INTANGIBLES, net		2,447			2,826
OTHER ASSETS		3,504			5,617
	$	47,384		$	40,991

LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable	$	3,604		$	462
Accrued commissions		1,746			2,247
Accrued expenses and other liabilities		4,259			5,627
Sales tax payable		612			247
Deferred revenue - current portion		11,174			9,882
Notes payable - current portion		1,654			163
Deferred tax liability, net		112			112
Notes payable due to related party		997			1,039
Total current liabilities		24,158			19,779

LONG-TERM LIABILITIES
Notes payable		5,007			-
Deferred revenue		8,576			12,650
Other long-term liabilities		539			811
Total long-term liabilities		14,122			13,461

COMMITMENTS AND CONTINGENCIES (NOTE N)

STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares
issued and outstanding at September 30, 2015, and December 31, 2014		-			-
Common stock, $.001 par value; 250,000,000 shares authorized;
168,720,370 and 166,435,370 shares issued at September 30, 2015
and December 31, 2014, respectively; 158,412,283 and
156,127,283 shares outstanding at September 30, 2015 and
December 31, 2014, respectively		169			166
Additional paid-in capital		62,222			61,924
Accumulated deficit		(51,267	)		(52,433	)
Accumulated other comprehensive income		(20	)		94
Treasury stock, at cost, 10,308,087 shares at September 30, 2015 and December 31, 2014		(2,000	)		(2,000	)
Total stockholders’ equity		9,104			7,751
	$	47,384		$	40,991

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 3

Vasomedical, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Unaudited)

(in thousands, except per share data)

	Three months ended September 30,						Nine months ended September 30,
	2015			2014			2015			2014
Revenues
Professional sales services	$	7,584		$	6,409		$	21,010		$	19,335
Managed IT systems and services		8,800			-			11,611			-
Equipment sales and services		1,017			1,234			3,077			3,264
Total revenues		17,401			7,643			35,698			22,599

Cost of revenues
Cost of professional sales services		1,701			1,828			4,748			5,282
Cost of managed IT systems and services		5,308			-			6,921			-
Cost of equipment sales and services		542			440			1,283			1,294
Total cost of revenues		7,551			2,268			12,952			6,576
Gross profit		9,850			5,375			22,746			16,023

Operating expenses
Selling, general and administrative		8,355			5,344			21,059			16,867
Research and development		158			180			430			599
Total operating expenses		8,513			5,524			21,489			17,466
Operating income (loss)		1,337			(149	)		1,257			(1,443	)

Other income (expense)
Interest and financing costs		(148	)		-			(265	)		(1	)
Interest and other income, net		79			52			225			151
Total other income (expense), net		(69	)		52			(40	)		150

Income (loss) before income taxes		1,268			(97	)		1,217			(1,293	)
Income tax expense		(38	)		(26	)		(51	)		(50	)
Net income (loss)		1,230			(123	)		1,166			(1,343	)

Other comprehensive income
Foreign currency translation (loss) gain		(145	)		2			(114	)		(28	)
Comprehensive income (loss)	$	1,085		$	(121	)	$	1,052		$	(1,371	)

Income (loss) per common share
- basic	$	0.01		$	(0.00	)	$	0.01		$	(0.01	)
- diluted	$	0.01		$	(0.00	)	$	0.01		$	(0.01	)

Weighted average common shares outstanding
- basic		157,288			155,186			156,502			155,319
- diluted		157,782			155,186			156,868			155,319

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 4

Vasomedical, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands)

	Common Stock				Treasury Stock						Additional Paid-in-			Accumulated			Accumulated Other Comprehensive			Total Stockholders'
		Shares		Amount		Shares			Amount			Capital			Deficit			Income			Equity
Balance at December 31, 2013		164,705		165		(9,481	)		(1,755	)		61,508			(53,561	)		108			6,465
Repurchase of shares		-		-		(827	)		(245	)		-			-			-			(245	)
Share-based compensation		1,280		1		-			-			389			-			-			390
Shares not issued for employee tax liability		-		-		-			-			(9	)		-			-			(9	)
Exercise of stock options		450		-		-			-			36			-			-			36
Foreign currency translation loss		-		-		-			-			-			-			(14	)		(14	)
Net income		-		-		-			-			-			1,128			-			1,128
Balance at December 31, 2014		166,435	$	166		(10,308	)	$	(2,000	)	$	61,924		$	(52,433	)	$	94		$	7,751
Share-based compensation		2,285		3		-			-			298			-			-			301
Foreign currency translation loss		-		-		-			-			-			-			(114	)		(114	)
Net income		-		-		-			-			-			1,166			-			1,166
Balance at September 30, 2015 (unaudited)		168,720	$	169		(10,308	)	$	(2,000	)	$	62,222		$	(51,267	)	$	(20	)	$	9,104
																					.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 5

Vasomedical, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

	Nine months ended
	September 30,
	2015			2014
Cash flows from operating activities
Net income (loss)	$	1,166		$	(1,343	)
Adjustments to reconcile net income (loss) to net cash
provided by operating activities
Depreciation and amortization		783			290
Loss on disposal of fixed assets		-			39
Provision for doubtful accounts and commission adjustments		109			(1	)
Share-based compensation and arrangements		301			320
Changes in operating assets and liabilities:
Accounts and other receivables		7,860			6,396
Receivables due from related parties		(85	)
Inventories, net		(221	)		(332	)
Deferred commission expense		(382	)		(75	)
Other current assets		(53	)		(123	)
Other assets		2,274			(1,639	)
Accounts payable		(5	)		(72	)
Accrued commissions		(548	)		(55	)
Accrued expenses and other liabilities		(2,129	)		(1,203	)
Sales tax payable		(68	)		(48	)
Deferred revenue		(2,782	)		218
Notes payable due to related party		(42	)		-
Other long-term liabilities		(299	)		214
Net cash provided by operating activities		5,879			2,586

Cash flows from investing activities
Purchases of equipment and software		(619	)		(227	)
Purchases of short-term investments		(38	)		(40	)
Redemption of short-term investments		40			40
Acquisition of Genwell		-			(1,136	)
Cash acquired through purchase of Genwell		-			113
Acquisition of Netwolves		(18,000	)		-
Cash acquired through purchase of Netwolves		733			-
Investment in VSK		(100	)		-
Net cash used in investing activities		(17,984	)		(1,250	)

Cash flows from financing activities
Net borrowings on revolving line of credit		136			-
Repurchase of common stock		-			(244	)
Repayment of notes payable		(83	)		-
Proceeds from note payable		4,800			-
Net cash provided by (used in) financing activities		4,853			(244	)
Effect of exchange rate differences on cash and cash equivalents		52			1

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(7,200	)		1,093
Cash and cash equivalents - beginning of period		9,128			7,961
Cash and cash equivalents - end of period	$	1,928		$	9,054

SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
Interest paid	$	66		$	-
Income taxes paid	$	130		$	48

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Inventories transferred to property and equipment,
attributable to operating leases, net	$	138		$	5
Note issued for acquisition	$	-		$	1,017

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 6

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP®) systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets. Beginning in July 2010 the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. (Vaso Diagnostics), began its sales representation business via its agreement (the “GEHC Agreement”) with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia. In June 2012, the GEHC Agreement was amended and extended through June 30, 2015 and again, in December 2014, the GEHC Agreement was further amended and extended through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns or controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd. (Biox), respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and started to operate through three wholly-owned subsidiaries. Vaso Diagnostics continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

In April 2014, the Company entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (PSK) of Chongqing, China, the leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited (VSK), for the global marketing, sale and advancement of ECP therapy technology. The Company owns 49.9% of the joint venture, which began operations in January 2015.

In June 2014, the Company entered into a Value Added Reseller Agreement (VAR Agreement) with GEHC to become a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. This multiyear VAR Agreement focuses primarily on existing customer segments currently served by Vaso Diagnostics on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp., was formed to conduct the healthcare IT business.

In August 2014, the Company, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone), acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China. Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCareTM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system.

In May 2015, the Company entered into an agreement for, and completed its purchase of, all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC (collectively, “NetWolves”). The purchase of NetWolves was accomplished pursuant to an Asset Purchase Agreement. As a result, the Company effectively purchased all rights, titles and ownership of all assets held by NetWolves. NetWolves designs and delivers efficient and cost-effective multi-network and multi-technology solutions as a managed network provider, and provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution. The Company believes there are significant operational synergies between NetWolves’ capabilities and VasoHealthcare IT’s requirements under its VAR Agreement with GEHC, as well as the opportunity to expand NetWolves’ existing services to the healthcare IT market.

Page 7

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment. Vaso Diagnostics activities are included under our Sales Representation segment. VasoHealthcare IT and NetWolves operations report under the IT segment.

NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in connection with:

1)	The audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC on March 30, 2015.

The audited consolidated financial statements of NetWolves, LLC and related notes thereto included in the Form 8-K/A filed with the SEC on August 12, 2015. The operating results of NetWolves from May 29, 2015 to September 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and nine month periods ended September 30, 2015.

These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended December 31, 2014, and Note B of the Notes to Consolidated Financial Statements for the year ended December 31, 2014, included on Form 8-K/A, include a summary of the significant accounting policies used in the preparation of the condensed consolidated financial statements.

Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured.

Revenue and Expense Recognition for the Sales Representation Segment

The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured. These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the condensed consolidated balance sheets. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.

Page 8

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

Variable Interest Entities

The Company follows the guidance of accounting for variable interest entities, which requires certain variable interest entities to be consolidated by the primary beneficiary of the entities. Biox is a Variable Interest Entity (VIE).

Liabilities recognized as a result of consolidating this VIE do not represent additional claims on the Company’s general assets. The financial information of Biox, which is included in the accompanying condensed consolidated financial statements, is presented as follows:

	(in thousands)
	As of September 30, 2015		As of December 31, 2014
		(unaudited)
Cash and cash equivalents	$	119	$	159
Total assets	$	1,037	$	1,047
Total liabilities	$	1,040	$	878

	(in thousands)
	Three months ended September 30,					Nine months ended September 30,
	2015		2014			2015			2014
	(unaudited)		(unaudited)			(unaudited)			(unaudited)
Total net revenue	$	358	$	368		$	1,183		$	1,126

Net income (loss)	$	24	$	(152	)	$	(199	)	$	(382	)

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

NOTE C – SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in three segments – the Sales Representation segment, the Equipment segment, and the IT segment. The Sales Representation segment operates through the Vaso Diagnostics subsidiary and is currently engaged solely in the fulfillment of the Company’s responsibilities under our agreement with GEHC. The IT segment includes the operations of NetWolves and VasoHealthcare IT Corp. Operations in the IT segment began in the third quarter of 2014. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the development, production, marketing and supporting of other medical devices.

The chief operating decision maker is the Company’s Chief Executive Officer, who, in conjunction with upper management, evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:

Page 9

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

	(in thousands)
	As of or for the three months ended September 30, 2015 (unaudited)
	Sales Representation Segment		IT Segment			Equipment Segment			Corporate			Consolidated

Revenues from external customers	$	7,584	$	8,800		$	1,017		$	-		$	17,401
Operating income (loss)	$	2,586	$	(187	)	$	(582	)	$	(480	)	$	1,337
Total assets	$	11,408	$	24,642		$	9,293		$	2,041		$	47,384
Accounts and other receivables, net	$	5,663	$	2,253		$	816		$	-		$	8,732
Deferred commission expense	$	2,533	$	50		$	-		$	-		$	2,583
Other assets	$	2,720	$	51		$	623		$	110		$	3,504

	As of or for the three months ended September 30, 2014 (unaudited)
	Sales Representation Segment		IT Segment			Equipment Segment			Corporate			Consolidated

Revenues from external customers	$	6,409	$	-		$	1,234		$	-		$	7,643
Operating income (loss)	$	723	$	(82	)	$	(405	)	$	(385	)	$	(149	)
Total assets	$	13,341	$	2		$	9,909		$	9,067		$	32,319
Accounts and other receivables, net	$	6,376	$	-		$	791		$	-		$	7,167
Deferred commission expense	$	2,388	$	-		$	-		$	-		$	2,388
Other assets	$	4,402	$	-		$	3,170		$	13		$	7,585

	As of or for the nine months ended September 30, 2015 (unaudited)
	Sales Representation Segment		IT Segment			Equipment Segment			Corporate			Consolidated

Revenues from external customers	$	21,010	$	11,611		$	3,077		$	-		$	35,698
Operating income (loss)	$	5,466	$	(908	)	$	(1,893	)	$	(1,408	)	$	1,257
Total assets	$	11,408	$	24,642		$	9,293		$	2,041		$	47,384
Accounts and other receivables, net	$	5,663	$	2,253		$	816		$	-		$	8,732
Deferred commission expense	$	2,533	$	50		$	-		$	-		$	2,583
Other assets	$	2,720	$	51		$	623		$	110		$	3,504

	As of or for the nine months ended September 30, 2014 (unaudited)
	Sales Representation Segment		IT Segment			Equipment Segment			Corporate			Consolidated

Revenues from external customers	$	19,335	$	-		$	3,264		$	-		$	22,599
Operating income (loss)	$	2,267	$	(82	)	$	(2,361	)	$	(1,267	)	$	(1,443	)
Total assets	$	13,341	$	2		$	9,909		$	9,067		$	32,319
Accounts and other receivables, net	$	6,376	$	-		$	791		$	-		$	7,167
Deferred commission expense	$	2,388	$	-		$	-		$	-		$	2,388
Other assets	$	4,402	$	-		$	3,170		$	13		$	7,585

Page 10

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

For the three months ended September 30, 2015 and 2014, GE Healthcare accounted for 44% and 84% of revenue, respectively. For the nine months ended September 30, 2015 and 2014, GE Healthcare accounted for 59% and 86% of revenue, respectively, and $5.5 million or 63%, and $14.2 million or 93%, of accounts and other receivables at September 30, 2015 and December 31, 2014, respectively.

NOTE D – EARNINGS (LOSS) PER COMMON SHARE

Basic earnings (loss) per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period. Diluted earnings (loss) per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

Diluted earnings (loss) per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares. A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

	(in thousands)
	Three months ended September 30,				Nine months ended September 30,
	2015		2014		2015		2014
Basic weighted average shares outstanding		157,288		155,186		156,502		155,319
Dilutive effect of share-based compensation		494		-		366		-
Diluted weighted average shares outstanding		157,782		155,186		156,868		155,319

The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2015 and 2014, because the effect of their inclusion would be anti-dilutive.

	(in thousands)
	For the three months ended				For the nine months ended
	September 30, 2015		September 30, 2014		September 30, 2015		September 30, 2014
	(unaudited)		(unaudited)		(unaudited)		(unaudited)
Stock options		300		1,402		300		1,402
Common stock grants		-		490		-		490
		300		1,892		300		1,892

Page 11

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

NOTE E – ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company’s accounts and other receivables as of September 30, 2015 and December 31, 2014:

	(in thousands)
	September 30, 2015			December 31, 2014
	(unaudited)
Trade receivables	$	12,792		$	19,734
Due from employees		205			110
Allowance for doubtful accounts and
commission adjustments		(4,265	)		(4,571	)
Accounts and other receivables, net	$	8,732		$	15,273

Trade receivables include amounts due for shipped products and services rendered. Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement. Due from employees is primarily commission advances made to sales personnel.

NOTE F – INVENTORIES, NET

Inventories, net of reserves, consist of the following:

	(in thousands)
	September 30, 2015		December 31, 2014
	(unaudited)
Raw materials	$	475	$	583
Work in process		626		679
Finished goods		849		636
	$	1,950	$	1,898

At September 30, 2015 and December 31, 2014, the Company maintained reserves for excess and obsolete inventory of $673,000 and $815,000, respectively.

Page 12

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

NOTE G – GOODWILL AND OTHER INTANGIBLES

Goodwill aggregating $22,582,000 and $3,288,000 was recorded on the Company’s condensed consolidated balance sheets at September 30, 2015 and December 31, 2014, respectively, of which $19,406,000, allocated to the IT segment, resulted from the acquisition of NetWolves in May 2015. The remaining $3,176,000 of goodwill is allocated to the Company’s Equipment segment. The components of the change in goodwill are as follows:

	(in thousands)
	Carrying Amount

Balance at December 31, 2014	$	3,288
Foreign currency translation		(112	)
Acquisition of Netwolves		19,406
Balance at September 30, 2015 (unaudited)	$	22,582

The Company’s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:

	(in thousands)
	September 30, 2015			December 31, 2014
	(unaudited)
Patents and Technology
Costs	$	2,441		$	2,489
Accumulated amortization		(742	)		(549	)
		1,699			1,940

Customer lists
Costs		800			800
Accumulated amortization		(467	)		(381	)
		333			419

Software
Costs		1,133			962
Accumulated amortization		(718	)		(495	)
		415			467

	$	2,447		$	2,826

Patents, customer lists, and software are included in other assets in the accompanying condensed consolidated balance sheets and are amortized on a straight line basis over their estimated useful lives of ten, seven, and five years, respectively. Amortization expense amounted to $167,000 and $502,000 for the three and nine months ended September 30, 2015, respectively, and $50,000 and $146,000 for the three and nine months ended September 30, 2014, respectively.

Page 13

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

NOTE H – OTHER ASSETS

Other assets consist of the following at September 30, 2015 and December 31, 2014:

	(in thousands)
	September 30, 2015		December 31, 2014
	(unaudited)
Deferred commission expense - noncurrent	$	1,845	$	2,988
Trade receivables - noncurrent		1,026		2,171
Other		633		458
	$	3,504	$	5,617

NOTE I – ACCRUED EXPENSES AND OTHER LIABILITIES

Accrued expenses and other liabilities consist of the following at September 30, 2015 and December 31, 2014:

	(in thousands)
	September 30, 2015		December 31, 2014
	(unaudited)
Accrued compensation	$	1,344	$	2,917
Accrued expenses - other		1,292		1,098
Other liabilities		1,623		1,612
	$	4,259	$	5,627

NOTE J- DEFERRED REVENUE

The changes in the Company’s deferred revenues are as follows:

	(in thousands)
	For the three months ended						For the nine months ended
	September 30, 2015			September 30, 2014			September 30, 2015			September 30, 2014
	(unaudited)			(unaudited)			(unaudited)			(unaudited)
Deferred revenue at beginning of period	$	19,614		$	17,712		$	22,532		$	18,019
Additions:
Deferred extended service contracts		160			244			465			791
Deferred in-service and training		5			13			10			28
Deferred service arrangements		10			28			25			58
Deferred commission revenues		3,516			3,457			6,847			8,840
Recognized as revenue:
Deferred extended service contracts		(209	)		(207	)		(654	)		(654	)
Deferred in-service and training		-			(10	)		(10	)		(25	)
Deferred service arrangements		(15	)		(26	)		(58	)		(72	)
Deferred commission revenues		(3,331	)		(2,975	)		(9,407	)		(8,749	)
Deferred revenue at end of period		19,750			18,236			19,750			18,236
Less: current portion		11,174			9,158			11,174			9,158
Long-term deferred revenue at end of period	$	8,576		$	9,078		$	8,576		$	9,078

Page 14

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

NOTE K – DEBT

On May 29, 2015, the Company entered into a Note Purchase Agreement with MedTechnology Investments, LLC (“MedTech”) pursuant to which it issued MedTech a secured subordinated promissory note (“Note”) for $3,800,000 for the purchase of NetWolves. MedTech was formed to acquire the Note, and $1,950,000 of the aggregate funds used to acquire the Note was provided by six of our directors. In June 2015, a second Note for $750,000 was issued to MedTech for working capital purposes, $250,000 of which was provided by a director and a director’s relative. In July 2015, an additional $250,000 was borrowed under the Note Purchase Agreement.

The Notes bear interest at an annual rate of 9%, mature on May 29, 2019, may be prepaid without penalty, and are subordinated to any current or future Senior Debt as defined in the Subordinated Security Agreement. The Subordinated Security Agreement secures payment and performance of the Company’s obligations under the Notes and as a result, MedTech was granted a subordinated security interest in the Company’s assets.

In July 2015, NetWolves' lending institution extended its $2.0 million line of credit and increased the maximum borrowings to $3.0 million. Advances under the line, which expires on August 26, 2016, bear interest at a rate of LIBOR plus 2.25% and are secured by substantially all of the assets of NetWolves Network Services, LLC and guaranteed by Vasomedical, Inc. At September 30, 2015, the Company had drawn approximately $1.2 million against the line.

NOTE L – BUSINESS COMBINATION

On May 29, 2015, the Company entered into an agreement for, and completed its purchase of, all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC (collectively, “NetWolves”) for $18,000,000 (the “Purchase Price”). The purchase of NetWolves was accomplished pursuant to an Asset Purchase Agreement (the "Purchase Agreement"). As a result, the Company effectively purchased all rights, titles and ownership of all assets held by NetWolves. The Purchase Price was paid using $14,200,000 in cash on hand and $3,800,000 raised through the issuance of the Note to MedTech (See Note K). The Company believes there are significant operational synergies between NetWolves’ capabilities and VasoHealthcare IT’s requirements under its VAR contract with GEHC, as well as the opportunity to expand NetWolves’ existing services to the healthcare IT market.

The operating results of NetWolves from May 29, 2015 to September 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and nine month periods ended September 30, 2015. The accompanying condensed consolidated balance sheet at September 30, 2015 reflects the acquisition of NetWolves effective May 29, 2015.

In accordance with Accounting Standards Codification 805, Business Combinations, the total purchase consideration is allocated to the net tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at May 29, 2015 (the acquisition date). The purchase price was initially allocated based on the information then available, and certain amounts were adjusted after revisions of certain preliminary estimates. The Company expects additional measurement period adjustments will be recorded after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates. The following table summarizes the current allocation of the assets acquired and liabilities assumed based on their preliminary estimated fair values and current measurement period adjustments as follows:

Page 15

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

	(in thousands)
	As initially reported			Measurement period adjustments			As adjusted
Cash and cash equivalents	$	733		$	-		$	733
Accounts receivable and other current assets		1,638			(103	)		1,535
Other assets		50			-			50
Property and equipment		2,359			-			2,359
Accounts payable and other current liabilities		(4,382	)		-			(4,382	)
Long term debt		(1,701	)		-			(1,701	)
Goodwill and other intangibles		19,303			103			19,406
Total	$	18,000		$	-		$	18,000

During the nine months ended September 30, 2015, the Company expensed $100,000 of acquisition-related legal costs and incurred $60,000 in debt issue costs. The legal costs are included in the line item Selling, General & Administrative costs in the accompanying condensed consolidated statements of operations and comprehensive income (loss). The debt issue costs are recorded as a reduction to long term notes payable in the accompanying condensed consolidated balance sheet at September 30, 2015. The amounts of revenue and net income of NetWolves included in the Company’s condensed consolidated statements of operations and comprehensive income (loss) was $8,707,000 and $227,000, respectively, for the three months ended September 30, 2015, and $11,470,000 and $377,000, respectively, for the nine months ended September 30, 2015. The goodwill is expected to be deductible for tax purposes.

The following unaudited supplemental pro forma information presents the financial results as if the acquisitions of Genwell and NetWolves had occurred January 1, 2013, and January 1, 2014, respectively.

	(in thousands)
	Three months ended					Nine months ended
	September 30, 2015		September 30, 2014			September 30, 2015		September 30, 2014
Revenue	$	17,401	$	15,101		$	48,850	$	44,532

Net income (loss)		1,353		(2	)		1,584		(1,397	)

Basic earnings (loss) per share	$	0.01	$	(0.00	)	$	0.01	$	(0.01	)

Diluted earnings (loss) per share	$	0.01	$	(0.00	)	$	0.01	$	(0.01	)

NOTE M – RELATED-PARTY TRANSACTIONS

One of the Company’s directors, Peter Castle, was the Chief Executive Officer and President of NetWolves, LLC. Another of the Company’s directors, David Lieberman, was a director of NetWolves Network Services, LLC. Mr. Castle and Mr. Lieberman owned of record approximately 10.4% and 5.7%, respectively of the membership interests of NetWolves LLC. Mr. Lieberman may also be deemed to have owned beneficially up to an additional 13.5% of such membership interests. The Company’s board of directors negotiated the Purchase Price on an arm’s length basis, and both Mr. Castle and Mr. Lieberman abstained from the vote approving the Purchase Agreement.

The Company obtained an opinion regarding the fairness of the Purchase Price for the NetWolves entities from a reputable, independent third-party investment banking firm. $14,200,000 of the Purchase Price was paid for by cash on hand, and the remaining $3,800,000 was raised from the sale of a Subordinated Secured Note sold to MedTech. Of the $4,800,000 borrowed from MedTech at September 30, 2015, $2,200,000 was provided by six of our directors or members of their families.

Page 16

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

David Lieberman, the Vice Chairman of the Company’s Board of Directors, is a practicing attorney in the State of New York and a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which performs certain legal services for the Company. Fees of approximately $85,000 and $213,000 were billed by the firm for the three and nine month periods ended September 30, 2015, respectively, at which date no amounts were outstanding. Fees of approximately $60,000 and $180,000 were billed by the firm for the three and nine month periods ended September 30, 2014, respectively, at which date no amounts were outstanding.

In January 2015, operations began under the VSK joint venture. The Company accounts for its investment in VSK using the equity method. At September 30, 2015, the Company had contributed $100,000 to VSK, and $86,000 was due from VSK for equipment and services the Company billed to it. VSK earned approximately $97,000 and $143,000 for the three and nine months ended September 30, 2015, respectively. Under the terms of the agreement, the Company’s accrues no interest in VSK’s income in the years ending December 31, 2015, 2016 and 2017 unless certain performance targets are achieved. For the nine months ended September 30, 2015 such targets had not been achieved.

NOTE N – COMMITMENTS AND CONTINGENCIES

Sales representation agreement

In June 2012, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010. The amendment, effective July 1, 2012, extended the initial term of three years commencing July 1, 2010 to five years through June 30, 2015. In December 2014, the Company concluded an additional amendment, effective January 1, 2015, extending the term through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017. These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements. Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers”, a comprehensive new revenue recognition standard which will supersede previous existing revenue recognition guidance. The standard creates a five-step model for revenue recognition that requires companies to exercise judgment when considering contract terms and relevant facts and circumstances. The five-step model includes (1) identifying the contract, (2) identifying the separate performance obligations in the contract, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations and (5) recognizing revenue when each performance obligation has been satisfied. The standard also requires expanded disclosures surrounding revenue recognition. The standard is effective for fiscal periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption. In August 2015, FASB issued ASU 2015-14, “Revenue from Contracts with Customers – Deferral of the Effective Date” (Topic 606). The amendments in this ASU defer the effective date of ASU 2014-09, “Revenue from Contracts with Customers,” for all entities by one year. Public business entities should apply the guidance in ASU 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company is currently evaluating the impact of the adoption of this standard on its Consolidated Financial Statements.

In April 2015, the FASB issued ASU 2015-03 “Simplifying the Presentation of Debt Issuance Costs”, which changes the presentation of debt issuance costs in financial statements. An entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense. The standard is effective for fiscal periods beginning after December 31, 2015 and allows for early adoption. The Company has early adopted this statement for the nine months ended September 30, 2015, resulting in $60,000 in debt issue costs initially deducted from the MedTech debt and $5,000 amortized to interest expense.

In September 2015, the FASB issued ASU 2015-16 “Simplifying the Accounting for Measurement-period Adjustments”, which require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The standard is effective for fiscal periods beginning after December 15, 2015 and allows for early adoption. The Company is currently evaluating the impact of the adoption of this standard on its Consolidated Financial Statements.

Page 17

Vasomedical, Inc. and Subsidiaries

ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreements and the risk factors reported from time to time in the Company’s SEC reports, including its recent report on Form 10-K. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

General Overview

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP®) systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets. Beginning in July 2010 the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, began its sales representation business via its agreement (GEHC Agreement) with GE Healthcare (GEHC), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia. In June 2012, the GEHC Agreement was amended and extended through June 30, 2015 and again, in December 2014, the GEHC Agreement was further amended and extended through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns or controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd., respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and started to operate through three wholly-owned subsidiaries. Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

In April 2014, the Company entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (PSK) of Chongqing, China, the leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited (VSK), for the global marketing, sale and advancement of ECP therapy technology. The Company owns 49.9% of the shares of VSK. VSK began operations in January 2015. The Company contributed $100,000 in cash to VSK during the nine months ended September 30, 2015.

Page 18

Vasomedical, Inc. and Subsidiaries

The Company continues to pursue acquisitions or partnership opportunities in the international and domestic markets and to seek expansion of its sales representation business.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.

Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the SEC on March 30, 2015.

Results of Operations – For the Three Months Ended September 30, 2015 and 2014

Total revenue for the three months ended September 30, 2015 and 2014 was $17,401,000 and $7,643,000, respectively, representing an increase of $9,758,000, or 128% year-over-year. The revenue increase was primarily due to $8,800,000 in revenue in the IT segment, of which $8,707,000 resulted from the operations of NetWolves. Net income for the three months ended September 30, 2015 was $1,230,000, compared to a net loss of $123,000 for the three months ended September 30, 2014, representing an improvement of $1,353,000. Our total net income (loss) was $0.01 and $(0.00) per basic and diluted common share for the three months ended September 30, 2015 and 2014, respectively.

Page 19

Vasomedical, Inc. and Subsidiaries

Revenues

Commission revenues in the Sales Representation segment were $7,584,000 in the third quarter of 2015, an increase of 18%, as compared to $6,409,000 in the third quarter of 2014. The increase in commission revenues in the third quarter of 2015 was due primarily to higher commission rates on equipment delivered by GEHC during the quarter, as well as a 9% increase in such deliveries. The Company recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet. As of September 30, 2015, $18,595,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $8,068,000 was long-term. At September 30, 2014, $16,760,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $8,359,000 was long-term.

Revenue in the IT segment for the three months ended September 30, 2015 was $8,800,000 compared to $0 revenue for the three months ended September 30, 2014, virtually all the increase resulting from the acquisition of NetWolves.

Revenue in our Equipment segment decreased by $217,000, or 18%, to $1,017,000 for the three-month period ended September 30, 2015 compared to the same period of the prior year. The decrease was principally due to a decrease in EECP® revenues and international sales by our China operations as a result of lower sales volume, offset by a small increase in field service and service contract revenue.

Gross Profit

The Company had a gross profit of $9,850,000, or 57% of revenue, in the third quarter of 2015 compared to $5,375,000, or 70% of revenue, in the third quarter of the prior year, an increase of $4,475,000, or 83%. The increase is principally due to $3,492,000 in gross profit in the IT segment, of which $3,483,000 resulted from the acquisition of NetWolves, and higher revenues and gross profit margin in the Sales Representation segment.

Sales Representation segment gross profit was $5,883,000, or 78% of the segment revenue, for the three months ended September 30, 2015 as compared to $4,581,000, or 71% of the segment revenue, for the three months ended September 30, 2014. The increase in absolute dollars and margin percentage was due to higher delivery volume and commission rates during the third quarter of 2015 than in the same period last year, as well as lower commission expense in the third quarter of 2015. Cost of commissions of $1,701,000 and $1,828,000, for the three months ended September 30, 2015 and 2014, respectively, reflected commission expense associated with recognized commission revenues. The decrease was due to lower commission expenses in the third quarter 2015 compared to the same period in 2014. Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is recognized.

IT segment gross profit for the three months ended September 30, 2015 was $3,492,000 compared to $0 gross profit for the three months ended September 30, 2014, virtually all the increase resulting from the acquisition of NetWolves.

Equipment segment gross profit decreased to $475,000, or 47% of Equipment segment revenues, for the third quarter of 2015 compared to $794,000, or 64% of Equipment segment revenues, for the same quarter of 2014. Gross profit margin in the Equipment segment decreased due mainly to lower average selling prices and higher inventory obsolescence costs.

Operating Income (Loss)

Operating income was $1,337,000 for the three months ended September 30, 2015, compared to an operating loss of $149,000 for the three months ended September 30, 2014, an improvement of $1,486,000. During the third quarter of 2015, there was a $4,475,000 increase in gross profit and a $3,011,000 increase in selling, general, and administrative costs. Operating income in the Sales Representation segment increased by $1,863,000 to $2,586,000, compared to $723,000 in the third quarter of the prior year, due mainly to a higher gross margin combined with lower SG&A costs. In addition, operating loss in the Equipment segment increased by $177,000, or 44%, to $582,000 compared to $405,000 in the same quarter of the prior year, due primarily to $319,000 lower gross profit, partially offset by $120,000 lower SG&A costs in the current year quarter. Our IT segment had an operating loss of $187,000 in the third quarter of 2015. This loss was reduced by a $237,000 operating profit from NetWolves operations. We anticipate that the operating profit in this segment will improve with the NetWolves operations and increases in revenue in our GEHC VAR business.

SG&A expenses for the third quarter of 2015 and 2014 were $8,355,000, or 48% of revenues, and $5,344,000, or 70% of revenues, respectively, reflecting an increase of $3,011,000 or approximately 56%. The increase in SG&A expenditures in the third quarter of 2015 resulted primarily from $3,679,000 in costs attributable to the IT segment in 2015 mainly due to the inclusion of NetWolves operations during the quarter, and higher corporate expenses, primarily accounting fees, partially offset by lower costs in the Sales Representation and Equipment segments.

Page 20

Vasomedical, Inc. and Subsidiaries

Research and development (“R&D”) expenses were $158,000, or 1% of revenues (16% of Equipment segment revenues), for the third quarter of 2015, a decrease of $22,000, or 12%, from $180,000, or 2% of revenues (15% of Equipment segment revenues), for the third quarter of 2014. The decrease is primarily attributable to lower clinical grants in the third quarter of 2015.

Interest and Other Income (Expense)

Interest and other income (expense) for the third quarter of 2015 was $(69,000) as compared to $52,000 for the third quarter of 2014. The change from income to expense was due primarily to higher interest expense from debt associated with the Genwell and NetWolves acquisitions.

Income Tax Expense

During the third quarter of 2015 we recorded income tax expense of $38,000 as compared to income tax expense of $26,000 for the third quarter of 2014. The increase arose from higher Federal income tax expense partially offset by lower tax expense at our Chinese subsidiaries.

Results of Operations – For the Nine Months Ended September 30, 2015 and 2014

Total revenue for the nine months ended September 30, 2015 and 2014 was $35,698,000 and $22,599,000, respectively, representing an increase of $13,099,000, or 58% year-over-year. The revenue increase was primarily due to $11,611,000 in revenue in the IT segment, of which $11,470,000 resulted from the operations of NetWolves. Net income (loss) for the nine months ended September 30, 2015 and 2014 was $1,166,000 and $(1,343,000), respectively, representing an improvement of $2,509,000. Our total net income (loss) was $0.01 and $(0.01) per basic and diluted common share for the nine months ended September 30, 2015 and 2014, respectively.

Revenues

Commission revenues in the Sales Representation segment were $21,010,000 in the first nine months of 2015, an increase of 9% from $19,335,000 in the first nine months of 2014. The increase in commission revenue in the first nine months of 2015 is due to increases in both commission rate earned and volume of equipment delivered by GEHC during the period. The Company recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet.

Revenue in the IT segment for the nine months ended September 30, 2015 was $11,161,000 compared to $0 revenue for the nine months ended September 30, 2014, virtually all the increase resulting from the inclusion of four months of NetWolves results.

Revenue in our Equipment segment decreased by $187,000, or 6%, to $3,077,000 for the nine-month period ended September 30, 2015 from $3,264,000 for the same period of the prior year. The decrease was due to decreases in EECP® revenues as a result of lower average selling prices, partially offset both by higher EECP® sales volume, and by increases in international sales by our China operations, and a decrease in service and accessory part revenue.

Gross Profit

The Company had a gross profit of $22,746,000, or 64% of revenue, in the first three quarters of 2015 compared to $16,023,000, or 71% of revenue, in the first three quarters of the prior year, an increase of $6,723,000, or 42%. The increase is principally due to $4,690,000 in gross profit in the IT segment, of which $4,669,000 resulted from the inclusion of NetWolves operations for the four months after the acquisition, and higher gross profit margin in our Sales Representation segment.

Sales Representation segment gross profit was $16,262,000, or 77% of the segment revenue, for the nine months ended September 30, 2015 as compared to $14,053,000, or 73% of the segment revenue, for the nine months ended September 30, 2014. The increase in absolute dollars and margin percentage was due to higher commission rates, and higher equipment deliveries by GEHC during the first nine months of 2015 than in the same period last year, coupled with lower commission expenses in the first nine months of 2015. Cost of commissions of $4,748,000 and $5,282,000, for the nine months ended September 30, 2015 and 2014, respectively, reflected commission expense associated with recognized commission revenues. The decrease was due to lower commission expenses in the nine-month period ended September 30, 2015 compared to the same period in 2014. Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is recognized.

Page 21

Vasomedical, Inc. and Subsidiaries

IT segment gross profit for the nine months ended September 30, 2015 was $4,690,000 compared to $0 gross profit for the nine months ended September 30, 2014, virtually all the increase resulting from the inclusion of four months of NetWolves results.

Equipment segment gross profit decreased to $1,794,000, or 58% of Equipment segment revenues, for the first three quarters of 2015 compared to $1,970,000, or 60% of Equipment segment revenues, for the same period of 2014. Gross profit margin in the Equipment segment decreased due mainly to lower average selling prices and higher inventory obsolescence costs.

Operating Income (Loss)

Operating income was $1,257,000 for the nine months ended September 30, 2015 as compared to a loss of $1,443,000 for the nine months ended September 30, 2014, an improvement of $2,700,000. Partially offsetting the operating income in the nine months ended September 30, 2015 was an operating loss of $908,000 in our IT segment, as compared to a $82,000 operating loss for this segment in the same period of 2014. The IT segment began operations in the third quarter of 2014. During the nine months ended September 30, 2015, there was a $6,723,000 increase in gross profit partially offset by a $4,192,000 increase in selling, general, and administrative costs. Operating income in the Sales Representation segment increased by $3,199,000 to $5,466,000 as compared to $2,267,000 in the first nine months of the prior year, due mainly to higher gross margin combined with lower SG&A costs. In addition, operating loss in the Equipment segment decreased by $468,000, or 20%, to $1,893,000 compared to $2,361,000 in the same period of the prior year, due primarily to $476,000 lower SG&A costs and $169,000 lower R&D costs in the current year period.

SG&A expenses for the first three quarters of 2015 and 2014 were $21,059,000, or 59% of revenues, and $16,867,000, or 75% of revenues, respectively, reflecting an increase of $4,192,000 or approximately 25%. The increase in SG&A expenditures in the first three quarters of 2015 resulted primarily from $5,597,000 in costs attributable to the IT segment in 2015, primarily resulting from the NetWolves operations, and higher corporate expenses, primarily legal and accounting fees, partially offset by lower costs in the Sales Representation and Equipment segments.

Research and development (“R&D”) expenses were $430,000, or 1% of revenues (14% of Equipment segment revenues), for the first nine months of 2015, a decrease of $169,000, or 28%, from $599,000, or 3% of revenues (18% of Equipment segment revenues), for the first nine months of 2014. The decrease is primarily attributable to non-recurring costs in the first nine months of 2014, not incurred in 2015, associated with the reclassification by FDA of our EECP® therapy system, as well as lower clinical grants in the first nine months of 2015.

Interest and Other Income (Expense)

Interest and other income (expense) for the first three quarters of 2015 was $(40,000) as compared to $150,000 for the first three quarters of 2014. The change from income to expense was due primarily to higher interest expense from debt associated with the Genwell and NetWolves acquisitions.

Income Tax Expense

During the first three quarters of 2015 we recorded income tax expense of $51,000 as compared to income tax expense of $50,000 for the same period of 2014. The increase arose from higher Federal tax expense, largely offset by lower tax expense at our Chinese subsidiaries.

Page 22

Vasomedical, Inc. and Subsidiaries

Liquidity and Capital Resources

Cash and Cash Flow

We have financed our operations from working capital and the proceeds from notes issued to MedTech. At September 30, 2015, we had cash and cash equivalents of $1,928,000, short-term investments of $109,000 and negative working capital of $8,235,000 compared to cash and cash equivalents of $9,128,000, short-term investments of $111,000 and working capital of $9,215,000 at December 31, 2014. $8,591,000 in negative working capital at September 30, 2015 is attributable to the net balance of deferred commission expense and deferred revenue. These are non-cash expense and revenue items and have no impact on future cash flows.

Cash provided by operating activities was $5,879,000 during the first nine months of 2015, compared to $2,586,000 for the same period in 2014, which consisted of net income after adjustments to reconcile net income to net cash of $2,356,000 and cash provided by operating assets and liabilities of $3,520,000. The changes in the account balances primarily reflect a decrease in accounts and other receivables of $7,860,000, partially offset by decreases in deferred revenue of $2,782,000, accrued expenses of $2,129,000, and accrued commissions of $548,000. Significantly higher commission billings and recognized revenue were generated in the fourth quarter of 2014, resulting in significant cash inflows early in 2015.

Cash used in investing activities during the nine-month period ended September 30, 2015 was $17,984,000, of which $17,267,000, net of cash acquired, was used for the acquisition of NetWolves, $100,000 was invested in the VSK joint venture, and $619,000 was used for the purchase of equipment and software.

Cash provided by financing activities during the nine-month period ended September 30, 2015 was $4,800,000 through the issuance of notes to MedTech and $136,000 in borrowings on our line of credit, partially offset by $83,000 in repayments of notes issued for equipment purchases.

Liquidity

The Company expects to be profitable for the year ending December 31, 2015 and to continue to generate positive cash flow through its existing sales representation operations, from the operation of NetWolves, and improved operating efficiency and growth in its China operations and by expanding its market presence and product portfolio. The Company has reorganized its EECP® business model, both domestically and internationally, including the start of operations of the joint venture VSK Medical, intended to reduce costs and achieve profitability in this business. The Company will continue to pursue acquisitions and partnership opportunities in the international and domestic markets and will look to expand its sales representation business.

ITEM 4 - CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Page 23

Vasomedical, Inc. and Subsidiaries

Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2015 and have concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2015.

Changes in Internal Control Over Financial Reporting

There was no change in the Company’s internal control over financial reporting during the Company’s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Page 24

Vasomedical, Inc. and Subsidiaries

PART II - OTHER INFORMATION

ITEM 6 – EXHIBITS

Exhibits

31	Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32	Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Page 25

Vasomedical, Inc. and Subsidiaries

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VASOMEDICAL, INC.

By: /s/ Jun Ma

Jun Ma

President and Chief Executive Officer

(Principal Executive Officer)

/s/ Michael J. Beecher

Michael J. Beecher

Chief Financial Officer and Principal Accounting Officer

Date: November 13, 2015

Page 26

GRAPHIC 2 vasojune2014.jpg begin 644 vasojune2014.jpg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vaso10q-sept2015ex31.htm vaso10q-sept2015ex31.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jun Ma, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Jun Ma .

Jun Ma

President and Chief Executive Officer

Date: November 13, 2015

EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael J. Beecher, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Michael J. Beecher .

Michael J. Beecher

Chief Financial Officer

Date: November 13, 2015

EX-32 4 vaso10q-sept2015ex32.htm vaso10q-sept2015ex32.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jun Ma, as President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Jun Ma .

Jun Ma

President and Chief Executive Officer

Dated: November 13, 2015

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Beecher, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Michael J. Beecher .

Michael J. Beecher

Chief Financial Officer

Dated: November 13, 2015

EX-101.INS 5 vaso-20150930.xml INSTANCE DOCUMENT 0000839087 2015-01-01 2015-09-30 0000839087 2015-11-08 0000839087 2015-09-30 0000839087 2014-12-31 0000839087 2015-07-01 2015-09-30 0000839087 2014-07-01 2014-09-30 0000839087 2014-01-01 2014-09-30 0000839087 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000839087 us-gaap:CommonStockMember 2014-12-31 0000839087 us-gaap:TreasuryStockMember 2013-12-31 0000839087 us-gaap:RetainedEarningsMember 2014-12-31 0000839087 us-gaap:RetainedEarningsMember 2013-12-31 0000839087 2013-12-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000839087 us-gaap:CommonStockMember 2013-12-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000839087 us-gaap:TreasuryStockMember 2014-12-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-12-31 0000839087 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0000839087 us-gaap:TreasuryStockMember 2014-01-01 2014-12-31 0000839087 2014-01-01 2014-12-31 0000839087 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-09-30 0000839087 us-gaap:CommonStockMember 2015-01-01 2015-09-30 0000839087 us-gaap:RetainedEarningsMember 2015-01-01 2015-09-30 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-09-30 0000839087 us-gaap:RetainedEarningsMember 2015-09-30 0000839087 us-gaap:CommonStockMember 2015-09-30 0000839087 us-gaap:AdditionalPaidInCapitalMember 2015-09-30 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-09-30 0000839087 us-gaap:TreasuryStockMember 2015-09-30 0000839087 2014-09-30 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2014-12-31 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-09-30 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-07-01 2015-09-30 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2014-01-01 2014-09-30 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2014-07-01 2014-09-30 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-01-01 2015-09-30 0000839087 us-gaap:OperatingSegmentsMember vaso:EquipmentSegmentMember 2015-07-01 2015-09-30 0000839087 vaso:SalesRepresentationSegmentMember us-gaap:OperatingSegmentsMember 2014-07-01 2014-09-30 0000839087 vaso:InformationTechnologySegmentMember us-gaap:OperatingSegmentsMember 2014-01-01 2014-09-30 0000839087 us-gaap:CorporateNonSegmentMember 2014-01-01 2014-09-30 0000839087 us-gaap:OperatingSegmentsMember vaso:EquipmentSegmentMember 2014-07-01 2014-09-30 0000839087 us-gaap:OperatingSegmentsMember vaso:InformationTechnologySegmentMember 2015-01-01 2015-09-30 0000839087 us-gaap:CorporateNonSegmentMember 2014-07-01 2014-09-30 0000839087 vaso:SalesRepresentationSegmentMember us-gaap:OperatingSegmentsMember 2014-01-01 2014-09-30 0000839087 us-gaap:OperatingSegmentsMember vaso:SalesRepresentationSegmentMember 2015-07-01 2015-09-30 0000839087 us-gaap:CorporateNonSegmentMember 2015-01-01 2015-09-30 0000839087 us-gaap:OperatingSegmentsMember vaso:SalesRepresentationSegmentMember 2015-01-01 2015-09-30 0000839087 us-gaap:OperatingSegmentsMember vaso:InformationTechnologySegmentMember 2015-07-01 2015-09-30 0000839087 us-gaap:OperatingSegmentsMember vaso:EquipmentSegmentMember 2015-01-01 2015-09-30 0000839087 us-gaap:CorporateNonSegmentMember 2015-07-01 2015-09-30 0000839087 us-gaap:OperatingSegmentsMember vaso:EquipmentSegmentMember 2014-01-01 2014-09-30 0000839087 vaso:InformationTechnologySegmentMember us-gaap:OperatingSegmentsMember 2014-07-01 2014-09-30 0000839087 us-gaap:OperatingSegmentsMember vaso:EquipmentSegmentMember 2015-09-30 0000839087 us-gaap:CorporateNonSegmentMember 2014-09-30 0000839087 vaso:InformationTechnologySegmentMember us-gaap:OperatingSegmentsMember 2014-09-30 0000839087 vaso:SalesRepresentationSegmentMember us-gaap:OperatingSegmentsMember 2014-09-30 0000839087 vaso:SalesRepresentationSegmentMember us-gaap:OperatingSegmentsMember 2015-09-30 0000839087 vaso:EquipmentSegmentMember us-gaap:OperatingSegmentsMember 2014-09-30 0000839087 us-gaap:CorporateNonSegmentMember 2015-09-30 0000839087 vaso:InformationTechnologySegmentMember us-gaap:OperatingSegmentsMember 2015-09-30 0000839087 us-gaap:SalesRevenueNetMember vaso:GeHealthcareMember 2014-01-01 2014-09-30 0000839087 vaso:GeHealthcareMember us-gaap:SalesRevenueNetMember 2015-07-01 2015-09-30 0000839087 us-gaap:SalesRevenueNetMember vaso:GeHealthcareMember 2015-01-01 2015-09-30 0000839087 vaso:GeHealthcareMember us-gaap:SalesRevenueNetMember 2014-07-01 2014-09-30 0000839087 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember vaso:GeHealthcareMember 2014-12-31 0000839087 us-gaap:AccountsReceivableMember vaso:GeHealthcareMember us-gaap:CreditConcentrationRiskMember 2015-09-30 0000839087 us-gaap:AccountsReceivableMember vaso:GeHealthcareMember us-gaap:CreditConcentrationRiskMember 2015-01-01 2015-09-30 0000839087 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember vaso:GeHealthcareMember 2014-01-01 2014-12-31 0000839087 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0000839087 us-gaap:CommonStockMember 2014-01-01 2014-09-30 0000839087 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0000839087 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0000839087 us-gaap:CommonStockMember 2015-01-01 2015-09-30 0000839087 us-gaap:CommonStockMember 2014-07-01 2014-09-30 0000839087 us-gaap:CommonStockMember 2015-07-01 2015-09-30 0000839087 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0000839087 vaso:PatentsAndTechnologyMember 2015-09-30 0000839087 us-gaap:CustomerListsMember 2014-12-31 0000839087 vaso:PatentsAndTechnologyMember 2014-12-31 0000839087 us-gaap:ComputerSoftwareIntangibleAssetMember 2015-09-30 0000839087 us-gaap:ComputerSoftwareIntangibleAssetMember 2014-12-31 0000839087 us-gaap:CustomerListsMember 2015-09-30 0000839087 vaso:InformationTechnologySegmentMember 2015-09-30 0000839087 vaso:EquipmentSegmentMember 2015-09-30 0000839087 us-gaap:PatentsMember 2015-01-01 2015-09-30 0000839087 us-gaap:CustomerListsMember 2015-01-01 2015-09-30 0000839087 us-gaap:ComputerSoftwareIntangibleAssetMember 2015-01-01 2015-09-30 0000839087 2015-06-30 0000839087 2014-06-30 0000839087 vaso:InServiceAndTrainingMember 2014-01-01 2014-09-30 0000839087 vaso:ExtendedServiceContractsMember 2014-07-01 2014-09-30 0000839087 vaso:CommissionRevenuesMember 2015-07-01 2015-09-30 0000839087 vaso:ExtendedServiceContractsMember 2015-01-01 2015-09-30 0000839087 vaso:ServiceArrangementsMember 2015-01-01 2015-09-30 0000839087 vaso:CommissionRevenuesMember 2014-07-01 2014-09-30 0000839087 vaso:ExtendedServiceContractsMember 2015-07-01 2015-09-30 0000839087 vaso:ServiceArrangementsMember 2015-07-01 2015-09-30 0000839087 vaso:InServiceAndTrainingMember 2015-01-01 2015-09-30 0000839087 vaso:InServiceAndTrainingMember 2014-07-01 2014-09-30 0000839087 vaso:CommissionRevenuesMember 2015-01-01 2015-09-30 0000839087 vaso:ServiceArrangementsMember 2014-07-01 2014-09-30 0000839087 vaso:ServiceArrangementsMember 2014-01-01 2014-09-30 0000839087 vaso:CommissionRevenuesMember 2014-01-01 2014-09-30 0000839087 vaso:ExtendedServiceContractsMember 2014-01-01 2014-09-30 0000839087 vaso:InServiceAndTrainingMember 2015-07-01 2015-09-30 0000839087 vaso:SecuredSubordinatedPromissoryNoteMember 2015-05-29 0000839087 vaso:SecuredSubordinatedPromissoryNoteMember 2015-07-31 0000839087 vaso:SecuredSubordinatedPromissoryNoteMember 2015-06-30 0000839087 vaso:SixDirectorsMember vaso:SecuredSubordinatedPromissoryNoteMember 2015-05-29 2015-05-29 0000839087 vaso:SecuredSubordinatedPromissoryNoteMember vaso:DirectorAndDirectorsSpouseMember 2015-04-01 2015-06-30 0000839087 vaso:SecuredSubordinatedPromissoryNoteMember 2015-09-30 0000839087 us-gaap:LineOfCreditMember 2015-07-31 0000839087 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:LineOfCreditMember 2015-07-31 2015-07-31 0000839087 us-gaap:LineOfCreditMember 2015-01-01 2015-09-30 0000839087 vaso:NetWolvesLLCMember 2015-05-29 2015-05-29 0000839087 vaso:SecuredSubordinatedPromissoryNoteMember vaso:NetWolvesLLCMember 2015-05-29 0000839087 vaso:NetWolvesLLCMember 2015-07-01 2015-09-30 0000839087 vaso:NetWolvesLLCMember 2015-01-01 2015-09-30 0000839087 vaso:NetWolvesLLCMember 2015-05-29 0000839087 us-gaap:ScenarioPreviouslyReportedMember vaso:NetWolvesLLCMember 2015-05-29 0000839087 vaso:NetWolvesLLCMember us-gaap:ScenarioAdjustmentMember 2015-05-29 0000839087 vaso:GenwellAndNetwolvesMember 2014-07-01 2014-09-30 0000839087 vaso:GenwellAndNetwolvesMember 2015-07-01 2015-09-30 0000839087 vaso:GenwellAndNetwolvesMember 2014-01-01 2014-09-30 0000839087 vaso:GenwellAndNetwolvesMember 2015-01-01 2015-09-30 0000839087 vaso:DirectorPeterCastleMember vaso:NetWolvesLLCMember 2015-09-30 0000839087 vaso:DirectorDavidLiebermanMember vaso:NetWolvesLLCMember 2015-09-30 0000839087 vaso:NetWolvesLLCMember vaso:SecuredSubordinatedPromissoryNoteMember 2015-09-30 0000839087 vaso:NetWolvesLLCMember vaso:SecuredSubordinatedPromissoryNoteMember 2015-01-01 2015-09-30 0000839087 vaso:DirectorAndOtherFamilyMember vaso:NetWolvesLLCMember 2015-01-01 2015-09-30 0000839087 vaso:DirectorDavidLiebermanMember 2015-07-01 2015-09-30 0000839087 vaso:DirectorDavidLiebermanMember 2015-01-01 2015-09-30 0000839087 vaso:DirectorDavidLiebermanMember 2014-07-01 2014-09-30 0000839087 vaso:DirectorDavidLiebermanMember 2014-01-01 2014-09-30 0000839087 vaso:DirectorDavidLiebermanMember 2014-09-30 0000839087 us-gaap:CorporateJointVentureMember 2015-09-30 0000839087 us-gaap:CorporateJointVentureMember 2015-07-01 2015-09-30 0000839087 us-gaap:CorporateJointVentureMember 2015-01-01 2015-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares vaso:State vaso:Company vaso:Subsidiary xbrli:pure vaso:Segment vaso:Director false --12-31 2015-09-30 No No Yes Smaller Reporting Company VASOMEDICAL, INC 0000839087 158412283 2015 Q3 10-Q

8817000

15273000

901000

7167000

791000

5663000

6376000

2253000

14200000

5500000

462000

3604000

12877000

19734000

1026000

2171000

21000

2247000

1746000

1098000

1292000

1397000

2745000

-20000

94000

61924000

62222000

4571000

4265000

167000

502000

50000

146000

300000

490000

1402000

1892000

300000

490000

300000

1892000

47384000

40991000

9293000

9067000

2000

13341000

11408000

9909000

2041000

24642000

32319000

15923000

28994000

0.104

0.057

18000000

0.01

-0.01

0.01

-0.01

733000

15101000

17401000

44532000

48850000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">The following unaudited supplemental pro forma information presents the financial results as if the acquisitions of Genwell and NetWolves had occurred January 1, 2013, and January 1, 2014, respectively.</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;"> </td><td colspan="14" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"> </font><font style="font-size: 10pt; font-family: times new roman; display: inline;">Three months ended</font></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"> </font><font style="font-size: 10pt; font-family: times new roman; display: inline;">Nine months ended</font></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Revenue</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">17,401</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">15,101</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">48,850</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">44,532</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 52%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Net income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,353</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(2</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,584</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,397</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 52%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Basic earnings (loss) per share</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(0.00</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 52%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Diluted earnings (loss) per share</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(0.00</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr></table></div></div>

1584000

-1397000

1353000

-2000

50000

-1701000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">NOTE L – BUSINESS COMBINATION</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">On May 29, 2015, the Company entered into an agreement for, and completed its purchase of, all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC  (collectively, “NetWolves”) for $18,000,000 (the “Purchase Price”). The purchase of NetWolves was accomplished pursuant to an Asset Purchase Agreement (the "Purchase Agreement").  As a result, the Company effectively purchased all rights, titles and ownership of all assets held by NetWolves.   The Purchase Price was paid using $14,200,000 in cash on hand and $3,800,000 raised through the issuance of the Note to MedTech (see Note K).  The Company believes there are significant operational synergies between NetWolves’ capabilities and VasoHealthcare IT’s requirements under its VAR contract with GEHC, as well as the opportunity to expand NetWolves’ existing services to the healthcare IT market.</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">The operating results of NetWolves from May 29, 2015 to September 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and nine month periods ended September 30, 2015.  The accompanying condensed consolidated balance sheet at September 30, 2015 reflects the acquisition of NetWolves effective May 29, 2015.</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">In accordance with Accounting Standards Codification 805, Business Combinations, the total purchase consideration is allocated to the net tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at May 29, 2015 (the acquisition date).  The purchase price was initially allocated based on the information then available, and certain amounts were adjusted after revisions of certain preliminary estimates.  The Company expects additional measurement period adjustments will be recorded after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.  The following table summarizes the current allocation of the assets acquired and liabilities assumed based on their preliminary estimated fair values and current measurement period adjustments as follows:</div><div style="text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"> </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td align="left" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold;"> </td><td colspan="10" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: normal; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold; text-align: left;"> </td></tr><tr><td align="left" valign="bottom" style="border-top: medium none; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: times new roman; font-weight: bold; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"> </div></td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-top: medium none; border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; font-weight: bold; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">As initially reported</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-top: medium none; width: 84px; border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; font-weight: bold; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Measurement period adjustments</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; width: 5px; font-weight: bold; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; width: 11px; font-weight: bold; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-top: medium none; border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; font-weight: bold; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">As adjusted</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Cash and cash equivalents</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">733</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">733</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts receivable and other current assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,638</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">(103</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,535</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">50</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">50</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Property and equipment</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,359</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,359</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts payable and other current liabilities</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(4,382</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(4,382</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Long term debt</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,701</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,701</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Goodwill and other intangibles</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">19,303</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; border-bottom: black 2px solid; text-align: right;">103</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">19,406</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%; padding-bottom: 4px; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Total</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">18,000</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; border-bottom: black 4px double; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">18,000</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 64%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div><div style="text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"> </div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">During the nine months ended September 30, 2015, the Company expensed $100,000 of acquisition-related legal costs and incurred $60,000 in debt issue costs.  The legal costs are included in the line item Selling, General & Administrative costs in the accompanying condensed consolidated statements of operations and comprehensive income (loss).  The debt issue costs are recorded as a reduction to long term notes payable in the accompanying condensed consolidated balance sheet at September 30, 2015.  The amounts of revenue and net income of NetWolves included in the Company’s condensed consolidated statements of operations and comprehensive income (loss) was $8,707,000 and $227,000, respectively, for the three months ended September 30, 2015, and $11,470,000 and $377,000, respectively, for the nine months ended September 30, 2015.  The goodwill is expected to be deductible for tax purposes.</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">The following unaudited supplemental pro forma information presents the financial results as if the acquisitions of Genwell and NetWolves had occurred January 1, 2013, and January 1, 2014, respectively.</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;"> </td><td colspan="14" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"> </font><font style="font-size: 10pt; font-family: times new roman; display: inline;">Three months ended</font></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"> </font><font style="font-size: 10pt; font-family: times new roman; display: inline;">Nine months ended</font></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Revenue</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">17,401</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">15,101</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">48,850</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">44,532</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 52%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Net income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,353</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(2</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,584</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,397</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 52%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Basic earnings (loss) per share</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(0.00</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 52%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Diluted earnings (loss) per share</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(0.00</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(0.01</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr></table></div></div>

100000

2359000

18000000

1928000

9128000

7961000

9054000

159000

119000

733000

1093000

-7200000

166000

169000

166435370

168720370

250000000

0.001

158412283

156127283

1052000

-121000

-1371000

1085000

0.86

0.44

0.59

0.84

0.62

0.93

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; font-style: italic; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Variable Interest Entities</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">The Company follows the guidance of accounting for variable interest entities, which requires certain variable interest entities to be consolidated by the primary beneficiary of the entities.  Biox is a Variable Interest Entity (VIE).</div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"> </div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">Liabilities recognized as a result of consolidating this VIE do not represent additional claims on the Company’s general assets. The financial information of Biox, which is included in the accompanying condensed consolidated financial statements, is presented as follows:</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">                                                                                      </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">As of </div><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015 </div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">As of</div><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"> December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 76%; display: inline;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: center;">(unaudited) </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Cash and cash equivalents</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">119</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">159</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,037</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,047</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total liabilities</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,040</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">878</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 76%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div><div style="display: block; text-indent: 0pt;"> </div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">                                                                                                      </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> </td><td colspan="14" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> <font style="font-style: italic;">(in thousands)</font></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: times new roman; display: inline;"> Three months ended</div><div style="font-size: 10pt; font-family: times new roman; display: inline;"> September 30, </div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="7" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: times new roman; display: inline;"> Nine months ended </div><div style="font-size: 10pt; font-family: times new roman; display: inline;">September 30,</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total net revenue</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">358</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">368</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,183</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,126</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 52%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Net income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">24</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(152</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(199</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(382</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 52%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div></div>

6576000

7551000

2268000

12952000

542000

1283000

1294000

440000

0.0225

60000

0.09

50000

2583000

2388000

2533000

2388000

2583000

2200000

28000

244000

3516000

465000

25000

3457000

160000

10000

13000

6847000

28000

58000

8840000

791000

5000

18019000

19614000

17712000

22532000

19750000

18236000

11174000

9882000

9158000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">The changes in the Company’s deferred revenues are as follows:</div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"> </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td colspan="14" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; margin-right: 0pt; text-indent: 0pt;">For the three months ended</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: center;">For the nine months ended</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Deferred revenue at beginning of period</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">19,614</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">17,712</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">22,532</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">18,019</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Additions:</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Deferred extended service contracts</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">160</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">244</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">465</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">791</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Deferred in-service and training</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">5</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">13</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">10</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">28</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Deferred service arrangements</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">10</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">28</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">25</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">58</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Deferred commission revenues</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,516</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,457</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">6,847</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">8,840</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Recognized as revenue:</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Deferred extended service contracts</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(209</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(207</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(654</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(654</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Deferred in-service and training</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(10</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(10</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(25</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Deferred service arrangements</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(15</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(26</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(58</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(72</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%; padding-bottom: 2px; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Deferred commission revenues</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(3,331</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(2,975</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(9,407</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(8,749</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Deferred revenue at end of period</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">19,750</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">18,236</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">19,750</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">18,236</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%; padding-bottom: 2px; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Less: current portion</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">11,174</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">9,158</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">11,174</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">9,158</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%; padding-bottom: 4px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Long-term deferred revenue at end of period</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">8,576</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">9,078</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">8,576</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">9,078</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr></table></div></div>

8576000

12650000

9078000

72000

9407000

10000

15000

2975000

3331000

654000

26000

209000

654000

8749000

207000

58000

25000

10000

112000

783000

290000

1000

100000

205000

110000

-0.01

0.01

-0.01

0.01

52000

1000

2917000

1344000

1000

265000

148000

381000

742000

467000

549000

718000

495000

2447000

2826000

333000

1940000

1699000

415000

419000

467000

2441000

800000

2489000

1133000

962000

800000

P10Y

P7Y

P5Y

-39000

22582000

3288000

19406000

3176000

103000

19406000

19303000

19406000

112000

22746000

16023000

9850000

5375000

97000

143000

-1293000

1217000

-97000

1268000

38000

50000

51000

26000

130000

48000

-5000

-72000

123000

53000

-299000

214000

-1203000

-2129000

75000

382000

-2274000

1639000

-7775000

-6396000

-2782000

218000

-55000

-548000

-42000

221000

332000

-48000

-68000

366000

494000

5000

52000

79000

151000

225000

66000

815000

673000

849000

636000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>NOTE F – INVENTORIES, NET</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Inventories, net of reserves, consist of the following:<font style="font-size: 10pt; font-family: Times New Roman; font-style: italic; display: inline;">                 </font></div><div style="display: block; text-indent: 0pt;"> </div><div style="text-align: left; display: block; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Raw materials</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">475</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">583</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Work in process</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">626</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">679</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Finished goods</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">849</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">636</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 76%; padding-bottom: 4px;">  </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">1,950</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">1,898</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 76%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div><div style="display: block; text-indent: 0pt;"> </div><div style="font-size: 10pt; font-family: Times New Roman; display: block; text-indent: 0pt;">At September 30, 2015 and December 31, 2014, the Company maintained reserves for excess and obsolete inventory of $673,000 and $815,000, respectively.</div></div>

1898000

1950000

583000

475000

626000

679000

85000

213000

60000

180000

19779000

24158000

13461000

14122000

47384000

40991000

3000000

5007000

3800000

250000

750000

3800000

0.499

-1250000

-17984000

5879000

2586000

-1343000

1230000

1166000

-123000

1166000

1128000

-199000

24000

-382000

-152000

377000

227000

-244000

4853000

150000

-40000

-69000

52000

1654000

163000

1017000

1039000

997000

5524000

8513000

17466000

21489000

-149000

-1443000

1257000

1337000

2267000

-187000

-1893000

-582000

-480000

-82000

-1408000

-385000

-405000

-908000

-2361000

5466000

-1267000

2586000

723000

-145000

2000

-28000

-114000

-14000

-114000

-14000

3504000

5617000

2720000

110000

51000

3170000

7585000

4402000

13000

623000

633000

458000

1612000

1623000

539000

811000

244000

18000000

14200000

619000

227000

100000

38000

40000

0.01

1000000

515000

363000

136000

4800000

1950000

250000

4800000

2200000

1200000

40000

2928000

266000

83000

599000

430000

180000

158000

-52433000

-51267000

7643000

1017000

6409000

1234000

11611000

17401000

19335000

7584000

35698000

21010000

8800000

3077000

3264000

22599000

11470000

8707000

7643000

17401000

22599000

35698000

358000

1126000

368000

1183000

247000

612000

1017000

3264000

3077000

1234000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>The following table summarizes the current allocation of the assets acquired and liabilities assumed based on their preliminary estimated fair values and current measurement period adjustments as follows:</div><div style="text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"> </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td align="left" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold;"> </td><td colspan="10" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: normal; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold; text-align: left;"> </td></tr><tr><td align="left" valign="bottom" style="border-top: medium none; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: times new roman; font-weight: bold; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"> </div></td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-top: medium none; border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; font-weight: bold; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">As initially reported</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-top: medium none; width: 84px; border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; font-weight: bold; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Measurement period adjustments</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; width: 5px; font-weight: bold; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; width: 11px; font-weight: bold; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-top: medium none; border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; font-weight: bold; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">As adjusted</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-weight: bold; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Cash and cash equivalents</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">733</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">733</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts receivable and other current assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,638</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">(103</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,535</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">50</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">50</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Property and equipment</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,359</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,359</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts payable and other current liabilities</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(4,382</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(4,382</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Long term debt</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,701</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,701</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 64%; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Goodwill and other intangibles</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">19,303</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; border-bottom: black 2px solid; text-align: right;">103</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">19,406</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 64%; padding-bottom: 4px; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Total</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">18,000</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; border-bottom: black 4px double; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">18,000</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 64%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9.07%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1.31%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2015 and 2014, because the effect of their inclusion would be anti-dilutive.</div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"> </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> </td><td colspan="14" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="6" valign="bottom" style="text-align: center;"><font style="font-size: 10pt; font-family: times new roman; display: inline;"> </font><font style="font-size: 10pt; font-family: times new roman; display: inline;">For the three months ended</font></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: center;">For the nine months ended</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Stock options</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">300</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,402</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">300</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,402</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Common stock grants</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">490</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">490</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 52%; padding-bottom: 4px;">  </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">300</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">1,892</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">300</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">1,892</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; display: block; text-indent: 36pt;">The Company’s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:</div><div style="display: block; text-indent: 36pt;"> </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="border-top: medium none;"> </td><td valign="bottom" style="border-top: medium none; text-align: center;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="border-top: medium none; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px;"> </td><td valign="bottom" style="padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom"> </td><td valign="bottom"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"> </td><td valign="bottom"> </td><td colspan="2" valign="bottom"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Patents and Technology</div></td><td valign="bottom"> </td><td colspan="2" valign="bottom"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left;"> </td><td valign="bottom"> </td><td colspan="2" valign="bottom"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Costs</div></td><td align="right" valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,441</td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,489</td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%; padding-bottom: 2px; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Accumulated amortization</div></td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(742</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(549</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; padding-bottom: 2px;"> </td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">1,699</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">1,940</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 76%;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Customer lists</div></td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Costs</div></td><td align="right" valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">800</td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">800</td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%; padding-bottom: 2px; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Accumulated amortization</div></td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(467</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(381</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 76%; padding-bottom: 2px;"> </td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">333</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">419</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Software</div></td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Costs</div></td><td align="right" valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,133</td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">962</td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%; padding-bottom: 2px; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Accumulated amortization</div></td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(718</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(495</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; padding-bottom: 2px;"> </td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">415</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">467</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 76%;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; padding-bottom: 4px;"> </td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">2,447</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">2,826</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 76%;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accrued expenses and other liabilities consist of the following at September 30, 2015 and December 31, 2014:</div><div style="font-size: 10pt; font-family: Times New Roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"></div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accrued compensation</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,344</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,917</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accrued expenses - other</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,292</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,098</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other liabilities</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">1,623</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">1,612</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 76%; padding-bottom: 4px;">  </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">4,259</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">5,627</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 76%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">Other assets consist of the following at September 30, 2015 and December 31, 2014:</div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"> </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="border-top: medium none;"> </td><td valign="bottom" style="border-top: medium none; text-align: center;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="border-top: medium none; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px;"> </td><td valign="bottom" style="padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom"> </td><td valign="bottom"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"> </td><td valign="bottom"> </td><td colspan="2" valign="bottom"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Deferred commission expense - noncurrent</div></td><td align="right" valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,845</td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,988</td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Trade receivables - noncurrent</div></td><td align="right" valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,026</td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,171</td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other</div></td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">633</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">458</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; padding-bottom: 4px;"> </td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">3,504</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">5,617</td><td nowrap="nowrap" valign="bottom" style="width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 76%;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 1%;"> </td><td valign="bottom" style="width: 1%; text-align: left;"> </td><td valign="bottom" style="width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; text-align: left;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:</div><div style="text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"> </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;">  </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> </td><td colspan="14" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: center;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; font-family: times new roman; border-bottom: black 2px solid; text-align: center;">Three months ended September 30,</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: center;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; font-family: times new roman; border-bottom: black 2px solid; text-align: center;">Nine months ended September 30,</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Basic weighted average shares outstanding</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">157,288</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">155,186</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">156,502</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">155,319</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Dilutive effect of share-based compensation</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">494</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">366</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%; padding-bottom: 4px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Diluted weighted average shares outstanding</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">157,782</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">155,186</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">156,868</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">155,319</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Inventories, net of reserves, consist of the following:<font style="font-size: 10pt; font-family: Times New Roman; font-style: italic; display: inline;">                 </font></div><div style="display: block; text-indent: 0pt;"> </div><div style="text-align: left; display: block; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Raw materials</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">475</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">583</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Work in process</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">626</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">679</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Finished goods</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">849</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">636</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 76%; padding-bottom: 4px;">  </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">1,950</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">1,898</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 76%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>The components of the change in goodwill are as follows:</div><div style="display: block; text-indent: 0pt;"> </div><div style="text-align: left; display: block; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Carrying Amount</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Balance at December 31, 2014</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,288</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Foreign currency translation</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(112</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%; padding-bottom: 2px; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">Acquisition of Netwolves</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">19,406</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%; padding-bottom: 4px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Balance at September 30, 2015 (unaudited)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">22,582</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 88%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>Summary financial information for the segments is set forth below:</div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"> </div><div style="font-size: 10pt; font-family: Times New Roman; font-style: italic; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">                   </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;"> </td><td colspan="18" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: center;"> </td><td colspan="18" valign="bottom" style="font-size: 10pt; font-family: times new roman; border-bottom: black 2px solid; text-align: center;">As of or for the three months ended September 30, 2015 (unaudited)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Equipment Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,584</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">8,800</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,017</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">17,401</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Operating income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,586</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(187</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(582</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(480</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,337</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">11,408</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">24,642</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,293</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,041</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">47,384</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">5,663</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,253</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">901</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">8,817</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,533</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">50</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,583</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,720</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">51</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">623</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">110</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,504</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: center;"> </td><td colspan="18" valign="bottom" style="font-size: 10pt; font-family: times new roman; border-bottom: black 2px solid; text-align: center;">As of or for the three months ended September 30, 2014 (unaudited)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Equipment Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">6,409</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,234</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,643</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Operating income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">723</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(82</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(405</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(385</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(149</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">13,341</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,909</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,067</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">32,319</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">6,376</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">791</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,167</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,388</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,388</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">4,402</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,170</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">13</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,585</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: center;"> </td><td colspan="18" valign="bottom" style="font-size: 10pt; font-family: times new roman; border-bottom: black 2px solid; text-align: center;">As of or for the nine months ended September 30, 2015 (unaudited)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Equipment Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">21,010</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">11,611</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,077</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">35,698</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Operating income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">5,466</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(908</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,893</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,408</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,257</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">11,408</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">24,642</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,293</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,041</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">47,384</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">5,663</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,253</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">901</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">8,817</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,533</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">50</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,583</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,720</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">51</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">623</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">110</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,504</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: center;"> </td><td colspan="18" valign="bottom" style="font-size: 10pt; font-family: times new roman; border-bottom: black 2px solid; text-align: center;">As of or for the nine months ended September 30, 2014 (unaudited)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Equipment Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">19,335</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,264</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">22,599</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Operating income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,267</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(82</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(2,361</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,267</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,443</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">13,341</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,909</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,067</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">32,319</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">6,376</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">791</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,167</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,388</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,388</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">4,402</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,170</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">13</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,585</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>The financial information of Biox, which is included in the accompanying condensed consolidated financial statements, is presented as follows:</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">                                                                                      </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">As of </div><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015 </div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">As of</div><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"> December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 76%; display: inline;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: center;">(unaudited) </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Cash and cash equivalents</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">119</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">159</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,037</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,047</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total liabilities</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,040</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">878</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 76%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div><div style="display: block; text-indent: 0pt;"> </div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">                                                                                                      </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> </td><td colspan="14" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> <font style="font-style: italic;">(in thousands)</font></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: times new roman; display: inline;"> Three months ended</div><div style="font-size: 10pt; font-family: times new roman; display: inline;"> September 30, </div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="7" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: times new roman; display: inline;"> Nine months ended </div><div style="font-size: 10pt; font-family: times new roman; display: inline;">September 30,</div></td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total net revenue</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">358</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">368</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,183</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,126</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 52%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Net income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">24</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(152</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(199</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(382</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 52%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">The following table presents information regarding the Company’s accounts and other receivables as of September 30, 2015 and December 31, 2014:</div><div style="text-align: left; margin-left: 288pt; display: block; margin-right: 0pt; text-indent: 36pt;"> </div><div style="text-align: left; display: block; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: center;"> </td><td colspan="6" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">September 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Trade receivables</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">12,877</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">19,734</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Due from employees</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">205</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">110</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Allowance for doubtful accounts and</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%; padding-bottom: 2px; text-indent: 9pt;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 9pt;">commission adjustments</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(4,265</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 2px solid; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 2px solid; text-align: right;">(4,571</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 2px; text-align: left;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%; padding-bottom: 4px;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">8,817</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; border-bottom: black 4px double; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; border-bottom: black 4px double; text-align: right;">15,273</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; padding-bottom: 4px; text-align: left;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">NOTE C – SEGMENT REPORTING AND CONCENTRATIONS</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">The Company views its business in three segments – the Sales Representation segment, the Equipment segment, and the IT segment.  The Sales Representation segment operates through the Vaso Diagnostics subsidiary and is currently engaged solely in the fulfillment of the Company’s responsibilities under our agreement with GEHC.  The IT segment includes the operations of NetWolves and VasoHealthcare IT Corp.  Operations in the IT segment began in the third quarter of 2014.  The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP<font style="font-size: 70%; vertical-align: text-top; display: inline;">®</font> enhanced external counterpulsation systems both domestically and internationally, as well as the development, production, marketing and supporting of other medical devices.</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">The chief operating decision maker is the Company’s Chief Executive Officer, who, in conjunction with upper management, evaluates segment performance based on operating income.  Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.  Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below.  There are no intersegment revenues.  Summary financial information for the segments is set forth below:</div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;"> </div><div style="font-size: 10pt; font-family: Times New Roman; font-style: italic; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">                   </div><div style="text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman;"> </td><td valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;"> </td><td colspan="18" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: center;">(in thousands)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; border-top: medium none; font-family: times new roman; font-style: italic; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: center;"> </td><td colspan="18" valign="bottom" style="font-size: 10pt; font-family: times new roman; border-bottom: black 2px solid; text-align: center;">As of or for the three months ended September 30, 2015 (unaudited)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Equipment Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td colspan="2" valign="bottom" style="font-size: 10pt; font-family: times new roman; display: inline;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,584</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">8,800</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,017</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">17,401</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Operating income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,586</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(187</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(582</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(480</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,337</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">11,408</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">24,642</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,293</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,041</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">47,384</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">5,663</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,253</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">901</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">8,817</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,533</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">50</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,583</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,720</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">51</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">623</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">110</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,504</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: center;"> </td><td colspan="18" valign="bottom" style="font-size: 10pt; font-family: times new roman; border-bottom: black 2px solid; text-align: center;">As of or for the three months ended September 30, 2014 (unaudited)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Equipment Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">6,409</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,234</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,643</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Operating income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">723</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(82</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(405</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(385</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(149</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">13,341</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,909</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,067</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">32,319</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">6,376</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">791</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,167</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,388</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,388</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">4,402</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,170</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">13</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,585</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: center;"> </td><td colspan="18" valign="bottom" style="font-size: 10pt; font-family: times new roman; border-bottom: black 2px solid; text-align: center;">As of or for the nine months ended September 30, 2015 (unaudited)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Equipment Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">21,010</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">11,611</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,077</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">35,698</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Operating income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">5,466</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(908</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,893</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,408</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">1,257</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">11,408</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">24,642</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,293</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,041</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">47,384</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">5,663</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,253</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">901</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">8,817</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,533</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">50</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,583</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,720</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">51</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">623</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">110</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,504</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: center;"> </td><td colspan="18" valign="bottom" style="font-size: 10pt; font-family: times new roman; border-bottom: black 2px solid; text-align: center;">As of or for the nine months ended September 30, 2014 (unaudited)</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="white"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Sales Representation Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Equipment Segment</div></td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="font-size: 10pt; font-family: times new roman; text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; padding-bottom: 2px; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 40%; display: inline;">  </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Revenues from external customers</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">19,335</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,264</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">22,599</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Operating income (loss)</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,267</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(82</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(2,361</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,267</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">(1,443</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Total assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">13,341</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,909</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">9,067</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">32,319</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Accounts and other receivables, net</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">6,376</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">791</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,167</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Deferred commission expense</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,388</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">2,388</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 40%;"><div style="font-size: 10pt; font-family: times new roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Other assets</div></td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">4,402</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">-</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">3,170</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">13</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td><td align="right" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; display: inline;"> </td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;">$</td><td valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 9%; text-align: right;">7,585</td><td nowrap="nowrap" valign="bottom" style="font-size: 10pt; font-family: times new roman; width: 1%; text-align: left;"> </td></tr></table></div><div style="text-align: center; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;"> </div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">For the three months ended September 30, 2015 and 2014, GE Healthcare accounted for 44% and 84% of revenue, respectively.  For the nine months ended September 30, 2015 and 2014, GE Healthcare accounted for 59% and 86% of revenue, respectively, and $5.5 million or 62%, and $14.2 million or 93%, of accounts and other receivables at September 30, 2015 and December 31, 2014, respectively.</div></div>

21059000

16867000

5344000

8355000

-10308000

166435000

-9481000

164705000

-10308000

168720000

111000

109000

390000

298000

3000

389000

301000

1000

36000

245000

450000

2285000

1280000

827000

7751000

9104000

61508000

166000

-1755000

-52433000

-53561000

6465000

94000

108000

165000

61924000

-2000000

-51267000

169000

62222000

-20000

-2000000

11611000

8800000

5308000

6921000

10308087

2000000

1037000

1047000

878000

1040000

155319000

157288000

155186000

156502000

156868000

157782000

155319000

155186000

P5Y P3Y <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; font-weight: bold; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Basis of Presentation and Use of Estimates</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in connection with:</div><div style="display: block; text-indent: 0pt;"><br /></div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr valign="top"><td align="right" style="width: 54pt;"><div style="font-size: 10pt; font-family: Times New Roman; display: inline;">1)  </div></td><td><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; margin-right: 0pt; text-indent: 0pt;">The audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC on March 30, 2015.</div></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr valign="top"><td align="right" style="width: 54pt;"><div style="font-size: 10pt; font-family: Times New Roman; display: inline;">2)  </div></td><td><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; margin-right: 0pt; text-indent: 0pt;">The audited consolidated financial statements of NetWolves, LLC and related notes thereto included in the Form 8-K/A filed with the SEC on August 12, 2015.  The operating results of NetWolves from May 29, 2015 to September 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and nine month periods ended September 30, 2015.</div></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: Times New Roman; font-weight: bold; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Significant Accounting Policies</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: justify; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 36pt;">Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended December 31, 2014, and Note B of the Notes to Consolidated Financial Statements for the year ended December 31, 2014, included on Form 8-K/A, include a summary of the significant accounting policies used in the preparation of the condensed consolidated financial statements.</div></div> 0.135 2988000 1845000 4259000 5627000 1638000 -103000 1535000 -4382000 -4382000 0 113000 0 1136000 0 -1000 109000 301000 320000 5000 138000 2000000 6 6 0 9000 0 9000 0 3 21010000 7584000 6409000 19335000 5282000 4748000 1701000 1828000

EX-101.SCH 6 vaso-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - GOODWILL AND OTHER INTANGIBLES link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - DEFERRED REVENUE link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - BUSINESS COMBINATION link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 061500 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 070200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - INVENTORIES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - DEFERRED REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 081200 - Disclosure - BUSINESS COMBINATION (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090202 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090302 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - INVENTORIES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - OTHER ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - DEFERRED REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - BUSINESS COMBINATION (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 091400 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 091500 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vaso-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 vaso-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 vaso-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract] Accounts and other receivables, net Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $4,265 at September 30, 2015 and $4,571 at December 31, 2014 Accounts and other receivables, net Accounts and other receivables Accounts and Other Receivables [Member] Accounts payable Accounts Payable, Current Trade receivables Accounts Receivable, Net, Current Trade receivables - noncurrent ACCRUED EXPENSES AND OTHER LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Receivables due from related parties Accounts Receivable, Related Parties Accrued commissions Accrued Sales Commission, Current Accrued expenses - other Outstanding legal fees amount Accrued Professional Fees, Current PROPERTY AND EQUIPMENT, accumulated depreciation Accumulated Other Comprehensive Income [Member] Accumulated other comprehensive income Additional paid-in capital Additional Paid-in Capital [Member] Adjustments to reconcile net income (loss) to net cash provided by operating activities Allowance for doubtful accounts and commission adjustments Accounts and other receivables, allowance for doubtful accounts and commission adjustments Amortization expense Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities [Axis] Antidilutive securities excluded from computation of diluted earnings per share (in shares) ASSETS Assets [Abstract] Total assets Total Assets Total current assets Assets, Current CURRENT ASSETS BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Related party transaction, ownership interest Business Acquisition, Percentage of Voting Interests Acquired Consideration for acquisition Diluted earnings (loss) per share (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Estimated fair values of the net assets acquired [Abstract] Basic earnings (loss) per share (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Basic Business acquisition proforma information [Abstract] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Revenue Business Acquisition, Acquiree [Domain] Business Acquisition Proforma Information Net income (loss) Business Acquisition, Pro Forma Net Income (Loss) Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Business Acquisition [Axis] Long term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt BUSINESS COMBINATION [Abstract] Business Acquisition [Line Items] BUSINESS COMBINATION Business Combination Disclosure [Text Block] Acquisition-related legal costs Business Combination, Acquisition Related Costs Property and equipment Total Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Cash and cash equivalents Cash acquired through purchase of Netwolves NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) Variable Interest Entity, Classification [Domain] COMMITMENTS AND CONTINGENCIES (NOTE N) COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES [Abstract] Common stock, $.001 par value; 250,000,000 shares authorized; 168,720,370 and 166,435,370 shares issued at September 30, 2015 and December 31, 2014, respectively; 158,412,283 and 156,127,283 shares outstanding at September 30, 2015 and December 31, 2014, respectively Common Stock, Value, Issued Common stock, shares issued (in shares) Common stock, shares authorized (in shares) Common stock, par value (in dollars per share) Common Stock [Member] Common Stock Grants [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Software [Member] Concentration Risk Type [Domain] Concentration Risk Type [Axis] Concentration Risk [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk [Table] Percentage of revenue Percentage of accounts and other receivables Concentration Risk Benchmark [Axis] Variable Interest Entity Consolidation, Variable Interest Entity, Policy [Policy Text Block] Consolidation Items [Domain] Consolidation Items [Axis] VSK Medical Limited [Member] Corporate [Member] Total cost of revenues Cost of Goods and Services Sold Cost of revenues Cost of equipment sales and services Credit Facility [Domain] Credit Concentration Risk [Member] Credit Facility [Axis] Customer Lists [Member] Debt Instrument [Line Items] DEBT [Abstract] Schedule of Long-term Debt Instruments [Table] Interest rate percentage Debt Instrument [Axis] DEBT Debt Disclosure [Text Block] Debt issuance costs Debt Issuance Cost Debt Instrument, Name [Domain] Debt instrument, interest rate Debt Instrument, Interest Rate, Stated Percentage Deferred commission expense DEFERRED REVENUE [Abstract] Deferred commission expense Deferred Costs, Current Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement Type [Axis] Additions: Deferred Revenue [Domain] DEFERRED REVENUE Deferred Revenue Disclosure [Text Block] Deferred revenue at beginning of period Deferred revenue at end of period Deferred Revenue Less: current portion Deferred revenue - current portion Deferred Revenue Arrangement [Line Items] Changes in Deferred Revenues Long-term deferred revenue at end of period Deferred revenue Deferred Revenue, Noncurrent Recognized as revenue: Deferred Revenue, Revenue Recognized Deferred tax liability, net Deferred Tax Liabilities, Net, Current Depreciation and amortization Depreciation, Depletion and Amortization RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Description of New Accounting Pronouncements Not yet Adopted [Text Block] Receivables due from related parties Contribution to related parties Due from employees Weighted average common shares outstanding EARNINGS (LOSS) PER COMMON SHARE basic (in dollars per share) diluted (in dollars per share) Earnings Per Share, Diluted Income (loss) per common share EARNINGS (LOSS) PER COMMON SHARE [Abstract] Effect of exchange rate differences on cash and cash equivalents Stock Options [Member] Accrued compensation Employee-related Liabilities, Current Revenue, Major Customer [Line Items] Investment, Name [Domain] Equity Component [Domain] Interest and financing costs Financing Interest Expense Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization INTANGIBLES, net Intangible assets, net Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Costs Finite-Lived Intangible Assets by Major Class [Axis] Other intangible assets, net [Abstract] Useful life of intangible assets Finite-Lived Intangible Asset, Useful Life Loss on disposal of fixed assets Gain (Loss) on Disposition of Assets Goodwill and other intangibles GOODWILL Goodwill, Beginning Balance Goodwill Goodwill, Ending Balance Acquisition of Netwolves GOODWILL AND OTHER INTANGIBLES Goodwill and Intangible Assets Disclosure [Text Block] Foreign currency translation Goodwill, Translation Adjustments Change in carrying amount of goodwill [Roll Forward] Goodwill [Roll Forward] GOODWILL AND OTHER INTANGIBLES [Abstract] Gross profit Gross Profit Gain from joint venture Income (Loss) from Equity Method Investments CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) [Abstract] Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Income taxes paid EX-101.PRE 10 vaso-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R39.htm IDEA: XBRL DOCUMENT

INVENTORIES, NET (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
INVENTORIES, NET [Abstract]
Raw materials	$ 475,000	$ 583,000
Work in process	626,000	679,000
Finished goods	849,000	636,000
Inventories, net	1,950,000	1,898,000
Reserves for excess and obsolete inventory	$ 673,000	$ 815,000

XML 12 R48.htm IDEA: XBRL DOCUMENT

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details)	9 Months Ended
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details)	Sep. 30, 2015 USD ($)
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract]
Debt issuance costs	$ 60,000
Interest expense	$ 5,000

EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`(Z`;4<]SG18X0$```D>```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[C,!2%7Z7*%C6N?V`81-D`6T""%_`DMXW5.+9L4\K;8Z>`9JHR M@ADJG4U^>J[O.L3ODV M+)G7S4HOB8G9[(0U;D@TI&DJ/:J+\]LUA6!:FEQNA=)[7FGO>]/H9-S`UD.[ MTW7J%@O34.N:1YN7U"E;TU'6J\F=#NE&V]R";7HV"MLCKXO.OL)^;=YE=7X*8?= MA7]+9FP9FA^6?ZPH]__X+#LO<6W[JZ"?S([!^F!C*N?::C/L&]63"ZM?SJV^ M:J6VJD/N3`DLV>7Y.*[K$:66_^7]]M.:5R@3QF6P@-^%)T.U-ZGD.>[ M_]OXO>!P.[%````*P(```L```!?.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?' M5$Q^#*G*_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7. MU49V[M,41Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997 M'L=V+YRO+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_ MV/P"4$L#!!0````(`(Z`;4=@@IJAT@$``(T=```:````>&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'/%V4M.XT`4A>&M1%X`Y?L@0$08,6%*LP$KJ<11$MMR M5:MA]VTR0.%11PPBG8DMV]*M?_2I5+[O4KUXCH4H'DY:$X)NBD'W5"";LM!MY2@ MNW+0'25(:B!CS4E"6'.T%L"U<+P6`+9PQ!9`MG#,%H"V<-06P+9PW!8`MW#D M%D"W<.P6@+=P]%:@MW+T5J"WDO;::+/-T5N!WLK16X'>RM%;@=[*T5N!WLK1 M6X'>RM%;@=[*T5N!WLK1VX#>QM';@-[&T=N`WD8Z*T&')1R]#>AM'+T-Z&T< MO0WH;1R]#>AM'+T-Z&TCM'+T=Z.TCMI+-N=-C- MT=N!WL[1VX'>SM';@=[.T=N!WL[1V\_T3FTSQO6?/.ZZ;;ITS:?A\%_.&=XI MOQWBY5-.4V'#F=9Y6BF&T_7B3I^FOH>$;W]>'_X#4$L#!!0````(`(Z`;4=R M3`$P-0,``((,```0````9&]C4')O<',O87!P+GAM;+U7T8[:.!3]%8NGJ;1M M6&"[HQ&-9!*7L91Q(MM,M_OF!C-$A03%[FAFOWZODX&&&9,M/"PO.#?GW.M[ MS[$%T](,;[*ZVNG:%MJ@I^VF-#<0_#186[N["0*3K_56F0\`*>'MJJJWRL)C M_1!4JU61Z[C*?VQU:8/1VJ,KPKLCK MRE0KB\A3KC?3X#6@84!FH?,?=6&?PV&+Z88:C,C51D=0*URIC=$MZF>PP435 M=J?*YZ!]2HKRNUGL9!4KJ[NLXQ=M]K6J]1**'F4_!!O,[3/TN7'<:*W*![WL M8M^^W,_B7M?&=?K[Z,,0/H<1[.-M;JV61?F0J:(VX?31WCSJW%;UBTR/]E*5 MEE7N1#?W$O9G!NB;,MHM/PT>55VHT@Z0*?Z!Q]&@+=M&F_5F9VP=?JGJ[V:M MM373X!!LEEUL=UU,PLEU@X#5,3(X=!:^C.VH;Q>1A=UHDZXR5=O_:11-3_M! M3*X'G>[W*9`JEXB4%NR(:-F6`O&Z(SFLHI3%A`D2(UB)-*$QEO`PPPEF$4$7 M<,;G<(2$KSO"+N#\<0'GHY>3\CEF]&\L:+,\S[#7'Y%H!`3.')H?R=.%BJ=PF(O MK!.9L(B>&(Y3A

?7?D;OA3;VZ]WK MD;%?[UZ/C/UZ]W/\>O?Z:OSG^;X:7_^BKV)M5;&YQ%@3O_3'QNI-W^NLB?^D MOW56;PEW1_X'Q.^^7LKI>[,AGG]YHJOSK\_)D<1O?LN]^N46'/_C"/\%4$L# M!!0````(`(Z`;4=1J`;;/@$``&D#```1````9&]C4')O<',O8V]R92YX;6S- MDTU3PC`0AO^*TWM)`\(A4WI0QY/,."..CK>8+!!I/B99IO3?&T)I1;QP\];M M[OOLN]FD%(X)Z^'96P<>%82;O:Y-8,+-LPVB8X0$L0'-PRA6F)A<6:\YQM"O MB>-BR]=`QD4Q(QJ02XZ<'("YZXE954K!A`>.UG=X*7J\V_DZP:0@4(,&@X'0 M$259]6JVQC:F)(.^*J/CF@=<6*E6"N1=.Y1=IF)G!*_#40ZR;Y_^_NDA94C6 M5>Z#ZJN:IADUDU07!Z;D??'TDLXF5R8@-P*B*BB&K8-Y=NK\-KE_6#YFU;B@ MTYS2G$Z6=,:*6S:>?APF._,W&-;=$/_6\[7$!U>3ES9VOKVF/H5G;VJ MZAM02P,$%`````@`CH!M1YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'ED MD81_OTV23;J;/`0LZ?O.14?GZ#AY\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];J MM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y M;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4 M!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2BW`A(5M>5`TR``6'!VULS2`Y9> M*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@ MPI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!& M&N*<<^9ST6S[!Z5&T?95O-RCEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L& M08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9-AIRM1:!MG&I MA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKM MHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T!Z.:60F]A%9J MGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT M/:'2MSAD6R4)RU3393>*$IY"&V[I4_5* ME=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y"M-2D&_#^>G% M>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7& M4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>7 M7%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^ M6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V M#P(RN;LYJ7IE,6>F\M\M#`DL6XA9$N)-7>W5YYNTB42%(JP#`4A%W+C[^^3:G>, MU_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_ MVU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V* MBH`1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ; M]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV M#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_`5!+`P04````"`".@&U'FUND M\T8"``#@"0``#0```'AL+W-T>6QE@%T^6,Z>_?B?)L9-`EC;K2OU%IT=WSSTZR6?'C5ES M>K^DU*!.<-DD>&E,_24(FGQ)!6DFJJ825DJE!3$PU570U)J2HK%!@@?3,)P% M@C")TUBV8BY,@W+52I/@RP%"/OY6%33!C^'@'UGW7'&ED8&#`!4.D410[W%+.,LTLV!)!.-K#T\MX,ZN]Q-,*NUR M^PS[>2;AF$E768+#_GE^NFQD=X/='N-\=WL`I'%-C*%:SF&">GNQKF%S4DGJ M13J_(]Z5)NMH>K45X`;(FRE=4#UDCO`&2F-.2P,!FE5+.QI56^G*&"7`*!BI ME"3<4FXB>@-H<\KYO7U3'LH=[JY$WL>><8B15;$QH1"].5X#5]1@F\US;].& M)_&BKAP20#2I:[[^REDE!?5B/317_>P8?72`/HW)AA4ME69/X&\O0@X`U1BM MJ#8LWT9^:U(O:&?Z&QQTY2&%IV[Y?VIZ_:J-:N`*OG5Y3D[NH+M69%3/76M\ MN:3+Z^-'YMY.O"?S;6_-"1)>H3CVP_9NIK[1_O5-!WWZW>OQ.AQ]0E+6, M&R8W&HC])M]9W7RG^8[='3B+;FSL;M60#'ZW=K(`64%+TG+SDZV4<8L)'NWO M5GXT&[P6`T6"1_L'+5@K/CL%XS]=^@=02P,$%`````@`CH!M1Q.U&#%?!``` MV@\```\```!X;"]W;W)K8F]O:RYX;6R5EU%SVC@0@/^*QD_MS-V!)4'23.F, M`85HALB,Y:37>W-`%$V-S=BF:?OK3S+)91WV/,T3EK$^2ZMO5];'^NJQK+X] ME.4W\F.?%_55-0EV37.X&@SJ]<[LL_JO\F`*]]^VK/99XYK5UT&YW=JUF9?K MX]X4S8`.A^-!9?*LL651[^RA#IYH]>_0ZD-ELDV],Z;9YR?8/K-%\.EC?;6U MN;DW5>W`)#L<5+8WD^!''I`\JQNQL8W93`+NFN6CZ=RHCH?IT>:^,1J.@H&' M/4]U59%UN3$G6+JS]>>G/P*R,=OLF#>I&^SS>R=!2#FEXQ/#/W9OS6,-@?X& MR=:-_6[2[&$2#`.2'9ORVN:-J>998Q95>3S8XJMC!61KJ[K1?KKMDWM;V+W] MY3>4/]WQXVQL>O.@TWVD/B5F`3C MH0-^M[5]L+EM?DZ"]CHW?B:#5U-IP_]R18HV.,]+3+)B0T31.`J1Q6GQ7&C\ M&-S#"0^)K$*Y%$*0!=`-#%.6@:::E]QU4BM%#I"W&6R%0"T"4`79Z#M%BX MF*8D$:LX2:5:G""Q6S*5)A$`?0"@#^<@$27*==?DW3+6^CUQ$W*8VULW+'T3 M)5#((31R>(Z*9K/X3J6Z'4J[=/.)$NGY$ M"1CA$/H<(D(OXGC^62Z78!C215HMI!\&)$&A0\3H4^=(:Y%V^D%_0T1@%XCD MSHDF_EYY_6!`EC*:0A0T.$04GHMKD22.E0@7D3L!^T)I0\3:N9AV`@?=##$Y M[[140FN__E.I6C=A?ZADB#B9B*7/KS]749)^(]/2YLDHZ,Z-01XKHV)NVE$)4 MI]HB=O:C8+FE4$^*Z-E;`RB'*&@L18SMK0(4EEP*C:6(L;U5@,*B2Z'`%!'X M=14@[]Q6G9OZ/81`JREB=7\YZ&R44'"*"`[K`3H6Z#9%W.XM#&P(]UIH-T/L M?ET8L/$PZ#7#O$8R'@5!JQEB=>\&R3H?$9VO",3JW@1AT&H&K6:(U;T)PJ#5 M#%K-$*O[4=!J!JUFB-6]N<8N(`JZS1"W>W.-74(4=)LA;I_GVMPTF]%>.XD3T`)F;2=LW[ZV(<9KTX:;8)QSYO.0F0QY3^@[*S'FWF=3 MMVSKEYQWFR!@QQ(WB#V1#K?BFS.A#>+BEEX"UE&,3LK4U`$,PS1H4-7Z1:[V M7FF1DRNOJQ:_4H]=FP;1/SM&>&6M/'OY`R+N\^7':^J$\`Z[QD(_K6D82Y(\Q MZ,241G-]C_Y-I2N.?T`,[TG]NSKQ4IPV]+T3/J-KS=](_QV/.20RX)'43'UZ MQROCI+E;?*]!G\.U:M6U'[Z)H]$V;X"C`6H#3/]KB$9#I`T@5ID.)U-YO2". MBIR2WF,=DK\VV`@YE4%$9+E0#TH%%9DQL7LKPCRXR3"C8C`?LH&.'7P%[5Q$]!D0Z@TC9(\,>/[;'VAXK>VS8$^L!N(KT,2#1@,2QKRS` MH$B4HE6*+%J'V>HQ)=64U*%D%L55K!\#5AJPQF M)`L0:XU8N_[(0LQ(%A04"*>6"MT(=DW-:194%3`:%[@1K,+:CQJSLD"2Q0#" M;$&+`3C!H`NSZVO4F#`8&HG_FS/U,HA<=/?W!?W24OP%4$L#!!0````(`(Z`;4?FY%K.?`0``"L7```8```` M>&PO=V]R:W-H965T&ULC9A=;Z,X%(;_2I3[&?#Q![A*(TVR M6NU>K#2:B]UKVKA--!"R0)O9?[]`4DS/Z[2^:2!]CWELS!.;U;EN?K9[Y[K% MKZH\MO?+?=>=[I*D?=R[JFB_UB=W[/_S5#=5T?6GS7/2GAI7[,:BJDPH34U2 M%8?CK%?U2U<>CNY[LVA?JJIH_MNXLC[?+\7R[8L?A^=]-WR1K%?) M5+<[5.[8'NKCHG%/]\MOXFZKTB$R)OX^N',[.UX,\`]U_7,X^7-WOTP'!E>Z MQVYHHN@_7MW6E>704G_E?Z^-^FL.A?/CM]9_'[O;XS\4K=O6Y3^'7;?O:=/E M8N>>BI>R^U&?_W#7/NBAP<>Z;,>_B\>7MJNKMY+EHBI^73X/Q_'S?/E/GE[+ MP@5T+:"I0*@/"^2U0+*"Y$(V]NNWHBO6JZ8^+]I3,=QM<=?'FZ&1ON7A8!RH ML=&^9VW_[>N:LE7R.K1SC6PN$9I'WB>V@40^19+^^D$(FB!HK)?S>OMYO9SJ MY5BO9O4R99VX1+(QX5TK4+:*R_::>8>C%'=+*)53S.!XWPH4KN+" M%6A3J5/%:3"ES5-R;`ITH#8XOII2A"!AO3H'J5%R=`K4H,F4X3$B>*N9F>WL*U">_SD:@ M&Q5I_FL?2&E#$33D%4JH4/[`;0C=:`1W1"`4-3+D]4FH3\7U22C&?HF3\5D3 MB-D\CY@V-%M=HD`5%RBA&8710!-*13Q0Y/5)J$^^QM@0BE'@??HX=)O%RY-0 MGIK+DU"+UG*3!T(BE1%+>/+N)'2GYNXDE"(IH?F/;B`F;);%\'AW$KI3Q]QJ M[TY"=_(9M2&THDY3&%],12STR)N3T)R:FY/0B;G.N#D#*4%&Q^!X=1*J4W-U M4D"*?-VS#83RF(V2].*4*$[-Q7G-O-L]*D'\D0S%I#(Q/%Z>$N7))_@FE.%# M\W'F-HGWIL1MN8FXSW*V+T?9&2X8B9MNON?Z,'*;PXM.HN@,=XL,.,S`H(9" M$2M6Z3TGT7.&[XE]Z9$;QHN*XE&_$(P;S`4LQ&4WIL2O6FXJ"0:L4=)`>:SV&T>+TZ)XN0W M82/1B5;`#\=V M\5!W75V-[S&?ZKIS?9/IU[YO>U?LII/2/77#8=8?-Y=WN9>3KCZ]O9J>WH^O M_P=02P,$%`````@`CH!M1_VYZ7&&`@``B0D``!@```!X;"]W;W)K.;*V(D)VVU/`FY:2@S9598``2(**%+6_6>FQUW:S8A=1%C5];3U^J2K2 M_MO2DMW6/O3O`V_%Z2S40+!9!<9W*"I:\X+57DN/:_\%+G,8*8E6_"[HC0_: MGH+?,?:N.C\/:Q\H!EK2O5`AB+Q<:4[+4D62,__M@S[F5,9A^Q[]NTY7XN\( MISDK_Q0'<9:TP/<.]$@NI7ACMQ^TSR%6`?>LY/K?VU^X8-7=XGL5^>BN1:VO MM^X.!KUMW(!Z`S*&;B4F#6%O""U#T)'IO+X103:KEMT\WA#UM.%2REL51$96 M#;U0.JC,C,O1ZR;)5L%5Q>DEVTZ"!A+TK,A'%-A(`CG_*`0R$$C[PZ$_F_>' MQA]J?S3PI\!*HI.D6E)K2822V,IC1!2G<)XD,B212P(MDLB9!*613>**8)BE M\R2Q(8F=-4W`O#\Q_L3-Q'KLVTZ"!Y!@`:QT\QG1)$EJ2%*7)+1(.DD\7"Z@ M?Q;,O&Z2!QL>[/)$%@]VYK%)/E-,,F2&(7,9K"VTS689/E-,,D#PJ!W`I4CL MXM%ILN?G[^R26=DTSZ"609AF^9)TFNM1WB!RN;#-A=RMF>`4 M@=`N9?FH-(G">"B=YGJ433A2-YWB'[J3Q3B"".'0YAJ3)A"E0^DTUZ.(0K>* M8KN>]YKG5SD$&.#4QOJ"LJ,*!A_-AISH+]*>BII[.R;D]U=_)8^,"2JC@H6, M=Y;G(M,IZ5&H9BK;;7=2Z#J"-?>#CSE];?X#4$L#!!0````(`(Z`;4=\S-C3 M0@4``%$;```8````>&PO=V]R:W-H965T&ULC9E-<^(X$(;_ M"L4]0=V2_)$B5`W&6[N'K9J:P\[9"4Z@!F/6=L+LOU_;.);3W01=`CAOM_3* MDAY]+,]E]:O>Y7DS^UTY456WY>G_-C^YZ6LBJQI?U:O MB_I4Y=FV#RH."U0J6!39_CA?+?MGWZO5LGQK#OMC_KV:U6]%D57_K?-#>7Z< MP_SCP8_]ZZ[I'BQ6R\48M]T7^;'>E\=9E;\\SK_!0ZI-)^D5_^SS[_SI[?ZJ8L/D+F MLR+[??G<'_O/\^4_D1K"Y``<`G`,&,N1`_00H%V`^3+`#`'&MP0[!%A2PN+B MO6^Y3=9DJV55GF?U*>OZ$SRT\JI+TF;NOO2OHD_:MEW=/GU?1;!KJ<>VTGV\GL:; MV_%FC#=]O)G&6]+6%TG82XZ])+230BZ-P46!43%I#BY"4*!(DW`5Q%K;VZ[L MZ,IR5P%Q=9'822E1I$A5$BXBB@U7``1`NFOZ59ZK=H+13L#MA,1.P.NA@(@2 M082:O,D-%VD5DDRI(,+`H^.%HZ>0>XJ(IY!7-S2*M&W"56%@Z$#D(FV#F!28 M/;MJ+15L3'HT=\/,;'K%EBTN76L=`LK%4$483$[X:+3&AHHW"1Q]43*#>A*^Z*S>B*EZ,5J4PBJ.B(%"1!C'1$?IGHNJ<)I(![0NH)N"=#,2*( MC&&FN`B0XB855;''L`1TOI#[TM07\C%G+>V"@@HQH'U04+5UMI23@BRP8>!A MS;$2-+=FJ#7-RHDC2[D@J*P.+;7&58BA":@U+H-`H<+>8NHMX@5I31<]@NH.#%V:2KG0TF6/G,OX#%6'>(C94`7E`1]T0$4. M5*!+@#5RQ+65I3U:4-'^+"7"@(SZ5"S.PY5#*G*D@J),1!.[2[:&@ M:1=[U),`5.MCRO$4.4]!4:`BI]M=P%QQ$7DF3-!A`%U)HCH M4BH513YOS.$=.=Y!4;ZC`%NDZ$H$5=O,[.Q#W!K3Q8^82_O,J.CPCH$PHWJL M$-"Q%#E+@>X^ULC)ULZH=/DCJ-@PE1*!H6TCJ"9[N.NV'$:18Q3HL@FEJB'/5*E`JJNT^RZ\8<2K6`4J`H'42WC,%M8SZ)4D'E:\SA5*/PTGU. M3"='I@*[Z-A;:P$X-D1Z1I6(.@OTN'$CZ@)+ES>IG$^#Q\Y`.X9I@6%`&:8Y M5%J+(3U(3T2=9%'2M5LU>J`DY^,6%Y/[@B*O7ON;FGKV7+X=F\L1^/ATO`WZ MAMU]`WF^AH<$A.<;>$@O=STN_6IYRE[SO[/J=7^L9T]ETY1%?Q?Q4I9-WE9? MW;<5W^79=OQQR%^:[FO8O8;+C<_E1U.>/BZPQENTU?]02P,$%`````@`CH!M M1Z:IHVH)!```7!0``!@```!X;"]W;W)K8'$,_]^^0J85F-1>XFQ M\W2K^Y70*]C>9/FKN@A1&[_SK*B>-Y>ZOCY95O5Z$7E2?9%7433_.OI^>-W=8@,O%:MRF2YN-#A"++VDS-R/\.2:L_BYO?XNA!]XF?)59U?TU7M^K6N:?(1LC3W[W MGVG1?=[Z__CV$(8'T"&`C@&]$HL!SA#@3`'L80`;`M@8X+@/`_@0P*<1@H&-`-8/7B=E-S2.IDMRWES:BN2;M@R5-#EVV.)G%[T\Y$&$/F3(PQ M=&2L1A-4&#H*0[L$;);``<+TC-4]<\4-U3ZG!\N/NH#-1=2\3(.(&M;]U^]L:B_8I1@'"501W%`*_M`M]X/`7+G`DU5!&JJ)>*'PRPV2^S) MYFRD7;!"]@/TJ-\!F/%1#5C!TZJZI(T@,==!%+N=KT?(XACKYG+R9')&DLFJB=3ZJ^1=S)E M@KBRNI7J;9EH+?6H1R($,8FZEVJHY6>MR9XI9L_*TY;6-`]ZY(@@1-F;(GVB M6)=HN>_)HBEFT?"I8X#FFRE8?2$"89LI@KF44@I%0K+QYGG(@S*AHT*A5"@@ M]IH%1/_).5;6E3&BZQKF7=O M3&PO=V]R:W-H965T&ULG9E-;^,V$(;_BN&[U^)P*$J!8V#EHF@/!19[:,]*S,3&2I8K*>OMOZ^^ M(BHSDPVQEUA27@Y??CTVO=YMM\WCR95Y\ZFZ MNDOWGZ>J+O.VNZV?M\VU=OEQ*%066XBB>%OFY\MZOQN>?:GWN^JE+ M-2]EF=?_9:ZH;O=KM7Y]\/7\?&K[!]O];CN7.YY+=VG.U655NZ?[]6=U=\"T MEPR*O\_NUBRN5[WYAZKZUM_\>;Q?1[T'5[C'M@^1=S_?W<$511^IJ_G?*:BO MLR^XO'Z-_OO0W,[^0]ZX0U7\[X,O[?Q/TDT%9,+P%0`Y@)S/7(!/170O@`.+1V= M#>WZ+6_S_:ZN;JOFFO>CK>XZ>=T'Z2+W%T-'#4&[EC7=T^][I9/=]GL?:-)D MHP:6FEFQ[:*+5PC M%7P@\9'RMD9DZ`Z"!@*&145^S4?"%#,!(1;84$)KZ(J91&]FF;6&M$=0Q3J- M`^R`MP/,CJ9].VG>#"``[5U)I34$N/$X4IJ[,=2-%NI)*!@EE0T9*8\V);`- M+76#O!Y#>2")%`2P37FX*2.X8?N-X>0!B]0.5VU4',(&Y5FI."S9HE0G))S$GXR9F?2.(%AWX?CKC\0D1\V+H0$V:MWUCV?H69*!"W'@2`R>QH;L] M<,1NZ$Y\$$0!VPIX"`.'L*%S!B0(IW3*""I0&&#&,Q@X@Q6FU`W'JTDL<\-5 M8)*`#0H\A0'YEFM"NM>C$P1T\I$6H!@KUB)!U1$VP(XG)PAIIJ'9'0A8I*\7 M!TD4DO&"9R<(J2;=OS+@6$2:;/Y<\[X53TX0\DU#MQ3@3&1.)&PJ'3+M/#9! M2#HYJS@2F1DNZ;P$O*)Y:FI.3<7PH`5LJB2*J!]!%S!*VE-3"_FKH1N*%O)7 M3;,B011BQ6-3*B$"L>FEJ`9DRAJ3D/V4`+R`0,V"&U M9Z86F!E39FHAE60?"@112+=X9FJ!F3%EIN9`Q(0O@9^1]7TO'IE:0&9,D:DY M#S%A+TR"*FR4T&,3!6S2KTX9SPZ44!G3-&)'(DJY7:X*HU,R+Q9 M?-$4N&D#5@)Z;J+`34NYB1R)_*/H+V$3/391P*:EV$3.1*79Q..BD+<_]-A$ M*W1LR,SUN$,!=_3S1H;"-TF6.@NB@/=\]+1#@7;T"UTVB:PX?I,1+E&1HF\4 MV\6I1.GJY^&TIED]5B^7=CPQF)_.)T*?H3_5(,\S=7<8SW5\F/WNFC^[O_+Z M^7QI5@]5VU;E<++Q5%6MZTQ&G[I^.KG\.-\4[JGM+VUW78^G.^--6UU?#ZOF M$[/]_U!+`P04````"`".@&U'P".?&J$!``"Q`P``&````'AL+W=O^>&/6.V[D%Q>X,# M:/^G1:.X\ZGIF!T,\":2E&1YEMTQQ86F51EKSZ8J<712:'@VQ(Y*4?X4C>N]V8R2 M!EH^2O>"TU=81K@-@C5*&[^D'JU#M5(H4?Q]7H6.ZS3_*78+[3HA7PAY(MQG MT?C<*-I\XHY7I<&)V(&'L]OL/=P$$:\<@CAW%/5&K:^>J\WNKF3G(+1@CC,F MO\0D!//J5UOD:XMC_@\]_YR^30ZWD;[]P^'NI84N.HW;REJ9INYT,>S^0#7I4#[^`[-YW0EIS0^9.-^]\B.O!6LIM; M2GK_?E(BH74AW/G8S%=J3AP.ZP-)K[3Z#5!+`P04````"`".@&U'%@&"T:(! M``"Q`P``&````'AL+W=OX<]:/^G0:.X\ZEIF>T-\#J2E&1YENV9XD+3 MLHBU9U,6.#@I-#P;8@>EN/E]!HGCB6[H4G@1;>="@94%2[Q:*-!6H"8&FA-] MW!S/NX"(@!\"1KN*2?!^07P-R;?Z1+-@`214+BAPOUSA":0,0K[QKUGSO64@ MKN-%_4N;$9)#0T?I'O!\2O,(]P'P0JEC5]2#=:A6BB4 M*/XVK4+'=9S^[/R\W#IX)=@]",.4^8?(U)".;5;[;(EQ;G_!]Z_C%]FQQN(WV[ M[G[(/A;8)8%=%-C]=\0;F,/?0[+5GBHP;;PZEE0X:#=M::JFV_F8QS-YAY=% MSUOXSDTKM"47=/YDX_XWB`Z\E>SNGI+.OY^42&A<"!]\;*8K-24.^^6!I%=: M_@%02P,$%`````@`CH!M1\&F"B2@`0``L0,``!@```!X;"]W;W)KE=3V0'OGACUCMNY!<7N#`VC_ MIT6CN/.IZ9@=#/`FDI1D>9;=,<6%IE49:R^F*G%T4FAX,<2.2G'SZP@2IP/= MT+7P*KK>A0*K2I9XC5"@K4!-#+0'>K_9'XN`B(#O`B9[$9/@_83X%I+GYD"S M8`$DU"XH<+^D)EA%N@V"-TL8OJ4?K4*T42A1_GU>AXSK-?XK=0KM.R!="G@B[+!J? M&T6;7[GC56EP(G;@X>PV>P\W0<0KAR#.'46]4>NKYVJSRTMV#D(+YCAC\DM, M0C"O?K5%OK8XYO_0\\_IV^1P&^G;/QQN/Q%4.O(-OW'1"6W)"YT\V[G^+Z,!;R6YN*>G] M^TF)A-:%\(N/S7REYL3AL#Z0]$JKWU!+`P04````"`".@&U'KQ,3(Z$!``"Q M`P``&0```'AL+W=OE=3V0'OGACUCMNY!<7N#`VC_IT6CN/.IZ9@=#/`FDI1D>9;=,L6%IE49 M:\^F*G%T4FAX-L2.2G'SZP@2IP/=T+7P(KK>A0*K2I9XC5"@K4!-#+0'^K#9 M'XN`B(`?`B9[$9/@_83X&I)OS8%FP0)(J%U0X'XYPR-(&81\X[=%\Z-E(%[& MJ_J7.*UW?^(6'E'^%(WKO=F,D@9:/DKW@M-76$;8!<$:I8U?4H_6H5HIE"C^ M/J]"QW6:_Q3%0KM.R!="G@CW630^-XHVG[CC56EP(G;@X>PV>P\W0<0KAR#. M'46]4>NKYVISORO9.0@MF..,R2\Q"<&\^M46^=KBF/]#SS^G;Y/#;:1O_W!X M^[E`D02**%#\=\1KF+N_FK"+/55@NGAU+*EQU&[>TE1-M_,ACV?R`:_*@7?P MG9M.:$M.Z/S)QOUO$1UX*]G-CI+>OY^42&A=".]\;.8K-2<.A_6!I%=:_090 M2P,$%`````@`CH!M1S.B@`NB`0``L0,``!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RK+2.(8L($Y1M(<"00[MF996$A&2JY*4 ME?Y]24IBG-9H+N+N:F9VEH]R0O-B>P!'7I74]D![YX8]8[;N07%[@P-H_Z=% MH[CSJ>F8'0SP)I*49'F6?6**"TVK,M:>3%7BZ*30\&2('97BYO<1)$X'NJ%K MX5ETO0L%5I4L\1JA0%N!FAAH#_1ALS\6`1$!/P1,]B(FP?L)\24DWYH#S8(% MD%"[H,#].40Q+FCJ#=J??5<;7:[DIV#T((YSIC\$I,0 MS*M?;9&O+8[Y/_3\8_HV.=Q&^O:=P_N/!8HD4$2!XK\C7L'<9W\U81=[JL!T M\>I84N.HW;REJ9INYT,>S^0-7I4#[^`[-YW0EIS0^9.-^]\B.O!6LIM;2GK_ M?E(BH74AO/.QF:_4G#@27FGU!U!+`P04````"`".@&U'NCJL@:$!``"Q M`P``&0```'AL+W=O&8XY\P97\H)S:/M M`1QY4E+;/>V=&W:,V;H'Q>T5#J#]GQ:-XLZGIF-V,,";2%*2%5GVB2DN-*W* M6+LW58FCDT+#O2%V5(J;OP>0..UI3M?"@^AZ%PJL*EGB-4*!M@(U,=#NZ6V^ M.VP#(@)^"9CL64R"]R/B8TA^-'N:!0L@H79!@?OE!'<@91#RC?\LFL\M`_$\ M7M6_Q6F]^R.W<(?RMVA<[\UFE#30\E&Z!YR^PS+"=1"L4=KX)?5H':J50HGB M3_,J=%RG^4]QL]`N$XJ%4"3"31:-SXVBS:_<\:HT.!$[\'!V^<[#31#QRB&( MX54Y\`Y^ M&ULA5/+;MLP$/P5@A\0RK*P!'7I74]D![YX8]8[;N07%[@P-H_Z=% MH[CSJ>F8'0SP)I*49'F6W3+%A:95&6N/IBIQ=%)H>#3$CDIQ\_L($J<#W="U M\"2ZWH4"JTJ6>(U0H*U`30RT!WJWV1^+@(B`GP(F>Q&3X/V$^!R2[\V!9L$" M2*A=4.!^.<,]2!F$?..71?.M92!>QJOZ0YS6NS]Q"_\+I&RPC[()@C=+&+ZE'ZU"M%$H4?YU7H>,ZS7^*?*%=)^0+(4^$SUDT/C>* M-K]RQZO2X$3LP,/9;?8>;H*(5PY!G#N*>J/65\_5YDM1LG,06C#'&9-?8A*" M>?6K+?*UQ3'_AYY_3-\FA]M(W[YSN/M8H$@"110H_COB-&PO=V]R:W-H965TU#I2@/[;,7!K!B>XAMEO3O:YO+HB1J7O#,<,Z9,[X4(YH7VP$X M\J:DM@?:.=?O&;-5!XK;*^Q!^S\-&L6=3TW+;&^`UY&D),N2Y!M37&A:%K'V M9,H"!R>%AB=#[*`4-W^/('$\T)0NA6?1=BX46%FPE5<+!=H*U,1`\;Q!\PC7`?!"J6-7U(-UJ%:*)0H_C:M M0L=UG/YD^4S[G)#-A&PEW";1^-0HVOS.'2\+@R.Q/0]GE^X]W`01KQR".'<4 M]4:MKY[+/"W8.>C,D.,$R3:0"X)Y\4\[9$N'8_:!GGU-WZT&=Y&^VW:_N_E: M(%\%\BB0_V_"CY#T[O9=#[;9406FC1?'D@H'[:8-7:OKW;S/XHE&ULA5/+;MLP$/P5@A\0TK2=)H8L($Y1I(<"00[MF996$A$^5)*R MTK\/24F,D`3-1=Q=S!)MYV.!E`7)O%HHT$X8C2PT1WRW.9QV$9$`OP6,;A6CZ/ULS'-,?M9'3*,% MD%#YJ,##&PO=V]R:W-H965T6C&-&^N0[` MDP^MC-O3SOM^QYBK.M#"76$/)OQIT&KA0VI;YGH+HDXDK1C/LANFA32T+%+M MR98%#EY)`T^6N$%K87\=0.&XIQNZ%)YEV_E88&7!5EXM-1@GT1`+S9[>;7:' M/"(2X$7"Z,YB$KT?$=]B\ECO:18M@(+*1P41EA/<@U)1*#1^GS4_6T;B>;RH M?T_3!O='X>`>U:NL?1?,9I34T(A!^6<%$6%D?B>A'/;K,+<8+=HI",^8P8?@99K,B6%"_V((O+0[\'SK_FKY='6X3??N'P^W7 M`ODJD">!_+\C7L+D?S5A9WNJP;;IZCA2X6#\M*5K=;V==SR=R2>\+'K1PD]A M6VD<.:(/)YOVOT'T$*QD5]>4=.']K(F"QL?P6XCM=*6FQ&._/)#UE9:_`5!+ M`P04````"`".@&U')!^R7J`!``"Q`P``&0```'AL+W=O*`KNA2> M1=NY4&!EP1*O%@JT%:B)@>9`[U;[XR8@(N"7@-%>Q"1X/R&^A.2Q/M`L6``) ME0L*W"]GN`Y2_1>TZ;S:CI(:&#](] MX_@`\PC;(%BAM/%+JL$Z5`N%$L5?IU7HN([SG]U,NT[(9T*>"-^R:'QJ%&U^ MYXZ7A<&1V)Z'LUOM/=P$$:\<@CAW%/5&K:^>RSS;%NP[KP4V26`3!3;_'?$:YO9#$W:QIPI,&Z^. M)14.VDU;FJKI=M[E\4S>X&71\Q9^;8]@",O M2FJ[I[USPXXQ6_>@N+W"`;3_TZ)1W/G4=,P.!G@324JR(LMNF.)"TZJ,M4=3 ME3@Z*30\&F)'I;CY>P")TY[F="T\B:YWH<"JDB5>(Q1H*U`3`^V>WN6[PS8@ M(N"7@,F>Q21X/R(^A^1'LZ=9L``2:A<4N%].<`]2!B'?^,^B^=HR$,_C5?U[ MG-:[/W(+]RA_B\;UWFQ&20,M'Z5[PND!EA&N@V"-TL8OJ4?K4*T42A1_F5>A MXSK-?S;%0KM,*!9"D0BW630^-XHVOW''J]+@1.S`P]GE.P\W0<0KAR#.'46] M4>NKIZK(;DMV"D(+YC!CBC-,GA#,JU]L4:PM#L4'>O$Y?9,<;B)]\\;AU\\% MMDE@&P6V_QWQ`B;/WC5A9WNJP'3QZEA2XZC=O*6IFF[G73Q$]@JORH%W\).; M3FA+CNC\R<;];Q$=>"O9U34EO7\_*9'0NA!^\;&9K]2<.!S6!Y)>:?4/4$L# M!!0````(`(Z`;4>$Q<#@H`$``+$#```9````>&PO=V]R:W-H965TVSGT@(5\!+/3,XY<\:7^^'/6.N[D$+=X<#F/"G1:N% M#ZGMF!LLB":1M&(\R]XQ+:2A59EJS[8J]C@54EVWB-U&"<1$,LM`?ZF.^/NXA(@*\2)G<5D^C]A/@:D\_-@6;1`BBH M?50083G#$R@5A4+C[XOFI64D7L>K^L4'V3C>^#V8R2!EHQ*O^" MTR=81KB/@C4JE[ZD'IU'O5(HT>)M7J5)ZS3_*1X6VFT"7PA\(SQDR?C<*-G\ M(+RH2HL3<8.(9Y?O`]Q&D:`<@S1W$@U&7:B>*Y[G)3M'H05SG#'\"G-!L*!^ MLP5?6QSY'W3^;WJQ.2P2O?C%X7\([#:!71+8_77$6YCBMR;L:D\UV"Y='4=J M'(V?MW2K;K?SD::?434$L#!!0````(`(Z`;4&PO=V]R:W-H965T6CG-"^N![`DU>M MC#O2WOOAP)BK>]#"W>$`)OQIT6KA0VH[Y@8+HDDDK1C/LGNFA32T*E/MR58E MCEY)`T^6N%%K87^=0.%TI#E="\^RZWTLL*ID&Z^1&HR3:(B%]D@?\L.IB(@$ M^"YA[/PL$CJA^R\7TPFU'20"M&Y9]Q^@++"/LH6*-RZ4OJT7G4*X42+5[G59JT M3O.?(E]HMPE\(?"-\#%+QN=&R>8GX4556IR(&T0\N_P0X#:*!.48I+F3:##J M0O52\;PHV24*+9C3C.%7F'Q#L*!^LP5?6YSX/W3^/GVW.=PE^NX/A_OW!8I- MH$@"Q7]'O(6Y_ZL)N]I3#;9+5\>1&D?CYRW=JMOM?.#I3-[@53F(#KX)VTGC MR!E].-FT_RVBAV`EN]M3TH?WLR4*6A_##R&V\Y6:$X_#^D"V5UK]!E!+`P04 M````"`".@&U'BC!8KJ(!``"Q`P``&0```'AL+W=OE-3V0'OGACUCMNY!<7N#`VC_IT6CN/.I MZ9@=#/`FDI1D199]8HH+3:LRUIY,5>+HI-#P9(@=E>+FUQ$D3@>:T[7P++K> MA0*K2I9XC5"@K4!-#+0'>I_OC]N`B(`?`B9[$9/@_83X$I)OS8%FP0)(J%U0 MX'XYPP-(&81\X]=%\[UE(%[&J_J7.*UW?^(6'E#^%(WKO=F,D@9:/DKWC--7 M6$;8!<$:I8U?4H_6H5HIE"C^-J]"QW6:_^PV"^TZH5@(12+<9='XW"C:?.2. M5Z7!B=B!A[/+]QYN@HA7#D&<.XIZH]97SU61WY;L'(06S''&%!>8/"&85[_: MHEA;'(M_Z,7']$URN(GTS1\.[SX6V":!;138_G?$:YC/?S5A%WNJP'3QZEA2 MXZC=O*6IFF[G?1'/Y!U>E0/OX#LWG="6G-#YDXW[WR(Z\%:RFQTEO7\_*9'0 MNA#>^MC,5VI.'`[K`TFOM/H-4$L#!!0````(`(Z`;4='8E;YY@$``*H%```9 M````>&PO=V]R:W-H965TV%Y M1@>!VPY>F,,'0A#[GGF&5[8$.M[2SF%07=S'X'Q- M%4(#?K4P\E7LJ-IOE+ZIRX_RXOJJ!,!0"*6`Y'&')\!8"4GC]UGSTU(1U_&B M_DUW*ZN_(0Y/%/]N2]'(8GW7*:%"`Q:O=/P.@ MC^EL.WV.TY\_#T,^\NQ*:,=<)$ZXP@4%X4MUJ$2X6U_`_>KA/CTR%D:9':_?$ MWQ6B?O3"`%5^H;9;T[VL;<$BZ4E[PS'#.F3.^E),V+[8'<.A5 M"F5/N'=N.!)BZQXDLW=Z`.7_M-I(YGQJ.F('`ZR))"D(S;(#D8PK7)6Q]F2J M4H].<`5/!ME12F;^GD'HZ81W>"T\\ZYWH4"JDB1>PR4HR[5"!MH3?M@=ST5` M1,`O#I/=Q"AXOVC]$I(?S0EGP0((J%U08'ZYPB,($81\XS^+YEO+0-S&J_JW M.*UW?V$6'K7XS1O7>[,91@VT;!3N64_?81EA'P1K+6S\HGJT3LN5@I%DK_/* M55RG^<_AL-!N$^A"H(EPGT7C5Z2:Q!:,.<90S>874(0KWZS!5U;G.E_=/HY/4\.\TC/M]WOL\\% MBB101('BW8C%AQ%O8?8?FI#-GDHP7;PZ%M5Z5&[>TE1-M_.!QC-Y@U?EP#KX MR4S'E447[?S)QOUOM7;@K61W>XQZ_WY2(J!U(?SB8S-?J3EQ>E@?2'JEU3]0 M2P,$%`````@`CH!M1QN68=:D`0``L0,``!D```!X;"]W;W)K&ULA5/;;IPP$/T5RQ\0LX8DJQ6+E$U4M0^5HCRTSUX8P(HOQ#9+ M^O>U#3@T72DO>&8XY\P97\I)FU?;`SCT+H6R1]P[-QP(L74/DMD;/8#R?UIM M)',^-1VQ@P'61)(4A&;9'9&,*UR5L?9LJE*/3G`%SP;944IF_IQ`Z.F(=W@M MO/"N=Z%`JI(D7L,E*,NU0@;:(W[8'4Y%0$3`+PZ3W<0H>#]K_1J2'\T19\$" M"*A=4&!^N<`C"!&$?..W1?.C92!NXU7]6YS6NS\S"X]:_.:-Z[W9#*,&6C8* M]Z*G[[",XHZHU:7[U4-+\KR24(+9C3C*$;S"XA MB%>_VH*N+4[T/SK]FIXGAWFDY]ON^_QK@2()%%&@^&?$^T\C7L/L/S4AFSV5 M8+IX=2RJ]:C&PO=V]R:W-H965T0' M*`Y.NBYR+#6=INUB4M6+[9K8QS8J<#S`#;$]DIQ\^<,$H=3LDOFPHMH6A<*M,CIPJN$`FT%:F*@/B6/ MN^/Y$!`1\%/`8%=[$K)?$%_#X7MU2M(0`224+BAPOUSA":0,0M[X]Z3Y;AF( MZ_VL_C5VZ]-?N(4GE+]$Y5H?-DU(!37OI7O!X1M,+<2$)4H;?TG96X=JIB1$ M\;=Q%3JNP_CE(9UHVP0V$=@-@8Y&,>87[GB1&QR([7B8W>[HX2:(>.6PB7U' M41_4^NJU8-GGG%Z#T(0YCQBVPNP6!/7JFQ9LMCBS?^CL8WJV),PB/5N[/]Q_ M++!?!/918+_VWZ_M>'#8S:]P^2LH_@)02P,$%`````@`CH!M1^3+4P:E`0``L0,``!D```!X M;"]W;W)K&ULA5/;;J,P$/T5RQ]0$X>TW8@@-5VM MVH>5JCYTGQT8P*HOK&U"]^]K&W!I-U)?\,QPSIDSOA2C-J^V`W#H30IE#[AS MKM\38JL.)+-7N@?E_S3:2.9\:EIB>P.LCB0I",VR:R(95[@L8NW)E(4>G.`* MG@RR@Y3,_#N"T.,!;_!2>.9MYT*!E`5)O)I+4)9KA0PT!WRWV1_S@(B`%PZC M7<4H>#]I_1J2Q_J`LV`!!%0N*#"_G.$>A`A"OO'?6?.C92"NXT7]5YS6NS\Q M"_=:_.&UZ[S9#*,:&C8(]ZS'!YA'V`7!2@L;OZ@:K--RH6`DV=NTQ;.;K/W\P4OAF;>= M"P52%B3Q:BY!6:X5,M`<\/UF?\P#(@)^<1CM*D;!^TGKEY#\J`\X"Q9`0.6" M`O/+&1Y`B"#D&_^9-=]:!N(Z7M2_QVF]^Q.S\*#%;UZ[SIO-,*JA88-PSWI\ MA'F$ZR!8:6'C%U6#=5HN%(PD>YU6KN(Z3G_H;J9=)M"90!/A+HO&IT;1YC?F M6%D8/2+;LW!VF[V'FR#BE4,0YXZBWJCUU7-)\]N"G(/0C#E.&+K";!*">/6+ M+>C2XD@_T>G7]&URN(WT[;K[[C\$\B201X'\W8AW'T:\A-E]:$)6>RK!M/'J M6%3I0;EI2U,UW_T=J!MY)=76/4^?>3 M$@&-"^&MC\UTI:;$Z7YY(.F5EO\`4$L#!!0````(`(Z`;4>+`K!NL0$``!8$ M```9````>&PO=V]R:W-H965TGW/FC,:F&)5^-AV` M12^"2W-,.FO[`\:FZD!0]1EH0;+F81'C$RR9$D\L;:S/H'+`D=>S01(PY1$&IIC2GKB. M%_6?H5OG_DP-W"G^A]6VP]Q"<%@I;L(758.Q2BR4!`GZ M,JU,AG6<3O)LIFT3R$P@D?`M#<:G0L'F#VII66@U(M-3/[OLX.#:BSAE'X2^ M@Z@S:ESV4I(\+?#%"\V8TX0A*TP6$=BI;Y8@2XD3>4$NT'?KZM_S MCP7V46`?!/9O6LRN6MS"?,)E'HOD&P*[JR);F/U5$;P:G`#=AOMI4*4&::>Y MQ6Q\`K$7U2V3!IV5==&ULA5/;3N,P$/T5RQ^`4[>%W2J-1$&( M?5@)\;#[[":3Q,+V!-MIX.^QG29DV4J\Q#.3<\Z<\24?T+ZX%L"3-ZV,V]/6 M^V['F"M;T,)=80%)_2-,&]T?A MX`[57UGY-IC-**F@%KWRSS@\PGF$;10L4;GT)67O/.J)0HD6;^,J35J'\0^? M:)<)_$S@,^%'EHR/C9+->^%%D5L#; M;B,.8P8OL"L9@0+ZA=;\*G%@?]'Y]_3U[/#=:*OE]U_WGPOL)D%-DE@ M\\^(UU]&O(3YVH0M]E2#;=+5<:3$WOAQ2^?J?#MO>3J33WB1=Z*!W\(VTCAR M1!].-NU_C>@A6,FNMI2TX?W,B8+:Q_`FQ':\4F/BL9L>R/Q*BP]02P,$%``` M``@`CH!M1ZS6N'RE`0``L0,``!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RK*=IH8L($Y0M(<"00[MF996$A&2JY"4E?Y]24IB MU-1`+N+N:F9VEH]B1/-B.P!'WI34]D@[Y_H#8[;J0'%[@SUH_Z=!H[CSJ6F9 M[0WP.I*49'F6W3+%A:9E$6M/IBQP<%)H>#+$#DIQ\^<$$L+50H*U`30PT1WJ_.9QV`1$!OP2,=A63X/V,^!*2'_619L$"2*A<4.!^ MN<`#2!F$?./76?.]92"NXT7]6YS6NS]S"P\H?XO:==YL1DD-#1^D>\;Q.\PC M[(-@A=+&+ZD&ZU`M%$H4?YM6H>,Z3G_VV4R[3LAG0IX(=Y'`ID;1YB-WO"P, MCL3V/)S=YN#A)HAXY1#$N:.H-VI]]5+F^[N"78+0C#E-F'R%V20$\^I76^1+ MBU/^'SW_G+Y-#K>1OEW3L^QS@5T2V$6!W3\C?OTPXA7,[<20-/EKA>:V'_'D'A<*`;.A>>9=/Z6&!%SA9>)348)]$0"_6!WF_VQUU$ M),!O"8-;Q21Z/R&^Q.1G=:!9M``*2A\51%C.\`!*1:'0^'72O+2,Q'4\JS^F M:8/[DW#P@.J/K'P;S&:45%"+7OEG''[`-,)M%"Q1N?0E9>\\ZIE"B19OXRI- M6H?Q#_\VT:X3^$3@"^%KEHR/C9+-[\*+(K)>':;?8#;*!*48Y#F3J+! MJ`O5<\'O-CD[1Z$)S>C<@_C'@-\[$)6^VI!MNDJ^-(B;WQXY8NU>5VWO-T)A=XD7>B@5_" M-M(X'S.F3,:FWQ0^MVT`!9]"B[-,6FM[0X8F[(%0&--:WT"%SF.O(H)D(8IB334Q^1I_^5$=D]1; M``ZE]0K4+1=X!LZ]D"O\,6E^E?3$93RK?PO=.O=G:N!9\=^LLJTSFR:H@IKV MW+ZIX3M,+02'I>(F?%'9&ZO$3$F0H)_CRF18A_$D>YQHZP0R$4@D/*3!^%@H MV'RAEA:Y5@,R'?6SVQP<7'L1I^R#T'<0=4:-RUX*LL]R?/%"$^8T8L@"LXD( M[-172Y"YQ(G\1R>WZ=OH")A\%_P(N]H`S^I;I@TZ*RL MNSYAR+52%IR5],YY:=TCC1L.M?7AO8OU>&_'C57=_`KCKZ#X"U!+`P04```` M"`".@&U'"I%S.]4!``#=!```&0```'AL+W=O&@V)C89DG?OK8!A[)( MW*S'PS__-Z.UG8V,OXL&0#J?E'3B[#92]B?/$T4#%(L'UD.GOE2,4RS5EM>> MZ#G@TA11XB'?3SR*V\[-,Y-[Y7G&!DG:#EZY(P9*,?][`<+&LQNX2^*MK1NI M$UZ>>;:N;"ETHF6=PZ$ZNT_!Z9)JA1'\;F$4J]C1O5\9>]>;G^79]74+0*"0 MV@&KY0;/0(@V4N"/V?,+J0O7\>+^8J95W5^Q@&=&_K2E;%2SONN44.&!R#H?&X2VQ]`8A&M^FAX;1-8@,@;1?QT$FR$G36PTG=%$C\>, MV#+B'0;:,.([!CI&)!:1["#"#2*Y0X3'B-0BTAU$M$'L:>(-Q%N=/PJ\-M=, M.`4;.CD=/YNU-_D)F?/[)<^S'M?P"_.Z[81S95+=`G-6*\8DJ%;\!S5HH]X: MNR%021VF*N;3]9LVDO7+8V)?M/P?4$L#!!0````(`(Z`;4<$Q`_J"@,``*(, M```9````>&PO=V]R:W-H965T+NG9P0 MHM9G4[=D;9\H/:\^%6A*YF-+1[\&\;O_.;[?FV[/`94HQWE$B6[?*`< MU3578I[_C**33VXX']_4BSY=%OY;25".Z]_5GIY8M*YM[=&AO-3T)[Y^0V,. M`1?@A&@\#40S@:A)-!^*5!-!I$D@=GJ&Z_-L\E+;.TPU>+G$N^8\&* MX1T78I\<*&1V0P,G#$Q7"+/*@*61*$2,(H$X[`@ MM9'"6Z0;J`HL7>0J$7M2G'=%MO=%"HU(O$1>-$@4W\_6$^OB]0+>0B"Y+^`+ M`;\7\&<"GBNMZX!$/=(.BY;(F>0JE+B!+Y751&EKHE1H(*!45X6B)`3WJQ.( MZ@1*=6`LEV=@@GE2D>]*^SI7J2CTY6VG0EX0)G*!5`K"(#%8]5#D%2IY`5=^ MG$,U+RCOC5R%'A@EI:51`J'D;JM3\N0*%3HI:/#$1"+U2+.D!GLB%@+Q_SUR MB1!([C]RB2;-1*JJ`5-HF,`@5N!.![^KJ9=T&&Y&:.'']2(I8".JT%*^P2L` MS-Y60!.T)P<-=(Y<.6@3JABI^5$3FQSD`$XQ0X.S9H26)X1\%.N@,);S4B$` MY!IMM10,#1*;7E'`,SAL1FA>0.C+>:G,`PB4%D-')8F&ULG9K-;J-(%(5?Q?(^;>H7B!Q+;<":68S4ZL7,FL0DMMH8#Y"X MY^T',*'PO1>JE$ULDU.'.D5Q/PI87XOR5W7(LGKQ.S^=JZ?EH:XOCZM5]7+( M\K3Z5ERR<_.?UZ+,T[KY6;ZMJDN9I?NN47Y:<<_3JSP]GI>;=;?M1[E9%^_U MZ7C.?I2+ZCW/T_*_;78JKD]+MOS<\//X=JC;#:O->C6TVQ_S[%P=B_.BS%Z? MEM_9XT[J5M(I_CYFUVKT?=%V_KDH?K4__MP_+;VV#]DI>ZE;B[3Y^,BB['1J MG9H]_]N;FGVV#P;2--@ODNJ;Z!<]Z#[!AHT6-T&JQOJ.*W3S;HLKHOJDK83D#TV\K(U M:9S;+]VQZTR;P:Z:K1\;'LCUZJ,UZC7;FX:/-`&_E\18P@;%JND`V0O^V8LM M1\UYH.YW$5$:#;I!:?Q[3>+@LZ,T@3V0&(95=`9B/!Z!L!O(P4!V!O*N!R%( M>].H3G/N-`Z[4,,N%.HC#SV[@1X,-.YCR,#`^%%Z"Z;GO->$=`4C"B5 M",`I&#MY)3:OZ60C>C&4C,D`1F-XDBD/SFI"Y2L(H=C)*W'RVO6J\;16>C1+ MI@>`FP'@Q+QVF1T&50RSRHD#S,"*$;1")&`85QX\!E9);)I!LI(QKEPECF,T(:",.]**[4].3$-J$*O10*73R M2FQ>T]$,MAGF-J[Q#*,4'32K)+9+DEG)=!P#;(:)C:LVYB=*8Y7$=DDR*YE. M8_C+,(")2DW0CJ%`A`A>*KH8)?-&TZL6`U:.PU%`$D0@H1*-Y=:<)6%59QY:'P)&0O%:`Y/AS-TXL)>BWL-N-[0,!M6^1Q. M'$*DI-8P&;%#IT+,#3,YM<*#U8ICE#%,AHB2"0&+;.SFEEC=IN,9AG+,4%R, M.2::TAI>=!(J+7RT]'?Q2FQ>T]$,0CE&*"K,G*">$B@9H<*7TTY>BOQ.8U'XU M4J(053&+U70N`U9!@!65:$'`4&K)83)"!G,Y.26S3M.Q1O@#C;)K,UT'L-/@?F)2[$@F`=7 M:80&!;+;)+,VTX$,-05UM]@!O,+@2?A?+,`&`X+"`"K`>+'37-ZB6D6HN)!P M;(D[G)X/;P52*JX=5A+"X$G@%1:NPGC)\Z!@28LHE?3@70M*Q8(0G=F$C`OM M<#4I#3HA"B'PX MMV,7I\3B-!W+L%-B=J)Z+#')8#FV2V*[))F53*)E%BN#MH=7H,7N>E6_=&Q'5XJ5X/]>WQ\'#UN&MB^^\?4P/MF_98\2( M[3%[3&Z/]8W]9GU)W[*_TO+M>*X6ST5=%WGW"/^U*.JLZ;OWK3DDARS=#S]. MV6O=?O6;[^7MS8K;C[JX?+XH,KRMLOD?4$L#!!0````(`(Z`;4>)\$-*&P(` M`&`&```9````>&PO=V]R:W-H965TB>XX5N[$J+=.`XO*B"(/]$6&OGD3!E!0BY9Z?"6`3II$L&.[[JQ0U#= MV'FF]UY8GM%.X+J!%V;QCA#$_NP`TWYK>_9UX[4N*Z$VG#QS#.]4$VAX31N+ MP7EK/WN;0ZH0&O"SAIY/YI;R?J3T32V^G[:VJRP`AD(H!22'"^P!8R4D#_X] M:MZ.5,3I_*K^55L$?R3XAF#.62<$(R&X$>)_$L*1$-X(H8YF M*$4'<4`"Y1FCO<5;I+X.;R/A3(E(9371R6I1&067NY<\<,/,N2BA$;,;,/X$ MX]TC]DN$GR0&XT@'JS;\JXV=OQ28';&"2.\AAR4D#1Z;"$P6@>8'=UE$CP5" M(Q!J@7`:5!C/PAPPB<8T@\G42V;%+D%>Y"?!K-XE*O'B3\0>&=:B$GX@5M8-MXY4R#:A+_.9 M4@'2BOLDWW`EV[U98#@+-4WDG`T=<%@(VE[[N?E3R?\"4$L#!!0````(`(Z` M;4>`X]C/N`(``.P*```9````>&PO=V]R:W-H965T<@6&2#K!PB$+\*U)&;>X,GO\/X@R]^'-:FS7-` M)=I33@'9Y1-M4%ER)G;RGX%T/),'WMY?V;\)N2S]'21H@\O?Q8&>6;:V:1S0 M$5Y*^HZ[[VC0X'/"/2Z)^#7V%T)Q=0TQC0I^]=>B%M>N_R>RAS!]@#,$.#)` MGJ,/<(<`=PSPG@9X0X"W]`1_"/"5$ZQ>NW!N"RE,DQ9W!FD@?Y[`BL%;3L*8 M^8THA2!EWA&V^YFZP$ZL3TXT8+(>X]Q@(N<>LIU"@$18+`%M%LXUB\R9A"L' M;*:(R%5RF"7)GY(\3-.59KDBWKTS:X%.3Q)X@L"[(U"2S'J,+S!U;Z4?.E&D M&**#^2`*%%-TL,"W56>T;"Z(Y\7Y4IRO$:?4*/,GYWBQIRB;8I0'"F M&X,%Q@Z@Y\YJ0,!37_OM$JI\CNJQ,&<4YFB$10LHQN8+=-UWB;UC^P6Z_CNQ M=]H+)^9.(5ZL-JEYGGR&IY=DW7S**]2>Q!!%C#V^U+3_.,E=.:B].GP44/8S ML-H`S?Z6#W9B=!CITZ2!)_03MJ>B)L8.4S:`B#'AB#%%+'?[A65]9J.G7)3H M2/EMR&WOA[%^07%SG2WE@)O^`U!+`P04````"`".@&U'D!1`5_T!``#.!0`` M&0```'AL+W=O\8FVLB M@M0D&K6+2J-9M&LGF(#&8,9VPO3M:QOB,@8UW>`+YQQ_O\'.!\;?1$V(]#Y: MVHF=7TO9;P$0YYJT6#RQGG3J3<5XBZ4:\@L0/2>X-*:6`A0$"6AQT_E%;N9> M>)&SJZ1-1UZX)ZYMB_GO/:%LV/G0OT^\-I=:Z@E0Y,#ZRJ8EG6A8YW%2[?RO M<'M,M,((?C9D$+.^I]E/C+WIP?=RYP<:@5!RECH!J^9&#H12':06?I\R_RZI MC?/^/?W95*OH3UB0`Z._FE+6"C;PO9)4^$KE*QN^D:F$6`>>&17FZ9VO0K+V M;O&]%G^,;=.9=AC?I'"RK1O09$#6`*-_&L+)$/ZO(9H,D6,`8REF(XY8XB+G M;/!$C_7?`;=*SG6(2M8=L[,F5&V%4+.W(H2;'-QTT*39CQHTTZ#/BL.*(OLL M.2XE66@E0#&N@B(+BHP_G/EAMGD<$-J`T`1$\TI1X%0Z:E*CZ<9%4):F3K4K MJDT:1H]A(@L3K;-=.,`'58&8[H7O[ MV89X%-,M-_B#^' M_FWBM3TW4D^`L@#65[4=Z47+>H^3>N\_AKM#JA5&\*,EHUCT/S_0"(22D]0)6#571&E^H?&7C5S*7$.O`$Z/"/+W314C6W2R^U^'WJ6U[TX[3FPC-MFT#G`W0 M&L+HGP8T&]#*`"8R4]%.R;D.4R.-$&3KS"F33Q8IT$)B[.ABS-[\*)+4Z\ M@9.L<&)GG2S*71Q7EJ#D+IS$XB0NSGJO$F>9,-=[M<;9T&5Y=A=/:GG2C<^3 MKH!2YZ](4N3RN+(LC%T`SZ3[YB?VUYX1R;523?GL69,$A49/*CJ&G4! MVP$EM=3=5/7Y="=-`\F&VPUKK_GR#U!+`P04````"`".@&U'1S>UVCT$``!R M%@``&0```'AL+W=O[:`P))<.K_SK*A>9B8&;)VDQ6R[:M>_E)^6?%<_$]64&L]O"C_1XDLV"NURX M@]P^S7E1I:)P2GYXF7V!^9:UD!;Q,^77:G3O-,Z_"_&K>?BZ?YEYC0\\XSO9 MJ$CJRP=?\RQK--66_^N5*IN-X/C^IGW3AEN[_YY4?"VR?].]/-7>>C-GSP_) M)9,_Q/4?WL?@-PIW(JO:7V=WJ:3(;R(S)T]^=]>T:*_7[A^?]F*X`.D%R"`P MV,$%:"]`E0#[7P'6"S!;"WXOX-M:"'J!P%8@[`5"3<#MLMONS6LBD^6B%%>G M.B=-Q<*\AI>-DEIS<]-N=JNTWIVJ7OU84A(MW(]&48]9=1@RPD3D'O)J0F!` MN+4#J!?DYL6*&.*:@;6)B*CFPZ22MVDEFTDE6P013<=*AXS35I[>93R>5L`& M!:Q5P,8*J*?EHL.$+::X;6OD>=ZT(7\PY".&0#/48?R1H4\`Q,I0,!@*#$/@ M!YJAP#`$,?,"*TOA8"E$0M(V>!4:N2/$C^YBZEP*#9<,X$.7HL&ER*P'2J<5 MQ(."&(F):64=FS$Q%AHA;1%<1.R2#)XB%0]QR==9Q9M.7T\NMLB--7*+(*T[ M!$;T"4BD@1XIF+4;F,E?][AQ]GT/28>ISO?,$-\0=<`L]Y*H"`D286BA0C$> M/$EYH#@/,-+3&[<'W>TIA`&2P6G@8Z<4/X+_7.N"8CXPJ0_I%)/['L1E"=Q8 M`!][K]@4,#JU>!F"8C]`Z,^J-A3_`4:`1FW$T^^//HD6R,X211X$(0^K-"KR(`AY,"-DDQ/J M5R28;PX4&,5VJ5'D09#IBH'N%#)>A0QYG6%`GUDZI>B(8'2DSQ($&<6".$:< MPFW&:",.IC&/79I]-U$+1JF!]WU`4-FK2T&I!'8.:6H MA6)SB=XP%!DWZD\VTR<3Q\"NAZDB%HH1BUZH*"BPL*.X@B)8XA6& M?9/IE=J#PKL*]$V?,-Q]ESUV2?$40\8;HU)1D#YCNJ/CKIR7Q_8HLW)VXE+( M[NQE6!V.2[^0YKA,6U_!?`W(^BO,W[K#4*5^N3@G1_XM*8]I43GO0DJ1MT=I M!R$DKWWW/M>;=N+)?GC(^$$VMV%]7W9'HMV#%.?;">]PS+S\"U!+`P04```` M"`".@&U'B=F6TOL!``#)!0``&0```'AL+W=OTXK5#(H#M,Z^_0):UT&S MG1OYXSF'WX="UG/Q)BM*E??1L%;N_$JI;@N`/%>T(?*)=[35;THN&J+T4%R` M[`0EA34U#,`@B$%#ZM;/,SOW(O*,7Q6K6_HB/'EM&B+^["GC_08F7U$WM)4U;SU!RYW_+=P>8Z.P@E\U[>6L[QGV$^=O9O"CV/F!0:", MGI5)(+JYT0-ES`3IA=_'S']+&N.\?T]_MM5J^A.1],#9[[I0E88-?*^@);DR M]W"V^UY"/H:U;V_;#&Y2.MG4#'`UP,H3HOX9H M-$1?-:#1@!P#&$JQ&W$DBN29X+TG.V+^CG"KY<*$Z&33L3MK0_562#U[RR.T MR<#-!(V:_:"!,PW\K#BL*-+/DN-2DD:3!&C&55`X@4+KCV;^<),\#HBF@,@& MH'FE.'`J'32)U;3#(BG"3K%+$=RDZ6,4-*&@%93001DT>(X2P-A!68I@F(2/ M4?"$@E=0G*^[QXM5XBAR2)8:A+^P)_$$$B]`0NB"Q(N=UY\0.21+$8[#Q/D; MEZ($I]CA!;-#U)$+_4G$I6ZE=^)*GT=[:DK.%=6!P9,NO=+WZC1@M%2FF^B^ M&*Z:8:!X=[\XI]L[_PM02P,$%`````@`CH!M1Z0F&T/C`0``404``!D```!X M;"]W;W)K&ULC93=;ILP&(9O!7$!-9B?+!%!6JFF M[6!2U8/MV`D?`=7&U'9"=_>S#?&H@YJ=X!_>]_7S&>-BY.)5M@`J>&>TE_NP M56K8(22/+3`B'_@`O7[3<,&(TD-Q0G(00&IK8A3A*,H1(UT?EH6=>Q9EP<^* M=CT\BT">&2/BSR-0/N[#.+Q.O'2G5ID)5!;(^>J.02\[W@<"FGWX-=Y5N5%8 MP:\.1KGH!X;]P/FK&?RH]V%D$(#"49D$HIL+5$"I"=(+O\V9_Y8TQF7_FO[- M5JOI#T1"Q>GOKE:MAHW"H(:&G*EZX>-WF$O(3."14VF?P?$L%6=72Q@P\CZU M76_;<7JS26?;N@'/!NP,\>>&9#8DG@%-9+:N)Z)(60@^!G(@YF/'.RT7)D0G MFX[=*!NJ*Y-Z]E(F65*@BPF:-8^3!B\T^*.B6E%\<1*D`58IL*/`UI\L_5%T M/R!Q`8D-2#^4D7IE3)J-U?16$R>I)ZIN17@;;^ZCI`XE74')/)1)DRU1\-;? MU!51M/V/;TJ.?9.0+4FBO%]E-RAY#]X5R!#HP>=%6MOM_<@$*C3'>C^V+Z MY:>!XL/U`G.W:/D74$L#!!0````(`(Z`;4=`D];;JP,``&D1```9````>&PO M=V]R:W-H965TUA]\QH5&J`N(#C[+]?O@3LM$MJ+@+Q]4N_3J>;L+C*_+TX"5$:GVF2%11L6S/(NL^N<@\S0JJ\?\:!;G7$3[QBA-3&I9KIE&<39;+9JQ MUWRUD)!G?#R5]8"Y6IB]W3Y.15;$,C-R M<5C.7LA\2^T:TB!^Q>):C.Z-VODW*=_KA^_[Y%^>*F^MF;$7A^B2E#_E]9OH-+": M<">3HODU=I>BE.G-9&:DT6=[C;/F>FW_8;0SPPUH9T![@WX>W,#N#.S!P/FO M@=,9.+HSL,Z`Z<[@=@8N,##;8#6AWD1EM%KD\FH4YZA.0#*OX'E-4C'7-\W: M-:15L(MJ]&-E,[XP/VJB#K-N,72$\>@]9*-"2(\P*P=0+^C-BS55S,$$@8KP M;.##)$DX3;)%2+QI)78?3[NQM^_BJ4'@]`1.0^#<$?A@05H,;S!9&VW?)0X( M&8+BG,"54U&4,AM&#N'R+.)/"V.],*8*.T>T M@]Q9<\45CW&P6H$*\BT.I>LPA3I,6Z[F,W5'R?%0NM=+]Q#I]C2!WQ/X7RL5 MQ!J*MX7X`#)AW8'N$@9NO``!40 MJ.5#72B*0V$(RF5P2TVA'DNC@S2*2-.H-F3H,.2++88,/88@34;-&T>1RV!T M50B!71G#P"*,8'2Z+AF:"\&ZBY(R:K%7]H$*>8+N;G1`(0:B3$/4T%@(UEFX M!L50GPG_8K(,=8Y@A4Y)%F]RE0,$0V&%QS!*A5$Q6I*&RDM\G6SQD556=@`" MHO!-!`/!7AQB(*[1B^G0#BC6#C0B0X?22\G7\H4.)8YB)0[F2P<:J[49@2\% M&,J!QY,-@G(]!Z!"!.5YCD;'IT/II;9&WG2@\;O%DVW;!&I#8+1Z087B$)CO MP`X68C"/._`%W1P="U.1'YL3?&'LY"4KVU-,/]I_)7AISM)@?$WF`4'&-V0> MMM\`!OK5XAP=Q8\H/\998;S)LCK,-D?.@Y2EJ+RWGJM5.8EHWS\DXE#6M[RZ MS]LO`>U#*<^W#QO]UY75/U!+`P04````"`".@&U'?O]DTZ:Q MD[0/GV0E%7?\Q"KURY[7)97JL3X$XE0SNC.DL@@(0DE0TKSREW/S M[J5>SOE9%GG%7FI/G,N2UG\?6,$O"Q_[UQ>O^>$H]8M@.0\ZWBXO625R7GDU MVR_\;_C^F80:8A"_6=K5A1:"7E M_*<5M9Z:V+^_JC^9X:KR-U2P%2]^YSMY5-4BW]NQ/3T7\I5?OK-V#+$6W/)" MF+_>]BPD+Z\4WROI1W/-*W.]-+^DN*7!!-(22$<@GQ/"EA!:PNQ30M02(E>' MN"7$KH2D)22NA+0EI"-"T'37S,V:2KJ8-80A0\SC%$.R>(AY@C#)$/,, M8;(.$ZB>@(TA76.($0@'Q89?"X2=0&@$HH%`-!IM@TD-IC*8&*$4H5%WGZT$4J"" M=/3%IY-!$C1LQG^-LLXH`XRRD5$V,0I=C6:=T0PP&F7X<38QPL31"".[6J"I M5>8BT5MP\&T3B&TT,0&JP.-%"P(1!Q^;8`Q$.',IU28/1S>.UB8&0Y&)QJ.- MIU]L/$WO"L"%4,S7`#"-';\7&U:<`!T<+X(@*';PL9G&0*@SAV4%V[3B[,:9 MLCG$4!#C\0P`29PY=I;8)!(HB:-E;-6"^HNZ0U.(#2O!@(O+-MK;1V_<2(G- M(8&VTE%?UV2Z1Q*HK4'O9'2B!_:3UH>\$MZ&2W7(,D>A/>>2*4UTISIW5`?X M[J%@>ZEO4W5?-T?:YD'RT_6$WOV;L/P'4$L#!!0````(`(Z`;4=Q8H,[+`4` M`!$?```9````>&PO=V]R:W-H965T5^DV*:ZS?;JK?GG+\FU25J?Y^Z38 MYVFR;(*VFXD.@G"R3=:[\6S:?/Z>3:VAC2(O];IH>@=C^KB M7[+L5WWRO+P=!W4-Z29]+6N*I/KX3.?I9E,S59G_:4E=SCJP?_S%_M"T6Y7_ MDA3I/-O\O5Z6JZK:8#Q:IF_)QZ;\F1V>TK8'4Q.^9INB^3]Z_2C*;/L5,AYM MD]_'S_6N^3P?,[#Q=/)9$[68NR-&]S%Q,,3,*48/$0N*L#"$W)\E>3A/\LB0V"'D MB6M(#3'/',95,ZD&E1U9W8VL;@A@0`#G":`C@(8`!P3HC=@1$S6878-1-FC^ MO(&CP.!\+=C5@DPMQKL%D*0P01"14NZ/.',.]TCY!"6;KF3#E!QZI1A22C@8 MNY-IPBY-R*2)O)$)21H58:!(RXN0M!R%"'0(*2&8,+;TLE.@UB:.13U&78\1 MZ5$%WE#.(]JC!GHC+BCNZ@CT6F3X5!C2#CD^8,;LD2/45C02MAL)RXC:GB>( M.X*8N5T\OYW'W$6SFHZ1%/@8D_L*M)7UK@(W5P2T>"NP--6;;M1EKJBH9RE*^KI**)P3JSPPA%TSJBH-59NY(\@ M]48RM9Q.YOQ1<0:)?C+&(5$SU^M>@CQ=EK,T13T-`V^U,5>,9TA3.<]0]OQ, M-&]!%TQ%RIF+XMS%GXP4=0VE,.+&FB)M-)RI3Z^#G&UH:AMT^FA!@RDM8A8/ M#$YK84G.AC1G0P(?U[WE'6-#7K%W+:9?;`0@*]:9AN9,`_Q40*^J`2/+Y=Q% MTX6>0NOG8E=PHDS.A#1G0KXO:&I"&HQL^:*=!VGJ01CX4X:FSG*%,)Q-3R=S MSJ(Y9PG]9-RR)1HN"4\G<]ZB.6_QG]\T]1855S7)DCE[T=1>E-9^,L9>Q/,& M.-<`ZAH81`(*IW*X4.7@5`X"ETYY$Y<"H/`390@Z!4 M#A*5PS=4#D[E(%$Y?$?EX%0.$I7#=U0.3N4@43EP*H=`>",ZE8-$Y?`=E:-3 M.7(J%T@4GT:B<"1"ER2Q8D; M)>)&*FY)%B=KE,@:J:PE69R>4:)GI'J69'%"1HF0D1&R]!9P,D:)C)'*6++' MYO1K./W&`@JG7W/AEH!Q^C62+0$CW!*8&ZIT%G@O`)ZNWAF#88Q!22B,7MU')^QR'3)\*GJ,5[6I7,TPSB:`K_+(\CV#>#:WPM: MM"A^*[YM3T+TP*"N!K#3C3D3-=1$4:'?F!4U9L\W)B%Z8%!<8Y/>:[E]\I[^ MF>3OZUTQ>LG*,MLV[^'>LJQ,*\K@NKK/5VFR[$XVZ5M9'T;5<7Y\8WL\*;/] MUPOH[BWX[#]02P,$%`````@`CH!M1[*I_P&H`P``*A,``!D```!X;"]W;W)K M&ULG5C;;J,P$/T5Q`<4/.9:)9$V:=KF8:5J'W:? M:>(DJ("S0)KNWZ\A+@ZV"19]*)><.3Z,/<<#LPLM/ZHC(;7UE6=%-;>/=7UZ M=)QJ>R1Y4CW0$RG8+WM:YDG-+LN#4YU*DNS:H#QSP'4#)T_2PE[,VGMOY6)& MSW66%N2MM*ISGB?EOR7)Z&5N(_O[QJ_T<*R;&\YBYG1QNS0G1972PBK)?F[_ M0(\;[#>0%O$[)9?JYMQJQ+]3^M%<;'9SVVTTD(QLZX8B88=/LB)9UC"QD?]R M4C%F$WA[_LW^W#XND_^>5&1%LS_IKCXRM:YM[<@^.6?U+WIY)?P96H5;FE7M M?VM[KFJ:?X?85IY\78]IT1XOUU]"X&'Z`.`!T`4`NAN`>0`V#?!X@&<:X/,` M7P3$=P,"'A"8CA#R@-`T(.(!D6E`S`-B*<"YSE\[^T])G2QF);U8U2EI:@(] M,GC9D##FYJ1=3BTIF_^*W?U<>,B?.9\-$<M M&ROL8YX->%Y4#`[=/N95AX$^9J,;*^HP#LNM-L'0)1A:`MQ[(`,"W!'@EL#K M$<12UJZ8L,44+09%;OLGI4X%NN-:O$Z+IVC!H2>M!$\9PG?=4)&RON+\,=Q& MY3.0['>2?35]($OQ%2E>I,N>BC.0$G12`C5[$1XG"#N"<-I:BCJ":'S^EI&2 M;ZQ+QHN*`U^%O:JPL`\;E!UWLF/-'*)Q`N0*FW.GI0[=."72J`#9!I&R1)`F M>>MQW+`DX2T(U/G$LB+0CB3K&4$-JQ%&A31.!8H-E,D[`JI M?N4940C[0/[$A2/*'JEUKSCXDH/Z#PS:I6.`')8ES`2%FN3$!A3"3E`T,3FB MM)%:VZHE<="H)ZTXT!\#K@V`PWN[L!5P#787#KJWO0R/)?P'=/[C&5#<]"(3 MFQ$010ZZ(I<:O16H;4;D*Y/PI($%FKG2P`!A!?<,&L^(#-,L/`,TG@&!K/Q> M4\+53.I;0#@/Z#J7T(!".`\$$^=;N`1H7`(B>;YU(+E''0$-BQ%^`VK_PC8% M68P.A&0Q]T'#8H1S@:8KP3!.@85]X(E="1:N@'6N(,^/#B0W"NL1T+`8X2]8 M[4<\;&!1^.9M!T],B:A@K*M@V52P6IY@NHEB4:18+5(

&PO=V]R M:W-H965TIA M>W9@`*LVP]HFM&]?VX";II%RB-G7Q$]:9;`$/>I>CT+FJ-Z;>4ZK(% MR?0-]M#9+S4JR8S=JH;J7@&K/$D*FL3Q+96,=U&1^]ZS*G(!67T&F.'5%0[Z+[U7:_=@@/^,=AU"D/3,,#BE=> MF=:&C2-20>?7B>N=FMMA:NG(A5=H4_MQ>U0;7M'HLL7>?TZ(1F MS'[")">854!0JW[1(EDL]LD/>G*=GH:$J:>GWQ+>7A?(@D#F!;)O`INS(U[" M_+INL@XFZPL"=V('_P4O\IXU M\)>IAG>:'-#8Z^.'7",:L%'B&YNEM8\T;`34QI4;6ZOIWDX;@_WR"L-?0?$) M4$L#!!0````(`(Z`;4>\FYK:O`$``!L$```9````>&PO=V]R:W-H965TP"#/C@3^A#UQ@Q[C'7=`R?Z1@X@[)=6 M*DZ,356']:"`-+Z),YS&\0YS0D54E;[VK*I2CH91`<\*Z9%SHOX?@2$]$#<[)*]A2M'8IE=X/?M2:U1;:OG*L_C$I\=T8(YSIAT@TD" M`EOV'R725>*87K2G=\5U@BQXS#Q!MB5([JX3Y($@]P3YAB"[WWW;Y(RY]1CA M,;O8/M=EBB!37,CD>?)-IKB0*2Y5\&9Z'%3G#ZE&M1R%F8<7JN$>/*1^^E_P MJAQ(!W^)ZJC0Z"2-/4-^TJV4!JR7^,::Z>U-#0F#UKCPUL9J/KQS8N2P7L7P M/Z@^`5!+`P04````"`".@&U'1Z\H2B(U``!5`0$`%````'AL+W-H87)E9%-T M&UL[7W;DN/&L>#SV:]`*%KK[@B0XOTBVXK@L#DSM/IFDC-:'<4^ M@"2:A`02-`!V3SO\X'_8IXTX^PO[$?LI_I+-2U6A@`)`=(]LV7)'2-,D456H MRLK*>V7^+HIBZ[CW_G1TQ\%Q'__^BTZG]87U:>?OH]]_L8WCP]=??16MMN[. MB>K!P=W#D_L@W#DQ?`TW7T6'T'76T=9UXYW_5:O1Z'VU<[S]%]_\+O*^^5W\ MS66P.N[_&1-]SR"%^RMFA5MG="-?O=5_,WOOL(^W&]H70?[ M>!M!G[6[SCZ=NX>ZU6[85JO1[&8?W@0/=:LQR']X:CX_C)91'#JK^']F>XK& M,W?C80L8XL;9N=E6'T?SV^O)Y70\NK*MZL^9=N- MCV&(TWSK12MH][WKA`@*Z]*)C7?6:LU6K=TL>-5WKN_7?MH'CWMK[CI1L'?7 MUC2*CFYH`JY@B(^!#ZCAA$\P'=\-C5\@MT.MG0>!ZN?;&M.>&;='N,H MALV'[H6XH0/]+?QH3#?;\LX-O6"=W_:/[<+>BZ>#L9G-1NV/V=]&T'K-[_,= M8]KWCA\9PZAWB*D5X8X\2?_M/_XC[[B,;V\N)S?SR:4%G^:W5]/+T0*^O!E= MC6[&$VO^?C)9S*WS#WOGN/9B=WT!!_K#_-(Z/[NPSBQO;RVVP3$"<)L@=%?P MXB:=TH[QV@^SV>1F88WF.I$6SJ_*_S@_NGH/3@^K-5XQWP+>%*+W7`' M4WEPHWB7UVJT6B'EBVC((-X"AH7NRH5!E[X;V=;>C:W@'IY:@'[!H[-?N180 M#&L=')?Q_=&W''V`%2"=%T5(2YSUCT?Q3AS@K&.W>EW+B>$<'F)WMX0721I& M7:%!M]_$!@`<\;P`0+-D@M;Z"/,)@QW,VH<=7EL'!TZ'><:F`()]'(2>6)2Y M(_5C'70K002<*')-6"^"&(Y+>9N[V>W=9+;X MWAK=7%J3/WZ8WET#+B3[L`+,/O)*URZPGY7'I!M!W++[G5(0-^WVL%\)Q.]N M;R^_FUY=&6"\68QNWDW?7$WFN6"\7;R?S`HPEY<_REVVQ/FKZ>C-]&JZF$Z, M[@I3#\X3[GW.\_"8VL`\9*\[2\[T\U)D[B&BQ\ZGHS0IW0A>0#!"R MIC:9:'6P-YE-[*J%G&ZN7H"3D#-]RMV`],AX.N(@=38,?I'&RA(X7-W>O*LM M)K/KLEU*O?\4H`SLX:T(]ANF6R63X5E7:CJ^O;Z>+O`8S>E4`3%?3&_>36[& M,'_K_.9V,;%N+C*]4`C\.CHX*_?W7\`QB]SPP?WB&\O`C<7M^-OWMU>7D]G\ M-W1>%]_GT`NQ[(B9\5F]T<2]L(!R']W?6DV[T6C@_T("RYJ1-F'D^0?>IF8GS[F0$I*)I6?6ZC;*YM;L#>Q^JV&W^PUZ7;/7 MLSOM+GW/S+F0*!E3M`$[HH.[BKT'UW^"EW0'=J?9LEN#-K^DV[.;K3Y]%R\Y M"8TJ;S*(Q1J8.AQ&0#,D]S7@YROGX`':Y9`5C2C?>RO/.)9Z$\$J0'H+W2W0 M(7@[<&CX;IR'!:@7T1$D3[$_L+95$,6VU028@Y#?&/35ME1?=OY1HE=L`W\- M(NYO2*XH(A7:4:,75.GY?%'J_,Y!@K1U8P^$S.JBU2F!YN5B3%567<2C3](% M=?"L:DUKD/*S+.%@N8 MLHD8S&@UW8-("0HS3>[>VP.WP)$1B#EZI=8VT(;/E<[%@258`4A7YY"W,QMOLA?*P>K+0-!CYK)&*.6\&>9-V4[;S)-]8#X(-^@$ MS>C3!6[%/"573TBNMGZ8`:I:G7!M3'WF'HY`57$LH/;YSH6\-F6X1Z;C M&F`QVU:0IN2*LT7M3HX=6?L@EG(8"N7N[N`'3ZZ;-G<8'/Z3&ZX\L0I"M^`0 MYUE]"AN6S2RADA4QP9!Y*F!"81_6YHJ]/`5CE_:I1$/&H_E[Z^W5[7%*R(C;()XW90R\XUSXPT0S'9JE8!\%O?)9-GBC?@8_R1+-\@K#QX((=: MRZ=*K[G4K:4DH.S0V/;G7%R^0G$(VJV]Z!!$R++O01#XA.0_WVJ+DR%]\7.5 MRL)31%,.@;]NW-R.XRT^(IJN@8-F2WTUK?WKY^G,!?)!J1F;V^0_NWGI%F:Q MB]T:Y7WN!*V+TH(SB: MJI_3TGFBQ4+#?9F9&ZC!RG778O[8M*AE[E$X%]"ZJ+3TR?V]NV*U\-.*:(`% M!\D%T@4/4"IW"1ZKJF[#F\D"Y)#)>#89S2<7:$N@3_"!F0.9&_`#"I@?1U?( M.?)Q*N=EP$B6[L;;[W%-J#.3?_8YW5VD4$4=YQ_N[JZ(F8VNK,OI?'QU._\P MFRC&-KUY>SN[)KM)H1Z'MMYBI8HVW6R0>O%\_'YR^>&*7GMS>U,3K_XXF:/; M@0#X=GHSNAG3M_%B^C'7DZ)Y+%FODCZ@`+$%``#2(`))$36T+L6AMSS&Y/N! M=@E1]5&JS/=\HL=&E[ZW;_]]?_8 M^"DXAO+C,9*?1)R&_!JJ&!KYBS9Q^,F"/8`?V3:$^XJ_T3OQ=>8B$0<\.!O1 M<1EY:\]!A,'UQ)Z/#A[#FMW]A@Q/J/JZ$:CP9+Z!5Q[O M81N.H?@:_N0RL49N>3S(P)/)?HO2Y]J:?()#@UH<14^YX>'H2YE_,AG?6?_O M_\(4-;\$3`<$7X2Q@$G">-XZ`0&/MQB9!&.%'K+@*V_GD7+\]MWD`N!O MO0D!-8$L?/1"("36-/)1$"59"0:$Q6Z]U=8*'D&\#T+:RS#P8:<>`VN\!5:` MA%X="^Z%)ZP&;[IWY=(X0,5=;?>!'VR>K*MXS8!^XP6?8$VP?T>66,=!G9^> MXZ.+M$L)1H4MS*TZ&^:\0:/-T(WSWRY/`G MFT>D2;+'#TC#^KAB3_)]X'LPO9$?!:1/ENP#DK[PB%-A"G-_#%F"\]&^@Z]? M'B.$7F0EB&FI/BQA*F?LAO>1C'^NG%D4.V',H_,&N$K:@+^@[3V"KNL_U6#K MT+.0PF;$>NO2A88@&1#L.__?5_1PK%%&+]EM:N M#S0/?-K#2"-2&(+'H&'H"H4A"-<@`0"@@*Y8VHD:P>'PA0M3WT67F!@>:Q@) M0W8V`%?:J4T3.@%<-I_C&`N5K(Z!"+ MU"$&6=*Z%O!2%`!^A/,E]W3#^Z&(E$V[+$S/#^H09^:2')=(;U MX9?8`\=/S4R2%1!>'*5?H04!F0@L'9$-=>XZ[LX?CB!PGMH<0`GT>8W6*/2A M-9R"^T9JP\X_CF;)UPO>P'>3]V,$WM(E><2Q]HXPH[$'S:'10CD:8SCO\PI9 MWG3QF\B:P8XQ5;L;C4'-O_/X"(]`#/8>)+E'<]\1216=E3EMX852F>"#0&)J M+.-+I!/"1J[K'PDSO-W!IS702+9./C2V@KOA`6TY^K'WA)&'J>7#IJ^.R`T2 M#D;A61[K$O`L!GB$\/X-4V6AG$(["MP@L=J@(3#$TMTZ_CT#ZOT82"40UD=! MB*P,(4*TA"%2X&1R8&?.,!`GHL&X^]M4+@[U;P)'$4V2;DLVB_"(07/=@2BNVTB:+1\2G,*(?K*1$A3,11*&N M^FL0D><>/Z!`PKB,4W"BR,,YK$CY,(:\'>D`0-1O!HKB"#14'4` M(?""259&-1?C(;S1W`0+`^D(8[V.8704,`0H4-B=)4T;R=$"G(>.2#/@Z&4` M29HE"S+RI8Q!(?I"8-&Q%TO_(^(G+QAW$MH(Z&U=GTZ?FFE=FS3+GI%P`OKP MJC#"UWHK3]('=+K5U$R80-2$],-"%/V2T'6=-.'*I(]5]A&:=JC$)?Rü M6'!$-[Y;BX#IKA)*!Z!Q8K'-:NJV&A8P[KA?`RJCM'.`31"4$]`7ME>C>B@A M.GXM]G:NZKP+]AYJ>LC%0A7?K9''Q#TL9YIX,^0$TPQM">!T'UA"0?D,:3;* M^0!;1`K%PM!7_01;MT&I52@PJ2Y".T):88``KT<,*G-!U7 M7,S&E1"A4/(;KA,X#FBUB^C^92L_7>SR1QM%DJK'L^F"[R]88W&X]L/%"9IW=U>3<Z"F)0A:HRP"LH*)M2#(V:`D!Z`UQ MAA-&1Y#B@,2?1#!6XZK/-=H&1^1U2'8, M>0DD3HRI"]=LND6LIA19$P:B=8LL( MMMZC&V.'`7C"^!V)'32G2TN/7GKFQ#IURJ)(1F(O0TE=*,6/+K!FX6(7]C;2 M;YCM>GMA;-%%H*KPRYU@Z-ZCD,Q2IN8\/L>N0D0@%PV2(G1D@C)(M#%I>T&O M03&0)$.0)2)I+W*L>\<+K:RIB,1X;Z?02&Z0.'>,;1J.:7M-H^Z?U!"\?813 M&/@@7^\1U5R3X/C@#T<:/X5SK6)II$>;A0@C2XTJIG5_!.#@,1@(&E'&2Q#8I4M7%/?R5KU$TQ,L54ROD31<2?B*TAD=MA!%6^E/.:2 M[UVB5;Z+&HF0P+DU&<`D_E5&$T8RC1>2>X^X9.*V-E[[6=R*C+99S":J9JMG M>2"049EV^F+2*G&$KME$C`/(PR\0U%TCXXJ1XLL1F:8RZJR()[$OD*E=O`TB M;<\8/\JV,-$I<+=9DN7X!$"F+9RW("11&LWR?`P26& MGDM1+O#3C\?U1AKJTGPLP;2T9N.BK8OFBOI%\?G&%OY&3X,A/@^5C?^[=J[^<:MF79P^>S813U7SB=BJ]0"3?O[8I#G//+YU2\2,P]]5`&^E<70\"/GW M/Y-EGYL^;E$H=U'<(Y[JHFXOK4M[/7R&E4G8-F%V>`(A$E!F1;A+5%0HF?0[ MR98A@A$>VF)U^-"+1%@01OVXZ/N`I2Q]:;\G8XX(7\.V(5U!AP9/A*DA'EZY M3!;!Z?BGEBQW,E=3G+.&5P07+>1(@LAC;TZ9WFF=1RXCFS6^>`E,_U&@6R@9 MW1-2%9"F-9H:UH)G[MR8%\!$'2;A$U%.`H'4')4^YC"O2HS*7NSFZ1]T'H`E MXWFP8=)[X?FFM"CQ:I@$LK%X`F#@SR@]X%/3)V\6$=O MK>S?"4'%0_\@1Y,69+1LTVC2&Z6$LI70S(N[B/.0WL$G>1R)Q"_=/<55:^1> M]JZSW]N+R&^5N\@GZ_SC=')1MZXT:4H#JI-8F84D)B;"<@T,#=VM=4`BL?+4 MHD=+1HJO?,?;$5O/.EW5M1.2Z5A:2'B*;JZ`-^-*)`"]Z$5:7;ZXZ6DR&>G0 MO,U?4Y!N+"-F+]#>#M/(43+Y@<&FK?-C$HA;'!IU9C6;0_RW.[3XFHD0<<_P M?G&[SW\[?X.\-_>@.;?'+3Y;ZMG&3=S9I.[VYD*'!O?WHSAUX)@JRI]3AE@Q];?_OJ_K$HCZ43MP7,?HW2@ M".$1(H]RR^+(A;*,:,4R@F%=3S0HS;!-,R@59;1`#1EJXIIV>LVM2KX]W8$L M0Z7@^+NDH4O]^A[858[F(IPAR#8B3QVQQ.)OL'CT.R]2ZTJ\3*;G(K%=Y;IB MA!OC-A6AD(::"&(0OP/I#=?6GXX8FT,1`W@^>4+&'B!@/C-R3,2PX/"KK>?> M:P:Z-8A2Q%U1S0SQ73G!-=!C\LE='0O3D/6X#6]@O?CSN$XNK!6^& MH73+4Z(]RD5!"V(0R(657IM,BPD)*-FI^XR``/R>B&47LIDB5W!M:WN$P1`% MR($H='^="VG.2MRUE4OIL)A-:O;0Q!C@2V\[>L8<>)TZ`/*N'OJ7D7.N01Y8 M(=H6AX+*TVBKF1.9M2T?\,*WQ1!`T.Y==FQCR'80\K38%::N"40I/YX40P3C MP=.>!&P0PQ)"(S]C,4^80Y096\1JLNQ!?LS@D?!1>#'W`4LW5$9A2%4!NWK>[`V1W`WO0:#!W;R+_K^'GOMUI-*V"^[+(**%SCUCD MH,\LLCL03+,S:-"'IMUN]PTAHPD##XC3VKU."SX,[=:P32,V.DWXV^G;;9A7 ME8Q39U;7[O6X-IE@!K`I64Y*OB1?1QE[=ANA4$RMK6_K-%/JQW\)& M71R^UR(AHHD_M.UNH_,R#.C\XAC0@[T8RAVW6^V.^-R'K6F7;'Z?`'"N-KS1 ME5*2^-#LH-R4W?JVW:8=YET?TJN'=J.'2-=NV6T03*OM>L]N]WMRKL.FFG6S M=WK'VX.!MMDU]5MFPSL`FI9HT+:;?3H@;7%JNN:&[ZN(M[_T?K?PB#?X%/:: M35I:HR_/?!L.TW!0LNU=N].C,S^$$\S[;`_@[(J/'?$K8%+WW_7<5T"#7_[8 M-X=`F;L*N5L]>>Y;``/0>,JH?HM.JSKZ<'9Z38D`^$SB0J?]ZR8`;Y_%ZG$Q M;$M/V^J$+4=XZSJ=+ZGEH/.EYN])WQ6HJS=7HCC57MP=BA?WBE_,XMQ9M]ZU M=FB!0^DWA"/QI7@`ZD!+?S)LPY/$7%6PH2_/PV5HPI/1[`8TT+E,:',WF6'" MF^O;&VO^?C2;/+=]L0:%S*[?1A1Y`$`Z5_<$$5<>15J*FDQ+L3\2:+6[C&:^(DG3V`Q1!U68 M$U"59%#!6ESD@17&,L`Z`4SY]'G>-)P"N%+R=`!:)@!S('?PCZ2.)8L' MS8:7_Y!9`P:3R[OL28Y.3@:"8_(!2XEK%QU;34JNO'>&7:`2+=! M,JFI/:XZA_Z@E9K#H#=0&V+8X=KG_.1DAXR9`>O%$: M1002=!N2Y"+I+<8*<&P`JFG'4%.#9%B:\(YBUN,G8?#DRX')&YW0B]2P&HA6 M22X5$QZ"$>R<)[KTL1*1DO0L%2[U"#*SA1/'Q?A/`F[%.UC/0W!/O_26`MP# M6U*E$XHGBH$:&'7L&U(T)B"X6=S.I@7T*_O\%+%Z2\3*Z)7-LR[B&%&2QM`P MCM"4+A-%PCZ??LR<1POA'(),1EI>'_5@5/R_PQLV'@;K!QAH"9I-S^KUAQ@W MQ3>E-@$>AT%G:/7:/3)S#+ML-AT,!];H.7I,.EK.VZ,YW%TK`'!VJT\T#:(M M2_0J47@)0XW0^:S7;U/&95*_!D!?,`5SN8XD\[5K3$-+U?Z\UJ=V_AWM_(DQ MW@%0Z0`XFPTR(3J^9VB'&+22Q;516*2O>']-Q7SD^/@K1:&\7.DDC99)W!EP MFTZCQT!/N5[2?C1;T"5=#'2,I#O"6>2[(9K-%C#4_)Y'%(+?2Z<_*C*QLT@(A?Y$!BPJ*AD5[%-K$=A^-\H@LWN1O M.S@Q$?R``M=4/)6/@6RI)%&R20G8GDVS[NCE_!XMV<28O'EHO>JP4#H^++B'\OWB\#EG[SML#E(7: M[;;5`:5I+N'`HS3M)CP8]EIE\VH.2*H:HG#5`6ATR!Z(R^*_`Z#$`@99V-MI MX&?O7P2Z2>\9D3M97*8_Y M]KY&,GRSTWOY\*?,=WI)D!>9WMX3OTD-DS+I%@D5S^$&GW^8RZS3-6L?[&7P M#PD6G2Z=@"$03E-Q2#5OV@TX)BW@$4VQ[!X>20Y^(E\%.4U`%+-G(J]=LJ+ZA6J^6?9/.UVC.)_8HM+I#WO*6N>67D[>3V0R`.YN`7/[! M,(UGG[]H&_]`VV@,M5"R1I1$KC M[6NR-<7/A4+H[*++JPF=!DE;U5#+,BK:M+J@2N62.+6;0(N:/?BWT^U;/2!P M?320@!`R2\4`B^;55G7>:J!(`W]((.EU.\F?DRNL@=")X2KBWU97[Y2[U/,F M68&`VJ(T1;)+OV7E4W:U[/.VW6XWJ9\][-,`*,O2A`=VGV2R/,1(Y3$D`Q?H MG+#Y+5!!T]^N0%O\.ELA"MWNS7['&MI-F&GJRY5*PV7$P1OO12M6EQRN0[O1 M'QC?3?KQQC`6EZ6EKMZ43A@DTO.H2U[2\XJ&"*D8\O40UJ4I_'`MO$8Y M_6EX/:5HY'V2AC(9WA>E1005ODVO`)IB^1"2O MH_3ML.Q#0)DFSUK)W,4]X*JZ?#+S&FE;)D!2GT'=ID M!UR*VVX>WTH/CFAEA>G%0M@6IMD$HR@GSY,ZU!AG8\DOW64L;KZ0 M`4GPT[D^ADC?\)1=U8E&`L4C:1;EC!):#&Q..'.P]+V-B"=.PU9>N]12".DH M3NX7I/SIY4=R5@KL.0*#O,V1WGYUEGYC^2[[^[P]*&3Q4:A2@IM@)/I9J]Y0 MD0OI-,`B)I>S[;,1?.=\\G;'G9Y'&/6P=C(&!@$+JVL"!1Q7WBEU-W]S.V+?Z7R8X(Z@1GN#C$AVE1$LG$\VU=J9I]-996^O0>=QCM$(8?)+F[;.F%B?B8-F/*%80,G/0 M?)A/;R;S.89/O)G>Y.;DS6MSBM-<$:?)[?D,SO-KRAK&I+PY4(7\**D+M%)D M\0XO9/Z]$HR)'#+F`TPI\P_//8;K2Z^;V1*2[B/Y@LZ:H&()2'DB;S9>=*M!U&3BD5PM02ZI4U'B/QK/3*[6?GOQSYNP2XK@_]!\78OMOW.ZEN>; M+PLL'*D8K4)_1))13PGV2T-!*'1,==)LHK9;2E M]"Z4+Y7\12ET.L\"#>&>)8L'138\O*,O&;)80BJZ+'7K!Z\5.P^.1Y>^!4N1 M-V:$9YFBB]A#C4N[CRGT@$N+$$[*#H")OH3R4"24\L5$NK2\H^I, MKKSV1-<5-7/J8SGA)72K':T<9+Z*MR@^V;Q7%M^X M8G3(V2E;7'K25EFRNFS4"R>HH&P'L7;#4NR'EGOBA7B3-Y4,#N$^BM>>`'#Y MK>`$F]2MJ.OR\9!]2F0INQGQ?#JN"?N]R2!!B!W1U""_Z;+>&=\UI]2\X[-E_/K24?T;IA">L&Z$CG3;O? M:'(3^3%Q/:O1$_I!OL9V`XU?;>EVY&AVMKTUY,T!\>4RR;Q3S=429XX@4?&S M9D,IPQIYJ<\]U3.'[9':X\$L+56E M\9VX+O_?G=WAM]E[C3S2/X!G\O2SBS*S57"0#5/0@'+,\_:G*K"\V`>8ST0% M1S8R-#%G3VZ79US\N1GYRJ(77BQO(/,Y&P"^:S["5JMO!HK8S[JXUI6&IZ;= MZ6O^P7:_=.@J!X-!JD5+Y.+W65DIE0D[)=>2]JO2!,G4[Z*N'T,O_6/6.UHA M7KM2A/:+O1HSE4!!7`6E",8F?>@,[`&%/G4ZY(XP$RDT@8ZWK?,6,X-!!ZEN M>XC6[N*;#QSW?&8UZO22<_C+]TBU'Y!NGX[C/SF&4;-I8ARDV#0V@5>^9ZY6_]-)Y`*7WRG,!/7;.GM^KV61/6Y3JUG58%].F6>%7 M-:!(64_4$^EYQES4;-3%K:ANO?]EIFZ*F'FN020U+S6+Y+5HD'6PY,E23P9% M63MX1BK1#8I:QX.P7VAB)NA%WM`Q`$.;0?P%A8!2;(.:, M1+%I=N#T=$ZXH^X@J6WP&CK&FC`960;HXRB#KX,603(/J_BS![0L$)P?I-12 M9/Q6E2^68A`J;,'9.M-1XRCLDF8G=B6S$,D%-.52)AVB>2$'/W`B`C1XK=T# M$C6*E?7"=>W@A&0(5J7DELZ>7`KW7KBKI\PQ^>]7]AN$U.%H4M^SCAI:^2+89B$=3/GFU;.6 M6F,5SPWZ"P16)E<_[IT=R,W(+(V#C5/[B*`:;V$KZ6B:E.&-1.#+A$10PJ<# MDCZ/J]#%\/O>55E0*.$@'\A'ZWN9D1\=2>3%P*W=(\$2=F#GD3:5LC"YJY]H M;@DZLSCZ!NW3:R8P=]*N+MP3288)EGJ577"J?>T\.U!HV_V]2-N-AG3'V: M+H9CZQ(M)YU)W"98X2=58B=-E=1]`5R+1QI)IM:D,-?B6"Z71MZY(%>M*_LP MR,B)*5)T_0PKK,V_5?Y7>2+7,C`?7TQ!W$K#U8>5=,'#W/W0$B49-\OXSH9] M/?*N_;,%]F'1-PG>5#Y"Y"^%/''>*9+2$URT; M$-5E1Y>\J-:'O::*>LIBI;D88R?=WE65`^Q9CD.;B=FOQ&) M',6`9@'DZ^OI@DL=BVQ6F-EJ(7R9G'UO36= MSS'Z5"\@,KN]@<]CKH+^XHZGB,*M5;.J#Y:4MQ*(_W8T?R.#<$;S#_2DUABB M(U>J]`2?L0J?XYI_\EX<%1O-U@[":F?2MA5J28B1D3MHLHF.>+G,75.L MRP,AA?+PY8TA4YLR65$C8L@%Q8T0":A%L7L`8K]V?=K4O('HNEV2ZU25(""W MHZ@[H-*(4_)6Z6$25D#V93).B@1K[@,Z5>\=>?TR==)D!M'T]%12OO/FA46Z MMW?_)$F(?(MMG;?,IQ%GPG;3<39:4$V2:E>.TKY069$5F<(+->\=FMXF*L>6`Z9I!!. M1T673-2*+QT*0+3.%Z"UKZQ>HW>18>`"K0!.^/XU5Q#>NAK49&D%C9Y4GY^- M;Z=:%``OI?(OL32C*TI/W!T!059)1E#52MP]QG0GK+>H/,@P99VZD6V&8_%4 M7;2J&]Q/E:%4]3NRP^"J/$5ETD_KUD0P?+VFFT?W;$5UH6!/*K/SR`J.] M3#&I/`2D4Z0<8!E?46(?E>X*3"PI+4?2F4?3D'[,)XSR8Y\X"JH1B:OH.LW< M`5,5$B).39G4"8FT;-[L3_RY"*'4W`Q"B&G<-=*F8]:6TQ7)YZ0$,-;$*ESN M&=[2Y&H_0+S$V:DYQQGRNLE.6M>H$U]N8PU;7>N+@QP@9DN3EZ$N<(L3$(@BLSM(._#U)[Z`ECE`59:BN`DLC!F/_7#[\+/3[AQ*VGZGBX;FL M+F.XIZI7+'QYS]=:AV2I?JUU^%KK\+76X:\T>/:UUN%KKOM0Y?:QUJ MM0Z-XC#EI0^?V?RU4N(_3:5$PV-A%DZLT.176%NQ:-6L`;RLU.+?8\S7\HVO MY1M?RS?^TN4;LR>[J-!AI40YKZ4@7TM!OI:"_%NUXN#/?>Y?*PY:_QX5!Y]=OZY(NID9Y<;> MR')C\F[UG,ME?1#6YXF\:GT'\Z5G(,:J4F.59*#7*F?_G%7.C+S>H*:I2G6B M1A87TYIHJLHD5=ELG*YJ)J=G8DUUW>^U[MJ_9G+K?YJZ:X74+T7NF0+/$G+_ M8@Q]+:OVBY95.UFFJ@@=4H6H;K@0U4S48:J$#+^Z2E;/K`)5Q1HX3O+]9XL& M808=D>VG\MG[=RM>5`9:IF#3)/$A)5BM3L=>BR+]ZQ9%*BVA4^5<,O(\`V-> M"^K\;`5U*FV0K`6CN4BK:5NO57$^ORI.X0YI[$QAGS2"5&=BKS5PW-<:.*\U M<'ZM-7!R:PL4492)2AG\%B/M/W+*8!FE"DH%\V@6+F&:+U937_,@O^9!_GOF M039.@;S3KZM%L'A.P*IYU;,=T\C[FLKU-95KM52NM[-WHYOI?R:A3'=7HQN, M<;J]FZBPCTLW=CP_1_1V#W4%2@K^%V+9_+B,O#4&.AHY>U1V)+I)LSEBPIN( M;ZRJ^]*9RAI)-/+A@+GMB+639?A!,W4[ZJ9T.D#XTG,V>U`D`?;3G;/AV[0! M7G:/K+_PE87B28ZW>!SU2X#)_34GG[EHO1^W<"*?:IP?-9(PP;Y_L4I`!$H5 MWX'S5>(*X`W99IUA?=CX\N>*49-;#,3IP_S2.C]#U/'P^H(XB-D7@6QYS2=P M@B?04`[<55VJ+^VJ,<#6#U=XLJ=P(B,CVY,1$64L'2-H?[BFTUS0V\E3W;\Q MXL->%ARE0%@.N-2A$;`N:].IT$:.4W";0M^,HN$2K%6!57\INITA'=PSE?%` MC_R=&ZX0EAM7NXYHD*P.,"6#9`UR M?^T.<]OV\GZM*P_`PW;>KZXF<(?"C.(E@]/@$%4_[9 MH)[/"4TX-4S%2(6285)!"5J.CM(PA)R@E5+,UM\1)>](!Q-4#R0H60X[R6^% MD[P(ZU/!%^_845[4MI)#_-FTP;"0&]MKN(2-B;W8,WS:HVNNQSAYNH\T^S#C M)LT^3GM+S3/-'E[.1/2)_*Q$CY91@,4?*1$UNH4-:?B4._7TJL;*V;F23DQ' M.5.5__.'&1G:@ M%Y.V:6Z'HDD8N*A[V(0?H;K84D%",OA6OH^R^,!')MH7N0B+WE4T^(?(Q8/G M>_>NR-V1AJ2A#C4X[;(Q22D\79%?M.AU_?S>RA-:U*^;WR_MV7PV(:OJ(SQ) M`$M;$U*_U!GX[#7E>.SD!Z?0DU2 M-![ISIXR`44<)J4&%[6]G+Q9%-O=_G#TE3Y?9$*X=I[J*B>5:"-KD)CC[4^: M)#A_Z!XXS9&)>(EL**NZI*J3@]R`RP<63PEMC*W;;##\+Y8%XEBXQT2U;&;+ M[70EJH\+Y:D(FK*9*%)^[ZPH@X)M%B>G*K\K-$4MW?N`;MP??&?EYEE!7C(J MKRV'TPIQ)%-.G0J"5UPTJ(=<\;R0`TMCFTQ7+93$;#LJEFX:)4L,*H0;GL(- M.[D='^985W,5^]3X:*[P/B4ETDM.H['RJ#JNDJ+#-GCTL^52M.:>1I2QI.9DT M+\VDP05F)BQ_)`O&P'%7`8"4W<_@";D^4N&#W;NQX8+T(,Z592_;$%#=*2Y86VI(J.%8-<3?7?UKXADH.U#Q6G_A.*P(0CF&^;[KP MR!>.<\*;_?P!2VE>QODI@E8+*88\0GH5[(/TZ^K>V&*$G16X/4ZX%=&PL@9Y M$6O"J%\++4^?.TY)P<9"<29/5#%%"M/;443G9^(LW5$-O(56N:'<-<&]N'*> M5N_!ULP%Z6KESQ]"UJ_+]L2R5M=4I,4'37'GE9V`L:RPY7'QWE![:\ZQ?(FZ<8:VI!DMN>4]=LP7A2I,`T]F-6I< MLA_HDTU7GS14ZWK?%%/*=CA)I'-Z<*R%:8ZN+5ZO7?J"E6,9T.+QJ=3A=5+J M<$&Q2&^QU.'3"UY67I&K.'H@SPV7U-@J,VNE:V.9=9;TFE_9WNU\D\EH)XIO MO6C0ZA6("L$QS6323YY_%47Q-_\?4$L!`A0#%`````@`CH!M1SW.=%CA`0`` M"1X``!,``````````````(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$" M%`,4````"`".@&U'2'4%[L4````K`@``"P``````````````@`$2`@``7W)E M;',O+G)E;'-02P$"%`,4````"`".@&U'8(*:H=(!``"-'0``&@`````````` M````@`$``P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4```` M"`".@&U'97)PC M$`8``)PG```3``````````````"``=H)``!X;"]T:&5M92]T:&5M93$N>&UL M4$L!`A0#%`````@`CH!M1YM;I/-&`@``X`D```T``````````````(`!&Q`` M`'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`CH!M M1TNZ+&PO=V]R:W-H M965T&UL4$L!`A0#%`````@`CH!M1WS,V--"!0``41L``!@` M`````````````(`!)R$``'AL+W=OFJ:-J"00``%P4```8``````````````"``9\F``!X;"]W M;W)K*@``>&PO=V]R:W-H965T&UL M4$L!`A0#%`````@`CH!M1\`CGQJA`0``L0,``!@``````````````(`!+C`` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`CH!M M1Z\3$R.A`0``L0,``!D``````````````(`!LS4``'AL+W=O&PO=V]R:W-H965TZ.JR!H0$``+$#```9``````````````"``60Y``!X;"]W;W)K M&UL4$L!`A0#%`````@`CH!M1]O\!9VA`0``L0,` M`!D``````````````(`!/#L``'AL+W=O&PO=V]R:W-H965T?!0E4 MH0$``+$#```9``````````````"``>T^``!X;"]W;W)K&UL4$L!`A0#%`````@`CH!M1W.@>!VA`0``L0,``!D````````````` M`(`!Q4```'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`CH!M1X3%P."@`0``L0,``!D``````````````(`!348``'AL+W=O M&PO=V]R:W-H965T*,%BNH@$``+$#```9``````````````"``?Q) M``!X;"]W;W)K&UL4$L!`A0#%`````@`CH!M1T=B M5OGF`0``J@4``!D``````````````(`!U4L``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`CH!M1_T+MVFN`0``%@0``!D` M`````````````(`!J%$``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`CH!M1XL"L&ZQ`0``%@0``!D``````````````(`! M15<``'AL+W=O&PO=V]R:W-H965TLUKA\I0$``+$#```9```````` M``````"``0=;``!X;"]W;W)K&UL4$L!`A0#%``` M``@`CH!M1\8UTJ*C`0``L0,``!D``````````````(`!XUP``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`CH!M1P3$#^H* M`P``H@P``!D``````````````(`!LF(``'AL+W=O&PO=V]R:W-H965T)\$-*&P(``&`&```9``````````````"``09L``!X;"]W;W)K&UL4$L!`A0#%`````@`CH!M1X#CV,^X`@``[`H``!D````` M`````````(`!6&X``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`CH!M1T@``>&PO=V]R:W-H965TD)AM#XP$``%$%```9```````````` M``"``55\``!X;"]W;W)K&UL4$L!`A0#%`````@` MCH!M1T"3UMNK`P``:1$``!D``````````````(`!;WX``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`CH!M1[*I_P&H`P`` M*A,``!D``````````````(`!N8H``'AL+W=OM*:\!```6!```&0``````````````@`&8 MC@``>&PO=V]R:W-H965T\ MFYK:O`$``!L$```9``````````````"``7Z0``!X;"]W;W)K&UL4$L!`A0#%`````@`CH!M1T>O*$HB-0``50$!`!0````````` M`````(`!<9(``'AL+W-H87)E9%-T&UL4$L%!@`````Y`#D`@0\` '`,7'```````` ` end

XML 14 R46.htm IDEA: XBRL DOCUMENT v3.3.0.814

RELATED-PARTY TRANSACTIONS (Details)
3 Months Ended 9 Months Ended

May. 29, 2015

USD ($)

Sep. 30, 2015

USD ($)

Sep. 30, 2014

USD ($)

Sep. 30, 2015

USD ($)

Director

Sep. 30, 2014

USD ($)

Jul. 31, 2015

USD ($)

Jun. 30, 2015

USD ($)

Dec. 31, 2014

USD ($)

Related Party Transaction [Line Items]

Related party transaction, amount of purchase price $ 18,000,000 $ 0

Secured subordinated promissory note $ 5,007,000 5,007,000 $ 0

Related party transaction, amount borrowed 4,800,000 0

Note [Member]

Related Party Transaction [Line Items]

Secured subordinated promissory note $ 3,800,000 $ 250,000 $ 750,000

VSK Medical Limited [Member]

Related Party Transaction [Line Items]

Contribution to related parties 100,000 100,000

Receivables due from related parties 1,000 1,000

Gain from joint venture 97,000 143,000

NetWolves, LLC [Member]

Related Party Transaction [Line Items]

Related party transaction, amount of purchase price 14,200,000 14,200,000

NetWolves, LLC [Member] | Note [Member]

Related Party Transaction [Line Items]

Secured subordinated promissory note $ 3,800,000 3,800,000 3,800,000

Related party transaction, amount borrowed 4,800,000

Director - David Lieberman [Member]

Related Party Transaction [Line Items]

Fees for legal services $ 85,000 $ 60,000 $ 213,000 180,000

Outstanding legal fees amount $ 0 $ 0

Director - David Lieberman [Member] | NetWolves, LLC [Member]

Related Party Transaction [Line Items]

Related party transaction, ownership interest 5.70% 5.70%

Related party transaction, additional ownership interest 13.50% 13.50%

Director - Peter Castle [Member] | NetWolves, LLC [Member]

Related Party Transaction [Line Items]

Related party transaction, ownership interest 10.40% 10.40%

Directors or Members of Their Family [Member] | NetWolves, LLC [Member]

Related Party Transaction [Line Items]

Related party transaction, amount borrowed $ 2,200,000

Number of directors | Director 6

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of voting equity interests acquired at the acquisition date in the business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_DueFromRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 12

-Subparagraph 3

-Article 6

+ Details

Name: us-gaap_DueToAffiliateCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35755396&loc=d3e33749-111570

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.12)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 11

-Article 7

+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LegalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of directors for the company.
+ References
No definition available.
+ Details

Name: vaso_NumberOfDirectors

Namespace Prefix: vaso_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Refers to additional ownership interest acquired by the related parties.
+ References
No definition available.
+ Details

Name: vaso_RelatedPartyTransactionAdditionalOwnershipInterest

Namespace Prefix: vaso_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=vaso_SecuredSubordinatedPromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=us-gaap_CorporateJointVentureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=vaso_NetWolvesLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vaso_DirectorDavidLiebermanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vaso_DirectorPeterCastleMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vaso_DirectorAndOtherFamilyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 15 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814

ORGANIZATION AND PLAN OF OPERATIONS (Details)
9 Months Ended

Sep. 30, 2015

State

Company

Subsidiary

ORGANIZATION AND PLAN OF OPERATIONS [Abstract]

Number of contiguous states in which VasoHealthcare has been appointed exclusive representative for GE Healthcare Diagnostic Imaging products | State 48

Number of Chinese operating companies acquired 2

Number of wholly-owned subsidiaries | Subsidiary 3

Noncontrolling interest 49.90%

X

- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of businesses acquired by the entity during the period.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfBusinessesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of states the entity operates in as of the balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfStatesInWhichEntityOperates

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of wholly-owned subsidiaries owned by the entity.
+ References
No definition available.
+ Details

Name: vaso_NumberOfWhollyOwnedSubsidiaries

Namespace Prefix: vaso_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

EARNINGS (LOSS) PER COMMON SHARE (Tables)
9 Months Ended

Sep. 30, 2015

EARNINGS (LOSS) PER COMMON SHARE [Abstract]

Reconciliation of Basic to Diluted Shares Used in Earnings Per Share Calculation
A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

(in thousands)
Three months ended September 30, Nine months ended September 30,

2015

2014

2015

2014

Basic weighted average shares outstanding
157,288 155,186 156,502 155,319
Dilutive effect of share-based compensation
494 - 366 -
Diluted weighted average shares outstanding
157,782 155,186 156,868 155,319

Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share
The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2015 and 2014, because the effect of their inclusion would be anti-dilutive.

(in thousands)
For the three months ended For the nine months ended

September 30, 2015

September 30, 2014

September 30, 2015

September 30, 2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Stock options
300 1,402 300 1,402
Common stock grants
- 490 - 490
300 1,892 300 1,892

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R42.htm IDEA: XBRL DOCUMENT v3.3.0.814

ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]

Accrued compensation $ 1,344 $ 2,917

Accrued expenses - other 1,292 1,098

Other liabilities 1,623 1,612

Accrued expenses and other liabilities $ 4,259 $ 5,627

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expenses as of balance sheet date incurred and payable, pertaining to costs that are statutory in nature, incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include, but not limited to, taxes, interest, rent and utilities. Also includes the aggregate carrying amount of liabilities not separately disclosed.
+ References
No definition available.
+ Details

Name: vaso_AccruedExpensesAndOtherLiabilitiesCurrent

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 19 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814

EARNINGS (LOSS) PER COMMON SHARE (Details) - shares
shares in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Reconciliation of basic to diluted shares used in the earnings per share calculation [Abstract]

Basic weighted average shares outstanding (in shares) 157,288 155,186 156,502 155,319

Dilutive effect of share-based compensation (in shares) 494 0 366 0

Diluted weighted average shares outstanding (in shares) 157,782 155,186 156,868 155,319

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of diluted earnings per share (in shares) 300 1,892 300 1,892

Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of diluted earnings per share (in shares) 300 1,402 300 1,402

Common Stock Grants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of diluted earnings per share (in shares) 0 490 0 490

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 28A

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1500-109256

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R47.htm IDEA: XBRL DOCUMENT v3.3.0.814

COMMITMENTS AND CONTINGENCIES (Details)
9 Months Ended

Sep. 30, 2015

Sales Representation Agreement [Abstract]

Initial term of sales representation agreement 3 years

Amended term of sales representation agreement 5 years

X

- Definition
Refers to the extended term of sales representation agreement into an amendment entered by entity.
+ References
No definition available.
+ Details

Name: vaso_AmendedTermOfSalesRepresentationAgreement

Namespace Prefix: vaso_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Refers to the initial term of sales representation agreement into an amendment entered by entity.
+ References
No definition available.
+ Details

Name: vaso_InitialTermOfSalesRepresentationAgreement

Namespace Prefix: vaso_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: vaso_SalesRepresentationAgreementAbstract

Namespace Prefix: vaso_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

SEGMENT REPORTING AND CONCENTRATIONS
9 Months Ended

Sep. 30, 2015

SEGMENT REPORTING AND CONCENTRATIONS [Abstract]

SEGMENT REPORTING AND CONCENTRATIONS
NOTE C – SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in three segments – the Sales Representation segment, the Equipment segment, and the IT segment.  The Sales Representation segment operates through the Vaso Diagnostics subsidiary and is currently engaged solely in the fulfillment of the Company’s responsibilities under our agreement with GEHC.  The IT segment includes the operations of NetWolves and VasoHealthcare IT Corp.  Operations in the IT segment began in the third quarter of 2014.  The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the development, production, marketing and supporting of other medical devices.

The chief operating decision maker is the Company’s Chief Executive Officer, who, in conjunction with upper management, evaluates segment performance based on operating income.  Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.  Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below.  There are no intersegment revenues.  Summary financial information for the segments is set forth below:


(in thousands)
As of or for the three months ended September 30, 2015 (unaudited)

Sales Representation Segment

IT Segment

Equipment Segment

Corporate

Consolidated

Revenues from external customers
$ 7,584 $ 8,800 $ 1,017 $ - $ 17,401
Operating income (loss)
$ 2,586 $ (187 ) $ (582 ) $ (480 ) $ 1,337
Total assets
$ 11,408 $ 24,642 $ 9,293 $ 2,041 $ 47,384
Accounts and other receivables, net
$ 5,663 $ 2,253 $ 901 $ - $ 8,817
Deferred commission expense
$ 2,533 $ 50 $ - $ - $ 2,583
Other assets
$ 2,720 $ 51 $ 623 $ 110 $ 3,504

As of or for the three months ended September 30, 2014 (unaudited)

Sales Representation Segment

IT Segment

Equipment Segment

Corporate

Consolidated

Revenues from external customers
$ 6,409 $ - $ 1,234 $ - $ 7,643
Operating income (loss)
$ 723 $ (82 ) $ (405 ) $ (385 ) $ (149 )
Total assets
$ 13,341 $ 2 $ 9,909 $ 9,067 $ 32,319
Accounts and other receivables, net
$ 6,376 $ - $ 791 $ - $ 7,167
Deferred commission expense
$ 2,388 $ - $ - $ - $ 2,388
Other assets
$ 4,402 $ - $ 3,170 $ 13 $ 7,585

As of or for the nine months ended September 30, 2015 (unaudited)

Sales Representation Segment

IT Segment

Equipment Segment

Corporate

Consolidated

Revenues from external customers
$ 21,010 $ 11,611 $ 3,077 $ - $ 35,698
Operating income (loss)
$ 5,466 $ (908 ) $ (1,893 ) $ (1,408 ) $ 1,257
Total assets
$ 11,408 $ 24,642 $ 9,293 $ 2,041 $ 47,384
Accounts and other receivables, net
$ 5,663 $ 2,253 $ 901 $ - $ 8,817
Deferred commission expense
$ 2,533 $ 50 $ - $ - $ 2,583
Other assets
$ 2,720 $ 51 $ 623 $ 110 $ 3,504

As of or for the nine months ended September 30, 2014 (unaudited)

Sales Representation Segment

IT Segment

Equipment Segment

Corporate

Consolidated

Revenues from external customers
$ 19,335 $ - $ 3,264 $ - $ 22,599
Operating income (loss)
$ 2,267 $ (82 ) $ (2,361 ) $ (1,267 ) $ (1,443 )
Total assets
$ 13,341 $ 2 $ 9,909 $ 9,067 $ 32,319
Accounts and other receivables, net
$ 6,376 $ - $ 791 $ - $ 7,167
Deferred commission expense
$ 2,388 $ - $ - $ - $ 2,388
Other assets
$ 4,402 $ - $ 3,170 $ 13 $ 7,585

For the three months ended September 30, 2015 and 2014, GE Healthcare accounted for 44% and 84% of revenue, respectively.  For the nine months ended September 30, 2015 and 2014, GE Healthcare accounted for 59% and 86% of revenue, respectively, and $5.5 million or 62%, and $14.2 million or 93%, of accounts and other receivables at September 30, 2015 and December 31, 2014, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 22 0001201800-15-000027-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001201800-15-000027-xbrl.zip M4$L#!!0````(`%6`;4=\,T`D+L0``%3?#@`1`!P`=F%S;RTR,#$U,#DS,"YX M;6Q55`D``_)/1E;R3T96=7@+``$$)0X```0Y`0``[%UM<^(XMOY^J^Y_T+)W M9F>J0H*!0$AW>HL0TL.==&!">G:GMFYU.;8`3=LR*]M)V%]_)=D&8QLP+P89 MU%\Z6-+1T=&CHW..WC[^_=TTP"LD-K+P34$Y+Q4`Q)JE(SR\*;AV4;4UA`I_ M__3?__7Q+\7B9X@A41VH@Y<):-]];CX-D$&SVJ#WU*5_0E`YKYV7SDN@98TG M!`U'#E`:C4M0!.62<@GZKFDB!]PCK&(-J0;H$80=2N`,/#RTSD'3,``O90," M;4A>H7Y>+++*WU^(`2BOV+YF?Z*;PLAQQM<7%V]O;^?LR[E%AA?E4JER@;#M M4/*PX.>G#'Y?DITEOZCV-/M[+/];A>>F#6E<\-1I5ALE9:1DE8M_?GGH:R-H MJL4H/ZQZ?58PS$WMPDL,LB+;JI:5^K+&>CFF!?`KM)UYVC;4SH?6ZX671HLI ME6))*5:4H!#MYJ&JCJ>E!JK]PFOP$UB1R_DB.D3)E=`$EKT:J<$A"]O0N*"I M04;LFLD9=8=<.),QO*`Y($':M("%4Y2Q<#%23K-<[)!)::IQKELFSEQJ5DI\YS?BDXQJ`CVQ`7=M\J#S!`>`#[)IUVTW! M1N;88..&?QL1.+@IL'J+067G[[9>`!<>(:X7:,=B![X[`.DW!8WG4TJ*8TW9 MXWFGN2'5/L[$_S;]BG3V?8`@`9PQ.->:0$JMSJ^%3R7Z[ZK2*%W5/UY$"P=5 M7234Y=JA`\#54 M=?#)E]U2<2I*Z2H70O1@YGCR8-B_FA+W4W8BC]R`:DX><_C8I3RJ2IDJC)S) MHUI4RE3/98./>N[53UT<]5.=BK.:3W%6UQ=G-4MQ*KD7Y[J38X;BK##E]ZWO M4'HF;5#[WRYM4\LRQQ:F/^WF.[*_-74=.=394HV>BO0.;JECY*C&%VB^0'*` M#IC)%0X9T]//?H).V7@?&TA#CLX`NSW"J3S/ZGPE4;9=,3J?3 M$UI\>B/]"3HJPE!OJP2S<-E)]'QRHT]OS,O./V3G9SCR*WGT=0^L"9N:YIJN MP=80NLX($I9,X(BA[!5VL&:9\"3&1VHYG)Z^E!`1'R)9:U7I.0GG.1UZXI!Q M$V'B)AE.$&F@()WHX^OV62!:6@CYM1"VC\W/(2RCI0YI8(AC8!P-8N2D)%&3 M@)I3HNCT_A\GF=C=D>RCVV^\J0>J+08>[`PFTG3;C$D'[=M(R5-NF M#=%4-G5T!SQEPD='8J%)CR!3)9-;B"$MA>B?^1XXFXAF-I[6D]%Q;9SQ-*R$ MUJE"*]/)>^[HN@39:8%,Z%L`YHZM2V2>,#+%N@$@+3-&6D.;MS):%;$:,P]V"O6^ M:D#["8[9S:G8X22/`O1I$+>J[;L<`1D-PA.P0:)^VT[AW\$#BYB641K.T&`Z-&8&LS$P=+:DRIHJF* MDA;2);BS0Y1`8^H$5OP3-D1)<$O-?1Q;H!+6^"6XI>8^CM5[[W[ME9!N:IKE M4K?C"6H0O;([VGQ4)Y1\GHRA%VL@4$=.+,'G-OTD;IR'`=]`K[4',)O^R[_:X9K@[U>V*9["$OU]NATAT$#WKV M(.F/J%QO)\D$O/T1YMBP)A#RI[ZZ8T8AW\,P0V'-!LY"JB=YUT"O0JL@^[5QI*>3/4A#-KMV? MKI5HS1]:1=.M=:E;)5J7Z5:A=K;M#ZW2CLV_'2L:>AEF[Q%&#GR@,M0[V%'Q M$+T8L&G;T+%O)UX`G#W.R#'8HU6S@Q!8GYUZR#<(UVB]'_I?+(/C6B/WEMO6 M04>P4/*`[.`(RDG`8CI#QMM_7%N4UH>$5!B"*8S,-["MI3#X_$[G;B_71Q$R)M6CK/G MY]?H-G!:\@V$C::(N9;+M;.M4"3-C8.9&\>**.GWB.SW"(VZ6J5T`&1L:QW4 M,KM+*(?RJ&8IC_G=I'=P``F!NG\DODD('5;F.G@/B2O2(,LKDE4Q-;F M\JV!5C=ZZD4M:OJA-G`(O+4S!93:[]3JU*'N2[5EL4,]6MZ-IM1P6MY\N24C/E4#.)9E>O#:G`=)@EG0J:%K9< M`FD3JTE.<2),<;FWE.04)^`4)Y35M#:DY!0GS!0G%)#6MI5DC$F4&%/NK24) M)5&@))K%M+96DH:W"(9W[C62M)+$L)+$TD<;K,1)(`D#)*'6X=8&DIS81)C8 M<@\C&5$2+:(D%J0VB"A)[TT4[TVTF-)EN4$!].)TL.T0E[73MXDTETJW[[Y8 M1$>8UJ?WB,64O$4FCY:3\SM[XRV>6D2IVKTOZ,SOYKLLEAM3N>QTKW^]HD@4 MY`0%]*I+:2.%B^S61JI.S>WM M-.0Z(R+`!+5:I_#HCRW7EMIV9X-C[;&ZJE,.-5JJZWL4M4SOQ))6A*B*=E^G MAYE'X3TSN-FQNG@KC\U5H-WK3XFI._K;[RI! M[-&;)SH&O#P6UBWHUK0T.:S`=U!45%^-X6`.;F.ZG11-%H0JT5*A(D0H)$ M--M(0N/HYXLUC9OIK7I]#6+J&%N>?>/_Z!'XBBS7-B9/<&P1.MWG&QR)K9TY M5:N:+>T:07':U/]T;8 M>*<<,_(6-O<@AI58YQK2NF@2,M)A6[#U7$)&0,B(MK4\G8\O(2,]_KD-'VO8 MV!ML@NI!!Y*6:CM&SD/>&^\XBDG@])S$;-\XR!;`=^HKTA\0I,5-->?/3FZ, MX20A2!@?#,:GM^!XR+B'W!^XF[4D"5L)V[P9R!MC?;/S`EUG!,F]:B(CYT^% M;K,_/R:$4[`TA!X%\_%+:43OSX@^@5AG5,E*>.4?7@)IK^B"G817SN$EUN)> M=*5&PBO_\!)H54>"*J^@FG^]+.-7?FE'Z:X!NP/VOJU#W29G9.D=3!T9OA$G M_A7"1]4,KKXC8XM0,?ZOA;#S.\WNDIR'7;:11_B%Q86".;:0WKR#)^%TI'#* MD10%M M9%O5LE*__MJ_VY1T)4):1]3BB8F/E7AT34A[WHJ%35/S$Q9P,L50=7<06R9; M7%A6X2KA1FN,$PU20^U.([;J@A[QUD?8/N=-.^1R&67V9K.*)YO2KBWEVGVQ MD8Y4LC'Y^M(A,*9_;DKY:BGCGD+9E'9C&>W`$4A'_"_%8I.RHC-VP+VA#HM% M+T&'Z'J:PA*`KTV>X"!Q^BI\&JB&3>45*SFMJ>42PNM!MJ8:X`^H$M#&.F#: M+%ROG\_+QG*U/8VWFH5B42GS6Q:6D9GR\W"4`<=VW8A"7/D969Y?V59@YQ>QM6 M1TO)1#G[W3)<3&>J">T[`Q([SL\TAY=A73XBQ:/U!\CQCAXA/`1,8[D)?/@Y MIQF]?*O9^8.IXU5DHFQQ9D&+=N70(I,X,SP]2%[-0]]4#49PULJI]EQ`,\K0 M$QPBVR'42P+,$HIS-,O`TE>S]'NSW_W2ONNTF@]GH//8"G,R3RO699#=A&V` M#M;A._@5)HC'S\)ST`RKN0E;G@O)Q!BQ3-.B(\JQM.]GH,]G7M!U'>9,ZE3( M"7SQ$KR`ESV4.\ZDHE!E#YA*Y=^X805TJ"':F_9-H?-X7_BD7%Y5E7+YJC+' M]Y)JXCHJK#3OZ4<[24O-=!W/DDY/S6NH"(F%C/@Z M45:T1;DLURL9-X9YAV..$=_:`O_RW+O_*W;'S(CGLXB79,_2=M>?U"7'MF4@ M7661VXX#39M[ZM/:@\JCISF#_1I!NO?,0M`<_ZOOVB^7R1LPT'K//,3>M])%.N&N((Y>26(HE(2715^F?S.RE M1A`MRUD^#K7-6S;?L'6D?EFK93U/+I-JNGX150%N*?M:I5[+6/8=/+"(Z8GU M&6HC;!G6<'(1?+E]FC7UAY)\!^K>6?[9S'[^DD_KF6./>.^^" M)V1_GPEVC@RO%H3JG>7[W`:_0-5P1AKUH7?=+\R9^3;')6/R=G(+L38R5?*= MRSH@/B/J=U%"R=G[>UP$L1Q^R2_JGQ9IN;9CF9#8_C'F63M7]^`E=;.J918Q MR;0CM^RE%#C8K8++94=>7NZF'WOJA.4Y"^*IBV3KY]O&Q:_6RHD9M,\`%?=*7F?YMXP!*>6K>K(7G%3%GAA/%?!IU"O)LE[*^#-1 M=1C6.:`(,!UG:W#].,V^F<1+Y60C<$$E>V(]CG0L%\[:8_>Y_:-JCC_\5:F5 M/G2`]_=565$^@&:K]?2U?0?:_^RU'_OM/F@^WH'N\R_M)_#0:=YV'CK/G7:? M->Z"MBZAH5&NDEE@A5X(N`C^7D!,)*D%L(7O8XAM EC!"2*=1L9#O`&@": M1ADV#.N-V?LJ"_B-'6^/4J5T!ACZ.)$[.HJ\KPK_6KT66R256K@;%_"9:5^P MNARN4#1H&&-59PM=-P6J@MEO>ZQJP>]44G.XU#"5&O&D]H9T9\2REGX(54BF M?^G@E3?MIO!B.=0<6UP/.R4,2=&QQM?`I,:=:S+=#59HW+KN):@K+^PZOZ<"LB^&2BT"2ASP",D&LW6:X;)+;1>?-J)Z=S>0 M7K][UH6SQ$K66(G9$GF%R@+-]S9"#MR]WIO*&V$#42V^+YVWHMZU,"P\-G]R ML>KJM/_TGP^!RD/IJEWV\;Y8$*('TAL_/G>,YD)>?9N^7OMAUVH\,U=3LTSF M:_(X\/(1XS>9D]Y5;P5.T`\;X&?G'"1#YW\RKKD1J9G+UZM:.:M4J_L:."L% ML:PO)#;VC8WR64.IBX^-M";6D6K7:2"OZ(7QI(8]B'F41M66&V7QAY,$R6%! M4FI=5\Z%6K:1+FLHEW?\"BSAB MD=@X'FR$5-P%WW4W_17VU/V_%^Z!3[M9=_E><__.4L`N+:7E5^]^#EURZF_/ MW&#[\XK-S_-U[+;]$`'BGW#F^R2T:0S2[66[;;GQ7@^6?9M]GN7RY7 M8\<4%E>Q+\Y3[?>O5V/[_=?@/+HZL8#AT%C:ZE1%J7&5Q&RE_?A\!E1-P9*G9HVNP^C(V`6VG$],-. MN!%?/*DT?[UZF:UX0@3]TQ!LUPJ!(W8'ZRNDMA_]#9<(A:\!M,)E.KS(@V6S M$XC=P;/ZOE';B^782<=UZCQP"].`OQ$["+=9`ZD7['AJ<:PBO8@PT-0QVU@? M:]0T9X]F[."6EVTCYFM*HQSA/YEZAGRF@5&M3/^MQ^>*P\XJ.Q*D8HV=#B(\ M-N(,7(,IE%DQ;6H@`%7_T_6N*8Y;BP&E>SI5^'3BUMU6AV\OHT?_UJDR=R)) M`XAJN7:Y"Y&$U&Q@1,4:$\K3'72PH^(A8KZ4;4,GR1>8NXI^N:$0NP5K:5W9 MLJVD9_NR5!:$[W?0]NOL0<+OSZ3M=!.UP_PU^UO6LBANL\>W72H4M;*LFLWZ-JZ[-KLNO80?;A*FE?1H)^49FH#6EH(>3/] MUK409%^*.X&K*'-96?+;:,HO)P M7ZSYBZ*[*4+J]@K!4OJW=&K#DO$),"S#8URHY): M(BG>'5@4A<[@88%&*;JDL83U+"[LWJ"MA[H1/;6<=O^@PMZDM.6M_4JE4DVO M'/8E)_%>EE!HWUVEEM..'E/:&X@V4Z*-4B-[)9K).S7ETAJ@WY\2%?)9B6JM MFEZ1KH'@5;>-4\-F*;R\GXOWNO+DK79A7C;*259";(_#-HRDVAY\U8AN@DID MY%:UD@]]3NMQ^?F\^=[B/?>]EZZCRSUT/9 M'=7=KX_/G2S^(`/$?[71NI>`A#YR3` M3RQ?H=]N%7X^!RU(G/]O[^V;V\:1/.#_K^J^`R[/[#-)%9T1]:Z9W:ER'&?6 MNXF=LCVS=<_6U11-019W*%++%SO>3_]T`R1%291$2J0(6GUULY$E$F@T?MUH M-!K=!E!KI9;[Y?Y\YN`O.#P8L72L1,-+DCX68O4V!B=<24W(HFW78^[,"K#E M-+O\T)QF<^6]T/L>W@2U7S2DV>>%:/6G;FB/@0YHU1`4PSL.%\']@N)M^=Q+ MD;;D\MCQK("2^`U#_[AVD]H+7_^?%%`>H2(#,_^_L/Y!NB?AX\P(*:W M8^QGEP6\W$`2VP&\SW%,Q++'?N1QE@G5SE-H+"-ZN]K M-T5P2%N'B=DG@8%6G_L$\_(\M4!//W/&OW'/M*31$WBN_9Y=22RY<\N)3L1@ MY,:CZ$/+#;-,`CT^L<$TPAL?Z6L<[&U4.`?;@_ZD.8F71&`G+^S;Q;/O9)&= M,4?[$.PL[ON&]R+`:;")87ELR0D+K5F8R]R:)=(6XSA:#M\S%,J4**9$0K3J MO"1-2)0+T0-ED71O"-P53HO;D)9B55B.R)B$P M!U??-9$Y(1&(M@#)'&Z`.V(!=R56\+*Z._#XOT,+]R8+\.)LS(P_8#[BC;#0 M8H;OA[,HVB&8&H#.R01!&@A8H(4$,V?,$FF2+CWQ:KKVDY&(&@K`0NQR2X>4 MK=0V#II`H00!0.(W='O01@L;6Q-HL0QJR6]9+/#X$W="?&JI()9I^%,VL=UG MGXU#(;C80+PT1'+)Q[CG"M#^C%N4B["4&%-LI\86S($GU\)@ZOJI.9/RNFT* M$]$6L^T+<7TPQ/;085-0,R[NL&W0%GC+&@:1E,>S/#.<`7]@M[E@#@[1LSCN M0/&K?X5CZ>".9GAA52^0)FF,J>!@^86"5@L&N)ERL;&&_WUTD74/Z,Y150<< MV[>UPU&K*)L\>1[6/]!EF9H#404^"G4I!USL7L_]!<,6%EP"NINI>5T2[&T$E&9 MC.16+@Z8^,8%_F?5KU"$.U5S(KT(>)(;_^%^O'J"#8[.9(YN2K'=XD]@UN(R M@T8&K`6>AXY9L=;P;[!L@=B.N0U/`L*G:&Z88N$2EJ//O2<+7L7OA4_40S&" M'[4(W?BCA5Z;;_*%,0?C)A'0QXUEF*6"-A:XIK),,A)5L87_#;>/2XM&>S:,=E':B`G_'D)+;E M@06VX(N@5>XNXF9DK[]D'6^,F(9FB);#F>]$^+0>.KB!P/[0%@0.+N M6&26D*=4'/81J"-3@-JRMC\8MNC/GW*.JWK&L.\LD!K#PS$O\`J[FZC(-+7J`1$+4Y`E/X>-8%,_U>">O"1@=TLU:%WPS/$CBX0N<.[/78)1B= M6=4-3E'7RX+8RPL2N/9-&PK0]^2D(Z(K><=/@L=H;I8`F@``$30]?R]SJVR?886BFWFCB4E0)6 M>@(V]D@,'M5`"-SYC[!Q&UOA#)88 MA^\@H+2\Y/MUGU7Y.7^9XG[^%.5[DK?+C$^3_%:LJ&[HP][/?U=>=O42.*M@ M.8D<5:VB=8Y2;=UJ25@M5K-D4R6Q1>^VT:-:X1I" M#94XJKDLL^H5F"\P7B\)W$.7.HP)'8O;E[<3%:MC%%'<($VZ7D=A3E*X#4!& M+25;:[0Z&Z1>TQD@2*,J)C=:JU-'U5G2J8W`1K\>-2QP,WW8QG+/2S&0F^(=\=%RPU)J"'XLW7S; M*R1+A6BPS?&U.Z+!-J/L(,_>CAW`O4@.)G*"1'1[$*=BV3Q9%MAT[_J/3:T!D&R&C#F3T"1F$C.Q(:7W8(6P0-K*Q MT>ZKCXU:8J718*-8:8J'594MA`W"!F&#L$'8.%ULG*RGZIH'RZ5#R5.EULZB MW55?>@@8-0#CK=YK*P.-C/2]A(CC(V*D3H(A0H0*B.@,U=41Y(Q2$*RT<:!- M9>U,(&P0-@@;A(T3Q4;1A!_;"5O+TB$?7[J?7'GFCEMNVH;OBP+?HGCJEN&\ MZJ)G%U$-1&^5(6QJ/'%9&W9FC$5MTKEGN1[6Q[7<<5*S%;XW75&Q;E$75I26 M=H+XT73AW;6RAO'G/_\0^F>/AC'_\8/A6_[-Y&OJK7-G?&!25(W]S M15&_N/QB]*S'QV+[\]D]\E`(AI2)"P(N)G([I/>X\Z1G3A9MWSRESX;C&Z:8T@\OZ5_$V_%`Q3CE,&4C;UCH6)*& M7UNMP1LVYJ8U,VS_+V\Z;WYNO==;W=2,[370LN?JH_%DC=EGBP/Y(#RO>;K$ M4).1YINQ5F]0VHQA^69KS#TCJ59N+!HJRN\+=_9@.:*II78%+V218CV#R[WV M*'#C3P7XOD/9=]PMJ>[-+P'%'&&;C.[J:& MQS7VT;)#F.VS7[CSS&U;)-<'\I\%^850Z[FBE[@3Z$-T$760P=GJ;R=1NPM1NZ4P%G&8`]+5SM-?2":;EPU2O M#*;`U+-:N8J6I%D=3T7SC=&F@MHFLE--J6\H.Y65]\;R4\%E?@,O4Q:LQFX7 M)>^OT"D`>VN15?!"CY\7Z?+Q]W#&QQI+"D!=+FH_'6#Z+^A)DR.I MB8D![J5(B2A!.N"'%!79FX5RM@AGL)<:=#J[=@@ECJ:6>3SWF04LL`S;?F$> MG[L>&@_[[J@5G>;?[P+87L^@K3O8^1J>Y8H'XS^^>OS)OC'Z\WD0M5KT8KO%. M[X'QDBE<6ZBL@0\E;P'6^3#H-H(/)1N;:WSH=GN==@/X4/(>9IT/PV$OVVF9 MAP]9MC::VA-A:5^)LQVAG`H8SZFWDK.976QY\W/665E\-/;]RMG8]YH\+=.8 M#RO-)#Y&7)RL%8]T/WK]@/LI!PILVWW&LXTDE0;SP_G<%BN.8;,Y;'KD5%@+ MIL9G:KXX;YO`ZN&88*R!J>:'-GQK@/TV$;^E'/-80)VMH%VN=6QJC)EKBG.[ M,?N;X82&]\)DO?*.)IY=_K*K85=S;@;6$[=?UD[UJCH^I=3JHI]FIE;?=="O M8KKU(C1G)%2O,X?Z+M)+O89TZHF'JTFUCA17F(8*6ZBJJPW)W--=-B7')$%, M38BMY6MO+,*.>_6@N5KV%2?A7:H%P"AA,V&E`%8:F[Z9L$)ZA;"B+%8:JU=. M-G_&+>5W5?'BLS[0NBU=_:L^!(XZP-'3=`('@2,3'-VA-NRU"!P$CBQP=+5> M1YV,&HKXMRBU!EV#;@!;"!N$#<(&88.P<;K8.%D_%>5Y;8HXZ5JG1V5&""3; M$SNJLPFE1)\J`4/7>D/*&$T@V9$H6.N,!LJ@A!+#$FY?W4Z#L$'8(&P0-NIF M"V'C]6#C9+U7,A<,CY/02`\6ICQ@/N9?(5^66L?DF)1(?6DB:-2Q]01LJ!-= M0[XK!2!!VH*@L45;J(,-\E,U`*VTIZ#]9NU,(&P0-@@;A(T3Q<;)^JGBK._D MJ6K(!D.I_07M/56"!GFJ"!*D+0@:K\Q3M;FB9$9EP&()9W-7D\!@]*LH&/TS M&D@EY@2&MV73V/#1,P/KO6$W=V+@)5(;P+RJTTN?Z9W1X-5RK_(DY9U>=B&$ MU\"\JC/=G^5/:[Z#=267@X@JN\H7-'833+FG8K402:=\4A"I:+60#7G;J^%! M/>AX'=-/\YBWNLOKF.]F5'VI#1JI'V&:7>?Q+.#>C'WD#T&-`$C]@#3=`TE( M4=7"?Z8/-M1CJ7YL*DRX^IJA*F`T24LH#*!-P-AA6+Y:W.QI3"JKA]A'RS=M M%Y4$^R?Z9YAPT.29P<6;B5^'"@FM95.XN;]<^#L_,_EYV-;UG]B'7^^NKB_O M[MC%S9R4S(FJB0!&";&\X+ M$_ET0;U83N"".F/&H\?EFC9Q/5D$";;968=HCY;L6K,R'F_M2:(QE`CA^@"DQ5 M:A)^!.\/=L>])\N$+Z#AE*L[^?36=&T[KL^D)8AHMWY*VDJ^TW]ZAV-DW^E# M#=0'_L?>(CFIM[[&@_WJ0;?I5]\SK&.58D:*VF<#1FL*MEG^%/@&C_FA`3R5 M/!9JAR5MGR$ZML@IJ<(A7XWW<=;1C][!D6DAQ,/3=\G(K!63[RT.0QX*[=@"-#O_#Q M/3>G[*W/HR__GLVN^Q2''KAM<9PKW#X`>.$_'R00U@43Y\D%@TXH8L-F_@OP MYQ%7]P=`(>X4>.(>_0T?`$\QH9VQX8[0V MQT)E"88.6["V9QFBOEP=`E=45HQ5-,ZD-8Y0!MH5=;]KBGF--(0#DPI=/5JX M]1'+N+/X4RX21GHG9*=V0H8TGP$BB!I7B('E,5C:P73'/B8&_/EDV"$^'"P+ MUMM5K"#<-BOU9$CS9-59;*`6HTJ3LE16$OX&?C\9EHV;@LCHX5Y@@/0:,^0Z M:E]<)L3.%D<[`3.%X7[%CTM,QB^`F-K6##COO22CS5XZT^L1:'`A)%@%(%IW M9MO]"\\6+`2-F710&71=T* M^'"VHVYW\!R`)>GW?]RB3"JN5[$2XG&2)4/S1*RN=7I(1@T.P\HSV..JM9 MIJJNF+1.8?6EE'9,;@6K5:8S>_M,UR_>1R[HWXW7[*IQ20 MXRLZ.!6-!75L^^D%1D%*N;A2CK>R2B&X(M16MC%_A8_H,<9 MQK1;;]'%A6-?7!AT*-GX*2/C?6NP&1QG)P^-]YV31D?#]4;>##VO;/&-#FSP MJ-?DL/#&ARC2ZYXXNH5;F]9C11,^Z%J_,U1?Q`@DU8-DZQK]5F^IHXF/?$U= M[=59#2W2Z_24@0?MDU>7:GEYAI9BI86(ZD$30FBO3*OQ22B2$]TS?_4P[C5X M$1ME]%?/\9B-EF1%):FM=7HC]86)0$*K,JW*2L"D\;KD9/?(B3M[;KQL\&6G MPK%IR594S-YVM*\K M%*53L>->A0IR6(3$=+3'2.O4$@U4T@T?@I\"\)/6PKX()/AM,S((@94KP&ZK MWU`$5N1'6*.MF]`6VPZC>:"J69.0=H\YA)2R7KKJ""^0PL9N"`9>G5=%"I&6 MEEJ1!E$!J>VJMVX0[O8W5W)`KP[O1P-0EVVM$/!(X17QMI1*OC!EJ/"]TG[" M;30HZ%0F;!SWJ.&DX4&G#*])>^2JJ*E89L[MS+D7S+GF1RNB\#'TXC3\BZS1 MF]-%K^29_S:76:&_TZ.\[9A"?I&W]\SCMLBW:O-'PV:FBXG]92)A$3,(+_:3 M=/`8OR"2O'/YX,84LDN-923;1I%F%A`.]-NVR'?["W>X!R^)AO`_=CZ>68[E M!YC^^"GJ\1C9NC>.:G7X8FB+Y+XRU?\X-&7&8I?92>"'XP9\$9998`PYTG=O M3@\>Y46&P7O\B3MAE'D<&HK&NY3?>W6.(@3]O^F4^&7G1<<\T-\-M4%K("`F M*@RTV^(/#5.\SQ>%(I93J.^4`=&4KFO=06O1=&>PM>D\TK61VX_Q::+E1ZFB M99;N!\2-``5.O>C*^(;YL.>NCTF8-ZNA5Y@^/:%Z.<]TZ!CAV!)("N=S6T`) M\Z![+A.YL9=R9`.8?`$UG+*)Y8!\6/!P7!``,XM/5C/9"URNU&"-8#\UQLPU M(UWW-\,),0VU+B:[(V&T_&5W&3U'F\!7GBZZVK1UI9ENAV3-$VWN3JV\C8\]VY&2R!+$C0NQZU5)M+,+RGN6?NI;=F19YDPB4'*Y0 M@4]F?9.U/7I!73`35HZ.E2YAA;!">H6P0GJEZ,:U0'ADKZW^-/>/F\5 M1Z"I>FI98_YK?:!U%;H256-X(H%C'1P]32=P$#@RP=$=:L,F)`(D<-0!CJ[6 MZZB3ZD(1_U;*7*,04`KB4I4MA`W"!F&#L$'8.%ULG*R?ZGH1?RFC(,ECI:@X MZ5JGIT[)(-I_*@F2M^IL0BEEG$K`T+7>L*L,-DA[*`F2M[#&C`;*H&3?C*WD MO3HQW#9IIT'8(&P0-@@;=;.%L/%ZL'&RWJL/AF^9C!N>8SF/?GR/=\X]YD\- MCZ*O%#LF;[VG\!J"1O;6$["A3G0-^:X4@`1I"X+&%FVA#C;(3]4`M-*>@O:; MM3.!L$'8(&P0-DX4&R?KI_IHV2$F%"-/54,V&$KM+VCOJ1(TR%-%D"!M0=!X M99ZJS?FPX\]__B'TSQX-8_[CA]"'Z?7]"W?V8#DB$>I'RS?!I@D]?@\]?T#[ MZ.?__B_&_OP_9V?QXRSUO,;.%PE1V6V4]OD"$QF?)>E0-?;Y\P7[YQ>1"^/_ MSLYDBUNH2+49-2E:Q/S`R)!;/OG+&Q-SK[0&+3UPQ:=1I_5[W%3J_?-OEO][ M0@G0(:EXPT+'D@W]VFJUW[`Q-ZV98?N8C_1GO87_MY51&TA,F/75PXS%P8M( M]LKAV3GFGST[QY3(\)9AVR_,XW/70WXEK-F?9;?<=!\=@-CX"HU6:V(A#LY] MGP>2'1X?GSOCS_"U90,!W(??PAD?QX1^M0TG@"[.(/S MG//UENZ-LOMQ$?=D[-6>?-S^U.;[1K4Y\`.NS;`APBE8Y3P^"*WA/Y>+I\Z#"\/S ML'+);X8MZJ&L\A&,_%W0'[6'2\C/U=6Q1M#5VQU]QPA&NLHCZ.08P6#4U]4= M03<'BD:M7K>2$7RPW&\;]=$!F/K]-]`,*+E7F,62^\$ER#)*Z8>7"]OP?9!K M4\C[S43\\B(T2N9++U\]X(3W\H$['-ZRX&.^16=E5Z`PRZ2W0`&6Z8>S+-+1 M6,+(#1^G6`3(G!I^7(?I62PMF6R+WOSDN;.T$V>=67K:R;)+]CN=]2%E]W3L M@723@>11`7N-`?`K/J1F3V-?I45RY9@>Q_&\_#H^ MLQM[V7TK-.IBZ#P;M%<,X_V&??/ER]7]E\OK^SMV?OV17=Q7M_<7[+K]7&ZLYDE35+L$08"(LT=$\W@$'ST"LD"<;):G/'H<;$_4Y11%3&ETX_)OG+8 MWT*'8T[S]G)I4!#"J.*C`7P"'HW%KMR5U?-^N?SK!3N/N<>>K6`JOM.8"[W" MEA1=<#[0#>\#G[\8+TP?B=3IK2T5*:-.-,8G$UE"#ZBSX]IZ0"`,0I9>1!HB M7Y^LH2GHPLI*+]SP4.O-9JA@G,=T"RTLN3C!9N53L84B6+"UAB/P"18/F0-> MEOG;S*OQ6%@40%GVB)8*!O;B0<5%7,5H8L*2/CORZ2%HL?#A7]`2C@3&8%OP M([X2>0%`KX_A&Y-[@6&!Y61Y9CCS`ZP2*O5W^EF<-3<,P%(/T3IS8.Z8,8$G MTCP;;)HO7,.7FH]*A&(Y4T`@-",=L88YM?B3J&(:4>4+47QT8377HJXCG`\3^A("?VHIBQ^(Z`Y=T&IH!-8&'MBYB5Y8GF?+CUL4Q3MM8W^LU8I$PNWM/M'XOL#!9GD3T$V_QPLHT0E),G7,Y% M2#]?O+87U]N]UJK+?4L?QQY"KADH90ASP\,@&!`T)'WLVC8NF$E\[+91?#6\ M&T]XOL="JF`/)CK-,R&=M=%@=)^>.9)-_=0XHHSYJ6)$D<*44ZFQFS#`-5@4 MA]D%KM2S>\IW;PCSUAYVMJ`KUF=0:.&MQ*SMQ.:PU[AT8'^PVI>QJ/P'1NF MZ8:Q'\H%V]D#:]SDUA..R3^3&_RHSI,>`8!VSCH MSI/GJ9;_QZ)_?=?L_K[V\@<\13"GL!?_0Y[Z(GT1>4!<=$+\Q?B7ZUW`UA[& M[_GBP5_X@M:LTX=!FK=M7$^&_31?-P]B/\9N8-XV?A_"V-58T#H9V^U6R=@C M(W9E+:F5L;W1*T+LRC)6KRJH%+'GZ9]OQ,^WBY]WHO?"XV,K8$MT,22L)H#' MPUF,(9J*C#?O7^997<"OS(/PP$<[YF#V\"!+F,I0'?DYB>6+W?OQVYI&`"%.R0#MNE$#V]K>K MRW=K_GJ%IVGESE\SB$Y'#WN+`&0#IP9F([3%[G8Q]?($#68.9H>-77&RE)P9 MI8_E3-NP\*S'21_N)&?J@Y]\]@B8\?`\283/OF<(\XGE`*+QP-%R`,6>#.?V0SV#Y@B(+K\!T$E';G?K_NE[0R;CFXMYLD MTT7&`TW]_#?A]R1OEQF?)OFM6%'=T(>-JY^1:&/?2_PE<+;49$OE)!^(1.E, MMO(C:\^_'2W_9(Z^MZ"NO7'JHIF*FWVP#?,/;)P)4ZKLM%,1]LK<09Z+$*.] M;:YCDWO'YT$4@!9%QZW1?HP\&EEPJBT%'&%[&[8;`^W%;*T&67:;"O&\>8[S M)//;S\H:]/?).G2B69".1L)J.J0EFRITC'`,`!F_VT8/Y=10CM-%CE/4 MS=(#HA(HRHF-UJK MHT[99-*IBF&CVP!LG*S9*O6JO3C[)^6JG@"IDV^=E*M*V!@.ANHCHY9R<'D\ MHU0.CMQ:=;&%L/%ZL)&KBD#QH,'FQ)!FT4R?Z!-].J5/F[54I1M8L2A00*.: M`8UZ]ZAA@9OIPS:6>UZ*@=P4[XB/EAN64D/P8^GFVUXA62I$@VV.K]T1#;89 M90=Y]G;L`.Y%AKT9-#'UF4C$M[$CHWH:&Q@,:&#=`>A@W1'E9<2RJ&X MKA.VPDJDJ9KSIDJD2E+XJN_>*Z8UD_](Y[3Y8)`[ES[?%Z M^4D_N)F(A\^=$R?/<>R?,P71:1Q&'[TPI81E`"77G@ MM!B#AYW:2"VF/P`+W1I)+2)R720T!Z5)C5+/"#B;)_6%SSY??;BY7=1F_HQW MJ&%$477G336;/_*'X,KQ`R_$47\P?,N_FWO<&-\D*\4M=)15A'O0B3$SP/K- MHI]/AHGI/%]$+64DX68B?X@J+J?;E,^XSMAUQ*`>#.>/F\D$1C?&G\5X=I9@ MOKK^A$686^UV;\&[O(-*F(HOL(^6;]JN'V*%ZWN^L=8R/KMX%!\4SS6OLG+5 M2;FN;^XO%Z;,WYG\/&SK^D_LX^6'^U7#Y53*F]XX[(OQPMHC66E+2U>G9>)F M@"@J&[C,8-+OU4_1H\HW^TSLV#ST_-*`QZ"FJ:ALPR_=#Z#YZ'BCPN1DB M07Z(URLM1]2QG8,I"T^ZW@M6W^5+72')2_U@,>CO.AH8%!IH./&GJ-L;#^J_6P\`K,> M44=.0@<,DM#/?E\T#^-YLL:RIK1O?<,VW-"#.?:X&;A>=@'I*X?]+00E*R=1 M<`J4F6Q4C'D0480]1'P%`N)AX2//KO>'*!=LS#$A$/)D[OHH]M^U%\.1D[-* MIY&0)SBP^#.1,ZQP['$;S/XGOGD$]DL\`B==/#DA`/N%J??<9^@76,F]!>_6 MD;FM6G;EDK6R<6J&.KB/F`E$V1"+/4!A]"<-F@YPC7*7 MU,@(O\FY88Z$BW#``$P&F,WB1UE-O@Q=0G[KZ?BUIC87()3K\>V9S!^^3`P^A^R`4!=2A+9G*QPI\4"[O6PSHM_$7.[)4 M36FIXO19#OQA"(T-0P-`5O9^F^&[V(&-].P-5CU MS>S!!VR]J.>RJ3$UQFSL&<^@9.:PL`"/88A`[W?Z^W8R.<:C@;.8<&\-]>ON MI@T&\K*Q?>6C[6$B-7YPEG!##G[K9B5Z$=_S=^VY?_\0^D"T[Y_CJN^+M4UL M.Y(.H;NL/<;2]@QL]_[RYFR-D&V#VV,0>;?CQ2E+=D4(G0C?N!?2V%T@-.'7 MQ8[R+D+TDA[_NC#]A`F0;V,9]X5=R8X6_62,'Z=NN0$Q:Q%!:7H6Y"`UN;>+ MHTV;Q6V$IE@)NU3DC.G.L'>IWV"A]?G9A0LFG%`6FSDCW[Y##\/%HH5L-BPY M;Z]`H'W!BJ2;:]>YXX](^DX.,/*$89#:PJYA MJ0JV[(>7%,4+@FO@:E[.-4,*#^9J;W7UVY^SAW!EUW%*;\5C7I5[9LC5H7SM=DJ4"8 MCF;2B'V%QBZDSV@3!\13T3/E:LUTRY50U]7;'7WG$7DK>^W)I.X\O@WH,--D)K%Z)N9<*8I*5=1Z._K[[H>8;S*.!S_S+GT?H;D7+NC&-" M\FF(;+E;I3%K_)>Q(RCF`@A!X!EF#J'*P8)!41;$Y$34),3D8T.WNSKP$!JSZ/W(P8$%'3$:NH7=Z>E])#*QX3RK'0+??VYL/\?!31-7#@5@-I.C( M:2FHA?\]%,"^^._V!HKBO[`*.`C_^IH'LG[\%^;`OOC7]Q][97;`'N*_MQV@ MXOCWT`'[CS_;0JUQ_2\\]WOJO_ZPN[_^JT;N]YCXO=>]_>W?JL9>V/C?=^R] M_<=>T9I?>.A[8GXX[.ZO[ZK=]Q1FP4%K_F"DJZ?W]UCV]];[!Q#D1/9$_ MUG2IX5<7=EI^UI*;^TOVMY50TT^7M[>7']GMY6^7U[]>-B!LIRRV+`>9F5/$ MO[\MLFDI^U=7_,VIZR M'6PSJ=2YL1)>1O5.*MBY;PK^NC/_;R[4>4!NKLWI_G,KGT]1T'R079E3O0S_ MKWPNER;%62U7J>B<4/7*O-!YQ37&UJ."UR)Z&U)QC+!R=*PTMCH=887T"F%% M6:PT5J]0U4NJI';J^RR:8YICFF.:8YKCTOPO$76OI9;`QY5C);Q1_<#A77'P MZT[PUK_ECK=/(26)/G9J1'VD]76J,D#@R`3'0!OHZN00)W"H!(YV6^MU"!P$ MCDS-,=1:NCKU*`[V[;PR8VT1JK?='CL943D:":\D2S5A@[!!V"!LU,T6PL;K MP49EKK-E(VBT5XC[4>RSA+3$F99D5(P2E(NK`.(.!SG2%!4YZ%U]62.(U`F1 M=I<\K@21K1#I]GL$$8+(-H@,1KKZ$*G(P=9@DPZ>]E-W8X/H2BK9EA M`LAV@[]#""&$;$4([0@)(=MWA$/U$4+^N75C+K'D4@EVR))35,A(#1-"FJ^& M"2&U(H2V@X20[?Z"!N@0\LJM&G*I8@%Q7BRRXQ25L([6T_OJ"QF!I%Z0='L# M`@F!9!M(^MJP2R`AD&P%R1!`T@#/P/+WEIOOH`"VB)'1DO='%!G4$J$E! MJ(0-P@9A@[!1-UL(&Z\'&^1MHVL-C1>XM^V6.O>Y,U*P$S3JA(8Z3A2"AE+0 MZ/?4N>I"T"!HY(0&Q;K1Q86F"]B9,M)%!QM*`N2M0@&1M#83,@@9#4"&0@&0 M.8VV$_:ST?6$)HF6KJYH$3+J5;KJA#L2,I1"AD+1YH0,I9`Q4"U6N`%"W2FC;J@-NG4$,AV`NA,M4I%548P[8ZHEIOS>4Q]I M@YXZ)TAT_*PF2H9:NZ..8Y-0HB9*2)<02EZ-+B'/YW;/YV?N^S\R,P2[SPG8 MW/6P2AFY/%_QADS7-7U01R!P@0U9C4J?X%P"P0'W9FRLM,]T,V]KEV<@A8W=\,'FFY!XC&K: MA4A;2E'5&]2Q^\V:4/67$8)=2;`;::V!"NL'P>ZD8$?:CF!'VFY?:_F'P(!1 M)G^E;<'H\Y]_"/VS1\.8_Q@?P=]*:_*CY9NVZX<>OX?N/Z"5^O-__Q=C?_Z? ML[/DM#YZ]NQ,_K2A*9'Q!QJYY9._O#';+;VCMSOZ&Q8ZEOSNUU:K_0;L6=.: M&;;_ES=GG3<_Z\.6/FJU6AL)+(V:7JO?:>VB9M37NT>AIIN'FL%`;Q^'FAPS MU6[W.L>AIM<:Y9BI0:]UI)G*0D7HR;>S9VM'HWLH.\B>GHOINGZ8"N\ MH\:KIS8/X$;#X5:\'8_8'*P=Z;UA$6(OIGA[TV>6PU8!ZN\@\\/+^>+N9X;^ MSH"&WM(#-P')SUE^CWC9^OY>K%O7L&[=XKKUO<;$-QK>/+4FT2*76O6*>U)6 M>JC&D]+IQ[3=3T&H%^P.X,\+=S8WG!>YM@[;^N`G?\W/XC/#XYA^>.+:MOOL MKZ4?3HVWV@&LF`#'(V%I>H6-P4QNVY'U\I9#/WKW?S6Z'ZT1/*-;?[( MK`#Z,I<%U`1H<"\*O17RY(:^X8S]C,CJ?0WI/4D_Q-]<^O:DIMB>PMTFV.J7 MM=')0$N&,LJM?#ZYGE#:P=3CG,V@ZZG/1*[18^WK"C9[G;$FT&EOG*$=1Y(E'ZEMUAQ[FS%W?![PV0/W6*>E,;2' MMY^=58/;-2'CQP>!<3[2L2Q*OJ M-=1CA`YMOJ/)H!L-_@[A!!"R%:$T(Z0$+)]1ZA.+53RSU&5\M-KK6T'B!>]MNJ7.?.R,%.T&C3FBH MXT0A:"@%C7Y/G:LN!`V"1DYH4*P;75QHNH"=*2-==+"A)$#>*A0026LS(8.0 MT0!D*!0`F=-H.V$_&UU/:))HZ>J*%B&C7J6K3K@C(4,I9"@4;4[(4`H9`W5R M,Q_/N[:YWE,C[3?5;B7L5>VL="IVU$9302B+D)@6VH[6Z=21U:=`G;3CJWE" M7<6H:VNC01U[#T+=*:-NI'5KB1L@U)TRZH;:H%M'(-,!J#O1(A59%<6X,Z9: M8LKO/?61-NBI35Z!+R?&[W?'[FOO\C M,T.P^YR`S5T/JY21R_,5;\AT7=,'=00"%]B0U:CT"7[5PF^DZ;4>TL\N$!QP;\;&2OM,-_.V=GD&4MC8#1]L MO@F)QZBF78BTI115O4$=N]^L"55_&2'8E02[D=8:J+!^$.Q."G:D[0AVI.WV MM99_"`P89?)7VA:,/O_YA]`_>S2,^8_Q$?RMM"8_O)PO+A)]M'S3=OW0X_=` MRP:]1IO6&A8\GO?FVUVF_`Y#6MF6'[?WESUGGS\Q!40ZO5VCB$1?,5$]O5 MVQU]![%ZN]]KJ4%M#M:.`/X'$QM]8(NDG6=WT26U%+9\]L\O?/;`O?_;,:3D MGR0%Z/K(])8>N/$8?U]I(-7I_-5*+<>EB M$0H>_5HBDWH)DWIYF;2@)R8G%X]&W=:@0BY=.>PNE:/B/LI142:G!D4Y=>7$ M@'+&,4&Y>-5<+G43+N46NKVYI&_5H`=RJEK=M`>8]M5->J^INFD/+.VIF]JC M06.YM`>4]N12I]/1*^3299P:,A:]"S=*#5GK3%5&5$)6+9?U>M[$Z:@_Q MVU='M;=:[HW`56$A/`A7[=:HX1S;PSI76!(K7@<+LVI/#3\<=)N/J\):ZT!) MK')74[456G@UW%?#][8Z$-3?U126P+UW->TJ+=$C[)(+0ZJ^_=^]\8U]MHP' MR[8"B_L:N^:!QBZVN]3@I=0[%XE/H^_=5_JYQXT8V!TK\;@ M+YOC1X'&\QE&_?Y'_+9._^*]Y"T`3/J=76#L:UHHYV;FY7 MY:30N'S3L^:"#'<"$'MFYZ;IADZ`:N.KYSKPV8P6IFLW8"\\8.=C=QX`0O^) MYP-,'!!D:):DX9L)-+MH=;E1:/-_>1"WN&N&?\Z*U8F/6KZ_%V*HW^N;^XO%P<_-^R,W5Y>7%[??_Y?=G5W M]^OE1W9^<7'SZ_7]U?4O[.OMS35\OKC\`D_W<-PDA9-CQL!,,A@$Z#@S`_XG,W<,;>!C5YF0\'4"."+ M?X>6!^_A``P'5@D6N$``]TS+YS#OXT<4?2"8"]WG6V-@-Y`6UPIA&/'F"]WJ M<9L_&?#P1/`+OS(MSPQG2*3)?4GQ*GF68]KA&/I]J[]C%F($@(8]X&S%O6CL M;7O]5Y_/#0]&C5%U,,H9]L+&E"OX8`,Y,] MA+[E<-]?/.]/W="&*9S/[1=!;:QR<#!IG0D28#A.:."\BEMB`(J\,!EHD>3C M(Q98$IXURV@&QVDENFKYU_1@+@W/MJ!U)-HRI>P`U^B`.=*<=+A2.!8^`>HU@&`N$_!O>2^05!PJ``&B( M,',#!_O)(U%6K)<$0+^+\^#]XO[95B'$:]^Q&P M9;57(0H<%#,L/V`!\91@+CZ5L\AT="&)O;5%!N3_)6O96"8@%CQ<5E.OP#!B MH9+\%VWB>($&#HN4$TQ104I_*3PO:6EI$<)@\*$=2*W`ONNW--CDX<=DPA>S M#2H6R'Z)Y@?:2Z;G"^S7.4RP>`F']UU/M&/(:4`:W0Q6;P@?.Z6-A/"DQ;.R M0^;!/MDB\ZG]-"+@"S?0A$)$G$EHPGX:AR!S>*]+?V2(2=V/DF2*O[W$^$-- MGC2`$SKWW"<+#P<`_3#3H?A:O`W-1`8OVD?CT(N)G"VHB@0F5@>KJPU^+PF3 M:TC<<](3=A+;PWQ[OZ-FL)#+GRTP9M"7L\E#'/)/T,:M;.*K;&&K7_'W.W,*BLCF M-Y-+0&KP\H4'4W=\Y3QQB93U;SF_!O,V.MGR`&_0U]],`RYWNXI;T M%J>XN(7LA%G"]+4>0KEU=0_ET[U[/IG`^@=MJ,J@%1:M4[QP#,;@X:#-W!<. M[,A&QF7\^R'.YG:KES5]JVU70%T^1_X:Y[92=WE^>WUU__OYYN[N'?MZ M>N^4/9QZ6M]2Y6GZKY MLECJ/A@^[,AY!#'VUG9]_QTNKB('-3H0I\(LD.ZZ,#*_D^>CS2\L**@AXU<" M(&?JVF/T=``7+#1B'^3&_IDC=7Q\9CQQSW@$D.8=<&.<$U8^9DU`8&` M#])3`92X8O.25"X6-G)D<*<'\`Q6<^+6'..+\`H,.I!F=9I7VS;*KQJ'VV9- M3I?@8@*]!T.PTEF"$EN'4@:&YG;H"R=5,N>X)1*S_K0R=9D`.Q<&-5ALMI5L M3Q^$\,!DCJ-Q1/V&/D\,Y&1HBS&!P6"&=N(Q,M`N%?;ICUNF[H@Z(2<5I2MP M<;%*Z!*3VW9T_0F-$_&W#[9V_/=A=ZM:K502U%0Z@?QWSJ*K9($[_Q'V1F,K MG#''=?@.`E;8S/:_\[9?_TOR;'+_FO^.V)WVR'6SS1]@P M05_F9IK?"OER0Q_DV\_(U[SO];P26%MJ/KARKA76F%%E9]*/PDCLEW79LDCZ ME#25]U./;_/1'>NR:$G9?&B>-U!YO=T5VZ1ISILVYVCJYH#5KP)5EV"NO7'2 M=H"HY%Q!$0S+-*_0+;`]#9"Z\"5T'`$=74('H8-T!Z'CE'1'99FY54\>*#V_ M:TZT==?9]IFM.*L1);_?DOR^-]#:0W4*P=:8_(I@L@TF/4T?-J!(`L&D7ICT MM5Y+G>+!!!-%8=+3.GH=E?04313=;D"BZ(_Q.:<,I4N.2,_D@2J>KW+'-ZCH MRBM/_-X=4=$!PEX]V#LCY!'R:D%>IZ]"UFC"WBEBKZE:[W@%"YM0:"6.4U3= M6]KH'/#UBW..9/#H$KFEQ,T=<2%)([(WW#B^$M?0`C M3R[;1]?#1":J5$H&>=5ID;]C]8+4XA91?"DN$,'H>,D]3^8(\:#,3?;`32/T M>2H[4'23W?)DTAF1T/A97(5[P!X"ZRR^,+7MQMKKO:FTG$CNA*XJ[;\4T$VE MUW13J71;8,=)>V67!`J?\.>XE+(1L]`"4E,AJ=A"55U]6EIGTLO+6M?'L,7J MLEJK0,P!0T\#[-.FS%&*SHF"EQ_I-M*Q8\;73=/MGG-U(\@)*T?'2F-O&Q!6 M2*\05I3%2F/URG&O=S=OU[8.8N7!^39TC'",607?U8'*YNVS:(YICFF.:8YI MCNN*[5,]C.].',7)+,W^]HFJ.$2`;IAMOF'6:;5J.-A7+HJ$(++E$J+6I9NJ M!!+2(P214]`C=)5Y8<-=I*.J'CT#JZ+4:Z3U"'FD]50/*\MWJ7G;J>B1187N(95]#ZD>%P/=@B/T2>_%<$0WT0E_ MI/T(?:>'OB9KOUPW@->+_VZL!)K4%I45Z?#&V=BU;<-+71A]MZNNJ$P(OE8! M-:DIVEVOU-I)UT)MO_GYK/6^I6^F5_10(:V]UF"I_NE66NLEM9N0NHNM+2"U M3I;JU;`T_I7!STS\KK$HS=(N2N-L3%7Q-&J_6E++DZHCD%NB8!V%VM(PNT9M M?S.GAO/(&1;;9F,+?O"X8V(R,(>9AC\5-^W%A]3=_[4AB?9N)I=1:[?0 MV(US`6^=.V/\YS*5-Z#0.-?*5/?:2U6JB_2LYO"WRM!ZE>X21A]5]#Z+*\%_ MMHP'RQ:%@346E?E>&V+T4E1K/O7*(37'VR-]L#R@7=T<>Q1Y(*EWNMT]1_') M<@P'DRRP*XSFY'[`+K]A$FN^2GKR9/Q@]%RI>-K4297T%A/_=K]7.\5;%^@U MBFMG[Y8U;QT.W6%A]EH!/_ML/8$(PD.@A2S,)W+N^SP`03PWS7`62@D]G[E> M8/U'9(4YNPA]V'?`8OG9\D$K_O.+N,'T?QGCA/9%\XO69>.IIM,M9RNBW[T"=(D83OXUAFN"5)!L@_GZ%)*)NY85\"D%?6ZE>)7?W6+U*X&YWM&9F M5<7=:[YFIF_I#9[>RT9O=[NYU1WT<43J<^V3ANU^5=0?OJIMG).JC:Y.IRJF ME+CZ1
XPM[[(8L4A.J$L$2A#*^AZ?KOM.'RH1SN.^KE=6L=4 M"L>PW/=6"EO73HW]ZO-):`-')CS1',49(UO!1G8=5NRC."(&_?Q5;_UO'@XL MJ-F'"P>CI")F9&'FYZ^#(W#D`/51%2]R*9.?O_;VY2O2W]W/,(10[.#WK+"_F><=Q M<_/Q'U>?/Z_1ZKKC9\NV]W-NM7O#Y;4D;F[_?O.XI3KMX3!GMU?.Q/5FTL69 MLN/N^.,,C]TWR>)VMOQ^%X!.Q08^A+[E<-^/VI-RE>IST67TQ,YEJB5])_V< MX\-`B[D82J5#2KHI,(R./L@[BB_<\$-/=(\A=Y8[9L88BU_,EI=2V*W]P[6? M,-+B\^>+?8;::X]^CT=X;L*HI,"(02:M0]NRY057[DSN&$"8>##Y(Z$QGP': MZN3DQ[''F<.9EW7B^CW7YC\/&SK^D\LEC1V?OV1W=S_ M]?*675W?GU__.R'K)!ZA8M)+4#[^.CQ1UA\ MG4?V7;NM@86B@0P(,'_7T9,()-M:(^BPE$>]^?D3J-@?9T3=%3X`K:KNX!RV+I%0V$=I`N>V6L*1NI!D$5 MLR_&BR#G?>HZ1?():W#!N@LVI.!71X,U6_`'6GF,66KYZ_1D\6IABT2D;NP2 MRW2YCEC;98<[&61 M)]LYN8)65'UF+]0U/O/_A>%Y+[ABG,_AT/U M$SU_B*Q;,&O7[-=:LP6JFHSSNR-<]-Z410"W-#7RS!<6>(;CV\);3+)5=S:%#4+V5M?5R7.[NF6H;)G:8F,U M2>(V>6)KE3;*PU=M'C[I3%,@OTF5^Y)#Y;G;@(35*5LTP\6:NW(,Y2O:G*_H M&-;KOFF*I`=?`3D^,$_1,5-J"EFOR]M`%F4NB_+XSH]2]FZ;TVU5/UR?, M..+1%A&/>/CGQR%_T2,EG&8M!K'G<5:)2[.R9UZ;3D+VE?Z-)RL'G4KU7^.I M5"Y6'6/I+'.#1>=`QZT67FWY;YK-#;-9T-=_Q,G<\Z"N($`.P(#RJQX M$N>$;P==%4X7MFR*,GPQA(JJ4='K[J]#:T'%@:&LN_1MV0LU0;)P0(/6'Y6R MKA^S3B5-^"$3/NKN7R!*M>*0*05S^*R7@)O2<'&4H]X*"2=V*N!H473SLKCO MLW2V7<@=2'`CZ56%G=7Y*!KGCE#'4=J(<*WA`;4ZF^``I4DX^MD*N35I\UB= M`ZO;'S3+@46H.`(J.L/]S_%4/IFMZ.38WN3,/ MF891?__(,P67>W)HTK:QRCA-O8XL9^305!L5W5&O6:B@.,U7#LFNOC\BR9W9 MO.D^X)R-8C1I'T_LK,TMLL<2FRNMVZ$ZEW+'E94[3NMV*]'.^^2"(V"H!(QA M>__3+T%1Q&FN1*"JE%&6!6 M\QEJRPD-\3_+,>T0RZ=93I0Y,4J7:#E143)3YEC$0C$YZZA!'Z)YZ7B5I=D, M8)5G(.4,TXC".[[E,_<).H1N+(]Q8,-,-!?*>LNVA;7/L+(8=[`&X!/^@VU/ MX`?VP@W/7R[#EEFH[#SE_67\VQS)1\I")ZJ#]IW>'RQJR_5:LM# MY^(G!ZF>P;1.?<8=Y-AZWK35LG!1DXOF]6Y__^:[J\-==69'GS,J1>8JW[A6 M.U)C]XNR!FQ1)W5C^WVH+M2G7/1]L&T%"LJ#7!O=RJCI=<:%.#+:-AK5'!U,42JJ"-(O3_=O=W^'ILF096A9]92[5Q5\8A&\9F M/T&CLDW99*K%7F[L>J-:_N983_`:/ M@]3GJ?T\&BSQ+==0U.6HK@!']6ZG7)9>P#`M)\3%^6;./:$-??;`88'A+'K^ MWOB&570OO\$"#'LMRS&\%W8%:PM\>>TZR"G/M6ULXPK-)^AW.\\7G2[Z_""Z ME,^)#I>Z$[TM]Q5W=:#2.]/;HVT\+976$YN)@NMT6]^F+V@B#A&)(@O>V5:] M3?-PB$`4L8'T=G]8UT3`R\!5N=MY^X$['(R==]FL@T>C)Z/G#AQV)VO0:YU4 M2G"Q)63%4JV#X&*:MJ?73G`QC=3N[T-P@`+`YH8UWD@E][_"SX8'LO"L MMTIKCCZK'D)!0W+0/F0,\>/L;?S".W2AW0B7VH4H$QDPZ7K9/3SQ5O32>5*] MY!#70'O-1M[996U#*Z@,#QB9'(+M.H]GL(S.F&T9#Y9M!1;/.Q)B%PZ<+&`J5[;%Y4W M\$0;W>+):9C#J([?B%XX6%X'N?51U./QAU34>%G;DN4<4+RRPQ9N9OD^NGIR MZI?+V=QV7SB_Y>(V4XFV2F^7U.WH_[B#*[H?7=\][SFZ#5B\=@.@,MH*:BQJ M`+[P\MEHXOWH]>CEZ-T#YW7KH#?WJM!X"TYU=Y>6V7_0>`CG!*Z7:X2IAP\. M*EAS\&WNZVAC*`;#3F?7M&2-X<[`=34PON5W!7WUW#GW@I=XB8P\9"^RI.EA M*G*G$MG6^=$&55!>U@\E]AF4>`V/IPT;J_#.7(?=P:X"!GH>!)[U$,J:LH'+ M/EIVB!%+['(RX::HORN>/'LP?*%!7F;"ZO8\PWGDF?%%JHP[SH_\(8A/W=:9(!\$/8N/Q6=S^ZOWECS+3(\JJX=L2N.RZ7C* MI#&'9QRT)XV)92$Z#CLP.&_52LCJHUJ"BYUN#U;=,\VTN`X6%S-_ M-Z)X*\791[+RQQ*.B=>6KT7+)=!RP"8O@XY;[G,/P^.2GD.3]@>K)SD[ M24\>T=@GR['\*:R&&*V.P4Q*&RR?\1!(>$E7D]+AF`Y>/%I[5*9ZI]PRG%<.^8_)YCR7*9; MSPR6'ZERDV)RVXYN]:(N%W_[<\.,_S[L.G6KE4J+FKKWF_]N='3E.7#G/[(9 M'UOAC#DN8&,[`:7=&M^O^ZR+ECM)2HJL]_-G<-J3O)QW0V7**7&[T0U]L"S\ MC)Q?^R:?*H&SQ[AL7A#X.?()L:H2!>R5RRA!77OCU.W(%%1R@L,*[B6OWSY= MNP]ZA'QJ)66X(JQ4BI6/W(R@HLN;Q$V%RH%9@0I2O,-TJTSG[3(9BV!8>6R^ M#1TC'..-SW=UH+(N757F'!^+!"5FX&0K'=P:SPP39'B689>1)WW_9%*%@5,Z M!?5EJ]J407)01PK;BK*7$3)*1$9ON'^6_J,AXT0K8O_#]?[`&*FYY^(Y`RG5 MNO/W;I"A_@&)_DB[G@9$!OM7I*M;S594MD-U[9N<*C[BL5VMRK?,C.DE)VE] M%0G6A]TZI/.8Z?<)>ZIBK]^IPWAHGK>S8,KT#._GD06%,FF7E$E;UT:]E@(R M4F5&=H*=@K`;CE0H!U9+OO<#E'-=QU*T$\VU$SW^"8HZ;"%LO!YL%$WE7V($ MX/8QKH5=YNOY/&#K,3/1)9V5\`A-A(5>R,3W;&983@#_\7$20KH[.!UC2[_K M#SJ+W.]#O8=_%$[BOBT0.2M8^SKKFD;T*P9N[Q-YK<-*G1UZ#2V6042N/'VC MM4R-&40L'9-NI`&>^A(_='A@>F^XX:[`QFXJ(S].?#9=PEU!UWX/KQ!][6._6/?.5FYG%&WF^I,'#]^`,7N8*VCCR5;4:+ M\VBN#6KQ3)QIS1844?K#9=-5ZZKGEV]-]R+KD4"M"VDI9*Z[<6U3K>O M;Z)NT78U!.:RB&`4[?T(%#:I+#BQA;YS9WP7@)TY=>TQ]_RH@,=^-D=GV-U$ M:F8W55.=!P&@+T8;$;"+:H?C)L#T^-@*V,0P\34PC6?&-VL6SM!MYHE;9\PT M\&X2D"CK4B6O7LA7-RH\>.QF(A_Z%#7_13;^(6[[(FXZ8_WOZ+\OORPT7KK5 MG7KNK/?F9Y$]>YE%^>E:L,L%/:S)-%.B[M289Z?LRWM_4S0HFA.-96304^MB M9PD7*4L_H;]>NFAZN731]/SBXN;7Z_L[=G[]D=W<__7REMU>7EQ>_7;^X7-S M[IZ6Q;)%Z;W[](52)N\CSM%OX(BB>F#IS&0]-0\,`BSL\)AV-B0<'OSDB]I[ M2>Y*F8O!2PF"(:KCY?5I_+B%@3LXTAX.#^,)7?ND:Y]T[9.N?=)5/KKV25BA M:Y]J!T+1M4^Z]MF$.:9KGZ=P[5.Z0E+[ONWBWM>%@H'X\!X&C M#G",M$&GJSXX3O0"Z,>0RV*U/"H$0=I5U="Y=HMNV!-$MBM;O8Y;#&3(YM.U MYW@F8C@F%]$>>#<@F(3VTB''=N5+LD21RA3%3MA0P;#=XM:,%=]HKP/^H^CD MA+1%R39FC#$/LRAE4:L-3->AAWW:U=K\.4[K`04#&T2RAKNFHZPWT M9J'N>-E:N@W(UG*^-1A))-E7:MV@:]HE7=,>:D.]#O6(F%6%+QL*OGEUA/S`XQO'LF%Y1Q*%U"_M2:S_D8+^J-0S-: M:>+[0-`"-.WQ\7MV'KT7W6ZP7T0+(?XL0FE_N?SK!3M_]+@HS,<,CS,_?/@7 MEBH,W-0^!R\%P@\^_W>(?\VY9[EC'\AP0WLL6A)MVB\8H^N+(JX"RQ'A&@OG ML&^"G:0Y%4\OQL@LGXEBB!HSIU@A<.V:KX*AT)7,?@ZG'\O>A"8PX4#63!2; MMEW?%TCP0SO`21%'-\AZRY&W,L2U:S?T`!L^""_W?)SRF?$'SLZ_0PN+Q\]E M[48P6;#S=(^&9_E)LREDR#GT!5[68``]3(T`^GB!+@"W7!`D?UNZ1OYLV39# MPG$P]DL$E\W`?<_63Z<06',/6O!@/I<9]X1<]H&.L2C2*0D%3/NNXW`[QSWS MO2Y,)/.7[@A:)@*=[P MB;I.][SH&)O,<[VQ,UR]]:/6V/%V4U5C;_>4'GJ_TZILZ(-C#?V:!_]P;5&M M[?/GBS(DX4,(RIW[_KD)"X%OX1TD)^A']J*DT&QBR#$0A9>F&\@^!T?B MN;:-B[H5U4E=9<$7RW$]L!SB.JHWSPXLFF"*?N4>QKT:C_S#RW);\I$\2\8@ M/0)!%2+!Z;F"M%Q?+_*W7(N4+-Y/4XW3GG:M7_9O@NWG,R#5MC M5X[YGCT;PF!WO;GK"0T$MO)';AO/N/N"SW\+P5[51\/!^]0F-OGTJV-C)B6T M@2,PQN:Z+UV-SY;/P5X'`]KC$Q`58>J"E1M?EVRW?GKFR1_Z3UKZ%]@/;/HI M]#?]LG(?<_5GCS]:H.`,)]CT1(I'J4=@ZY!^"*;+D/7CT\^(,>+PUOF,6Q8+ M]ARX.['&EH$%3C>P-+!LO/31TM@SA__W>&KGP)U'Z%?,TIC[`!30+'@SW0DG MA@D*(OK3^X.+?9;8B(=SF%OQYZ4SQ7 MEQ=?$<6(U`P8#UI_^HD]<6@/QA9C5:`M<.?;3]\'72DJV)IPVS/_Q0_X#%2. MV',SZ!ZW@'//A0'SP(!%,.#FU'%M]_%%0[[.IR^^95JPWQ%#F[K^'*\.(@(] M-WR`W$97@EA/'#%:8(#DE?^>?0!@.(Y<<"3J M<0[2&T$M[D5,Y/,4]/K+F?N,Z<6267T14\\^6L:CXX(`FWXT_V]7OW\'H^:/ MAB-1(39]'H_N&\NI>(@6;O9D&>(I(W&-O$6R4G!Y+XX;%Q>C^3?3AO9@\[P^XB?I:L#N\4?L*IHQ,;IQPCH&PO"($Y7X MFW!RY[!<3^!'.:'PZF/LC1!-=H="0UF/H1L"OR4PHC+"ZVC!;S^BGK!,,>8+ MUPYG#Y:1*;$PP0`8AR-@VEJ6)PN5K#%#/]A8-`_B(O^(`25>7[H&;CP:EJ-) M;1Q=!ELDN,MH?A)ZXFAG:S>K]\J&6MK!Q@W/ME!_@6%F20&)?!PFR#N0PTS+ M,\,9,$^H<<&HU+.(-!1`TPA]+H09R)G`$]$B(KH_;9F@F8OOTD),Q@'\`"M?PI^\U"$MB5;^/M M:'0N26TE'9R@H-#OQ2)3%%3EL\LNIBC3,$G2F,14)N(MS-1R!CU->+Q6"(#= M)UJ8?0[&+=L9#,AU"@SN$P(.\/;6FIP) M(%N7<$3H85_.=^PW&PR(E87&ZG[G%`FG\"Q+68^M7:E]>_:`IQ)9M! M.VF1>H)'WXE%/7Y9$_`S9,\V-T1NEX5*@FF#IP%%+)[?R&Y%O1&_Z0HL@E;^ MEPNT,DP9B:*?*./?[O[.OD23GVAR^!+T9"QUCU)B$NM=DW:0/.QX2I3Q"BT+ MM9>I">Y3S!1+07?T?O2GV/)9(C9>,:19NL"E,(B!&Z@AT#XY99S&=MY6F(+: MLD/.SL=H>V&.4-L&#"WLM;>_G=\N_DQ,=+#IA-D,F(%99\D6Y4FT9HC6O+@U MJ8U31OW5_?<^NP7LRG7ZZ_G%'4#=DBO0N6=.K:=X1PA4ST)OQ-@ALV8 M.PG$KM^/%:UXV).9%9/S7"TZWQ,[I=G<%F,0+6GIU2^U\]R`2PM62SQ5>P&[ MDRUQ!.;9#-'D6>Q[@4[^#99]81Y$1X0+&W]QH"SRL8[9P_H^#)MXX%/#GDC> M_?4BVQX0P05RM66KFSM-M+K$=+G`:2NK$2RWPO98V4O!X_'2<,I"=!X^0LOK M8I2UP5Z;`_:/$N%F]#`!5',-D"C7]%*CJUJ=$%%2@_V*+B%$0CVIX8G-X+P MCEBJ-[:(OT*+,-[83X:41&M')I;B)E/8B%<,_"#\"T+VQ<&S[UMR9X74&.S1 M!:/$$>+PB.XJA-58+FCB^2_N@W4!Q)=LVMQ_6;)H@#Y0`,*R15D]FQL>[#!Q M3S<'F4?B9B[LGEUAM\ME,?+,V&-I[<%S/`X80->+C5OZ$-0:NGF`MA<9.^1' MRR!H!=G,-@$IB&E%$]POR<070RZN>LL'\R23:P,1U2E4C,PM-68$>;5#<^`Q+R*XQ^P?,I MM\6"E!"?2<-B:-*O*]L<&$U84D[2XB+1#/:",O]M/AF81JF MUW0:%8\-?8A9VR*Q(SW(@I M]?B4.]*]&!&XTR9^``[S)[DSQ:TZVC_H5@=V&^G=&6:X?H$)?D2?Q`.0R'E* M!%)[V77OQ9K-L+3SC,E_\`BF:?\*2ARH@XV.D5U.#@D(X<9(/`:1 MV9O/\8,9TI\B+(H3/2&JXU3#=\+9<[OL[-G5Q[(-O`2Y]-`CABPBY>#AI.F= M@6WK1]Z+XW/0[A>&/\6`"=150L.^_=47:^4[AC4;)-;/D_&#I2:=8/CUHLFU M8,-QNQ]>L-$K)VEQT>"BN2UG\BLI['<$IIWIJR%*AY'3/'ZMQC#LXM=@ MM)*=_#@,NTGU36[-#R,6?`W!@H68MKOX@@<5V=9$P&-9-=!RU3$`L:]QIWNKC*P M%Z?/QV,K,KF_&M;X#'TFAHCS.,HH%]UC[U=.U'>NP=8QARF=@('XUUBI MM"R-H'1BT-^-CFZL^7$4)LL.17^EP^;<-$/8W@L?I*RQ<;&T\Y5O'V68*5($ M)4N$R%[*'W[9RJ'@D(^D'$J`;#&MUUC(%E3N-4!61,J4,[C?#,_"6/DX[OP2 M;$PT-C^\7-AX@#")/&PW$_&++`R4^=++5W&V]O*!.QQ=B_`QU\#/]-':!J+" MX0\4&WY[;;-9V>!7B]_5/_BSSK!]Q.$/5!N^WBLX_)QWH8H)0?[[/#LNY0P& MM8Q&KV0T[7;>T6QQ4WRR',,QRW13)"U6ZS9L=W,YP7)2TSQV%=O\=X>]M?UV M*>QRG4589634O+W\-@?K@K];XT#J8?EL].2!6-!7'W*XR9!=Q M:IWU1VJ07CFYH;B\NFKW,>4EU6[_=6]-EZPQ60ELO[T.\4 MI.S*]T,^SJ1'_J0?*#JKU$2M'DY&0<73T@?KK,DF)KH;+?*_!&X28SC'\LW; M9BY5YAF5<63X\?%!,]KJK,IP[@YK&E8>5(Q&&;-1=%2AN!&!Q7#7[DY9<0:= ME>/@J8'Q$=S!@`^,+N;CU*VOC/M>RU&LBZ-K=K5RO6"-@8*XFXF\MG7E_`.I MD0;^37S=(`?CNFG&75U_0O,@Q;7=G61P*PY,W41RN=)$0O3A"CI6F-NE$E?,[ACV],X1B2NX$@RZ*V<^5;.NR'+9UKO#46'JK,A2PU16 M:V;:S;+Q5,J18'<#C1F[VE*I+';`W.UN@&&U9!8\[&WW!O506>A\O-,YG,K, M8*YH!5AX;!9O)PO0)F_.'J#Y'3;)(JFPZ/T*0S2%2V=M18JRSB0>^UC]Q[_+ M!#0XHN4!1;_G<]BV^X=S=1N_KE*5P5/W9-=X?CA^RN5KBNX%V44X>Z8/J^7L M(N*Q'&;JU3$S(;4@`T>':\]C*1Y5563EH?#U5@)$*J-L8-7SMBR9#.7ZM];-H']0T6&FA,2>P^U,^PU M:,6J5$#V6[&ZK6H96*DY6J$%=;BZ&94@A,>$9H6+XG[0;'?Z>J4QM]834L#KDPM_\Z6/5>NT(`5;BU.=2#L7H'I4%^H0J7WP.Y.FCGWWI_ M]JNLZY,[Y? MM'^>E#FXYL'-Y-[X=FC$@MY=L4`JH;(IS"OFEF\3Y_8.41L2[_:^Y:IWB7E[ M7A-3#T>JNBJC"_#UN$2DY%25=1U)E6O)?B51R-O:Z6ZG@-*@K M';7>=7BM#LE>;+I&H/!O!7G_E?D(! MHLIW2N?GM5)NT_:@W=J7B3D.,0[GRKZ'%[J^][BJB/ZH"QX''\/V]"IDK,#9 M:SY]HHI&,JRAS:>]!;#?)H@"RH&`&U'PO+/ZJKBX$'KC7=;BOCO.6X M:TTE!^6K5W?4U)&J!/GV5T]JM[-+[+'ESVQ1]WQK:=54BQF5TJG,ZEJ9U44N MX+\F6=QU_2>6QFH#ZEN4Q9M%#FB)OBCQ.^`&2SK$*?@GKFV[SRB[1I`J-[94 M]6^U0%_WQYQIN,L?2JX+;&P10?;?TIU:&7?!ICY1T8VE_>/+A!X,Z2?K`4-O>PB,:/HJ!7 M.&..NU(;+.9;,-Z_O26P8EEI[NWNPW21-=!)_\VF_M;XM)&`[0R4[6";/S)T MK%OF9I+?BCJ<;NACC<)WZV0[[K-GS/_R1OZ[D?1R M%4/I9MY'/N&>S"UQN$W#-F^RU%4J MPCE8JN[8PH:#D+QCJZD"THN0F)*$?J=3AAR4Y$&@Z:YXNKN]4HRF>,>91? M-P\,#L5:KDY*-\0SYQU(86,W!+NL3DN]$&DI3':T7JM;!2J[]2@A`D9)P.AI M?7V@"C`./B!9V^T=LD2I9)WO-K=+D8<\G9ROQHO,J(. ML]+?\GGHF5/#YQB^D[Z)LDIX_-HGUUN\=#-)70$IK[S#[KYJ&$W!BLHKE8KV M&5+@QNGJ4QGL-?:+Y_IK`AN_=.]&KRS>$,\?.)R,D6SJZ!%8U]MPPDT$?Z8 MQ`?OY$+\NGCYW!DO@I\/DX.^/MH^QHT=JS':@LIXI6A>2:.-JRUBC9B_80T8 M]AL\`@;PSH'&;UXYXKWHM0IU=':']8ZNH.;>)95[#/%NZGK!&;PV@]&"BA!W M27*U>W@K]=*!H^L,MP\NJ\O:AE8,EMT=\[9]:%X<->.CC:1AC2G<_(:< M8:3MV+5MP_,9""_SIX:W7EDN:4#86%\-[\83=S?&OV$C7[EWAZ_EV2ITUBK[ MM-ZW]-3`Q.CDP\IFVHS+;;/B[=&2"HBFXC#$`I6?\I M3OOYXLV]Z-?7MB=;.ZEG)+D05/9(W##P`S`G\6)1P:'KSRX2IWSDONE9D:BX/W/$OFPN#=Y`?ME`Q28M\H0-C6>N"R-.L/H4MB4S!&*:,H" M%IDQ<\-HLP*(P]0#[-D*IN+N:.P*CQY-WZA_O_LPJBCB$UG"^N\/KN>):ZN@ MHW%43Z[]A)K6MASA339!65H9FL$U.1_[GSQW]AF=0C>3"_%@B7OY35T5QG>1G.ZV&\U'$_W4"6QQ?@KJV251/*=]8U] MA(VX&;A>.M\3!VG$?5*(@1Z6(U+[03-X=\7U7AAVL]F=FW_TYG3/,__"2_D4V:7U+1IS+*3SJEGNNEAH>(M/,BB:A,O M#%N,.:>S.]T)O'DSJ<"1O^KMSM5GG<,[S)E?>'CIX\'ETT$-MB]9!FKVP1S: MO/OX#]JCE0(=VWHX%N%Y?`7M_II)O9ON2&\QH;A86J?ES1FU22>^N@12>V^2 MN_K[;MXT4E^6TDC=7GX^O[_\>/;U_/;^?]G][?GUW?G%_=7-=1.22E7B5+B1 M:QBZ`C`WL.&\)/P:_.1#PY&M"'+(`\PQ;OB!S37V;/CRI:G%)^SR&RPA`68= MOYE,+)-+\^.KQWT+.\0>EJV.]ZFPV.33.5@R:+#DH^>C\63AHLQA]0->29*, MY(FE/O'3L^O]`6NY]P3T142P+][[:$2"8/PS:9"YSYBI&YJ!!L&\8\9\[KG? M0$$$',PIO?6^^R?Q5N_]X$\:/.3/H6/@`?P8C6`FEF9_:LV9%9V5^\MT;6+% M,B4SXX6!6G+9`P<=Q6=`5N!*KX\D\H$['/AN&39T'L[Q5WC-6%1;T#OO>W_" MKOW0G&;2E4G&_89I>'`-3[`FF0_F\$;*D9 MFSN/P90]&+[ER\B5!T#`]EDQ'OPHA[I8L;&O)S2`Q>P(!\Q2]^>/'A=I`]>\ M6:C2\<1-RK MG`X#FIN'(IQ=8TC+G`N"X"7+&Y_-Q:IH)88*3+WS!W8]L;Q9)@*_T[L:V*X: MK,0;2$*Q%X<,2-O#"S,-?XIXFP)V)*CP)8_/8.38U7<=;1@UB*]ZAN6GP>1' M)J"QO!&--P%B%^J[MI#`+WR,^5LS";^1Q'[737J3#L.XK^C=[)1]&ONNG0Q; M#!"Q/49)?V&^]0T)=$,O)7XP]DBJ(S99'A.8@ZG9!GW5T)HK.:!J1*\M13CS MOR$X+Z8@3V(QV;RF?8B5Z29_:_ MN+(AT`VPW!SA^`7D._&_8$PI'V M[]IZ1\(=UB/V8-FV1+M02DA[W$TP!8TN7G%P`SZ#J9]&QQ>HC<9"6-<%*KT^ M:\@8.;@Q\M%QDS,2T7OJR#@U&K9A$/W68A#ZL%79(+H'#.)$U[XKA_W-<$+# M>XE0X,KLPK@=>P`4.[`#'',Y);_=_9W]2T1=/LE`QET6$3-,4_(;9]6"?U,+ M&X@)-HBN,+FP9O]DJ0$BU8TV1LB&<]A+@J?:=':P0L1M"= M%H$P63;&(9>K#=*"5/(DOC?=;+R>6<%[\20W/&$D+.-\-$CAO"N%=1N>\TIC M)C-^3>8%O3").6+$YIRV49W"K'@A7J%U$^,VFHVEQZ(JQI$^?>$8^L=EJ,=J M.L&>^-^^&!Y\&`!H;#218GT8*4C#`84?`#;QEAL&`AHF;(Z>>/9L?XHXEX=? MTFJ/FT80P$Y)'O@N^MAY6%O`L9!R9\SC4%=<;-!9RKYF'[PM'KV9E'CP-EP. MV-C42Z44[WVNF8-:'Y"'9B!@:PP3:;N9@?OQ:+3"XBU] M54QY0==OIZ4,Y<7*/EB=6/AJL@@>KFX6.J5C_*- MO;RX9[UVM[.J0W;U5#'=N4HS]_1V?[`OW;2KB>F[?#I.56;/FV!>Y)G_^%^.L>K%W$7 M3#.TRC.9Z$>53-[Z8+<*I\[%.]A-<6'-^:$A2FAR]+F@58>;/G1?@M7T*,Q/ MQK]9?B!QB2(`1IDO#3(/C3B/CZ6!.A?D#_0D`U6,YJ=X]AE8,+4@7WL,=\*!"=QL^.-A8V;!`^B#8\!?\LVNB_X M;2PE3Q_'ZR_V<8NTG-$*&P64IP`E.G$1E+Z,TX]JV.`^W[!% M?_Z4\PW^]#L+I,;P<,QF2F=&P1LX:^C5DPP$'6`BG7+Q@9_$)@!9)&(.5P$1(X7O0"C>#^SHT#Y]<%,_U>KIU+ MCI5G;>U+/:ZQKS!-Y@O[9_3OUO/7U<[D.PT^=:USB4OQ\;16K-:.!2L6ACT6 MG3&WX4GO1:AOUQ0QW&)Q.=9JM(?$K@C1JK1&YT?P,_?PP#)6Y&M!-\GSAVW` M!OWNZJ9`MIN?L')*IFT@G"O'!0JOY@'T@ZD)$5 ME,/NK/JHT^E5 MJ`CR<5D)$^]`3@YZPT,UZ@&2EE-!UB)I>XYAU\WT7G^T>K*B,G(K7,`.1&Y; M%VM$@XR!"K7`P<;`5Z^$Q1RG)>R,TM\*4E9M6[@T-U_^%CJR;I M['#0RJ>B,^\:1A:*>"#S>N%AONB5YDLAZ="-=A4T'2IJU?#I,*L]%TT?+/?; M1EDH.).__V9X%I[?Q.E8+Z,;.1]>+I8R\MQ,Q"_R!GGF2R]?/1B;]_(AOD[F M[;Y@+[EP;!ZL+O3U\T#7V_VC,V&@&!,Z_>,+@ZZ8,.CZ,)\VESMR&0)F6CYG M]\:W.%1Y8V(\\1)>/A>OP!O1"XFM5'=<066WW7-C+');;@LKRZ`3\V9PO%@J^>76TG MU@_$C9PQ^V18GDRFG(3>(3%1F:4HU_=:@N4[<\K'(28.N4U"L*XP8@54(Q_+ ME^-W0812E6W@MW#&Q_^I"DTBW&4F`OLPUL]UHFNU"^,)[.!%Z=E-G$) MH+C;&3<-N.R@SB1DW\[<\-,_[[L/J.K5:J1'RJ$&&^.M%KG48%&0-W_B-,]-@* M,1N7PW=1(WY]YI(K#ZX]+J_,Y?$H,EV<%R!);QV780XZD>S=48V1H(B!O!6A MNV[H@VCZ[_:N]E<=NP^JHED0QAN)KJCV>9[1'D>=U2Q3^Y793@2M77Q&=U2W MKGYR*UBMSO'R+JS0(MF-Q^>N!^OO]IFN7[Q+JNNN!N&50C9:JH>BMO!KQ.^7 MK1:A4D".YJ*'4]%84,>VGUY@%*24BRME">+34,7YBYCG,<@BA/:[?RIC\BNU MK2XPNY;8W^('O%,'8]JMMZ)QB_;SSWD^N?Y3:CB6@^GWRU,YN2G(QL]W%?>\ MI;;YH-,I3_@.9,.VF2!D5(.,]ZW!9G"LK`@_;)JTNU++U#2['20M1KJ2]!A)":UV':*]-J_!H4R8GNF>.J M36*CG.2`HR5944EJ:YW>2'UA(I#0JDRKLA(P:;PN.=D]$A<-"R2SMD)6#26!U2V!7\V;+MU#;9<@+#>;1@ M[USO]GBO*Q2E4['C7H4*'=Z/!J`NVUHAX)'"*^)M*95\ M80VMCRPX#K!)\Q\W0DVE*+[^9=HA5P$4-!JPT'`9)GM-+ MPW-$O?"OW&-W4ZP:_D_1U[82V(O1I/M<=!GW^`DZ3/5W,XE[@\Y$7RJDB*JL*W>DG?H^,U+5>7/3*%V7380K]`+F7RK/#@JD1L&<.$\F7)EY67E^: M?#%S\#N/03`'$/@"!!/7$V\$4X_+P$MX@C/H,ICZ#*M&CP%C\T!D/&>=EL9P MJL2#F-988P_<-$*?BT;`/.1F$*75M?!8"@@3%=^?W=`>P[/P8F"=Q4A:*R"] M(F++#;2%JDL^T>)RF9:+-Q MF6M+2E-;SC)?UZZQL+&7@*N_<8(V8A9:0&HJ)!5;J*JK3TOK3'IY6>OZ&(9A M749R%8@Y8.AI@,4SM+;^*SHGQW93Y3C:K4S15)R:=-,I;,E'AA6D&UTW3;>? M(%:#W"/GOR6LE(.5+F&%L$)ZA;!">J58@-*I[MK60:P\.-^&CA&.8?[&[^I` M9?/V633'-,E^5\*Q#/WVNK?B[X31W'N'$_7*!N)JL$&G5KB[]2* M\B2([,B=W&VIDW6"0*(D2$B/$$1>AQZIX/H9FFN-O$-_D8ZJ>O2,N@N7T;W1 MG"*XY[U1%:X!*7AIF9!7.?*Z(Q7N`1'V3A%[I/4(>:3UU`XKVV9)9]S'S3@5 M/;*H-.J2&](/P1_DC[$?I(^Y60J&._ M.\IEW>K-O*;\R7*L@)]]AK;'["I)4,KD)>A"MX]E4Z*E14.RG>7[TLV[7KSJ MP=YR21CGPG!>)!R&;7WPD[^6_C6J-(I\\"U?7,4UC;FX6_@?F(:Y$6`U%=/U M`QB5&?J`/7C?AD=]<:?7=R?!,]X+CAXQ_.ANLO_C*K!28\XYB!4@'^_&[=)< M*7GA=M,MS'T5Z<9;G0==B2UP!ZTY-V)SL>H8CH,R?5(4K'_C:)P[0AU':2,N)0\/ M"*ML@@.4)N'H9RODUJ3-8W4.K&Y_T"P'%J'B"*CH#/<_QU/)K;F7WX$[/+.3&@73TZ1IK*S,J>(HEN71?!Z=#N'W)DDN8UD M)T5]DC-SOPR+>CDV-[DS#YF&47__R#,%EWMR:-*VL(8;NY1 MKUFHH#C-5P[)KKX_(LF=V;SI/N"&^U$NU<97H[`L8Q@#%L]U4!!BW;#5UGB)U5+=O[Y5_,G=<9;#BG)6EC`]M;E!"2L;L%)- M1LP:H'*@3ZP@Q3O*FU:F\ZB^_?%069>N*G..CT6"$C-PLG&^\5;3=&>XURPK MFF=_CZJJU9]KS%JH:YUN]UB"4WT$(V&CU(R6([V.RZQJ1&,W1;LFCKPSZ<8C M#5MW1,M&5=NNI483J=I&@:0UJB/>5A6;=HM+1%U5?+-Z?%*K#J:BT-5&'NI: MO[W_+9ZC!#_7J-P)?96C3U<\<;8BSM""\814DOS5A)EUM79/A33B5(WWI M`\-`A>1?M01#'J"/U8./P.N,[(DTSPUNE;V"/ M:N'BQ==1';S:Z$W)X?6*X97$K58&%!^;JFT^*%#.-G0O(]\PCU/QN;-+-^W7"<.)&%GN+J; M(?SL!"4<9!Y^)_,5A53IVK!;2IH:93,`OJ+):FNCX?ZQ&!305E`GW7O&F#,/ M#!;K"7>@OGJ:J!$^.5UKE9-D05D=TXAI:&OZ8/^B'Q2:56)H5JFZ@U*U%0U9 MZ5.AD5.:[FZO%*-)@8`CRDCV6D(S.EJOM?\U)\I(]FJ!T=/Z!]QQ4BT(AS*2 M44:R5\#.@R,U-L9.9(9H_(/CN/F8G3]QSWCD[#H41R;PT]W4\`KF(XM;BQJ3 M;=U,9$O*1'+@QW-TMKB.:=F6N)N-`WXP?,MD@0L[+CM$GOB2`Z$/G\5Q,F?< M\!Q0=3Z;`Y/$[\PT;!-K-V`KEL\,/XJ\\//&4OPK]`-K\D+A%$<*IR@I'*&\ M4,TZ4GSIW=<8KE$%:Q6,(*[QHM'.K6F5<4/;22NR9T]3>3_U.&&@]D;=WIN1H^S]>6\UJF^;BWR2BEH((1,)1$D-"Q%1V-S1M(Z"#= M0>@@W5%M/:H"$0"]MOH11!^$\^HY=N<9D3LO`'L+4&]FZ?V5R',W2? ML)+8I=Y`:Q\0='=,GA!,:H1)3].'^P>Y$4Q.!"9]K=>BG'L$DYW:I*/7D3"F M_L!P-.L:&=CY$<\GK2?.P*3EIKCP+>R\LP?#5RGG-.5#JSC:<%1'^FK*Q4?8 M"WXZ(^01\FI!7J=?Q^:'L$?8:Z[6J\PMNB4Z6W'[&0QEU;VEC8Y\KU^<Y$R&0$%BO$[KDFVO[W=@I<&LF MN<-SY3R!3>MZ%MYYN>;"!WS+?>X]<7_S_9SXK9<+F5A$F2LY^69R:W+5$F_1 M)-0M<=F17/8B+FL;\ZV*>S](^)ZCDH\OWYO8=8:E^B<4`1Q7EFRDYG]UIC;< M+-KO;E/.QNV3NK:T_[)0QZVE5YECM@K.-O/2$MTB>"49;TN8'HH+5@TKU>33 MK0$JQ[T]55>)ES*+UBN/S;+S`1]Z7'$D757F'!^+!"5FX&2S']\:S_`PB)]E MV/76:E4U++/&K+O=P?X)DH\6B4G(J`$9O6$=97?KC]%M@DK]A^O]@?F!YIYK M(O;Z'15BM-3W=A;,&Y[A_:1PGF:FD]:U4:^E@(Q0%-F)P6XX M:FKPXK&/X-/*N:YC*=J)YMJ)'O\$11VV$#9>#S8.CH[='K.:F=3^%]<=/UNV M72AW??R2"N&P^/%^RD4F!]>!0?MQD*DY-9Q'CM[FQWB0F(,^7])YBJZDZ,J2 M8@(HNE(QTXZB*Q6,2KHP/.\%.,/.9VZXJXXKQ6Y"3JN4+;I^IX_EOAY#IZ#-/`5MM[5> M8_-8U70,*F2=CD&5MBA/ZJAK[0@J\W3KCC_.0/>S6SYWO0"]BU?.Q/5F8FND ML8>7Y(DBQU_1.TFCJ38_O$0_JG(T=A?.8%U\81/+@37/,FR0G(1:>-L31V6^ M)-K'HLP^#_#[8,H>N.T^;SLDVPZ78Z6@*5C(N2#1.8]A2JT&77\.FD/SUU`- M[5=W7%KD/#+748`^I#/4_4E7T%94[5SU>/#<3MN^19C/12@++-'Q,AWLJ+Z= MO8&ED],&8#4_+CNO-P;@SK"A/["K,7&@$T@;-3*HM_MB5)B85QR<<76?;QK4 MU2Z*8.05"^_EOT-K+O;2)+'US\:%Z\U=SP@X"2Q!9!-$'$$J@&3<5)0<>XM# M`7<-"[BC&:`9H!F@&:`9..T9J"#^I=M2/^SZEC]Q)X0.)]`;@T>XYQ@V,T,? M!L0]2L"F6.CU0.L-ZRA4K%P.",+&&C:&VK!51](0PH;ZV-"UECX@;!`V%"G$ M2[A0'Q?Z0.NV=/7!45K&,V9N,.4>\[C)K2>\ M*^QK0,>.FPHD4\>6J9[6[]-:3-C(7HO;/<(&82/3AF_"<38AHP9D4`P,X6)# M3&43XN9.U-/^D4^XYW&\Q3";6;Z/Z0#XMSEW_!W76DF0:@B"Z9!91MC(W,ZI M<[Q-P%`)&&25$2X(%X2+(I&V#3`R3M;5?B.\ZQ09HZ;L#-IDAQ$V,@UTIJ)TPRDCGLJH4!D55=E"V"!L M$#8(&X0-P@9A@["QOV>['$I5J]*1E9)[YR0VO:),ERK*-!&K^7'YBHM24$49 M12>&*LJ0\%)%F2;-!E64(8A011DZ&:"=>A-VZH0-P@9A@[!1-UL(&X0-PL;K MQ\:)WE"E^DK-"D[K:]W62'UI(FS4@`VZ=4:XR,[&W.XT(*"5L$$Z@W"A""X& M6K_;@*LSIWM3E4HK-4*,Z/X9(2,3&6^IB@X!8KF*3JM'B"!$I!#1&1(B"!%+ MU?BZZCC_5A%QHAYTJJ:DKKSH':U#A2\('-D)A0@7A(NL).S:B([8"!L;L-'J M-R#=-F&C!FQTVEI';X#B.%F?.152:IQ,];7.H*^^2!$VZ.B:<*$(+@8CVO$3 M,DAC$"[R![OH3=C5G:B#G8HH-4:08`<\'*HO2(0-6GP)%X0+P@7A@G#1,%PT MQ,8X62\[U5!25W:Z6K=%80^$#5IO"1>YC[4U?4"E<@@;V?&5!`P"1J9'O:?0 MW86#/>JETDF9$O>7Y&/A=QL-JH&8L$'8(&P0-NIF"V&#L$'8>/W8H!I**7Z] MAAI*#DCCCA)*/2JAU$2HYH?E*Z["0B64%)T8*J%$PDLEE)HT&U1"B2!")93H M8(`VZDW8J!,V"!N$#<)&W6PA;!`V"!NO'QLG>C^52B@U*S:MK6LMG2):"1R9 M$:VZUMM*IOE+C9*JG]?NT%A,VLM?B=H^P0=C(M.%;9*41,B@.AG"1 M%Q=#;:B3IUU5TYUJ+#5&D-I:KT-F&6$C$Z>J_5 MW'@8*K)$N8V:D]N(L$'8(&P0-NIF"V&#L$'8>/W8H")+*7Z=2)&E+A59:B)4 M\\/R%==IH2)+BDX,%5DBX:4B2TV:#2JR1!"A(DMT,$`;]29LU`D;A`W"!F&C M;K80-@@;A(W7CXT3O:!*19::%9NFC[1.IZ>^.!$X:@`'W3HC7&0'M+;[#0AH M)6R0SB!<*(*+=EOKC4;J@^-TKZI2?:5&R!&LO0W(ST38J`$;;X?JY'*GLBDJ M`**M=?KJ7&4F3*B`"5VI%80PH08FNEUU+K:O8N)$?>E45DE=B=$[6H`,5QLKYSJJC4.)GJ M:YU!7WV1(FS0&3;A0A%<#$:TXR=DD,8@7.36&)K>A%W=B3K8J9I28P0)=L## MH?J"1-B@Q9=P0;@@7!`N"!<-PT5#;(R3];)3,25U9:>K=5L4]D#8H/66<)'_ M&JD^H)HYA(WL^$H"!@$CTZ/>&S8@7T7*2/\AP"B0Y*^TT1I]_O,/H7_V:!CS M'^_,*1^'-K^91!E>;_G<]?!6YI4S<;V9R-?\X27Z\1YH^H!&],___5^,_?E_ MSL[B]S&I^6^&9V'/[`KS6G(_8)=.8`46#/&?]^('?)^)!O[O[$RVL4Y(W$S< M2MQ(TCDS@8?PQRV?_.6-V6[IO9;>T@-7?!IU6F]^SMI3Q#S__EXP_1J8?HM, M_UYCXAN-^=RS)M$,I:8LO4O!C_=3SB:68SBF9=@@*`F;D`;QIZGECEE MEH\W6^T0<[I;CDCV;IBF.YL;S@M>>X5AC-'UC\,7R@TK;=9__'U2E.#7MUWY.]R<&7'CSV0Q9>*7&2PG*CM3H- MN!%%V*@'&]T&8.-DS5:I5VW+>+!L$0-`RE4]`:*(.L)&%C:&@^;>;5@S6(_N M&:52L^36JHLMA(W7@XU<<:'%@P;SQ`JI$3*813-]HD_TZ90^;=92E6Y@Q:)` M`8UJ!C3JW:.&!6ZF#]M8[GDI!G)3O",^6FY82@W!CZ6;;WN%9*D0#;8YOG9' M--AFE!WDV=NQ`[B?>IRS&30Q]1D'Q3?>VQ0LVO52).)F)=^44"U%\#=H%OZN MX;LE^)4829O9]3+J-F.-8KOS(NX5Q[]B>#3I(T+'1G0T-K"8T$&Z@]!!NJ/* M2PGE4%S7"5OAHY,ML%4>CND[`S6@LB[U1'-,$!\_@3=T*J#:!89%NGUX#(-D)&'WZ_@ZW(NTL MCBU%[:[ZTD/`J`$8;_6>.M63,M+W$B*.CXB1.@F&"!$J(*(S5%='D#-*0;#2 MQH$VE;4S@;!!V"!L$#9.%!L'%X+;67\M*?YV;IINZ`2^R"PLBR7?M1MP_[-K./ZY,_XDRYXYCXLFDAYKK/A60C*3\NLDB1)TH@`HLYQ$IS[H1E ME/[`Q]>*)6RK1K>#(^WA\#">K`A$7B+R%\FC/`YUYTDH?'&^+/)D.TM)&387 M4:#"5'1YN=E7S-;5_?9S'74OG!%6JL;*R15,HKN)=-]ESZ/W!MYI.A8)2LS` MZ>99]XPQ3^_[MHL+'<4=VP&EM[7AH`&5"@@<=8!CI`TZ#0CT.='B0!]#SB;0 M$>.SN>V^<-*NROKYVZV>^F)$$*D3(KK>@'HG)VO(GN.9B.&8>#SBL;$;/@23 MT%XZY-BN?$F6Z%B5CMP)&RH8MEO7[>!QMC+&P MQZSVPL,UY@A/45$DK7)-PEF$Q'3D<%=K]^LPI0L@.]6:BK MS%)?(ZJ;H$VYI6)AOF\-1M(P)Y92ZT97'0D&4L1^Q^9U>B@+D9:N%:D-]3K< MVUD3JIX_AF!7$>STGM8>U)&5J0S<'1SH6S@,-PG\O>./:,2S6SYWO0##2S]: MOFF[?NAQ]D]\GHD7_F\M!EB^F+RW>(UB?3=_?+F\ MOF>WEU]O;N^OKG]AY]WM^?W5S?;>*@^(5'N&E!X_]D`4JY6H\ M+D=&1V'.[,GBSSZSP)QX"'W+X3[&1K-`U"WR)1#])<9BC/2=@6'/`%`93BW# MJ*.G-?'$Y;]#:R[@GWR-Y@K^='4??_<^);:IDDG;VV?NG'L&"",2Z8:/4]'H M;X;O@GP9CXX+##-]YHQP+`;$H]'!>$5,^34/_N':3UP:>SC(OW+##J:FX8DF+EQOGMG%S:*9 M:'BI#A_XH^'$WP=3RQNS?X>&%^`P)B(^;2/9:_.*G(WY"2W",`"WH+0TP*,3 M3@PS"+WH3^\/+M0@#L4/Y[%6O+R\^(H"@T*1(3&#%BP%3QR>-0T[%@L![,"= M;W\S@=>XYALV$/+3]"&4O?L!G(`U@6F"XM.$Q7!DZ MPB8LD_OO3UDYF5.+3V)1`":-N6D)W]C,^`-89?D;I?-"O'GYC9MA8#UQ=C.9 M`#<]C3U/70T!"@OGOT)'S(J44I@*Y+[A`(3EO'&P9$*A86*,PQ/BN@B>F3P8 M/@`(WEZ0)[.[9,K,^7AF.98?X)-/J&-DUZB?S"FB9B),":ZQ:0CMHW8!36+B M6BSQMKBF$G!SZL#.]Q&@Z'$1"NC!1/P'J,%'/6X#S0CM.7=\U!@VL%Y\%;B, M&]#=-K4K;R:9H#W!'',#F$#85**R-(+`LQY">;$#6EH,.UX>M&0P(I!0@_7] MT;"UJ`G78Q..X[$L)ZD4I)@\>`+8`8&$REWO=8>+"O8VYJ)73D'('[*L#^GVU_ZDTXVP8O=(*H7G=MKV+<)Z M+G9;:*I$RW2P5K@WZW[OZMT)NL73`*SFQV7G]=Y(R_2P1(['8P1_T57!#1-S M=9]O&M35+HI@Y!4+[\()1Q);_VPDG@426(+()H@X@E3TQC45)XKR&R]\G M=3&89H!F@&:`9H!FX+1GH(*+'MV6^K?J;J.SP>@:$BRR=,="ZK3HN MW:F0$J,)QOO-2BPG5>I34H[:8+,WH`8X8:,&;+S5A^J8952:305$]!0NS4:( MJ`,1W:$ZVWI"A`*(T+5.1YUE@WSJ*RF7W<"PHUM`9(LK)CDZ[&F'ZHL.@:.. MC5I7ZW?5,;X('"J!8Z2U1W7D$R%LJ(^-MM;J-L!12MBH`1O=@=9IPI']R7K1 M5<],1S*U)E,]K=^GM9BPD;T6MWN$#<)&I@W?A.-L0D8-R*`8&,*%2MEKR=.> MKT+MA'L>QUL,22&"*),8F>QJ"5);ZW7(+"-L9&[GU#G>)F"H!`RRR@@7A`O" M19%(VP88&2?K:I?I>BDR1DW9&;3)#B-L9!KHY#8E8&0!H]]NP')+R*@!&8TH MIDW(J`$9':W7:FX\3$7IAE-&?&TYY!H`VZ.1\$K*5Q,V"!N$#<)&W6PA;!`V M"!NO'QM4468])??.26QZ19DN591I(E;SX_(5%Z6@BC**3@Q5E"'AI8HR39H- MJBA#$*&*,G0R0#OU)NS4"1N$#<(&8:-NMA`V"!N$C=>/C1.]H4KUE9H5G-;7 MNJV1^M)$V*@!&W3KC'"1G8VYW6E`0"MA@W0&X4(17`RT?KA4 M34E=>=$[6H<*7Q`XLA,*$2X(%UE)V+41';$1-C9@H]5O0+IMPD8-V.BTM8[> M`,5QLCYS*J34.)GJ:YU!7WV1(FS0T37A0A%<#$:TXR=DD,8@7.0/=M&;L*L[ M40<[%5%JC"#!#G@X5%^0"!NT^!(N"!>$"\(%X:)AN&B(C7&R7G:JH:2N['2U M;HO"'@@;M-X2+G(?:VOZ@$KE$#:RXRL)&`2,3(]Z3Z&["P=[U$NEDS(E[B_) MQ\+O-AI4`S%A@[!!V"!LU,T6P@9A@[#Q^K%!-912_'H--909.J.G]4=T7U5=\YTJ*35"CGI:MT^9(`D;F64Q1BUU M-"P52E$!$;HV'*ES.9$PH08FNJ0G"!,KI9%[#=C1GZAGG4HK*2PY:FE3,LA5 M`D>[J_6[E&B(P)$%CI'65L@T)VRHA(VVUJ)Z?82-[.1U`ZTS[*H/CI/UI%-] MI<;)5$_K]VDM)FQDK\7M'F&#L)%IP[?(2B-D4!P,X2(O+H;:4"=/NZJF.]58 M:HP@M;5>A\PRPD;F=HZN-1`PR"HC7!`N"!<'&AG#!A@9)^MJIR)+*LO.H$UV M&&$CTT`GMRD!(PL8_78#EEM"1@W(T"E7`2%CPW7T7JNY\3!49(ER&S4GMQ%A M@[!!V"!LU,T6P@9A@[#Q^K%!1992_#J1(DM=*K+41*CFA^4KKM-"1984G1@J MLD3"2T66FC0;5&2)($)%ENA@@#;J3=BH$S8(&X0-PD;=;"%L$#8(&Z\?&R=Z M096*+#4K-DT?:9U.3WUQ(G#4``ZZ=4:XR`YH;?<;$-!*V""=0;A0!!?MMM8; MC=0'Q^E>5:7Z2HV0(UA[&Y"?B;!1`S;>#M7)Y4YE4U0`1%OK]-6YRDR84`$3 MNE(K"&%"#4QTN^I<;%_%Q(GZTJFLDKH2HW>T#E7`('!D[]$(%X2+K&SLVJC5 M`!<88:,6;+04LLH)&RIAHP/;>+T!BN-D?>=44:EQ,M77.H.^^B)%V*`S;,*% M(K@8C&C'3\@@C4&XR*TQ-+T)N[H3=;!3-:7&"!+L@(=#]06)L$&++^&"<$&X M(%P0+AJ&BX;8&"?K9:=B2NK*3E?KMBCL@;!!ZRWA(O\U4GU`-7,(&]GQE00, M`D:F1[TW;$"^BI21_D.`42#)7RFC-65G5YR(,.<:F'.[;NO_ M*_0#:_)2!LV=?DSTIR@E>S#U^*Z<[#T1>H/)V37VRR7[*S?L8&H:'F>&C,V! MES#%>[?[)_'D$/YU)\R3Z6HT^.#/N1E83]Q^>9_B5O+I4_[\\'EIZ8TB6OJ; M:='$$]_UWO<83(.-)Q3P9K_]I^@'O?N^G?YEU(%?H#%C:T02,X)-9'^$I^2W MNA:-89DWJQNOZ/.??PC]LT?#F/\8Y2:^Y7/7P_O$'RW?M%T_]/@]S/,'1,'/ M__U?C/WY?\[.[CA0[CQJ[)$[W,/;#D"",9Y9CN4'>!WYB9^=R:<7S8M7?I$O MG#OC\Z7'+^7Y#3-ABJ"[6S[YRQL31]?26WK@BD^C3NL-"QU+_OIKJ]5^P\;< MM&:&[?_ES5GGS<]MO=4;M5JM]*CR=%O#P+K)P+HY!J;WA_U!4P8V*#"P7J?; M;<:X>LFX\B!QV.GU#AK7%!2/K[&;,/`#&!.F`[[WN`'R^,+N`A!&]L\O0N+_ M;VU\XM74B^M3I+<[^N]W@0&:!$0>\Y,'+Q?N;.XZ\*=__LWR?X\[$WW)GI:' MK*\.^4QO=5K#Y4&ODK)U?$#!#,L:'&%TLJO\8]/[_6ZG=\#82IN[3C5S-^H. M]?JG+L_@BD]==]!28NJ$WGBU8I=G=,7G;CAHMW*/#0R7,S#!9[#O>N)^@&3X MZP.!I^[AH:O%,]DJ9->2K*\*S'K#5="69_716Z,"M(F)O_+]$`SY8[UMAOAHVFK6#ZV8/APQ,XI;!4B1(T&FPL`K1;P<"L`8W%]4-B\;%TV M+ML6+8MV/V"SZ5:WV4HY)J8S6D%,80(J8\WY>&SACV"G?#6L,6R>V(4QM_"^ M\$;!.YQ]*S;T#AE=T(@D7CD1@5GRNFY_CX:JLCZ?ECLVLW>I"] MHA@J1'9G.%*5];<\,"P'GKPT/`<:\]6!=TQ:3%DN5A.7"^+Z%7&YG\);UQ-F53/^G#"I3]`IREZB5Q#88J/7/1D&K M[E7/QK&,NV(24-2X*TWU7'[CGFGY'-GD"YZXQ++H MS<&MPV%5`:.*HJIB'E7-C5T+=C^_T.PYPK*W-A5@XJ"=S1$X6.%B604WC[Q6 M;N6J5#ZW?!YZYE2LAEGK92DL3G6R1J2B+-U&)D/R'GQ4 MS)*=1R+K;LAN;UVGE8;S*"AE#R]+>[:OQHOX^OS9\("9T?JFL7B%\QEP4G9VD)TMSP-K,+37 M#BN%D.Y>\[<0G&M_'!_A'FV#'!%P/]=K>3$2-%GPR>;(;O6E:[_49IE#).'^I1,V4= M3(R:9:`J.5^YC-62YDLGL[7,:2ENMC9+ORFSH:OZ?*"OC]J-4F7U[BBJ.;\\ M$W>>&C0)M5NQE06CG_7T]NK-:[7GHLZEHHHK+WH_X^:%NNQ79ZFH^K)7OPW_ MUZBI4=+J/6;T]MGJ95JU)ZS>M;V4Z]K'7]N_&([Q"`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`17 MP"D+;*X]1A"]6LH(.O$(ZI.U])/UKFF3TW_PJ6]\L_/EAH&J[UO*(<` M+SUX[(<=11E4*XAP/Y4E!&9SPWF)]-L8LWV+&ZJ)F<\FEF,X)DJK'Q\Z^6P* MY@U[X-QA("9S`\L>@Z+%YKPQ/,W9LQ5,X[H!V/C!?+(?P*8H@U$`(A-S!)H%D\V/NPMV]^?7_WGOUR?O[US3LQB_/0\T,#I#QP MQ:NIKO#G<5(F@'FAJ%$`7WK\$4\K\7(K-HZOW7$S].36#)^X_&9.\>HP'L'& M-9S?XG-O[BXOWKQ[SRZXA^$:0/#$]68+4"WZ\YF#O^#P+'%@MAA>Z!CA6(RP M"*NW,3CA2FI"%FV['G-G5H`MI]GEA^8TFROOV;GH`+B(Q2*`9IEQ/C>M_M0- M[3'0`:T:@F)XQ\%R#\`GI/C'JJ4MJ>(B?%0FM^VY,<8!_>4-K-#XMS\WS/CO MPPJYM-)E#@,O*1,3N/.,PHE169_E2HF];CGJ-;.VC_XNJ_;(UF*'1]-;N16Y M4%,+L=D!0`EH&4SAN*A%,#"!`^I7A?%"*K[O?7;N."&T(DN,,`#J)Q!@&.O9 MWT5A%7SXA1M>5*`EHZ2)X0,Q-OPF9%*HE)9I#EI/#I12TG-A=7R#>7=%).$RALH_K[VDT1'-+6 M86+V26"@U>?"WIL]3RW0T\^<\3A97!3*])Y=22RY<\M!&R8YML<^M-PPRR30 MXQ,;3"/0>38SQL@_^?U;?-7RA5!`?]*?2>ZL<8<[4.PL[CO M&]Z+`*?!)H;EL:4=-;1FH3_?FB72%N,X6@[?,Q3*E"BF1$*TZKPD34B4"]$# M99%T;PG+=RR.+)ZXK$4FFP/1?4`>8_VOJ&H9MB<+BJVT&I$U"8$YN/JNBB<3!"D@8`%6DCHVYXETB0+:(M74P=H:!)%HH8"L!"[W-(A92NUC8,F M4"A!`)#X#=T>M-'"QM8$6BR#6O);%@NB4GOP%)?ELJ+5P_"G;&*[SSX;R_PI MV$"\-$1RR<>XYPK0_HQ;E(NPE!A3;*?&%LR!)]?"8.KZJ3F3\KIM"A/1%K/M M"W&5F8,`3%-0,R[NL&W0%B9\A$&@FA'N,\LSPQDZ'TV^8`X.T;,X[D#QJW^% M8U&?+Y[AA56]0)JD,::"@^47"EHM&.!FRL7&&O[WT476/:`[9TNYP'T=:8L@ M89!@<@C-B'6-:NI87N M+@7>L$^):KM+*=-5V_CP/2^(Z[[DY.PBH3DF3^PWDN_!P@%M@<$.,05^"C5I MUV,LPZ&_8,#*DEIP==JEB8IH@T0%W48[KZ^&!ROXO6MYQ M->%#Z,-.R/?/3;`Y?/&RB%=)R`0B)0&_;^C3__"2_D6\'0]&C"492E9LRR!] M\H:1N>_U3B^:E^*#3&;G(X5:5Y9BXQ-'Y!/+]X?/'T?N&; MHRA,(U\?QR0_U_V+890TMB#Y($4>)D2\3%M8\K94*O)(8Q<9(XG>C5\%DT"\ MF'KOXH`1==M1;=]B?=4\LCQ0Z_6C'()[CBQ6!`BV!U"B0I7=V MIHD%GVC!3?ISZ8PV&DMJ*(N1I`A9\>3A M4])?S,G6GHY#_G[LSTFXYSY9PJV'/O:Q&SX$D]!>Q#]$82VQ[R^E+I<'%#?S MR?4^1HW$4@KBN7#5G:?T[6'3=*:G)FF/[I5D0<'D-*U123P0=T>B8UXS7;-% MG+(NRB,M#SF[:`ITEBJH=.@8XU+6^3NL95#%L-N)$ECM,:@KYPG^=CU<^P,\ MD8C<]*!XYAX&WP0O8GP8P#&704?&2IZJ10B=#0816CD.7[TSDW1RO^CC'LQ5 MV0,0=QFWOYS5Z29N^[-H&LL+'<:JU):]3*I>$3\+ZHRT'[82CG[&N$8P/RZ@ M*2M@GPP3K;$7C7TQOEFS<,8^N)[G/B._+@R,%P8.?^"@>SD>+]N&*>]PK323 M:83C,S<3^43<3]1+TDGSVPSNI7*3'$YEPE9Y MVX_=3%A\M.F?W5G?%G\M6"0NJ>#17?@@+F?(4V(PP6`!<+T7>0Z?R=#%E<*X MT,'7BA`(O8.LOMT[XO.L>_BI[DPT(2DK!D8K274Z4?, M7QO15H8F1^"+C>0G$;U1;'.8AXW+!>:J/02/=TAR+&4Q,,IWA+&"5Q[9L$](@_+JQ6^ M#S,7J]L_IB[ZVS%229@$OC6V##3Y,IL'M\&HMEM>QW MTRZ)X]%8R+\WZJ0/@G<1Z0<*%HT&1(JR\S"%V-_KXV`":.'[\ MQ]LB&JT099C$YT=GQZ='(Q2'9(KCE_.CE(T#%F)\](^___$//_YI//Z*8D2# M!$U'S^O1U>77R<,,1YR4C>X?[O@_T>CC\0_'I\>GHPNR7%/\,D]&9Y\^?3\: MCSZDP7"YR,KG$),O/)R>OKZ_'KQ^/"7TY^7!Z>G;R MKY]N'\,Y6@1C'+.$MX:.1IS^,\M^O"5AD&06E]C?GFDD!7P\V;:EI1#_&TNR ML?AI?/9A_/'L^(U-CW(5Q6-`(Y+\K4&?V\2=^.DD>[HEY8*P0?36;.Z]T6CC M/THB](!F(_'WSP\W6^Y5P,@"37$81,3,*0IFEZ]+5',$)O$T[MD MCN@M#IYYS!.,V"5*`APQKE$F/5DOT?D1PXMEA.1OV]B'J,7_!SMY$R(U-8JW\0K M%">$\I!\0\D.6FH$M5:,0XBD<;+%S@,*$5X%PNK=%`4*;JWX54!CD3-O"6/W MB%Z0Q8+$C_.`HAV4!@AMK?`%B:?B-9WR?S`2X:GH`1X3_N>"1Y3=S2X"-K^. MR"O[.0[2*>9/VYC0JIG^C+I;BJZ.=Q(""-R?2XKFG`&OT`WO(!=(>+I?>QTU MZ-857X)(=!^/<\0S7_=VZL27C>!*AFF4>>"6_[_2-'I+$!>[54@8TIV5F1)2 MC8B$E:8C,7@@M&IVWG+6!\\"]IQUQ'S\]!($RQ/ACA,4)4S^DCEH?'J6CQ:^ MRW_^;=//2,E1\(RB\Z/JCPE.A*7RQY.A5)6=3DW9^L^YNL7/585+(9[0JNX! M#:40_L]*?)NCG9SBA/$!9B9MS..XD/PS2A8-/Q*MLB6E/H\V7*.$C`IJ0J>( MGA]]%*/E5R3&J_G0>;!HE$8IWT@.W%80Q]#`K:M.VEBJ M0'-.*$`-DI=#_'M_(/XX)S1Y0G0AY@4LR88\-4R82'+7J$D\C#K`%G.8U0+R MN'[P)ZZ7:(:XTGR4Q73ONHDD]X6:Q,.X`FPQQU4M((_KW_R)JYP5%[/A!Q2) M(?1]0$6]IMY+`NZ\-12B87' M0["TL1:65"P2_9O/RF+QFJM9PX3J4>Z,ZB,/(VS0W1S(*F,>KQ\L\1IVGNXX MH\G@JIRT>)3#KG',3;_%*S0M/K+D!84&4&'$N4=LQ#Y%ULDP3:AM,OR;L-Y3 MLD0T6=]'09SPA"IZWZ68AC4C#R'=5C%,I#Y%W<$H32"\T-@22[F%_)`,U&1#9P$BZ'`J?^9`=9N'E`?&B6(G.I M2TU4*W;5B7R%!<@H``)T#^\F?X#X&4=8% M7[V%F*&GX,T8:""U_#YAH_85`&YF`L!@%>A?>5/F)ZZL=40$HJWE>PVMKY!P M,=$A^VO$^?L%Q)@>S$2U$N5[208@HP`AU\GILM#37'\F?OG-ON!8&T\WOB+$ M4#Z/H][*=!@0H*+]JTWGRF<=FEAGBYG8/&&$CYFV"AD=K>@8GHA8 MGD?BA/N>J_)R$R>((M88BGXWN'`&7+? M0Q@.":G.#NH)G!`]?/S"G)=$,D>H%L\9*(I5\4V*0X*8W04]84K9L'\C[2>* M`I;2M19#>H+]FZ[`./KK';5E(UH06.G4RV_>"02@UL$08)#FWQ#W MEL0O8B=D>7U)/;L92&1R4Y)X''&`3;!@JP4!NS%?QQ2[9$/(QQ6_T()[L-\@<<7%*-9 MHYINH=KNZ=-0#9>!U"$@4(LJJ:8B:[/33R-#U>D,7"HJ-+_FCMGDP)2GP2*? M?$$S0M'6)L2NWA(:<%-P'-#U#7-]D(735XQ4,BY MLHIBN//'J#CID))F7E$\D:>0E9\,N]Y<3K0:>P)^`K*G6?ZNBMFO@&R+VL/JU6$BG!YZ1ICPE:-)X&2^(/;:` M:63X5_%]0N$\)A%Y63\BNL+AUI#ZQS\;G?P&J*?S,MA0NVP!-\@![D_9IT-4 M/1VQ=2$5%Y0DU!-4Y[FIJUD@X_.S+'N*N7D>I4<^/6_D,QOA-JGI"7TPTVR; MV2"5%?M$*"`(Q&9.!;!Z@9M\71.TE[Y5M-GL*90ATY-58JQ]!M!KH'$V5 MQ/?0`6<'^EF[WPJ5MO/-J7R'`,P\!P1H!;Z?SAC<#9GZ99,0:%UHG[XP%1.( M:89><8)"2G8.=YG;OT\Q6ZWE[C9=H:7^O%YF*9X/-\E'60%K<^V/N%]D,EW@ M&+-$:+A"N8;U:;\3DRP$`)D\P'0C;J2ES6JP2_'9>!PHUK]A^@-BB'M5'%5Y MR7OMB&0'/:D!`Z+=KJ@WTGH*#Q<+[:BP2/-P<:"E/["E1$BOH)"A>BN&[AGW M\2�*KY%9_VJ%4E-F5M_,M9W`!2U52=KZQTVQ-_M'0#?K+;A*6X*TSHU?C: M9B+:?BA3$PWX7=8:%P*TK?J)5B=V\[E6+ M?Z!]<`3H!?HX,]M3_P--D?OLA0PZ>3ADLBPRV<=2",A"E9[T``X.]EL"LR\J M(^;U6;7*EU9>AM:J'/]&2Z9=W]<\[O@E/[4E7#_1(&9!F(4IGF;_RX,V_7>Z MN4[+"'`%?UC\S<9S]YH8NWI]-.#Q7FZ.9 M%-UC?5;9B;!B)?!.PH8[`R%89R_!$YF$//(4:0^-K[G/G5&>F.#`..APL`MT MD!T<51\.[J!/=IZ"@QZ=KGW6?,=OZ/,5Q:\HBK+/33:PJ6AU^*K2'B2D#.[H M&T75IE5EF($7S3)MD9>@F_B?!@ZI:DZ]N_F^43)#AL&BQV_)18#AQ(.N?L#U$E#3Q<%=VJ"$PZ MKH96/T$X:)1_B-M)$_]6*&LLVBYDZ*)L[2C,7+8&"QMPN>LR'U;95/7.!.P$R`9%-CZ9M&LKE4/AWMRC'I-*-<[I>&<)Z/-5JC\(%#- M/,/.4)MIF!@.`6S.CND8=I#V/3P$N%PZ,N0S&YFB\'=X^0SHA*Z!I6W5OXL6 MRKK>BKDV?P'X0+9QNJ'321U85.-IIHRHF/\X"B+T&V8'$A5LP'^:K+":5!_()4'XB= M>.0>8!C/(<"MC7LZQAE0!?_N86Z^(-FRX>*`YM+QO=:4:&?5ID03ZR%@=`=G M]9X239K(E.@U9$7Y..:M03"JH-6"LD)[F"C4NZ-WV%6:EFNY?"H<-E7.[U-V MR8EZ%BWL5"R'B3ZK`#C4T&M!V*`_3`2: MW=([_!K-RSSHTS(MS8CA:K&,R!K)693S0-'.;QXMFO@/$ZQN;MO/N-&DCDRD M'GVN5_8`)!6UQ4U-X(D&T^81'BY,IGY=P7284`4X:!]]NT('"4J/=G_K59O@DNL00-;.1?NN?DLE9,(Z];J[K5TU"ZX"J8^3!]`?)A#-;ME;%:A^ M)/\'CW:1:EZ<"_>*:T$N2 M/B>S-"I-AHI;*XKSJ!2;Z%N+*%9"MA!Q"&#LP'D=@[.=1OZMXKM$2XI"G!G& M_QTAN2YD06B"_YO]7D.R"TON?!C+(2"UA7,Z1B9,`_\VJGT-<"SF7'?Q)69+ M(O<[;O+\60V#,&)Y$ZB%^!!PY^20CA%G:UMVT5Z=S=_QDO)V*Y7[6%(.UL2_ MTL;5;(;"Y&YV]1;.Q:K$AR!!=[':+[6$T(8U#X(;Z_M#[`ZNV0F?;NU:MK/O M^=36JX#&_'5A(JW=9Z?4BAU\8A'M)4H"'+'!SFC]-?,-FDY6_$U^0=_2Q3.B M=[-+'*7B8%FA(KM+$Y8$\91;4'M-6G+G<'#F'K8:(`;=052*'9LD"<7/:9)] M;B7%HNA\XZ9AB7MW`LN5A!T%#I>+VN*(].#)2I)R5&Q;9]A1(?_Z4HTC&A[@ M-N$0EB7,O.8-]EQ#>Q3^[HM6Q[1R8IWYTJX8%!'PT.W37:M8NKSO67A4G MGAP"0)[A:D(I$MN"Y5'`TZH0S=8XL,G*!;O!+?U:16 MF\^:S3X<1ESWFU]5[-R>AS?6&,Q0W<$`);>#;?`[&#J!EO6.A9V`5+U#P9,B<]:+;/0; MN@,IJ5*LX*\AUDA3OK2V23/L=<#*-=6*)TT;AGRKS.XF)@LJ[XU2SO9:V_HN MC1X/;).+\\6E3ZQ8=ZK%&YA^NW;32N]Q-%VMA<48(-6_69BR%"9#:5#]] M)Q!QLQ0&$*M,2P%G_]]EQ2E#5V_B:$"T+0*7#LMHWY-JTI:]26U1WXVO0"B4 M;]ANU>H!F+U`Z_;\,<,Q=`1J;?U;!JR=;7>MDN]E`J^=!69\1:"OQ`&`!&IQ M>Y@86K#,?H981ZT]\T@-&#"]7#%MIW]G`'+U0'L@`5IJ6Y_-'X@_G@.&^"__ M`U!+`P04````"`!5@&U'-2P"KF$@``!`"@(`%0`<`'9A`L``00E#@``!#D!``#M75ESXSB2?M^( M_0]:S^NZ7*[>GIWNZ-H)VW6,-]QEAUW=LV\3-`G9G*((#4C95O_Z!2A"XI$X M"0J@2R]UB(E$)O(#D``2B5_^^K+(9D^(%"G.WQ^=OGE[-$-YC),T?WA_M"J. MHR).TZ.__L^__]LO_W%\_!GEB$0E2F;WZ]G'#Y_/;N=I1DF+VE//_TX.YZ]>WOZX^QNM5BDY>Q3FD=YG$;9[(:D M>4D9_.?LZNKBS>PLRV95J6)&4('($TK>'!^SRFDMWWYF?]Q'!9I1H?/BYYGOS?KU=W\2-:1,=I7I2T-G0TH_0_ M%]6/5SB.RDKC1O&7>Y)Q!C^<;.L24K#_'7.R8_;3\>F[XQ].W[P4R5$M(ONL M40DG?^G1USK11OSII/JZ):6,4@GKAMH5?7FZ)6X2_EC]+RF/:"//9IMF)CA# MMV@^8W__=GNY+?<4%7B!DC2.LCW*$9YF:TOBV*%DK,XQJO*HC<$ MY_2?,5K0S\4'5$9I5E!AJAK*]1*]/RK2Q3)#_+='@N;OCU@=QPPK;W_ZX2UK MR3\95G!BJ\@%9MBLF)WER06N*J%](45#I-?A:BWR+1#%# M];#65K"T%O9\5:0Y*@K:(O>T_S.N`^24<;,6\0.Z+P?(U"H^0(@Y(@0EM^@) MY2LT2!Z8D[5HM/,1V@<_OBQ17B`&Z.OR$9&K-+JGTT`YK*<8,+=6H.)X5A1H MT(@$<;$6Z3/&R7.:95S?RYP.VP_I?3:H,76X6HM\F5,\E9A0DWQ!0SJ,@-$0 M?++)88L=-G6D3Q'3>IB@FHRM!?\8D9RY45>X*&X089,&SN\>(S*D^VLPM1;X M#CVP.>T6+3%A,]IF;F,3-:G&XJ+UO]NT^#9`D0&5C:?@F/HXF&RC(BVNYS?, MBZ9=GW%EM1`ZCE*ZAA.%LW2@AV-=E?TH3AZB//V#5W631?GU_'J)AEM&E[-+ M)^AK-8PX\H$X,U?>A[UP`D8C^A[VLNKS=N%YV,L),!G#[[`74(.I(Z_#7D:8 MST@^QR!,:O`=P>.P%UG-<[SIV%YJ;=9[FXP'S`B6->U--?[W/I3;U35@@T5G M[VF\7:UQMK,<[V.-L('E*0^?6E1O3B1O%?=NC=[,/KV:\?9,1-DP& M^2]YPH9A9LV"ZIZPR?V.-M#&,[J>7T3%XZ<,/Q>_Y=$J2>E7.[_&HIKQE+HK M8+*S]?3F_II@1B;FD]3^;PF[C--*\/$G2Q4E-$9?"MODZD/21"D7BU3TZWC:$0WE![DVI*4C2/&7][8K^MU4Q>BD1'52V MPQ$3=\CP,%JUUF.?+RDD<\KX(CF:V_53<5_UG51P_1-'RA$U0)R@K"_Y+-64=OSVM`Q;_5/_\CZU\M`'0)?WG=EV0 M1?W\D)J!]@S4)1'#B2QUJ<8*B`GU`F[\O\WZCW^(L^X3)N& M,"[=;J4=%L](N[WH*,NKJ@=+O,2T05_V>M: M+IENNZ,;ID&")E84 M>FB8O<^AMN`/_@>C6[18AH,M.:QZ8-,OR6&SF)2F)V^ M]8JS*A9,<%1!QV"4/N07*T)0'C=C6\_RI/I?MHF_2?ZY*JH0W2^HO)[3\;J# MQ7$KJ:TT5B5!8GHO+:K&_5AB\+[A=ZN=RK-3IP-I\%O=;IUO00)()K_:[IW2 MW%R>MY.YJ-7E$M'A8>MC]^"P_CBFQ1HA-'J3ET1NG8FI79Q;JMHV+D]_CC-, M)Z/W1R5A.XCL!YR7Z*7\F%6EWA\5FRC7$,RZ.>]@HPW.J^L@+ZGPB%A&VS4Z M3#LF!B1!*AU,M*V.S30$X5%Q;$$#YA3$86='M`^M8*G:YE*:NB4$-*..S((0 MKXZ!I6;$>MJ!=H88,[,+&$[;W/]X%Y3!VU&(+BS>4W"XS1G+((Z!ZSL>;)7T M:\N/J2TN_%XW!?#=D\LE[ZQ8K4K3JB`S9DV`21"]]RN+HEF1M=B2$HJZ`4"* M4*VI5D?+GB";('KF69)4PD?9390FE_E%M$S+*`-MJT5;-XN"-E1[FZBH97D% MPR!"/&Y9ZID<)?QB'FA\.5'=)"*B4,VMI926G46<@HC8.(OCU6)576$7;>?`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`XU[W-BS0Z+[9+$'K1)"FNS2-/9*V9L`.B)B@;F^(()#=B^&0PAH-`.]; M6-?-P`C5&<2X^25:4-U:XH'+024=WY\7T_G;>)!8'.NKUH1%GV.U02_F]#J, MW5O"^CF;/PSYGJ^;XD2Z?OP%SN"ZY:*73(W]-\[MAXXPPVZLE M"&(;KB\F%Q+>$=8D%X*N2^[/(="&"`@GJ=JM731%-3!6NNP#':`&8:5_8A`* M6B!_PB5TV54MNDJVOVYY"DQ^,^^DD2:&``+]6AY41HL-TDQ M.*L@T%O?_&'R"@(3)11U,X`4$[&L6CL;(X-<@YB?P'L6X,4`S_<@3`VIO-R@ M:[O.C06_,>#RJZZ;),/=R'"C,MS8>F6F@@6+%K""BEX]0<2>\[NME2M5918H MFIL2-7845'5;":DF@@\]+6T0(>0<1-QZXSHW>R$1'#VD-'S"AVDF8GT=#:TF M?9AO&"]$;??X)-JRI%X*="U;CG<\7^_/ M+ALY7>J:91O@2O+V7KB$W*_G*=P#UU40\`)Z>]\27@-[J,"FC:'_*XH?%$X4Q2,F$,/'O M+"O,#`)!)Z`%8`I;.RBG>:"]H7`5OQ87A*E8FEP5E&)H]&!"4+:'CWPQ`,[M M"JKNT6Z7RE\@BKS[8EW-Y,;>3?I";H%T<4*G);H(_")?<2GIMEU<2!>PQ76U MT[6YA%^_AX=UA[<73>7[4F]/H"M!4)2:4!0U>15``-3AH!Z,$^S;T,'QO+@6 M\T-YW\/W=W/'6P\:EM>ZY8C0NLGM?6G6%A$Z@I43B8SOXR#5TMBJ$U)#,[>/ M/B?T]O-W?3%*@8IA=YU@YD;7EP*;,0[7EP[7EP[7EP[7E]PN8W9.L^@13"E9 M9['2)PO%"97<8]+4T?0JDYAMH&/&^BNM4\_KZ%**'8X=Y?1\#8&6UF[&CE\0 M0T!?=EJCWH31IQ0N2AJ40;D4/>."ZQ21GHIY@3.'5RL-IF$.!39`4#L-'J"@ MZ2\88L'42]!$0S"^P05!25KV)(7/&W1H.2+DM*&X"D"GQV:*RF>(+?L*#W*V M08P/KS#IFMH?,,JC)G8#)*G1_(81'5*C'5*C'5*C'5*C'5*C>3KA%[^K[/LD M_RPOTR3-5F7ZA.Y0O")5KOZ/+W&VHAI^HO:CPBY7FQ#UZSE7A"I1B7\E./=W MS9;O/3ECZV\S;I@*FW?MW+9VFZ>;IN8\/0TYSO&'QVGEYJ#F2N9J0]*-K$$X M-+NH[8%:R6]`NV3>NQSMAOE>C_O'Z$*CMO98?A/3$NZ]'Y"R4ZJ3>H]T3:S29$:LGI%O(TS$O$H M/L[NBY)$<7?_UZR0NB%:A3P-4T:FQ99MT!R_="ID8YAN14%,6[R[=T\/.S_S M,\/MSQ,QND`/&[/N6`7A=9XMV%W@/VKGNBMY=W&D12&<;0*@J M""*R1ZS,;P6:K[*K=-X]\3`IHIPJFD4F`AP+_=U.$\UJ@L@B+E'I,^F_':%+ MKO8S:O+)`P?4V[%O45<11,IQB9AT/;5:K+*H1$ES`-6'D(*!&E1"!M.'F5[; M.`:>L-(@0`Q)!)QY?$AN@5[L1_J@GN- MZS`%D'4+V(#)I+(:6'^93AR%1"?^*&L6%5!02,:'1'KQTXBN"H+XI=I87`VA(* M'L4!44S/\FI%!]H?K""(`Y--S!HB=WA>/D<$=302Q?;HE]G%^^B4F2!V+!IC M*)KTJ@SB+.7[?N#.9.$^_%T[G:6ZWG-V?F>FPW-V/1L?GK/SL^!\Q<_9'1[' M.BS."8KE'Q\6=)A$6W#P*_2Z#[-J@CV M\67X4+\O?XN>4+[RGA*D(\X9(=2UJD;P*T$8MD&)&J-:)?PE0<-/E2R7>4?. M6YQEGS"ABY"DTP0F17BB-*TBGH8C$Y-B*_6;PY1&;56"-:U:@G`&.P+";\7( MB>"NXOLU&$-@:*EH`041WR`6=!WAON`\UK%_GPZ&0)-NDB@0*CH<"$W606PX M=N23(T!N]XE:V[F-`]GJZPJ?))56*N>H2R;PB'9DDS2Z2,WAUF]P#B(8NNN* M\+]B_)"G?Z"NHZA+#L,"()\D/%1J#X<)4$,0` M0T\'#BDZ:CL87P35-..8IQ%N*E9,\/J'?@$ER`)Y"\0,0E+,:;P0HE6;''*] M=T."6L9V!`6/.DR*:,'(__F6`2B4$%*>?:DK4R,HJ'.QD3#4.W0*"D70X9I[ M&$D/WMP!:<1#N7JS_`Z1IS1&%SBOLB?`\5EZQ/R03D$/>?%DQI:_G'U*"8EJH.^0(O_-7M?K?PS652AE-&P%L M`CFD;8I\F9>(H**\C4I41:\F-XBP-_^BA_[.O&E!<*J1%PP7%M;J:^+%A/_` M,V%!+V?B7,\W+W=^BF(6$[C^-7I)%ZO%.28$/]-EU$6TI%_*]3F:8X)NT3*+ M8K3HAWLXX<6G]&&\PH64RT;2=1*&51G$*;2)#@-@.0"%KP5TXV,LF)/JIC;G M49$6=TN"HN0Z_STB*?.MV$A\*IT2U<7`"5%6+%P86:IN-1G*N`>1#\YO8:2ZV?#N5B3;W M(/K^+:K2/M]$I%Q_)5%>1'$5>7^^;GX!IG+S@G4[FA0,>>JW;@`-E\"$=Q#7 MX9IB@9.'F`"`A7_'P,*X6$/)INGUJ^@B(BCGP<+RO4G5H^TA5\&5\:7.PU#S MC^A.I"_;PSO8`!!R/Z64B$-OPKB$41T M0ELP]%24S6,ZC27^HSZULT*,_(TJ8]K\&K52'_R-RL4D](W[#! M/!A^U3CJ!2=?,0%PK.YY@I7V0ZRAB]B8NVD58A)$+VV>JP+3J.ASK7K_<\A3 MJ$(9C0FTSR&(/!U-L<"!5DP`&-+_Q"DT%-90I6G&+J.N#8.:,"VLV)M8/-H1 MFBK-#"F=)O5,&SQ&[!T,%O;H\O[Z%9TV3,KN+#SIE M/,VMDLZ*[?050:(QU>IQ[7?YO5XLXJF"+_#BGIV24*Z^[QEQD<[B?ZW2@BL* M7C;2(:T-)B?UUC^!]K_`="2CH-BDCF5[DIO+:]WP/YNBG<;0*^JITVH9%P]J MAV8OEE7'^K-9-4',Y#?1NKJ>^A572A'$=4#@<].ZY-MG>53D@0/'4%\3L*A9 MA^(=O+9+C[K&-[SYJ#*X]/JCWTU-8.!J:%%OOU_@HA3-KOH%Q=.+L&#@,+%N M@X%3B["2(!;ZU;9$4:RBG.4QZ2-'^+T9FM;^'C@.5!J9F!O@%<3-)I[SH!(*SO`B+_+GWJ94-5]4665 M4D_EX]0G]@!O?=X@/]#=>R!7$#"FB'&X(_L6=Y&J_S*+J,66'Q;I.T M\$3`;-46-LC4K:AY.2LDF!5<:O@Q`H,28D#U2TP/10JM!T*GSYUOR[T-%C`R MW\ZXG`9XIN43VK:`*R#!ON2IWVU>R:#Y,2(L_61Q@\C=8T00N\L>ZT]TTN+J MJ4Y0?'H8,VD/1].=H"J..+_[Q@9R?TBS5=E[F\.>@3GJM@Q>#^[@-AD)>=O* M./:"V\ZV7[Q$Q2/]P!Y??8HR=F`SYKI96-D8BV:@LHG@?R]M[6VY#`C&^Y7C MA&JCK?(I%T2EIR6WK[BVON]K[TE7CK'WI-1R?$\];X"%@MC#4LO,^ZO?TYK1 M&J!2>5]]N%79V!VUKNQ[[8U06P?1Y6K!>+_R>[CF4DOJ4B\1*=K\CCJ;;LO[ZG,2^7C7LST5W9\+VOP0QWA%/>@ZW*HS6S<( MQY_,AD@UWJQG)]5WU&/=6<_S/&JG`>_U89S2CM,5BK7M,]^>Z+7<_!XXV@?PF6-BQX!'\ M89PE&V*3JP%B]`MR-%3JUC)L7%37$C@L]].Z>QCQU!+Q3N/WQ/PN?D3)*D/7 M<^BP_WS=^!^4-]NV.,_+95Q\KQFW=5$[L!5,X&A>%7S(.%0`$&)'I MJQB">'H'#;:O$QZ]1!CA``3*\N$"(=+<'T,P,EZB4.I7_1UG3W0A>74!YO,0 M$^SN!?4(PG&9!5T8:RBF,EZ+C/"(I!N9[*0W'!4PSV5E?1^>A$[^@CB!2]'"1?LN+ M)8K3>8H2<%)0TFUWF(5T_J9_N9&QOG8M)$!,-UO&0F9A#`5#3=Z;+/T;'?($ M[*TN]0;,[1Y,2E8NX0U!3RE>%=GZ%BTQH3,7[#EHDG=0(";WY"NH>S4DB(R#I0Z)--`0(*Y8Q-W^?7'PWVFGJWSNNV M[#X]Y3O_KN!)K*ON&;#\!<(>N?S=P09Y2.<-M6+KKMK%/I.%O_`HG/DJ22 M+,JNGW-$BL=TR472ZW(:#.2=4,I@`M@:W"ZFN+*I,`@?]#O-#&T"I@'9H76@ MHYTAVN_.Q"O,$&T"`L,LT3J&EV:*]IO6]X;@&*&D^$3;26)P%1D?!81D$S"\ MIH[&O5[(=F`&8%%LR(HUP_5\^X9F-S1$])U'AO2_3\!X*JU,K0;P"R(/\!5Z MB+)/J'?!L?<['X9WOT_`BB(MC`?<'9\@Q3%95<=41M/;#"E&?<#Y/LY0J!*-"2L/C`F":"6!`1SM3 MTPMX!I$_ELK&_(&&&JEH.-`AW=E?0CH-&.CJ:H$&">LPDL3N\HPR45FNAG+] M*RH?<7*9/Z'-3G9WXC=9ID)`,9&>U/D:-811F+879B$0+7B?-WZ(KWK M9L&C=^'-B,=>;[V9`,U%FY@"S[+.5K[8:=R#T],/B)PR+RC?#@<+!A)C90,\ M\0ZYNHG@Z"L#*23;Y6#M09S'-\4"HW/$!`"T_(=@69@?:RBI,98!5701$51X MEH7E>_%*'FT/16*Y,KXT+FNH^<>+V^:;=Q^BIS2Y2A%U-1=1#L;7Z)#R59:4 M-`"GN1]@8Z"=R+*[Z!HYLW'.SWF=-ZA$Y"(JJ*A2,PKI.C8$Z((VH$HO?>L! MG,;MA#PKV:=HD69KJ?5DI!T#PJ1!VU!#.WTSPLR".$?^GI);6/KF0S)<&#KB MJC07P;TN+W^Z@!$V;`X8<.8" M,-RI*@YB^'2(K)Z'$`BVP#NF>P&7_#[JJ/`*YN[J!29+3.BH_+^8VNAWJMB* MP)MO&I1U,THI/?EGFL,,-M&S"1=##JM##JM##BL7.:SVFK#@`B\6Z2;"\2Q/+G#.;DVC/$[1 M-FQ9SKS,UI=%L4))_<@1K9^V5$[_&5?A:VTYZL9A?]Q'!:*__#]0 M2P,$%`````@`58!M1WHL-T.JA0``%&P'`!4`'`!V87-O+3(P,34P.3,P7VQA M8BYX;6Q55`D``_)/1E;R3T96=7@+``$$)0X```0Y`0``[;UK<^,XEC;X?2/V M/V#[G8C.BE!6I9W5W=,],WI#EI59>L2QE]?1F;$S0%&RSBR+4).6T^]`Z#J(4&YB`JZOYCV`6AH!J)2"&"8P?X>['MV^)<^SEM[^0_[OU$@AP MHZ/D+T])\!^_>TC3PU]^^NGKUZ\_?GW_(XKO?SI_]^[LI__^=+7Q'^#>>QM$ M28J]P=\!+/^7A'YXA7POI=^XIOYT&X>%@?<_E;ZX$N1?;PNQM^2CMV?G;]^? M_?B4['Z7-Y$\5G!2B#]UY//OA'_$/_]$GY:BV%`@,%U^;?SK`9#]?C$*X0V\ M`^2_GV^67.T__T0D?HI@>N7=PA"[I.KI\P'^Q^^28'\(8?'90PSOV';"."[- MD%_GS^37.?LC^77^5V7YIR'-NR=0W*+4"\VTD]KKMK7C9GBC5Z9^6E&35R9_ M99PBX`E^Y9J;X8V^AG&`=HMH9[_A;5>F&K])O?@$4.DZ&_X%[+>:T=20?'2% M_VKXA4\IC'9P5W@FM@6YD[JFR99:+FTCOV$U)+T(BIE?AQI,H/_C/7K\:0<# M;/CL9_+'6_+'VW=G>4?QO_!'_S/;X];A_Z4?0N^^,$>_R7_\CODL#5+R!5K/ M?FJVEN@WVHN[5'2,?=CRT&G!_X2WH=8OU0ATUC2>T7V(W9+:`D9O/V]^!X(= M3W9:?@3(9__^4]7F[O>+%?-`C_*?D2N<1//L+]Y2%]V_@^=S':\Z*` M)#]>_EM0>W\!#3&0(L#1_>DTH)L?XYCX#1+?"_\&O1@GKTO,JA8Z9&+Y=^2+ M#4`ESZ@I@$KL\[`J5)OF3T'V&)#G``L`(C$NB*6A1.H_>Q/:/(T"Y6*+)P+\ M)?*/A&EE5\U`NU`F_\X"\P`/G]/FO,`S_,T)?HPWT$A3!W3))CC!N@4Q)-O_V$MD!,!=: M-@5W%2<\V,MUIYD((#)O?R-"H)`"F=BX/%`+--*,1Y,70K6"'PJV3\J37U%X MC/#PYOE#$.(Q)I,?')D&+SHR@_G0LFB6!VSC8ORS=`K3UU`P\H)M.G>.">'MF@%HLVL,T3'0QQMF&S2!?Z$`-> MH%K@OBCJ2QF0";F`?TF$D5XD6&Q@:S5)(;)\4FY04LYQ-7:/XFN(QV\.D_(3OYD^#,SZXJF>*N@8-DZ+9S1?H^B38K\WS8/'L;8^IB2E^ID M<00;VPH*3:`+%8:C7F#>,`7DGB1\D!DHR4$%`96<@$P6U(2=X(H*#E"?2#%9 M)-!M44KJY<13\=4+@0_XD_8`5B+5FH[O2!F8D&_9-#TESS8OFY1G:573\O77 M3O2Y&Q/SO!@BY1^#)!S_GI1;"OJ;"!W[%Y8NAOL5D.VNN/6@#/'AG`-#%D M&L8UFS+DEJ(56,E';J"S\?LC\>_&QB"1:L.NTAR(M#LON:7?ZYB\O?>\`X'; M'WZ"89H4GQ#<_:&&N_SC_YGY/CK21<77*`S\`":S6S(J]M,64N2"Q3(K@6!/ ME,H;:P*WREY82%94GE[,-LL-6'\`US>+S6*UG6V7ZQ68K2[!_&:Y7+#?A26/G_1E[9)4P1]7RV'Q*9M%N MG3[`^`;Z,'CT;D.8K&":3_NSJ:6FTV293,<,X<1>+'!/R:$"#17L3`M1@$=V M`!%A$%?2$Q#!U`G.*<*C2S_UZ#&9*%9GD%+%WZEP>:8#S$<8WZ+VNOV>^#PS M!=`S)80"=(>?`B\,T5>RCP7C^*I$'I^.H2^UT)H=_-53X2^ M-X70]S*$OG9POC\U.-\[,`:H&O>)=I:Y_A0(1=3 MM4DG"@50PP+XDLFZ,5KF1YA!)5$TV.1I:[#XPK8Z.D.NO6?2)O&PF"W48D=; MR!`WFF9UF:$QH&`Z4J$'0[$BQR%[Z`8+.'%D<(#_J[,9T)1GX9]ET1I$M`:= M*MF3[:(?.NKCR?SII%BP^_)Q(AFF]0%*=R`V9B4AG404B7(K"@M3ABSCNOE3 MN9(7.-,K,=J3@]O8VT'W"G5AD(5%A<[$'TM+7%Q8FN;C.3">:$6.A@"IGG0K MF0G`4HXE7U/(DB3BH=!R+BFO\$^KGI>[TJ+47)>VP:C*OMVA'\N5-JM:%KH9 M&KP%42GC(*D8L9?QBAT@!695BE)RM7V,3J^\$IM%._Q)?(2[J\"[#<(@#6!R M&21^B))C#+?P*;W`K?E-/'C4M<(>7:I;,3NV4/5KK;[JUPZ-`8J6Y>EL/K_Y MO+@$B_^^7JPVBPU=/['>_K*X`5?+V<7R:KE=+C9N<+\O`/G#G3YH$`Z'5`T* MQDMZ;1J/';:&YKIML$0-QN">3I#F!D#-`JA,@"_$"*!6')DQ'93)HLK7G9XMRBMRUNO.IM.K`XKRMQJ5?^,DQ,ZV\]=D<("(]P M.4P%P2&3=(/34C0(RV!^Q&1U<%-37`BSO)P`?!8G,MC.AN*.-Z&12X+KUPP\ MY;F-8<@;.>&37FGCX;0R+Q>,<6>>Y;)5JA?)#J<:W[J=)"_U)V&:1']:5&[5 MJKWQ2:40;=0C*!TV\=5:5)+9MPTKD^E;[FD0HLXJ2%$A4$FY,Q-M&&#\?&T( M80YDZMKX09BE^7+-#,V2,T.CKF7#L\Y")PKDX>B6O(%/!Q@E=**9KN-S@BZ" MN':I(@X!DR5=%09#>';')L=UC.X@):T7?H`2ADB$FS3A"IOA"L>\C7E>N3L% MZH@,3.L'+83PW@O!'18!WIY4PDZ02!;Z+I,4`L2D$T>/P2FA!^LH,UW92%P- M@UBMMJE+`2+F5G%C%&CB\L8(TD8N<([[(QT<7\)##/V`7D:$_PXA^8/,H>[) M*8K_I)_C;W&`+?QR#PYZ9[8V:K?H%0V:'<]M(0PP79R;;),D6 MYEQ-KV_6UXN;[=_HB\;%?WU>7G]:K+83LK&N\`)V-3>C)QFST$9V8=7)6T8\ MM#*M[[;> MDSZS6=KJ_&YJVV=YW=^)N;0/T&[P.JYSS=F9C2(STOT-K4 MKQO23`#=-HR7!G:[(*5#KVLOV"VCN7<(4B]LTUTL5=":)S64OFR[1FDJ="&D MHT!S6CT$!_ST;1`!/WL^,M4D\41:/WZ+.FR%!D5$-EVC`KNR59$5T\)4!2NR M?@**J%>J4OTZ7:YSNA3H<:0B50J[G#W2RE.DIL`D-RK,ZI2?+;J!Y&<-Z)+_ MJA/4P^]+$;<,C]@-MG M@`H?P"N=C)W-++('G0ZM[=QIWELSY=KZ-N-EZN+XM@\HOLP/;^NN%.2\O>ZC M6^16/=VA25/'FW(V%-VFWDJ*/?P+LYVVO>FL]SE](V>J7B!#!F+?RBTZ9AI) M0]__J=%N[I5['\]&@:YP=F7_$RN_-2;P7O.?C`JC+@*HO9U;WRVC%&,T(!NH MD@2FG>U'2L)%WR<1'DI_H7FCM;Z*)R&]Y0:F=9EB(>3(1%0+-NH3DA;3A'H- M:BEX&(]*41KL@O"(:U^X@?XQIA7PXLD/C[A(_H!_5#)3?DSSUB^\.,*U4UV55FX`NQ"ZCAL6*[49\M!(@D9;[5BZ)%>&7J*] M%T1*:;`K+DQO=7$K::MR8#\==7SIIYF6"5[ZF-";;,&73-3)A,``@I3H[&"I M$+C2E!.S[<4QPBGGC8MGMH'94V"X9%'Q9*:*$7L:M[`1MAF1;+'ZEW M;D7TA8@XF:MJ>T5U@9A-TTZ:95%S8'#?I M9JUP*+TV&F0QD=;\-%-F4J5,V!A$^LU!)%4@FWB+P>0!#R83.IA\@\LD^E?R MPXO.MRW8F\NL7=09S:&9>8/9LM[>\?(BG?/CK9MA/BPR5>OAT)33,&?C-!26 M`V$NZ"I,9YO-8COVT8WLJ""5W[+%B(9<`]H,"\8#;.Y5(M.T7FS)R\!LIMR9 MRTQ[Q)GW%DXCT*.^1V.^+V.^%S/T_LO\>R[E]UFU]U9;QB*LCGV.P.#_=G=PA6E3"^TU9P&2M">GJFXZRX9I$9_E25R&O2%PY M'$0[O,+$HQ)?9]*0<(#$D6&E)J0JB7.Q;@C"[LOO"1(UG?7&'.X45Y^Y,0FN(^"N\`GATQD"^^"Z/X: MA8$?P(1WL84)4_DO.LS40'X-<6YA\L)`C';+#=@_0%G&G6%7V/6 MNA?')(A@DLS\?QR#A&X5OH:8R?A[W,/UW:^(M'H9I1!_N323BN&NW?4/,E)T M^CV-#,U-O=P:/^AT4#.$*:F_X>E-[;:.9X#KU2@A6U/)B=SH:X2_TD-P`$&N M.W+*&09!9!(0K2S3RUXCOPQHT6CL,-=G#VJ"'6J0?CI7!C7M":CT21>>60"E M"5#8^,X57I<$EE?E62AK*Y:>,QW4WJ5=AT(Q-H88?!?]V8LDFO8H5%=77O MH_.[GI5B]`'%>Z^]..@R6PBF4&*K&1"4US(#%HH'L-7Y:;]F2_ES;;0[LN#U=!03#U[LH5@ZXC'K6C), MLO$]1^\/%'HP\J;&[S^R:JCKCZMR]=,5DM3AF&.J>@,,U9&52?JJU'^]HZDF MVOI5CQT$]"X=LQ^[7^%8:\4(X!]C#-5P;AKY/<=/5/_;1/_PD9,1^+LP:F*T M=QG=D?_0=0OB(9">LKR'9"K;2Q$,=S9&&EJ>>R8'GL$J,]1>,I!CIJDX""HU MYXI_37"II01)R)7S`<..8C;@MF#T5&!D0.`E#_E%='BX28X_M3E[PG5F8^J$ MX9-.\ZP5^E:;>[)I$W8#IN3S[#!?\@>L'KN1%"W3QM9TB!"<%N=".GZM M381POJ'S&<+X:,AN4\=-#_615LW+!%1^0-U1L;.V7)A$$DO-&XT!X=,*]/\ M'VYD%Y7`BT=VHLA(AW-M9XQ9GBXFZ/[:6O-H!K<`JWG M[_1SJ%H[G'M89/*9O%[)9E%K>LXQ6@E6VG.G*KN5]0SISYZ*]R2[4?4V;OG3 MJ'V9>@H5<$O/8AW<\&3CG`--WWU+XZZMZ:I]1:=SI);@1+%@YH90O6QNF%`M MGAE^3PE4F^__Q5Z-853AC3\!\3('\=6W!&+U=_N&4>S"S(OQ-7UK48PWMKS?GN%`\UJ=:NY>0 M2:0$KPQ,7/[%L6O[]8#:I5LB3?;4H0NW9`N']+ MD]KE]Z0V!E>^O:SFPB"Q]DTU#DC1.-O$ZK$DISI19.!A(*US/"X^;Y:KQ68# MYNM/%\M5=J*^:]OUA-$69XM^)V2H'F[A\+D45_B#90KW"G,M'5'^A$M-U/RL M2VG<\M1+VX_F_$M3G3,)0X0`E7*$0$XB^=CF'&13LJ46I*9F9;UT3E4H_=E MD/@A2HXQE"VV5%/B]TQ,)?-]%,/-*:8C^&XU.R^>(68WY@;O%)$A[L4D<9/V M9PQ]2<_&]7@R4-H677+1F'LF/=4^^Y MQ>L8'6"%%]`"GPZ]$.*VTM5SCF4-/M5+('$[ MIL5C^B8'%L^<2Y06&67IK8P28.V]C^&ZM_4J1O)]7UJ7\!&AW=<@#)G?=04- M=0*J7H:E?;F7<1*]K%VNK"A2;*>%C*[D>;I%J1>^R)2MC/_A25H';$;2LLRA M@42L]IW<)??8:WA4VS@2LX>NSIF`PLN$OU`'^_J>.@Q"^37ECC&'\OE1;>0_ MM>/:9NG+4 M"%)E7;*&(2%6;^%]$)%K"+X=Q'*Z,7N0'7XILK*K'0:QV$H=.HEL.S9RN*;] M]S+R8XAC>@FS_RH-(,2JPG$$3]5*G\=VICV+2F83]>LTH7/]3E!@;KI:;,&; MR\7\9C';+'X`RU7V%_X#S&>;7\!L=9G]L?BOS\M?9U>+U7;C`&]U<27M+.7Q M5NDRV5;D/:?(^XGA;6P>L8]CD]BN#TCH'S6M"Y]%^ M'Z1[.EK%:0KAED7W,/(#V%YDK2!9,%HD.93`?-M&^2IU(Z2G1'LZ7W_ZM-Q^ M(K5C5E"N5]OEZN-B-5\N-N#-:KU=@-78':]"O)%V8%H$XRLU^"2S[2)]Y/O@ M^BG+269C7YR>.POGC_=J0$^2 M[.7:+*3)F+!2RH:&C2SLY-Z[,;#.&Q>>$.RCC@U56LLY?Z27KDXW9^R$$BUO M)ZHWN8X'9X+FH2;BFM25TTWZ84F7^?+S3[3,:-/>D1-22%M1M$EQ_F&NB.(\ MKE&W^=@`.^L&C2_AYCB0$:VC,LT^!0GY>`+^Y<=W[\[`P8O!(Q'Y-W#^AW>3 M=^_H_T#RX.&O#;QC^H!BLJKNW\#9'_]U\J?S=Y/W?WI'>^2S/_YQ\O/[/]!_ MY^)!DAS)"6DIV&"BP/TMC,'[=Q-``DEU+J&??WI&/_UY`K#>`?II\`C#9^SD M#_\Z^?GL?'+^K^\S)W_XX^3L_$_TW[D3=$R3%#\CBU1Z>QH_73`ABM1@U25] M7;+-ZZX5"X@W6G^RC.O"_:S$^R;#.WTR`4N*T9<9?T&UIP.`L2NVO#T;RN(39O=PKF*[OMMY3 M-V'+)*M\S9<;?-[7*2^)#02:D\;`B#([YP/Q[]S7B722#LD'>[PE%K4 M$=NV"R>3.5GF9P"6SMI@6N9@NB)@HL>[D/V+6'H"9FD:![?'E"XRQ[\T'B*/ M?M:?6<#QL[4!Q(V=JX]XI+5!=^E7'+9EA#N1^Z`XU84WE:"N4\O?"CH&J"?U M8G@:0MFAC(QJ=J:%B#NC4PTPH`&QZE)/JMXFH:*_$=F(?^0',PWKFVS+).Y$7-+K#UM"``B`8B(*]NA%"*-M$/2)A-7J4DA MB6UWB'/Q3-K&N#I=09)'G+JD:>)4MJT2I^-&BS@M;3YQ'+A1727.(MJP`R*A M3:4DI$W;MCNTN>)<@B<7Y)&F)FB:,Z5IJY1I>]%B3%.911AW+KY3B+&(,,QH M2/A2Z@CITK+L#ELN8.0_[+WX-[42C2/.[6[:XL;[G*8#NQT/TY=>[\,PP6)4 M*>=J`L8^#-`PR[NL3,R@;]P5* M9W!?5E%JTT],H-)Z*:)QM5E)9G"3\U M;'%/IAN=G9I@00/CV.&KFHD6<77\GA*M)FLT/:_&H$I7P]3DR49GWJ&*>6R^ MY/]UZ.2<4\&:7^Y9QO7(A6#54#I=S9L5%HJQ.IZ&F$GFU@P;+O1$/I19V59M M+.)*\XK#PN<4(@8$Y-@TN4CE6':,$>%0F$N)0P-0)BF+5+!_71#D^1 M304WAC:B4`II(!W&,.3%%'!BR!(?$!Y/P?^#@BC]%0^NCC'DK*N42I94$$@. MY@/7MEE2R-R(F2'6GOZZ^4_P">X"WPO!5;`/4KAS9L&D/,I(.QQMJG"5FGR1 MV!Z?-"L4;>`].3)-3!F>7)LP73E3=&E;MD(6CA,EJC!UI^5CU^C!C2B+'*(? MGT.-M@J3&&R[(](B2==WY(95R[B''JLJ2+.PP>.-92[,%BR*WOH1 MJW5Z\0M)S>*CB77"H\HO]B'$:IY6J1-!_<.N/$X(XAKL@_>#Y0F?A"'N^ M1D6V`7ZNK!$6<*R;IX/8D9P7(OV"(*QUW6[,Z2A%O<,9A>"PR,-1Z[)(:-^1 MGH/ULHPKP.PUS+PDZYBTUV.HOAQC*W5["Q=>BO%#QNTI)"_#.K+\7L*%EV#' M)$5[&%\%29JP>P:^1`%KEL107'=M&@4VU[P0V1RM:?$`T">N)'=!X)#R+]U" M=U>X`6^>K='P?0EOTV6$A\]',@2[XNRBEDCEOP%7:B#6.79-XEWL0H1YD>:4 M/`354X?V3,LBBK1^_B8).`IU(@AMCDH&Z<5P8J$:%2Q<]<8V:YH(O2YO$RA. M+Q<76V'(3OV2G,D.8G_!=V*/<;-&%EP3) MYA!#;[&EGO[*N&I,@(C6CK.$[LDW6@*UP)(?:D M/@!I:M(1R/@X5[SG7>'7%@T\F!>W"VW:0X>QE6X2'SV!<9;GQ.HQ+M!=V?9H M!C&O^N'1L`,)KZF-:UHU^DN^(!797T M4J,O2&QZX1\]F975Z,K;LP]-EXDQ1S=U,:-CG,JPO9%.QX?Z>*>EVA[U3``1 M<&0MEC2PW#$0.PBBD5"EP1\/M:TZ0HQBGH=,0F0WF%8':0FIHJ+()(]8T2B= M1*[L5!(ZKM5Y)S66UQXU)@;U^3N7F*B$&RXW52,J8JO(!I^_O!!F=DSE38([8QO5Q\6-S<+"[! MS>+7Q>KSPJ%%.*H08#!**4IL;G%562R3^!F=;W0&8WZ,R9V5'(JQ1%JL:HH8 M(E+=J)6W1%PW*JSIJ+G?X3`#R>`&[X=GTZ$NS6)`UYHE?!@<*/`=]('&60T; M]-D$Y$]?-BZX97L_8+A0BN?I>A;'.,B0+F2AUY6Q5S1JZ+#+$)Z.V5*$[<5B M.2)TJ%&2".Q4C,IE04UX`FZ?\\OXW%@JJ0,4?K$BCZ.P8&&K"XH6D3\'F=J^ MX5!*T\Z5B#*.5@K6",JZ=]$>.UO>^E&S843(2WPJNK*/5'QM[.RYV&NO:*;;+[GR\EX##\I= MD?REOEQ;O3MRY&4_9\*-OQI:54$VA6QRC;3,A<6),*G37I/)G474S=EDI]BG MO%)6)TJ*D\BG&JE;/T^W:J/\$%'@I>`6W@=1%$3W9#-RUARG"*+` M!N4L+("YC?RJG4RSGW\1[32QH)E"V_FRA@9(KFE]R3A02X$2()C86=TQ>FZI M6RUL:P+@O-MAOL1XGYN(][D[G9GX%3U;B-VUF7Y-WS1K8;&QP(T&MANOZJ]@ MDOP%^/F[R0.*R6R24S!7>!W+_^&%F!>\D659M(826\.)'B_L69K=;O#MZP., M6J^HA1B'!@"U::HK[J%TRAK2V=@K@X?527V<9BZV[:[?5.Q5^T`[P1M"ETZW M4X>&TL0L,W:J\[)7[!/P%'VYPLB+YUH;M:=H5;793)5KFV6MS)]%!BNZUF"S MDL7I_(&()""(0)ODHV\0[X.3>BZ MG%GJ5I9M#V>J.&,84X`97(:T&0VA1C#P0Y M-.U8_L=']U'P3]B^D$Q5G-V#,\3-4J?C0+D__W-&H`C>DSW#&MF7YU*#36P3 MT^K?P$N*=.S6TD!^_/FD$L9(2*V.IH!A'"\G@)NM>4ZNLZ%(8RR9F)1S-97H MZP2>6EDP&'DNS))NO:>KP+LEM^0$4+('5"C;2NX<64-48UJWN"I.Y$^%:7S] MBF6I]P3"7.AY`B+H2(TDCCJ#6=+@L%G%5&-12F#?-KR,IW&AIT'(JB=P+`1J M4K@.AZECVT_-H4R2O(?#;-RT?8BA']#[^O#?(21_S*+=;$_>1OZ3?M[)WNHJ M91)741E,-KD3*RE=V:V8?XIFIG5)>B>Q5Q,9FWP:T$#]0]=FHER[24A5;R=" MI,%>0-VA"3">-=$X`:4P!>;LFP$FMX^P@\QQ>XS$CX,#:IW^[1`SOZ_= MZ(8I*`+KTAZB ML0G#[5W'8LRH_>\1?L!QN8$A/7?4BP7S;`JB16\J%!V:'P3&C2Y8DOL13@-T1`D(0$&?RX)`IC$Q6E9`C_="TF"?0:A!,:GU,&FW1[.XN M"'&YS=L((9*IB,.2&=HRB-@]MC,:AQC1>"4"*-7[[# MA*YXBP(\>V-W(8O](43/4-)[\*2:'4=7RDR?T;9KH;O@N%#H*9B:T\NB8X#% MX]&A+XQCMS<0_>C,CJ"MP.@#V#9'H\#"B\DVY.0:QIL'+X;D9E%_%NTN@_"( MD]8Z?8!QM?8UX9P7/=!*_EOVMC*08CW]FJ3@L":(*#K$\O2O,+A_('V7]PAC MK/Y`5PO;L!\_>G3>@4VO\QN M1CX&2!Y?`?T4=GQP5404TWN_U[=4R,MR2/\&;(`([ M%(9>G)!=&5F/]8-;1&C&4=8':?8PTO[#,>#G?9D$^BTI#OA+*^ M$+S!8ZSD!YI&ZV-AM[BA,[[5'\"JC%"%0U"3X+&64=M.^B+G3#X\<^;.+U,X M4LRRND`:-<_>W4$_7=\MGGQZ#`.Y\7(=S;WD81;MR'\6_S@&CUY(7I.WD?L+(R,FG[P`L-#WN+VQI6&GS7]CY>"LC?W&Q2Y/^VIJME/L']+8S;?)?) M%>3FRPUE,L^R4=I*G`@Y*M2=TH]!]GD"OF2/QNX;I5%%F@%H$8BGTF"+V.[H MU,@7N$@W/BK+MZ@BD#=$&:X'\R,518\J/!+;F,Y\/SYF5V>2"S,=V(>@#@`& MJY1BQ&875Y7%,HF?4R#.W/!&U=M@N)$!3R[WMECZU-@CZ<3V2'L`Y`U^C"-P MU.%0A+_=\U^#7;$!_Y/W=Q3/CTF*]C"^XIP'JJE5)']5K:&$5/-CM(;2:?%0*GW^!-,'M%M&CS!) M(5QY>_95:FK"!44EPD.9*31OE)`JGH0\E!N89I]G5^F29XYSHR1DC3LFJ>*VP'%*![&)V-/.DNCB_0BT>0%3Z-.#;%5B^`Q M-B27.>F+&SP`+Q^#$D*YP.N`#6>,/10W8XZH<;N"%%X%CQ`7.BF.>W`;PEF2 MP#29^?YQ?Z0S`8+CB/H;J%*QMH'A/--T:2=]]VN$A*!]C$YK#QTZSV@`MI"I M:'>HKFFKE01ZM604N)OL<'JZ-X_TK)/"BF^I)JA40:8[`74JN'."TIA4X'=[ M)^>"HUWE"K9?-:H)R[M`*FR/_]B\\3>,2NYZ4KLP,%VNMK/5Q^7%U6+CP-FJ MBM%68V(K)LJDPWJ*!"L]6`>65B>2HM0+AR%K0*]16IC6.@4O[Q1>)<+T\[HV MQ(;?FR'W8>SR##57P^!U+B]`5J\1:YQ[-4QB; M1ZLX,3F?K^&O)_6:9B3\<^AMM!9"U-C(C*`R):]8+Z'5O;G(SNR->8C[>>XK MZ9[:W1E^7O1$P6N.Y):JY%:?^:KSXAJBZ]!^\+,S7BRV*OG`-8AA33 M`;\-+F:&CS%*-/KLAKB<^[FX/;)3!R=B=]U73SI7)J9S)]XSJL59C7R=6"BS MC6HJTJOFQ44^73Q7_)\]!1K4XFG*6=;5M$>XMJ\3<8_CMB<-F=9D%?/MU,N6A2X[(HS,JT;AM19#C;MXMDQT-RSI$`>DI*$^3&C@M0&:.%&>C)(?/*"FKSXWY/Q&?D[@W3&\"NX8 MB^F45:1,K:M8XVGEY(2OM3I.^Q&U96::_1N$^`.R2;S#5U?YR<"&$CO9L5/E M9J6MQLRVMQ-!\@2K*KH.3>!1MG)B`G*\$H77#4WM]V;#L#GFFH>/7A!=X6'E M.KH,D@-*@NRRCJQO.VMQ04TX_]%DP@/Y*#9O83F?DD,1$14,3,ESD7[H(G>GGX^%V"8OQ1GR@UJ2;6JY-,Q8-UJ!E+^FJNAJ$,)WHB!-Y5[B$KV5: M"/NZZ+3X%]W@@EJCX;&1W8X'$O^6+;`6WZP.RX:6P7":2VLMHZJ1)*EJO;[\ MZ_+JZF4$C9=B)%$S4`[5K&FMESK`.$"[3>K%J2H598NDFK(E&2?@`MX'$3F& M#UQX6-L?>1BA&E3.TB994+O+E88$];W1N8ZV9=5POJ_"^3)B][Y?[-X;C=W/ M^H1<1.+!2,NZ:OQ^KM-Q06]8>5E<_+E?/']VH"Z;^?\X!C'<71YC<@,F#3.G M5A.)MNHWMJ@A\+*,FWP[HN!'!=E<]2E]4HUL5C#]BL)'5TI`89@9!)"%@\T) MEA:+)WSKXU,GZKQWJ>XEXMW_TT^Y32]%95.$4W)G<:BEU0`E;JH;+&M],%M= M@O7VE\4-J&T#FABL5@[QAQ>*]EA,EVC!2<'MO%!IYYKLY@^:\U%=-?6 M5(H.74D^!M@E0^=3H-V%V;MM[$5)2/?#SG9_/V;G>;77TJD)M[HRGK`AAK/- MVW@1H^)0A<8"`],/*(;!?01\>BZF_PS22M@-;DIBS^"B/$)LZK'U6%03>;`. M,^,=A]C5,(2=U0?B-3%0DWM].)/D>!-`+"E7:6M-Y=F-&0"[(B.-G,E/E[=$QHA=JW!=%U1>B!W)%1ZHF M5G`9-.%$@TV-FC"+#QU;=A!C/,4R[/<`2[W*?CV`D"1+/42XD!:%A3AG-7DO M79TY'&-KR[6\69E$U7`\>)3;7'`NGKAQ9LEY/S#ICFKE"]"US&@/:1U9CDYW MJUW'Z"[H<+K[I&!L_*R\ZIZ=H6$JHE/N:C:>Y4J1K5R.89T4TKU]<-'GUA5(XQZPGLBM3R4*\#_AK=X]R M9\V8:>GD/XBBSD!<*WFQ,%S3\2LBA+J=;-DI@2KX.PKP0.X1/SJ.?::D7F>@AK]30=)8$M;R:`2-9]75R]DZ:(K+_**`3`/45%X[1CF=@3V0 MCM^!;%(OA:0]G*&G1*K123"DC'"P8]?DP%'L0LXRMN9TOEY=+E:;Q27`?VW6 M5\O+V1;_8[/%__FT6&TW8/T!K*\7-[/M$@O0,>-\_>GZ9O$+5EO^NL!C1_SO M17&M]9O/D7?#,2%*&C0X%A8%D<:ZCT&49QZ8C==D<16D0'8/H?GV` M,9VJ3R[@'8IA)K?UGF"R>,(-1_$NB+SXF9XDML(_.M;$`0AKA^D+JSDKGI@U MH&%/1KMIHVTS/F*VWU;UJL"\][*4"&DI<4N-@2#[,"7F7$A7=OG"K3JL`5-4 MJAAURB]P+'PWMY."I8K?2CM'S`CLT47E!E1^BFR1RU-7$]!PEAU6.@%-?^4= M/-]SBP5\O\;D,OZ8"S%_(.)$]87+M!>U599RG[6Q9/#6%_,R>^1FIMFDEG-BW^*?L MT2%:TL-"YW2;0YHM)9*2DJ_"I21+Q3@ANT[LE.ZJ;O4XR3&3G^::;41)G3@' M3`L10DZ*(R9C9%=;S$>>MQ,!T>2X0-FA"0QF(P8J`MX4PC^0I?D9-G,%)PX. MLXU-_M#""CA''G2PVDCFE[)F7@7>;1`&:0`5^PRAJKCOX*C:H2[3F=W23NJW M!Y'YYO).)431_=L4QGL05@).\E>,'#F/I1%5HC/3B@*M!=X=8C/W?S!B^\56,F1YU*R(V^**."PR=<53/ MZ;JV`:W1D_U).Y8OV_-V/)^&`"F;O:MT7)[`,XQ9O6D\0Z!UJV8(XDK&-6ZK M`$GIK:XDOJHO=QEFU-[QRL%ST;!S.^Y&B#/NK&;;Q?DRIV9+92[ MU;$58[H;^`BCHWR-$4=>.EU6REN;L\@]V-G]K^2SW\1%W48U719GG[K&3E[X ME28H&!%2G9_(5=7F)QI^3H&W$\R1M;P-AIK"'-G-ZX:@]AQ97PRZE?#S[3'1 M_=P[!*D7\C?T:RKR9\JXBN:G)3BN3M(I2)QKSE"(C.7G?2:$KJ@0S"?1:)57 M>]'Y%]?X*\61>))"(<+2:0J.#(;R!(9U7TEU-)]<7O^D1Z=N97>=[/,'B.JGS M'O/M$IOEPIUJI8!SDQ.J4)+/LZM%5VG"G6]*8>I=U@Z'\L`*I;#8'I(W]]J+ ME5*`7)7+?I&J<>+SG6D?,B.[U;*'9]Q.#V6(-*W=L$LG\.C9#>*XX`;DJR'6_+70K5[-V MX.U614N.=XRP-Y6NBR'+[:L:LL;Y7+-^DK?!77]ZM&WK3VL?3$`$QS\+2"'4 M0LIQ(B*C6$U-S*F.?=N8LM@I,#P-@A,_[=<$7QO"E+-X7XBYE:T#A M#A?3V?&\-]S;JGIJ]K"`U.-UX='6/]^3JB2Y*R!%2736>,J:+[(B)+F_!N#PGIX1[X1SM M]RC:/'B8,;,TC8/;8TH/ID'TLPO\5?``\YD>*1['Y'4LYRH50P;K^6"@01,Y M8E`3[$QFFFB2-*$,=S*]#,)C&CQ"`._NH$^OZ$R(UMM;HD9>?Y#MD=D-MV]P M24(?)N.?-6@*R.WT9`Q*C)0UR'8GC1EHJ1/<,SO,-M(<^\0K!NR9(9!9`IDI M4+=%PEYR=%%R=%/C:.X"U'U\YZ<4;NX3=-SYA^ST:5P77<+;-#]4M5-0B(3* M(H$M-#CYL,Q:Z,P%;L1Y@JLX+4\0=^3P`6$4D)(EJ2CQR4]R9>?)1E"W2S9$#)'@II9 MLU,E`@^*%&@K-AF0;84,Z&,G7I4)P\FF`>?'Y[*@)L]A0?=0" MO*&3S2MC-L"M?*9Y2[P"L@N'F3-BP4"K[!CS2HJ%3"<.,,_>XCW_ZH5'.G-Q M`Q,8/S+6-\@$2ZSR!0J^E2BFL3*M'@.[HF`([Q2``&+8&I1XC"-K\RDG,S7:9!G<`"J M[,\`[,ZJ56O/$U!"D`I/`!8G,Y.%PFO&)'<4:P.4XXYO\R9>!HD?HN08PRU\ M2B^PR]]X78%`M-T',$5-49!AW,K.6ZD[)>;QU*?+U:^+U79]LUQL,,<66T=X M)8HRBU"2:'"(Q-!B,HAKW3*8S"=R@:,A.*JG;E#)@"]$"E"QT9>2F466+$L$]^RE1U>6F23A[6:>H?$]-]Z+U0SKA/:\,,REU4'*--H=$ M&J:XQ/=AA5-2=TKFAP0T(%!-&BJIUXFHX6\\*L)[+_P`.QU=Y_."4M7G M0VE36#)*C991(?P;LE/R%UUL$I+/`4F4@3_V&\=N&)#D%VQAMA!IX+*I-Q[V MJI/8\HN.VR#D"A1H9`@,A67'I/:J#ME<)=>%$*ULI>F6>"NO@W?F^D]!Z)#J MC]V"V@6F.)2MH,/:"CF]>'PIGN)>N'DR*6]A?+@PX,]I]<##F>[5:BZI+ MH/B)KBO3S75U&7,`KZS:S'@=+XI(;^GE><_!&\O%L62CGOW3\KRHB0]'LF.>KSFSUG)!;DUH;,Z:;]KH&$;F M1:\V:%VK\/GF9K':@JOE[&)YM=PN%QMG^,"+J[!2D$]3\W7$A8,CD]1,VLI) MPI<5U1,VJ-*U;HDM7$?:'4B3,U?KU<>WV\7-)R=9(PBTK#?1XDY73=JYN,>@ M6;3K'L(F)Y.26I=7$C5S%!,ZLL0V%9^*Q).;FM:8!V:K2[#9KN?_^NNH#F:BNC.S59NV7S$_-\'-%X.W)%=-C MT[D'L-#P@+=9KFZER7A=[TZ0G[W\ARO`(+*IA3T=D[9(J;YDAZU4$BQ[XLI" M'7[,.!R1+L'IR/+P[L;B&N1%";VU9QM[.UB/M?7[G0VGZ\_K[;95,9Z^\OB!MPLYHOEK[.+*R=V M9`]#'3((@O8:O![FFFOR>K=G+#J8&YL-:8$5)I!1'-&=9!?)30#5IZ,Y:@'4 M3+BYP7Q\HO"&AJ,Q9=1!)(KNMS#>UZ_*ZW2H?)%JW3A#9/@R\8Y1XP=&"9Q( M5H*SU:8;Z./X[D!RQ$.T71!E5Y=BZ`=)0DY]B+#&V`P4Q!.I__Z=Q=X=Z=;: M;HXU2S#1Z@64JB*^GSY0P:G\XIC@"CQ)R/T.MP0J`8HF``/E2,+D%/=)+=9;1);R#,=G9"1]A=(0WW`MT=52*C*&D,C0Y*#@QF@?4 M_0DIKVIF.G\@5R`EY!2!72X*XDS6J9MOM0""^@>P16,%[09CE;V-1LZ5MX?K MNT8]`4$8D>H/WX9]6[:) M=[8E*\@P]G*,;UX?%&BKPD@7`1WA1'@E59&3@YF08QL0JB5@XS8 M;^0M@RUV+=7E[32;ZGH:%:JZ^.HD^I08<3U5-<7 MQ/)4-P!"2JE.T[Y"JNO58M=2'3D3,Y%_";44IVE,G-J4C=E):8KNC6]2--*< M'GE,Q\&4'*WODQQVQ+ID\C@HM%U/8+H0E2>N'D!12EB*=A42E58+1V>3N8D+ M(TVQ2Z6SC$NT'BC,@-MG\.9S1JP?0&D,5-8FH+)7FT;Y3C@NEMQEG(,S/8J% MC=%AC]'ASLC#G%/5!'K-L3>V:=4$AUH>>VT#&_,#&EL#&7,#&)MU@483;-<% MFDVQ2R=Y75`:>Z%UP:B$TZL+1F'9794]9IC;VF< M8$[US;&8`WIM*^3,KXRSM2+.W$HXF[.K&DVP/;NJV12[Q)+/KI;&7NCLZJB$ MTYM='85QX\ZN?IWY/CG#%3<+?X<(_^G3?8/D_.%\1^8RJLO@D6MP""%_)&3, M8EDK&+`X.*D-;H/9`9"IYHB3FQDO4W)LXFI[]3>PW&P^+RY!?K+B+3@ARU^*50''OKC4$4(VLP:N>TP<:;BE(U9/1I*/I5)A:M&Q--Y^OKZ]HBIA=@SF>;7\!R]>MB0S,*V=WY8;F:K>;T7_/M\E<'[H+2QQ0:&.Y6G[')'JYN">;:%X\'6"4M.DCE:N(S),;3ERV9?-S"A)/$G8*=/,K91`] M^[5XCP$S@1\F(((C'\@CCS+2#$B'2FR5%G5$=FW"R-SP6>:E-X;.Z%E.U8*\ M98ZB7&3L%V+&`,0;?0Y&T*AC1E[#^.64FKPL^YHLG\0>#)=-2LYZD:E9)JV9 M*=E1,DD*'O4`*7*+4^"H^!F1:M79HW/FI?0"B9).#(G!!.K8U"Y@I(MJN#[$ M3&%K-0^T!6]!ZU$]X96/3,`Y-V8GQ36- M2S%<%Z?8SD"EJ,@HU MJ:;!7EKBR^Q82->M:I^N8JU5`^Z.=+P=9YKXXWCLBVG[8(=3#F@$E5\E2(SP MJ@F#[\40/'@) MN(4P`M[A@,CA\#L`G_SPF`2/$-/\@']0"# MY=Z[)].2AQCMCGXZ]K(:#?BAWOAH90&YCC_GD<6?01QPA-G^Z.BP"\2Q;A9:YZ0"IF_ZX.JL#JQ(!LU>'(]Z\ M@@$@C3GG4/8-^3LHWO(TJ5S^LPCD!K*%:UDW#ROLN)7Y$A%&K#NMCBW)7Y6. M7*G(`XLT8]`D"%>ES@^)79O(,99FI5YZ@^:LCII"P)E5R^8`Q$FQPQ'D5(*5 M)5990C5/!^/+`'D>M!C06/;G>M)4PKI&DA1"VTY2M)L,>R5!;O)[J=%7S7#2 M\#N1T8KIA$^05+>\O,:6:F>WMI0I=#?MFIS-$KM0PCE#LP;V M$U`6]OF_/H<`304F#5@VQ^<"][@X@42;`P:/CF/8M-?+:QTCQ].J`=^A8XI$ MT6,!7N5X.88P$^B&CYKCV#7?Y>L=.\=5>XV`D/7_6H@8M0:([[TH^"?=3SY' M48+"8$?_,8MVU^4K3Q2M[_*]6UY(7]-E.SDY4TPF;1:YU8S-H=0ST0JCM8O! M!@G);QEZ4D).(Z!>D_PJSK[O[^S%)R;=:P71]M_6>VKG/JI,B M&5IR,C0[6FF6T71ILX7"_&G/\337S_>D^,\@K73R4@O<>\'(:[HM$P.=$H:M M9&O%7R/[6OQ&XZ;C69+`-"$G!3"70PMEZLFP*V,BE[6M&D]%'`?23,+4FZZW MORQNP&RS66Q'/J]"'+ M??C2H<$;>_?&QO!]7ES3>B?%2R?J1&YZ0>,\?S'WTC'!.3V^/R:ZI\F/TC-> M!HF/*[AC#+?P*;W`3G_C=Y$"X6Y?R10V1P.&>>/++)7<*=*"9\#-3E44:39= M)/'@TH:AQ^$/UX-U4)F;^59R-0Q196><28%*#'PA@H!*CCWO90%J\FY[,-9& MG4BO6L?/T/QT;)(FEH8I>@FU=J:,,UB6`%`B]A]E_>.QQC!A7F+%4-6IR?5&O"J>8BM5K3=]Y1PTG>9?EU0T[<)V80 MIHHSB/I`49\M5+.M.C.HTU(7NDU1)F)+=+M1L[FB:=-2MZK+9H968Y#BSLM3 M0>#8';`B>YK"G`[9)7Q?!=YM$&;'^//GN?E2=9RSI$Q@O6O7.-ZY+J28YVCF MW5)8/74`\8(PME$O_LT9R.\J=-#/L^D,`\0O>X2"'!Z8?NW#-&UC&7HFXZPL?3&M*P5WK.7'U].=E(/\+@YB)[J1F[]F?E^?/1" MWD!?0;+,3P+)P5CFVC8Y()*[$:-G"56J21V)[3";1Y=0?4'P##QC"#UX"UW=SM-^C M:)-VEP:H*U2\DBH,IY?$A3++_IRQ+(+WY+Q(<8V@Z%3".14CT^IA=OX@>0P2 M\GQTCJFB`?6-5X=Q$MT6\90\G02`!@L857?#L4=+G4R0GE#91&(F##:O&XG< M6LD\%$>NJF@+MR@_?ZHZD.ICW-V[K"K>Z@?XXH9(R'-@8;)-T:4*"X4FIL6' M)/7?!A%=?#_)[S[W@I$/4E,&`H-X*L%BLXZGR>*6^O6+#YG/H!`,OX*IE]1^#CVA*\MS$E2O2G0#5\=KN)%;Z&X?%),S>-0S)V3_,F=# MD?B^5OOB7S07K)UD.@%4]G5B[_UIL/?>I8KW.B:'R:7/UQ@WZ2S:+?"GAWWW MM;*^(J\*%BB:IB37E<79$67G6EP5&YM>YSU#0KH)6#P#7K0#";I+OWJQ:]V% M'#XB\BH%5L)BK@TAGR6>3XI@X],KZF[-@?>,W>44.A-`M284RZ7BMP-FU?+< M`IJ=FIE91KA8X)R%BV;+#4-7NQ!A$1^U*L"T8QW!'7VA?>_$ZIDN. M4[24BLY$46DH797<&%W$I^-12%=U0]-2-EM4-"%O7L`CD0-O<`VX0V'HQ0G` MHV/M*EVEM"URJU0<& M3G.-!08)V3@1D[.MIBBC6\?'F'PC*_GS:QQGT:YV[!#[?!\-C8IW;K-*`T M.9Q7]6<`D6<5)'-1BLCZB<`3,'?A>!6[D.3/#%C`Y+@S!P&*LQ,8;Z`?XF03 MW`5^ZT:62YCX<7`@'W8ZCG[J92^BJSZ8O7H.S=9WO7R+6=W#Y+0M.GKGTA-# MR$QY]6C,A]Y$.X2S[@,%R1O13KNSFN:8-N=2B1*]G,E1M,6XYE ML_P4.Q$34:0[7<$4W*(X1E_QZ``/M2(0PT<4/I)A!6Y*=A(#E1^;BK)((\V@ MM,G%46FR2&C7";JL4`J3_"@6`5M88@RR-,4,A(E2X=U>GL_CZF MB^2*'9K'))OM\O+5/Q%6<8,(+")\F=0T>2[I6+6+(X,A&[*0O@.@8 M)GL,2+0H7,`A$W@=L.$.3X;AQL!6[/%#1*)YECA,50ID@*:Y!.`%65+L4P5D?N7M@G.:P@8Q`A%:VZ$H'H<&9RC=L8.,B<28@H5I]>WZRO M%S?;O]$SPA?_]7EY_6FQVDY`!.DHPO/]X_Z8C==W\!!#/_"*WN1?SB=_^OD/ M['T.],7VOYQ-WO_Y3T3`N0T/"E!"^B'O<):KU6*JQ+IEQ)KL0:2.AL`UZRWJ M!^PTS]>9D%,O7Q>T^/V!$6R-F?MO<%(('K/S]MF70@@D\I^#*3&0+@R;)M^$ M\LV+J,'3(I<]K#^OMO5+'FX6\\7RU]G%U6*#&;'8.G/3@RB>2#D`328PA.L$ MX-H:$?:T.[TFL]_;:O);=-=Z20=MS9(F&IJ#Z:/LR\(H6]^[F'5ZUJ8WBZO9 M=G'Y]GI&:JKMS6RUFTS51E(TT&:_H^+7Z-%4\]_!J$ M[EGU7HZJ@+H.J)3`%Z(&J-[HOPH4J2=0E)2'+$5+O6O7U0F(R??:IV?E&&N1]0MYX"8U14!1Z#C% M(53K-KLV5'I-GFTVRHCUQ8TF[-+9(+PYMKK`UFAP16;4('8/S:F(G?5%S5H,- M7>E(!8J;IE\';KB37L.`,^YT5@+Q+_@PBW:7\!&&B+X.S7>1=U*K@FR97X6R M@YDBL&ZVH2DS1V!6I-`4OLCDBC%XQ&X M6WAQ1#;=?J*K>SKL$0F5M&$+#>8+RZSQY5E"-V*:B'%%J`9`]!\?05`85;>_1'RKAU M1[-5-9;G))>D3[X")Y6R%`PSI>O";"VBZ$V'/QPCC:R[RQZXQ2%!_`5\$D=( M3*VNKHAF/$\C,NX11D=X`WUT']%[T3#'+/G6'8@*JVIGFHMFBWKPBKNF!.X03_0.DFT02,@K%OQFNB;,5Z1MX M[\(H0@<_:$!XV]154&^R5]F?0P2^1F'@/_/71RK*2%P#\F M*=KC;L`)@(MJ&7FYPJI(S&R?KAO32G>J':S2/NBF;%7>IFD8K.(X#S7B?%0$G)V7D07^),5?+7)*@#S_;E&%4ZTA3C0ZML*T9\/-F!_82 M8\TYB50OUF.>.TJ;0XZQ>/*#!&Z]IWQ1&?OB)47I>J\EDC:!<+Y]6T6^U*.4 M!A(+T^QM3.H]N;%F5C7J;:JHA8;!'+YBATDR'_8A9G:4(/$R#1TCO>J)M7CSYX7$'=^2BCCG:'X[9?I;U7;&QZAK&FP>/?RRT/0>=M&K. M@;',:JI)QG=B6&NB6I(UZG1:MP;(#B&RX2HEO"43SX]>2$<_A?5LR7+-/LG( MET2]OE49NP+4ERM)V3A]F'G9!F!YJ=F4+W9V-OM-G,P(YEZ76FO>Z=,!>2F; M&R;$;N2&RK8X&W2S`/A"NVUW]O"\Y,3`>W?\`C/#J&^HC7TCQL%]=HP;K]F, M'!)HMCEV!L(&6W::G%R=7V@O';^:',P[_LX>,FVEWO9)>S:^@0,9]P-Y00FO M\%?9+:,4LRG`KE8;:6V=/N#4 M5&GE,WNNI"=]K#%S4*_@\Q*-LC%V-M%LRS@$L#!`T_9O`?NM(5:F^Y8J=SG@ M\,AI#%I(QSZGY(4CHQ??CX^P/E.NV(6J*G9''5)%Y#O=B M]L$LGZ^SAF8W>BA9I]I[D-=[;'?"BM;.?):B5S/5:[=S4JI9G:&X,HQZU:)QDJO,)J/$UVDP:*%/5P=R5Z!]1U]*Z':7?2PT>E`M&P8H[.&5XN=C'XKU%BO:W=*%GU&/AZO ME&\G+[PD\`FXBS5DF3+XG."_@XCU]G+NA3XYC'[T0XF'`929/7KBA9=.-,RQ M$XQV>\9BCH6NL4<+K-"FU7T6VB!7!YD^>91SQ]T^=2R>2/O=4Q/%C;[YXI@$ M$4RR%?=)D%^X7?N7>'Y&3[W3(ZNJ&TLI:@[MS-AH^59+(QHF&PFDT`-UQ0FX M?:Y_X-HDCB;6F$E#/_Z\=*%FB9TI=%KA0(Y81H\PPEZ>\Y.%%$MV-;5.3I"I M&316&R! M35\5KP[0=A'A+_W\UV`'\R-C+IX_>7]'\;RX8^`B/^`"#Z[RZY4D;V,&6^R0 M?8!%8WF@=QOLI(BAS5'+'L.\-(J)XN(#7#U0$Z"T02N*TDQQAY=S;X>&PYJ9 MG(S@BI>W>AMGI[2!;74AV^'B*7W^!-,'M",).CN7I/LIA"MO#V=/0?OZ&1.F MNOFMARESB4W;N:6,UK<=BJFLG_EI)8MK(_P$?"'/W,E*_5'(3D>#T,#-0]I6 M.0FH9^L8$@:2PL=VU:W&O"\J7&;K=TH/^8/V`PD M)]Z!N1?'SZ32F.W1,:*CG<*`*ZSF0X!)6F&L>)SL*+$IQ[%M%V<6)NFY?@9` MK#7A7L@X/*]N`EC2.?(AR')COOL&TCNLK[TX?=[&7I1X?C[]UG@B'`;WL,$X MPDK#AL&#JI2]VCJ.2K!Y)+/C(N1\K+Z`[%>[I,X>(Y?RA.+=H6.HE%PX*QM*+L MTTY2T76OEE+TK#822OZT-O554Z8YI9!P+)OHPX^92WKA@9=)E(VQ\XAF6UY* M%I&.-7M9Z9=-+(Q1M?Q:7#;7IQT&TTMKU'O<[[WXF>R]\"(_\,)Z6@'XKW*& M_47E$[4!2V]$#,HKXG%.CS:-QQ`+(^]>;;!$C[-A7;"+0_HQV2.="AB#/FY, M(?SJQ0&!S#+"'0E,4OKNC&R^E/;)RIJ=?EA!TUAFD?JRV-^J^E9+(FK6&GFC M4`&%#BB47,D*ZB!B9@*MZ/+(+S7")KRB[],BV4*_J.S7((S/5''L<(=W"FA+ M.S:;V':C`YOY/GD]EJQ0"I,KY$7D%LE\4!'=WT`?!H]J2SQ[6V*=**-KR>0Q M'7J^+9U0V;,9RL=X]+`^+=3HE9/9MLU*UID^L3\.>6=Z]`>$X(P//:/<0S_Z MM,V!M,/-D,(9<24M]7K9\,RWT(^=-*'BSYG9N<)6(%0;EB0QG),6R4@F(?0LZ)5*>;Q<=/B]46 MW"RNUS?;Y>HCF*TNP7R]FN-/;V;;Y7JU`5\*G;%9)HLTTHM*BT<">_\& M!U=K[D(^#<7$9O^$LVLUV^R`*R#"77/ZS>#K`*.E,F6HIE=V%FM)@?JJX,5O-:7@4$REAWNMCVF2XECCYK9) MR7M>\*_[?"C5VA9U676`<8!VF]2+4V$YQO$CY!)39WKA80T?@C=X8)U0D1]& MI@DW:DCQAVZ!ORW:P#G;C@T8:-4_&0X6T4X;!=*RAZWTFG#`*U6T@=`M0XP@ MX=Q8/\NSK@V`<]Q_TL\GH/;DI0+@W!0`SD?MW7")O(7QOCJ1H3-[*!`I^SB6 MR&!4=XT:K1_Y]L7(YJA-Z9.W*7X$@NK9V/`6!`^I_]AMC'>EFS#G61L/Z*F7 M0M*0*]XD.5>@`#E#8"C$.R:-`IQG70AOMM*T_-RE:6M^R)#JC]P"=D>V`6N. MI?%!O;[;I,C_[0&%.Q@GV9DZO'4<.CIMZ(MU3+%!Y,4*010<*G%&:F?(^^X"U*X^\&=E2):6&)Q4C74')J*U)G,E?MS@ATM#N,X MUL$K1.KVXO&;'P8>7&`1$F>)=-&;5/&%'CK5JU@F.%`"G'[2+%25X1YD6P;^VQ94QQ@6;?"!8$C M)4YP]6M+HUWBAC#$+([((L'A"DN-R1F^_?&Y0Z]DS@Y?ND;973WR4;A4I3L: M%ZB8&Y5SG5@:G[F5H#W=F\>Z61].%$$F2;(5$&F.P%4>P+J;*A;*"^&^X#B.QBD MQWCT39^D!/XUX\P=@/<.-U.E"1ODK_R=:WF4]8 M'LT6R?V<]\XE7)O3XI\D(R0TJZ!,SN&<(`24:DJ0Q5@C(;!,*><#?CO&S08W M\(#I\T`R5:?1+/:KR-?9+I8WP6Z1!V4V_SEC4Q%(;TTJ" MTI:N(W6`KTH0:/-3-4H,/HI4._R3^SD%YLP6I"K>!L.M+#=K@LR:\[4B4%0C M&H6@@Q5@MD9]0`FH8$!<`PH-V"D"!2YUJT#Y(2Q]F]"C%I09Y1>##NW1Z0\S M>66H&'BETE!@2Z$VE+9D%.3;GDY1<&\>]F?-FN`-Q0J%I2ZUY.^HQ#Y M/-U+"H56]$\V/5Y3O)0^=NB,K&KT=5)&WRE9>5O&8<").EK3+R[D9H5O+HK] MP"_^U<6)F-*K=[5%E='[5\[H.FNWQHQE4T%ARK)0L#A_E+DX\:1EPVG?::2: M$>:TI6.]GAHF%&>0NE%3GT'*=%6GD.J>3@+#D\QC-MT-1Z#*3.;&\47IZ!5C@:*$IQ9'!3[HN3 M^;EK/6T8K_>--.R]2S[U0UC*J7R]677]Q8*6JL%#..Y$5;)VN:;)S] MA-@XP_,UI#Y[*<]V56(^PSE4A5@ZP-1HVT[#MK/O=--'S,OAFX$C7XVU1>N< MV!2E7G@:LDE/F#7H:;HEWRM;_Y2;_#V`U.AW_BD#Z.7PKWOB[GC\>^_6<+MH MTFFH]SZ?GB])EYF;@-(@R"V"NDF"BJ;1\L;:[WQ5!MS+X>O[,4?>Q\,AI,L! MO;`XR:YV\QCO?8&>5C%V5M4:FKW4_!C=_Z;E4IA]-"Q--Y^OKZ_H$8ZS*W"Y MW,ROUIO/-XOR.,?EZL/ZYA.]ZVODS*$)�HFBWJJQEH<%O'YVCP/@Q\&%R`Q]AU-G-)I7+?R^!W$!&4[HP=GD9J0DEQV76_+P(LU(-/G#5:DS1F+7(8[,4=*Y!$(BQ>5'+F6<'=2N M76[47>@QH]*,&51`SHV9S/%[$T$N.\3.M8IDK M"@42!1]8$D.YT+5IE`=<\T(.<+2FQ8-L;F4"O!3XA!+.+`$4!1$I_^HMS'>% M&WCGV7(#ZY_@_A;&(JPW)5A8+R1,8CVS:0WK#?/*6*]I55C/5AQ^R9Z-?.*< M*'`\?'=_:0&^,V$NONNVW,`WZS@+O@`+W68.K.B:M+#8F^M$&>&U,R@XR7P" MSMY-WK_[U\F[?_U3L<0;/]I@1&;8>/]N`DAD:,ES"?W\TS/ZZ<\.\8-[:(`X M5@)V=$X%X%FR`B9C2[GXYO5Q=-;.E$Z<)3$$!YPWD'V`,.8:HU^]."`SL<7, MZR)*Z:T#48+"8$I`Q&&3,:[2?A^]NI)84B+1@._L5YF6!/L(!_W5H5R M^8X19.H34#>`_Y6;`)F-"9A]9XMH`]*8='&OG[V.@[T7/U_`"-X%?H#_9`[$ M^RD+^U6^LI64PG-GJ)&R7R66*J3GV9&37=P" MQSC.STQ76#H(@S3HS#(;L-2SJFY8.G%U4?-M/R_H-,-DE=&VGA?98?6QBUE# M#WH#"@@.!H85$36C0RJ)3MOF2C/5=]IT8=T$-,2'* M+5(3-I**Q*GU;*+F7SN-J)CEC50(UEVXD&H0SF2)1"/N"AE$8DV:.I1:,WK. MN,&)39`/VH];7*\>&^)Q8=`&1UNV5?C74*FX13YVBDZ=,#&HPOIIV30H)%D0 M;UIQ`KZ7:.\%[:,3^0(,"!<"!D&[`K9<$/@'M+@B/V%ZQ:N5(3H8)74OUQ-&O%CQ4*7W+(.>L4#@=RL=Q7DBV M5A^P3W(Z`3V-X#Z&]*R"%HVT]?)?3$.O)\'UOI9N+[5#_G%?6&E]MUZ>67SN M86AZ`^_PD)!`B\[`/*54&^!QXIY>'T$,@+AA`7B%"1!$6-'#GQ"G]!-(YR!W MY!XW2*C*L#QZ@]7-I!N6XL\KEP3;'-54! M31U0*GT3D.5T2I8QV_\<1GU?>N M8#B@?EI&01IXH7;]I*V7_T0:>D/HJ>S&>/VDZYG+3SU#K?HIR)1?3_FDCS\XV$U5/(?1DUE"!]5/)CK/W2\<0FH M;F0J[B6<6<^CA0S4-W)-LJFHESS3\'4*,!KL%W1<#D;D^7=$"M*_%40:3?KD MS7VROKNN.XUVGQ.XOELD:;#W4IA1KS1!F?W>% MD_7T7X/T`=R7C?:*1M=_S++1(\\_#&$L,D.A9IKL8:S,FKT;,D(",5-Q#G!N M.G7DZ_(HU>JZE&2?,W*5^N!+9@$0$X#:&+DD&)$(G!)V!"8,+'![>C58[PYH M@6D^G.OPX9O%/J=8'@'[9N=/@ON([I+'Y7K9ZU.G@:R&[J-:S*=HJ0X:RFIX M,EXN]W#.']OJVE(JD''=!Y+**G%Z!E4EYB:M+Z$,#4=$: M*&M8J0;,VJY/"7]#TXL]O!H#/IENK"&Z/@`K$.U<37=2,/,F(D^!YJ$3DYKN M3$Y0]G!M#-/G4DQ_0_CE35N>`K]&:Z_+O'[`1=^"=JGRJPUU5/*?1TUE""M5 M/)CK7'2\<0FH;F1:B-+A4"8,:M+.O"K0@@;J&[HFYU342ZYI^#+'L6L\B(K2 M!/NL;KIBGNTK%\R_NDAP"(OX=HV/2Z2NN+R1:$X73WYXI+/9(;SW0A"3S2G@ M/L;Y-5O+1D82]^@1QE&Q@(!\@KY&,"X&&H?,!^5;6GHAHO#I$**`,!$$T2,9 MAI"I;CR*`8<8^3!)LC$-.34B0#MJ+]A#D!R@CY-\UH#0^SKRR$4!:4@+$TU. M\G5*)LK,VH.QF2Y`[J,G@'&ZOZZAKQ)QY"AI8]#AY//!V!E8WXN-&ZSFY8YZ M(NC\6T$0IPH?C""S%7800Q\+8U_TC>L';Q^$[/Y?1;2HJ(6B@RII@67C58"" M,W[]+-.M+8>_15Y,.^-=KI11`]%7X'=4$>RIYMCOF)4P@#1CU:J8!5I5I2PU M;1-DAH9I"EYZPXMN.L]$*):RY129E".)UBB6>,,O$V`:V&7+S!OLM%5<]8;4 M>06IA(PILB?T[=%NOY_S@&<37?$&?^P`$[#$9?R#8`@\@(*IHLU[=5I/R-0I]3/YT<^P-KK7Y.M2JP1QC?(D$- MUK\)ACEP7G'@0#F05JH3<0?QC9*`4^:=G`169GBN(78P]Q+\S833.URYUMP. M0\[$**ECUMJL#L^3=(#$5IS2CX%//R]G^8+' MN[NCAX%CVCJQC$R.B_8H2AA"]@BJH](9/G&,6H.KHM^8*O/[F2PRR0< M&WL/A(QD3J/`>R=Q)SUOP%42;K_0:@R6@1\A+]`+TP??"]F#\OY`OE78PD,07W7GO'. MG>N""W".QO23]W=ZP@"NU870<_?6'(.)(*49-S'=E2Z3SS)B'CYE^EV];$SBXC_VX`-43 M1U)@[\AS.E'MT!M=6+[XQS$XD#RP@??D/\ST)A;*OPY/:`A.V3:-ISJA&RYJ M!5I3NR/KO/.919+COCX$_@/):1C104)/2ZWV0<60OO,M%I5GFU7Q MJ(>>B%(_OR6H;=V@HR&<2OW2:7'_8)$T68>HC)Q`)9A"R@AHLHDM7S)*9,X. M4,TD5;']'A#%R;5\"/*GCB38PT#":K,VH[2FM=I>(^@EUA?("!;G"L).Y9?:-]Q;*+@6'<2M9J"WA]$_9 M=V1')V);=`DHN4<\QBH9>U]DOZ*!6M0+5^T3P66ZM:/`U=S8IXBIJQ94?0TD M![U>@6_V,->AQ[U$PC+W!-R>H.#'Z]D3=Y4`,DFL2MM\*WKBW'QC& MF]EE%:0#C>&.%E9X_+4/D@2[7^'?[X@_[UP3I2Q?++"0RP]ZZ2@S;WZIA:)' M_MM')0/3ZM_`]^*8GB?M[4G50@N".5!FY`5R+/+M02J@C!/4)8NL5 MI4RU>D^IYL0Z&`VMJ5!U-0R&9'5%+I??S%1)@DKT50*.M]3"+.*&+KI0\6%R MG:6JOV&X.Z_AKI;AX-,!1@D$;T'TNK''6Y!A%GM&"XF9[\='N%MD(4J*_;M7 M@4>7^@6X&^??":AF:SLHB(Z=;`CRZ;?W6 M"TG-`9('"%.P([,C00:G'=VI@>L/[Y;<7'&`<>H%47ZQO(^2-,F7F,203GD< M,:B>R;1(A/^.L49I!]'[).C1;4>RU^HV#.[I+Y1,Z,%B1PR"[?(/=:^.%QAUMV>TRI6!CL@Y3>XS$!J?=$[MPHMG]-`*4>:<8QS7_1 M'\$L3%!A)KL8Q+N_C^$]:3NCH`NK:%!_Q014^`QVV;G+N'TCW\&KS50TA$2M M*WA53517\.HY/5F2,'3AN:Y+,^F!7'B>R8-%F1W*`U-J.A,P=Z%_/A%F>3>> MVP7MT!O/=7P9G7_2]FP&O.<5>&$=O-G)4;4,_$U@EG?7N5W,=FM.>YA]KS7N M0:D7FD'L>V.(??\=L:QXGA2Q[TV.DE8P_2L*'V%R=35GOC[F"^1?FB4PA%%= M>\9',EP77))P-*8K;U\N1"]/Y8$N[/L6Q`TI_=)-3'=E2_#RS)@'@9E*E6]; M,_RX]BP?3`!^Y,@+I=ZAYU2-VK$WNN#E(XR^PC#$.1$[^TJ=<7;:2.3*#3=< MN6$;)SAF+6R_$7L2;*80*=:6KN2"M&[<%1Z6VZ4)H MU!IZ3.V^D;CHAQNR%X<)%S=RH2'(<'?H#,*,T3QY<4R"""9D*DKN`S(?.D@2FR2RO5G#+:F4F?H:3SRZO-C/)&SI+233+PK3Q MO(7GT=M1W%\]7CL&W=PY5K.-]U-C?Q/^-:*C-JQXG[$[0D!R5+GKE9[*ZX M2%"X*]9]1F1-3PA\C,'L\M/;_`>9T!2>O0-(J@;2P7W#>>O`43H7X&=O(\C[ M"YR/L>/\W[Z7/$PR_W2OK_^`@X(?D;NY@X@>I_4,O1CDEW_GC4,'2&[ZQK[\ M9S_,WJEXC3<8V92#1W]8W+8[$")L-YY4XS#\:Y3CLH0>V$9?$HU]S_?H^1$Y MP0-FASI:DZH[:\?]45YLUV'H%O6QOX*;G0:YT3WW#VH-`%4+0+T)(,=TT0B` M#=??A8&\'<4KL4*^UA2JDKU$:PI]3YY.X.%[]F3^*B\V?1I<$C?Z]W`SAV8O M6[/2MBJ;:V^OBB5KWO<\YTJ>X[P2_L;SG-%EDA:^2?U!SKCK;"E>ZRO5!.U/ M(@UIE;TII7ZM0F*W/5W4>%:,J?*6U59?,\2_ M9VO'L_7I9I9>2[IV;]:I[S=Q>PYJR+=Z"4F[/C]UJ.72[Y7O2\VEIYN]>BVY MU.C,UMQ+'HK&?L"8G56#R_5=OBZKE9%U5/*@JJD,Z2%4/!B?3=%PRDVNRC:F MVP=(UXF0,\U"])5,"R`_NT2-+!/IS`V@NW*-ZNX8%S>U'&`F/5EQ^%#+DA\NE"CA.`!5\59#B5!J&,#6P MMI#:5RLJ_IR!*J(G^>RX9862M_[8HK-7[M6QAO'$J1,,X)O>'<-B+F86[:HCV&:[OQ^3E+:L73`,,%'4$;U,#&)5#X_FJX[^C>!3 ML*_-VBH/4D44,\GY;$EQA"&N]F.R+<>[]X(H28L-./2@,Z*&[NX2F!9GFB7@ M'D98(,35"<8WK4Y"7/[0\]C(_,LN;V%UBQ^9RZX=G>A5K%PQW8\\-#>(B,L2-5M;K8:U*AKV;,D9R M,%3>#?!N/"V08K!0U6;L-\P%7DDY!AF&%J`]W1H]>FU((XR3XOP[*88AP@%2 M&*VB-[@J@A=>`HD_4BC1D@B[G\4QV<;,*INU=(K;^=1T!MU9IN+">"6LXY5_ MAYFR$3H?5YUK6QUG2\[GIAO1R>U*Z?/;6V(-+/:'$#W#;*'%"M.Y_""&^V.4 M5\!D6@Y7O'OON=A]3JO5K'C$MI,4^;^1_>O'*""%-?'V`$?"\D=T'1??2D]*53BUGE3IIQ^US;9^_Y:?"8K0P@[T.S>I@]H[`-_]9B%^@*_=16E6CZ'`_,\!^;;;QV8G(+/$C"-EG3+Z!'; M13'NZ+;839+=2[%%N-XD]P0\8__EA<^S%/?8M\>43!9MT;KH*Z\@;G2R@NVK M(VR8+B_E-&EZV/5PYEIBO-RTT#C!C7.&?='BM:PJ@\H\.>RIL$_8<\@]T)P# M"Q^XC*QY(7)5<1=21_2&BZQX+.[\)(5?M*/.DE89./H-H!;(A"R#N'W3GCDO MM3OY3#?=I6Q@ZDY3\ZTZ61Z@]Z0:Y_Z$#`"_,UH?B"^0TH,O@#7;',-7Q9IO MW,FH??Z=V@Y0FWLO[@N@MN&AT"8[TP&W`K>.WI#&/%M=+E@.4_B"PU(2SZZ% M(83$E2!;"#6G,T"^**GM=\5=DC'$\,#U_NUS?>X@.RXCOZXNB-[F)V_0O)#F MAD>OSJ6(0%JQ:W.1IU-CEMBL/;B9JE%E/GH"C=:/8%/#3"'CR)GLQK##K=$& M@F=P_20R;G#V4^ZH)X1HG?+V6X`0MQ88""&S.UG+=]TW67_!O@%%)E;L6.6* M#=HIQ;%J?F>JV!%_2Y1(KV??7%L(DDN//6LFQ0#2B%=K-Q1'H]H!)31I"UR& M]H%*//2"%=GO62&D>.Y("C6"%-Y6SB%0,7HKRN(I)9$I51@-3\#<(CS<2%4CH]*,4?2LG%H<5*T,6P93==%25U;`,#,U%*Y8ETE M7V[04A>>6?/K)R6>^&M:A(H]$W(Y$56S.O::0"D2D$[06NM9>"K5&A:Q46L@ M,[2N3^:B'[S(^KT<*8V%/VYD6$.(X:W-&P89P]G4/V)F;XZW*-Z1H[W@[AK_ M!+CP1O'S"J60DUNUM,I,JZ@UC!)*3BQD81V_`M*HFYENZXN[8WC`OPLET0[M MR5(=GRP?OT,Q#.XCD-0LXH1^F_X(-NV/P(.7``^$Z"O&XB$.4!RDS]FZ]$.V M,YDL#PJ#?QR#7;EFG:P!A\6)WMG%&*/G>SUTHO[0:1-;R4"-YAH.3T0*4[V& MED,3=*`]"I5N`KN2!T3!F1[&.D:YO8\UD`Y=':[NR>3Z<#VO)J!Z_KOIMP5% MWEIP>U`TN\4O>+JD>YQ0S!EK<@6*TH"SX#V!JU6^/I[:U' M&E-RIRSRXAT=7Q9:Y!_E!2%C5Q'\F"*E*+2PWI&M8,TQ8QX@ACIWKFU-:)`N M.W@"Y1-7$F+?R/-Z7-W0&QWA%?9GT:YTM3F@8\(>VJF*YU]1+CX$Q3+KQI.> MHD,NSI7T:PF1D0+)4HJ$JM0_=RDS*D,$]0ACDSHRS9)(:BYL8]%,?E7U-`B% M./<6SRCDJB2<23J2BZU@C9.GC8)MX%A(Q87!09"JNT&0.^=`[O?D6FGR!N'Q M5:..,P@RBCJCPYZK((+KNSD><07I!\\GES`\?_*>@OUQ?X'B&'T-HONY=\!/ MTN<+2"8:;^`A]'PZ']D"M1%;^0\WT-806@YR;;Q:,=$:+J.'&Y_FXKC*R>6! MGRN`8[2#V8E^/O4`[G(7]$AD=$S)0HXDV.7GJV3ESW-Y,F%Q4`HY1@7@Q[7C M^>BY?CXZDEL<8.X:[D!^?F`FE!2&R,G)QS1)<3HBS:M:531GY%++#&V0:?0V M,]@@LV5Z,]"X49EMIO8ST@Q[G,95([%!Z)A9`869"2C87EH"A2F0V0(U8]]I MQ8*.D[P:6,D.]F]T;ZB1UMCCUWG%KU:_.`%[?F]ZF_$K_LXO,8*C;(7IJGPM44W%%8=.DT.<T7OS/2@"L[ZJIL!<9;TXQH1GP@9T^ MTZ;!^2JN?;VPGS-Y_R+#SNGC-,-N_F3<9(7299(X#BHNS4[?>4W&MYW/[ M5;J64OUL7`6EP6<72GV8?PVOXU9\?*&:E=K;J>ILW"#"Y2BYZ^W-#F9__4"6 M`GJ[';W,Q0O!P0O(&6&D)@U2_.\WL^OE_`I$AV0V)HOQP6SI3 M$Y##:LE_2+MHCPN+`W93[ZF\S'CLSE<3EJ@W:!BG)4KUF\FX-@/3\.TA9L3P12*T,V__Z M@,+P>?TUHJL''M"OO6(%XBW1K2L5JM M4OQ*1=\B(DMV493"(/LHORK5G`4.X,,H0/+^#,[T2!Q M-`1YC4F(3`Y005"7?'4(DTQ8&("8H=AP]E:(7NC]<0%^@5Z8/OBXF'3F MM"<60KH'^'`"RCN\IR;..+FG8\P*Z$P?[\0PKP^WQL%.27&R$UB-?0SO0#Q( M3W/2`L3`CIEKU^B2`:$7?6!D%PC>0?K,"_.$DA^;,7*G.Q`=(O(O+^/99+L1)CLR')&9UHM MLWQYO:D$'T@CEFV6L#5J1!&9M`4\4YVKV$,OR-$N-DG):)G1U;X"H'`[VP%( M&=SE\DT;[G7%CGHAYCQ'#![V'MSM@PT@A]L3#T!.V1_7?Y\K_!?^L/@(_Q^Y M]PY_\O\#4$L#!!0````(`%6`;4=J5E7D9T$``&QO!``5`!P`=F%S;RTR,#$U M,#DS,%]P&UL550)``/R3T96\D]&5G5X"P`!!"4.```$.0$``.U]W7?C M-I+O^SUG_P=O]O5V=SJ9S&[F3.X>?_;UKM/6L9WD[M,<6H)L3BA"(2FWE;_^ M`A1)\0,%%$!0`-1^23MBH8`J_%`H`(7"W__S=96W)Y\>GT;ADG MC#0_F=W=LC_)R??O__K^V_??GIS3]3:+GYZ+DX\__OC#R;N3[[[]^,/)_6:U MBHN3JSB-TGD<)2>S+$X+QN!_G]S.:OE M][_Q_SQ&.3EAC4[SO[WF\4_?/!?%^F\?/GSY\N7]E^_?T^SIPW???OOQP__[ M^>9^_DQ6T;LXS0M6&_GFA-'_+2]_O*'SJ"@E;A5_?<+__>7N&BS]XP=.\2$EQ4WT2!)695F\V*[)3]_D\6J=D/JW MYXPLQ7R2+&O8<.W\R+7S\:]<._^VY_QA3/.>.!0?:!$E=MI9\ANV=5#-^$9_ MMJ5:69,_V]0R,Q'D`%IN53.^T3.2Q71QF2ZF;WB_*EN-OR^B[`!0&58V7H#I M6ZW1U)C6493]N>_X//?MC]]_6[93LP)C0_"-4/<]B&+TCR:\QEYG+85+(T;>[;)XY3D.=/((_-=.-<1[91Q,V[B M!7DL1K2I4WQ$(Y8DR\CBCKR0=$-&M4?,R;AI;/!E;`Q>OJY)FA,.Z-OBF60W MYTRE_,I?DQ&*1/# MU;C)URG#4T$SUB7,/1K12H#1&'SRR:'!#I\ZXI>(2SVNH4C&Q@V_C+*4+P%O M:)XS-X)/&C2]?XZR,<,?P=2XP??DB<]I=V1-,SZC[>8V/E%GI2W.._]W%^>_ MCQ!D1&73"3BE/!8FVRB/\]OEC.\`L*'/N?):,F9'&5W+B:))/-+#,:[*W(IG M3U$:_UE7-4NB]'9YNR;C>P;+V:83]%":$4L^4,W,EO=AWCB`T82^AWE;\;QM M>![F[10PF<+O,&\@@JDEK\.\C6(^$_D9#7/Z:9C\U:C61]L M,AXQ(QC6=##1ZG\/(=R^KHDWMZ;;U9IF.\OR/M8$&U@V=Z[L>FN6_+21FU2F MNU/V'$,++N&DSN`T;J`=!W"DZS>-TV?9W;/FZ(UW\29S[NR[=9,X='9=N2F= MN$GX+.O_]F28+DN67?VSB8CNM=-+ZIA-SCY!RN*[6 M&7EF!>(7N:LCFA'/C6A$;5 M=0CQ)I9HC&M+YQL."X:$2V9KB^UUNJ39RMC?E_-K-W/=LOHW[(=.9>2U($S\ M1G&\K2,$*:NM*T[HO%-7PH/Y:*:2C/_R#UDMIX\YFW?GC6N4\.B2G[[1*<(^ MBC*0224S2%:&-B-.L*TZ4S6N.[,\.'(:QBQ7%AW4YTM_- MG^.D0=(RHRO-3J$H"=NM_]L)IH*3@IZ(&=.,34H_??,M#Z=E?'=+QYN=LD&I M2Y&3=DC3@;!Q7CJ1 M`4@#0PU*XE%N#5!!A:$?PL!0B?QS-LT^T4SL_`HI.HCI400&%)E\8_#1XUO! MXJ]AP*(Z-^";C.7A07Z[*?B5.GXU4FQ@$`6Z9D9:(#`,:4@_RN1(JZD0]N^^ M(ZR6>>_I7[%?^O.6@JJWV32@"@9`.#G-4`/RKJ#R'V%!97=/3PT6`9T0+AVZ M0`$#RVH#,AWN%6A^#`4T#XPM@)/VIQXT=I^"0X-`HG$`V#&LM^J\W\P]96U> ME,!-HKZ'(OQ6*:GW+9A^E\EDUO$]CG7/>[]+6\O77$(7;-%*:7H&H$<3#"(P M,HXS"3W.-4+&[LO^_<-`M3?LA^E.6W4.I\=A>!GECZ7HF_S=4Q2M.9!_^$"2 M(J]_*8]I6XBN?OY'$_)PNVP2QLQH'DO.:G6*5'C`%1DYD,V5L`N;!,05?ZS- M>N^C8Q&JO2*I)`!-1Z`!C3.Y>'05#\!A__#PHY6)&8ZUZ_/X$4;PF6;%`\E6/"XX+SIW M-FJC)R&IC9R0Q%_$($1"`D3,R?7Q^PAC*HW!KA30-ZXZ96ICBROC+X1,A$9B M"LG:_,S^A62/M)<'RR'6]O)5]Y1F4=:^I]*#F8J\AS"8W']P(475Q!7,U?ST MWA-(U;=;MJTK*!5\1)\J_74_^0L+B0A("'0YF)_%>]+=]:VY-T36,PRLH[B^K)B/8UVM-!#B4:)2L.H$OYB2%]@ M)*10C,U/ZHM!`D_7.PZRG0;9#H//Z+"``W&/&YR<%X/$N,XTIE05L+,D4AFH MJSV/<'<59AE=DZS8\CN/Y=[W'YMXS=?&0[<,0]J87!FIA]C0D$T%$3DK\_T& M+^QI?5>^!XW^SY6J]C][V.5`FU7=NR_F.A+?O!>OXC0NR$W\0A;[9`<[48?# M'D=<:4]%["$.M.13H4/%S'S9[L7P;WF(GVDZ%[I54II*C0"-A^C`2*,"!<## M=7S]6*]:Z$X+_6@O>U;87IS_-V;A[863K'4Z3A7'RUV=85CO-6G#A?9D*Z.5 M8(EY?<.4%,!YMVZQ2NGX8CXH1'[DKR8<"NW/X7^]5S^+MGRC7G[P)B;JG8/T MB9R9"43'4*1L72,!,VZ??O09!F\BJM1L]U%"\C(588^*53PY;JPP90+`T+:&C"`$Z:.X,_[RS'#]ZY> MYW%.'J)7Z>2&I*XCD%34GF--3UH=A"DY!W_HW\N=*C\'%A/U3H+[1)Z#!R6; M#F8@AN%N+GRF!9$[TQ**2H-""L^AH99*!Q=";B-V+7S8?:RQSBRCTB="T?9L M"4#K.6YT)#6Q+`!?\\``3^:B]@CI1M>=)Q%;*BQCLE#;'V1)@5U2EO0<=^9: M,+5CREI<7_JWN5>FW"-3[HUYCR"KYDIBHPQN]GNQ2Z^]-2S4*6K7'EN56-/' M$`C3DFI_2*?>L(9IA^-21.M.7IH^\=LP;0/;%U-"4DLG)/%AQ$@ZAJ)$`P?( MD',Y*H0-ROI!,OV+TX]D?#!2ND)F8D;!WN3EL,%1%J0!0O(B5L M!XT`A/Y#""VF)H9D?(/?A\;@!Z/38%$S`6#D6#&)3#L"7UGIQEEQET6UA'L! M&?$V7YWK`/&*7Y7A0/U`7R#@PLML#BUI'>&&)P^%OD[GR691OA^5E?U=%%G\ MN"FXD_U`^;!BLK.VLZ8\7:<%81J%UF[3,&]2R-AE[O)>W@XPI42B_"42BOV] MNR&%PY#'2?J=8C31CY"TV9+J)M^P!>9+3R\.>UKI787I(6&T]30U>3(-< M/]@R*NZYEJ;JOQ,BMOE0_0Z#&\U*;T/&4&E.OC04DJ.O.T;&*0U MI;=R]@949.Y+>F%0="_R&]XV-[OBCZ_,TB&HSX\GS,H^?"8%Y_#VDH+3&_MO M+RGX^I+":9+0+WST7-'L@FX>B^4F&29#!JY!FY2M]:!7UN-\D".4@,T7J5>% MY1!8CW('O:62A'9Y+PAK.K/Z7';V=T+*WDH7IRN^-/BS_!W,DPAO_UIA.]P7 M'LG61WQ.HS,EI*U5:SDJSF./_"VUUEMJK;<(N=`CY-CJ[C8KQ^>B/"R8D:Q\ ME%H:-*YU]=--\4RS^,_]]H@0TQ"Q M$,M#XJ/'L$(_A\7NL#'AWD8027:=YQL47KN$$JS6A%\)3H5Z<8'1NB'AQO*) MI+K=%'D1I5Q7")`*J"5([5!_)7"%->0"LYW6A!N\UPKS1GJY&B6&X?I?E7^K MKZD#!O4K/=L``_!:XBG<6@3E$+Q?A4.+U\P!P0JZL@;)[KP#J="/55!!X#QB M#Q:GD8.#LN>[&L2N>0=(V''%D$+0/':754,W!P>IR%DUR*/GR8%!)WI[)Z`L MT+Y+(8JTKRF.$)5J31PTUKYN@7GN/M>R(^#QLIRJ_4J$ MB,K>>-_'U74D57.Y0PG<]8P8J'QHN$8;C'CVUY^1/!@H=T920"J[J?!Z4SW_A@,!2_X]]+=F'RUDJ/VZH.=2J`&`KT.`1 MA8">TYRM@DJKP)H"-IU/7MO0=1)*`9-UVBXB>0JR#'Q1#3XH+.]CJE%.!WFE%%0B"<%*:``CD'*ZWVA*< M2PN;SO;7H9WGC.;Y+*/+0>I'P9=*=9TO/H,"%@'=^QT6YN88'D:'?$%E=Z21 M/C5/3HM7.DJZ^OT4F,[=%@DI3PH_D92U+>'W0Q>K.(UYNXKXA50M[>^<:!6J M-U20A9P-$'4W4D/1NZ,'K*?<0$#R#_=NTQW3!>N,9R;;!5L()K2\<2P&&HJV MR:0KI?4;5CJ":J!)P3;<:7@@M2WIGL5>S7/J!.[*VHR"I)83)GPP/?610M9G>T*&O@XP;F;.#N^I7Y MN0G%3' M">OC=XUU9VJT&X1@'.X=P;UK=\44O7OZ<<,$W<=!GY$ES:KHYX?HE>27KTQJ M)C&;Y;+M-=-7CLKO?X":.A'-$]7D\Q`XG(K1@V?2)DV1Q?_@8X_)7-F3,Y*2 MX8&,@JJ#>0&5_WA5B::)-0$[@WN(?KG=GTD![F$(O]7.4O>;SUB0B8&?JKM, MS._^>6$?,*]8S4@6TP7[G=]])!=D]R]TPF>-8;T[9H&AE^J]8E-2_)3NLBK/ MMP]9E.:LM;OG9NV$D0WC*G$W5F"/:#2`_5![^1B MM`#E!NQ$#0_WU%6@#&#@(2CW]^Y@RB,9`GAM3(%C:>TC'GL.9&?"^K2+/\&Q M4'/5/S^&9RSJ1W#KA&.`5Z0BJY0.DWDCX%F4QW.%=!T:0+2*QMF84O8(QW`4L['%W$^3VB^RU[X(D/(8$['_N251_=B[!3 M*M]MHBE'WNEKW#^K1-'V!133^I#$^&?"3?MPXUG\?9BNN/[N/ANEM#^H6B@@ MWZ2(;2]M<,TNW*V63MI9(20D%*(DP>'`0BV8)C"$#,,-?CU=+,HDJU$RB^+% M=7H>K>,B2H0@0='6C\[*:?T'CHZPFA!2L`XWM\8=*:(X)8O:Q16B2$[4W#$5 M$_F/&Y1XFH"!>([(GN'#MD/K$67H&%!LAW3+#1_"5I7S'V>F2M"U5?AJPGTK MJ2?\!5VQX=;?\9;1U/O98AK_P8013A,X`$O+]Q!<*+.[UJ5Z:T9`BR7/W3L$ M4E[AKD$:P6[83%;&S$,K[P%!?[G=(G`9&=^)1KE.A[LW=S1)KFCV)1]'JE`W^]?0`4FTRMOM;N=J/;"%+6GF11[8?KM,[>BRQC3.:ZC#MC9B84&VT-^7163R2A\P0Y?`(%&Y^_;301'Q'MV MEO'8>[].9Q?*0T#NWBX=C+?ZB)Z43VV1-"]U*0*H$8,V8#49!`O@,8JR`VC- M%IAO;'F29@P0>C>`QR`8[HH4\AJ MI93219HXU93)Q577"/'X&/D?W[T=)%L^2!ZHU+>C9),;6+NSP,O4_7I5]R1Y MB/`C/4N>`'?P:;)!=+<<0BXBX6X&D5IT;&P3$!_7U%1ET=2KP7+4G%]!A\-. MT(PT;#$(]YZOWM5+"FI6JCL9[XY**YZ6<.??A=WS*'^^2NB7W*M[NDVKU-=S M0=+AK5P!JO1L^TOK).NT^89G%.V6'R)BY@_W#S,8PT](&.5 MZ7YQ9H7IVZK4],4'N[VJM5BU4S>\A@TUS\I^WR9_H'>$K3'F<4(Z,CY0I.:` MP3QE%WR-,])D7_LP1M' M7+^YK2`^6DAK:>DP8%8UR6!Y9RO8`@CQ*07,62O96OV";AZ+Y28YG<_IAM]X M2WF$TBK.\\Z11]\9&\.BZATS%D>+;`L:/0S>S1IJGE]ATD"W04@>GX6R+$J? MB`CV6F7:.[?J,D<+;!.='0;)R)8%GO!AN'';J*7*@0*L:O0+@E=EX8(>J:5E MQ,IX`88T$K_P3<6^&3`J"RI'6M:C0QYE[PO/(?":49W\0/6+3R>D]1[!@[M] M>:_3%Z8\FL4(M`IH071V:(-'(RRY7?1UZG&X`I@*;1>5%.=L"GU"(`Z@!U$W MH`\>>7(-V$7?H*[@KZ\*-%*&])5!>\5NK:UV7\`BL.,B*!(\%)5ZL(M&477! M7U\%Q.1!3/J8A$K)83DL=1S(5&AC`G`.:S2X?>H[/FN'>!9MRX"[+%KT$U#H M%5(N:+J%@@(6<@@R\OMJ*Q\\*#5 MT]`$ME56M_E#[?Y!F0W6;*.'7KB(S+0.B@2/4:4>K)O5077AWAH=RC?+*--' ML:UWOAZB5U+/(4I,8@J#Z)07#AZG&KJQBUAYQ>;W0OW#;KUS<4=>2#I(D(:F M5^XK-?3!@U*N@6GVE9JZS.\_>A*B,Y3Q,RV:L57Y++,H0\WGZJ(@+F5%@X-+GO@KX'<8`0^ZFN4TS3]'!?OQJGV=YL9H>9E?M31S7>K.IUPHM*HQII M'I1:4&:P75M9U-7*T7V)LI:RIHSOJ8'5"S"="J`!'BB4V[Y%:LA4;@6UF3I3 M-5OS5;/MZ?R/39R1>O]LED1I<9HN^"7R-2?IWVK0+EC?9=`HZ-LD80H6.D)? MJ`E!LV'EW02-!@4?`SH0]OZ99L4#R58[S0GO[>B4@<`M+G/,N$9HZ6"0%KIH,TTBP%V56HU!$!UTQ3![.R4&L,@EC],K;C=&9U;]SJGOA1#0ZK>IUJ MS(QMY(BW5H[@9'#<^9&5DT'M)AQ=/,15G$;IW/+)H"%3N1749NK%)O,-7ZDP M4#*8Q(.#0!6=8"NY1^>;Q3?M>8K7!LJ8:[:COV'(#:J[NBV?ZI9R88 M7:WH+K4^X+ZK"_0\=UF!8T*IKGXF@RNB(<$?US')*C%OE^U`^QYH56155\!D M1P10I"ZF@B5ZMZG6JT3&VD2,."H]@]V+<&M?*[H5V$\QC75Q;OBY?F9^; M/I$[IK#;M#QX21?\'QYR^1(E@N@MDZ)5+^D5]1[)(S2AAU>]BL*=B\42S[Z*+>HW*$)O10J5?1%+.;LGDDR[9L>O@U2@:)+[3* M2,$X*!,H"N6RVX#?H`;SQ&OK$LFL&5EQM.@;/.3Z5>%/\8RM700:1*RLO7D) M>;->)Z4JHJ16Q76ZI-EJU^?`(Y)ZI>J7-["E'*;QV$5RS*)XT1-9]*E)P]'^ MY&X`:78*E0K5&S`XWKO$"FV>X1X([;(!5*F]!'`0?MTG9NE^#0L4,M%&X*+' M]BC>699.569F4F^J0M<1;DI%GGN'2;8/04D7S89.^68W%'.A6Z[>GL67LW>I MI/5"Q4,6I?FN?QYH*]=@SM^F$XCFF06^%DNI9?_^8:#Q&_;#[IOP4Z^;P[6J_S9ZBM'I(F(G'LS_<+ELG9*ZL0[M=YZPA-(D7 M32-;*KA=5CT2)4UO0EZ'59X5H"SQ=&>%(WXCHM/E/5L,$M0664#@S'[8[6** M$+]K4:S47YH>0;UVI_R#FYJS*(_SVV5;#7PG+XL+3E<]X<$LZXPI;+H: M$\.F``9%35B!1$;H;.B+^^,^?DKC)>L1YH0.6OW`>OTL&4;7$,SD2[K9VI')5T#(*B0CWW#B@*? MOUOG(B[-0=V,[5['@%E`4/8.X824#N,G!JV"K`&&%);5A[&-Z2RJ)6AW*$OX MMP_]Q'P#'[F?*%U\B9.D-E37C'7Z%'-#Y6P8M]JT;\[NL6KEP#8J6Z%"LZRS MP8]J)V0.S`KK:,@'DV$&`SI2/5VSHM4&;FATZP[<])3VIGJ#WMD9Y;X-T(DC M3%&?'XHHG!F'5FO4Q@!'/)33K\$NZR*J*63O+'#(F0]4%4?S@3F,X'"QU.)8V!*9Z.XWF^I6E!Y.`[TIJ('K7!BCKXI8`4T?@#OX%>72W%\@K1PQP M&5&#:S&1PZ'<;A`\?J540N'\&*G2/J%8R?IC4L1U-Q`!;H&/OOIY@G.Z>HS3 MDJNSP2AH"^2Y8TCK.#,IJ;N@O&&SU*-5KQ"L`+_&,JHSJ:'TW0$NJZH,H$-6 M$;2C?4<2GJ*0=4BQ+2\H,>&=QL=5#9KU&P2>UN/(FZ-[%;G#E*'BIJDM@4%) MA3K\L@GH/J9C=-$_K)?7N4L9JE%7X+X!#["+=T\/[F)I>6`A29V&[$O:I/3C MC"946 MR79WW;5U:R&C*?MSOKM'YQ\&/%PF![8'HZH'17V M4P*/;N!N/\:H88&;1=V;E6\W+%5B`JE@Q(K^A3]:<9D7\2HJ*N5N]6Y*HCA( M+T@J.`1Y+U)'*^.O0RIJL[FU8P.*TMN;<@R:%*UOVVD5]1QU(_2@`S>]:J9( MX'+0K:OR1)(YZI1)S=4CQR*:OMFF4M)[CCI=B76@AN!MGC_?4WS=D^PEGO-G M`]A2.,\%*4RTRH`X$Y8)#FMJRJ`1WX:=0Q(A6^#V:/K79IMDOSSP9;$K&1Q3V*LK<7 M_]SDY19@:_';CV@U+-Z\\Z5;W'-PCM2'#D;UJS+/GN_VFK?N+L1#Y/2BF/=[ M$)9RL,R?R6*3L+6MT$!*DCH9E*Q7B3HE/3<5YEK06B/JU!)TE(DR'9-CLW#\ M29D:J/4;UTI.?K:M/JJ-@Q&7@:'0Y.)W0B?B/QTW-!%JR.?-ZI%D#(:\H3M#KK8?!CP&UD.+A]<)I6SH!9]L MRK`V9V;)AMH@_N6OBK%%]F#"MSA[4?*-BW M&F&F3#D-[9$^)U_3OME3#RKYVZCJ0DT-VJ@EZ2-U&W6*UJ0`I!]9!0!E> M#CB\X",3ODDK"OYUN+UTS/&)"W+#UE@#Q2`G*VT.`V1J<`@9L::*LH9DC0:8 M+YF]"-EO98%S/.<=7Q;#/9[Z6E;;"F6)@6V0E/`UJ:&^N*C,ABBV09\YJ=,; M.A[,7T^2P\YV22\)'G*L8PN*-KD4!7W/7FBL!*V$A3JU!&T7>OG8'!N!MTR% M3=O.MJ=9QN^.EE&6NFD+L:7%>E&7#C*AH:92QF5: MVT]/U066/]FR<\'Z-U[&9%'YM_,_-C%#$YOA6I,7^[9AO8GT,ZQR'S@CEKA[ MG^9M6GWJY8.SWA9+%LRAQ2C%S7=W#C-ZQ<,.6]&'JLR%FJ5[=@5=VGN0C].' M65)#=%WF6VYNI]GVH^S\'?8D2ML/JU^0(HH3AQMP-M^LK[?L;/*L-_GL\'1F MJ9J81MZH_#K][3F>/^]N">[`0/H7AS5*U-F5,"7<;0M:104U45!O(]%&@[@M M0S4DW$FV%J\VV:3Q+@#$PH0]H(H(CP^?2G5,#$M1_JV_O9,DV1[ M^R4EB_O-8QXOXHB'9P%`4U#WT`92'Q_D<(J9&'=@(P+/`O)SG-*,V?;ZDB27 M,,N?X_6,9/PJ8?1$SK:?:3JG:<%:S>I_VI'T4#R:3]6-(_@<#_)M*7.B,3&B M>9;REWA_(]_U2NCM2GY]V9O_".XGHDKAK^+O2CG3!M2NL^UY)UO&[7+GSY^^ MQGTS/H9%I22,%A2%I:A2%+87;)S$Q#0D=KIY3K7:`*?OW6KMKS:/V#GC#)G M=-0([W:124/*O%Q:#0BWHW2G9&@`Z4U5O<00N#:`(TA9=[B[9F+8,;^:7+/U M`&ZU_L&? MZ%M]S-?]%@(29.)HXZ#'S#SGM.P2;H#K6W`597F8G6]7'8T:>BK<,4JEC,]*EJ(Q1L`M+UPDP$=%XGC,7*AT\)*^$8 M[@:#9IY;Z1FJ-H?!>:H&!W<:JR,AZ@"T&@:"0U04;:T%.:T[>7?-$)Y["K]U M;>.(DTOHE;;=RJ`]<*NZA(>/6/+NVDM"[MKL#4\0-444FKS]H:":FPMS!X"A M MB,B_GD>)H^AMB(?E[;A#J@LU$U/YE-;3FHQE:4B[K([A3%[?Q:-Z7A"T>X&N MN%2\O,)PO?5.L&ZY*R-P.N5$]4DS0.21:.)(.P49*)[S"+K!LE$X&2FHZFN# M$)6[X#=5OU"L;+V(-H`O'^8@OY`'>,8,'+->G^6+&B5=,PY`.J^A@I4/#Q8) MQW#WM16FOO]D*&PO57ILHA!!=E^M=X.:;JVX-5!-EO'K<#>^)?X-$%*H4P38 MI1<7&#B'?<.VC,)Q3&'WH/-Q2%P&(&$ILI_<"(P,,%I,_]U0]5=&'@4Z9 M[M5-59EP0&2@`T.,X6JR=*O989+/\O2'/_P9YWD\>/1>055TDW8.J((!%DY. M,RB!O,UCVUR#IY6;G-_V%]HK*4WMU(AI@H$-1D9#QT;,N8+,#T<0#FEVM*"_ M&K1SPH"J-^#C,OM/UD&X?X6+TB3N?GGZ)\T.]_D M!5O@9/G9ME%%O0TNC](:S7$0M36"H[ML1YT&"D[18((Z/Y&`P%W49[1B'=%I MDO#X3$E71WW"=/:B,SZ1_TNBI'B>,S,D/.6`":IFB@BXVO&3`43QPN^H;\BP#>6%>X:K/IH&G"/,'N5'&M9?YQ`2UAKO-V[GY M"5XW#(KI0)&#@O?)?;GT*8M'%M.( M+X`ZG]K0/32\!XH[MI=R%UP'#7^Z0X]VJCU`5-KM5E2=+"LJ"%?1EB=&32L] MR32I;D.X2]^!8CIJ&6SJU#'<>J7JH&YL*7]FTGUBU8^J651`"LV@'5)G(U6W M$T6C$1:Z.Q*1=0E'6Z<.FV_LA6\=S<;A)$82W92O99?6UL:?R:[MB+HM=8]_ M5^$'=N7M;ORA9U/13KF<")I!7>]GO^TU?&U[#75$RCX21;C=H"+K108-R3Q: M(<.;#D@I]?<=8,;AKHC?MAY<*=KN;H*8O=8&P7'LJC^P.G&37)\2GM_VE/Y( MRMN$F]6&E*#CTJ)T)RD#7UP,VB:^^H:AK:65TWID&(;]1?5$59F&IH+2/L@9 M'Y'%%0QYD=D%QXMR0JO9"\UNF^T1*14SC0&6=L0,MN<8[N[V6]C16]C16]B1 M3\;M+>QHXKE!,Y((GA(DP4$!7OD:R#DX'(%\^P$AY-K?>'"`^7:S#1@GPUZT M%=T5#V25C1<\-X,3:ENW2CT[ MH48=N.$/G2%VH:94OXRRE(F8\UP&;'CQ"Z,TO7]F*G=]7ERWC+6J;`]P7JPB MJX.Q0#)G$\EO)'YZ+LCB](5DS*35"<#+YN6WFR(OHG0!'Y2;%J\4HE_<>T7Q MQ[/GAEKJE-544576F1DT1@(=IY^NU=1M!;>FFK6'>ZQTGP240]GF&0(\"Z)LS^JK2@//.!3>:#)`AVF+O;IQW7_+.MF('@A/,`-=5[PE/6Y%E/ M\<,EX=$KEERJLS:YNYMAJW5"MX3<%W3^^^V:=YKX/0\57;WA`-.Y>Z@0VUL4 M+V=WSE'54%Z=@3F'.\E4?CH7"4BI#GQO]O\'WX.`B4HN?7@(.$ZQEG&N3[MS M$M6VQ9B>L=+&\FA0V;9P@Q0F<@'!'IW"F8'N2-J0".Y_2Y*$.VN,5,O@5-". M$PP=-MIC&ZK"3U<\P,&NMKL\[:BZYAGJE#=$X'AK*-2SU4GPIA,,8Z>U;].B M]6D1,F^>SX$W@XB-`$-?,)N@DVZIX;=(;3?#4J<=/$)$'M7G.DJDU1H@3D)" MT3QZ(Z!P'M.Z;Y4RE%5&"M[`]B)P5=8YPHO7R$!5`5_Q?>LC"DR]V!!NB^KM MM5R,&055_<8"1.4K4G!BH4`"L@KW8MAIDM`O43HG5S2[H)O'8KE)AF,!,#(F M96NKHU?65W"-40'.+NE58'`2_N,.B"EYBHJ*UH,Y[FN_MX&<_LPO;"CFP M&QI&7!S<;[U.7Q@WFL5>^*EU:[87<3Y/:+X!`YH1E$W(GH328:ACU:J[Z,O/ MS-AD<93P'KA=WK'^S5X&3U'B"_3EEA1P-J0QW4<-A.Z.:TDMNP!"-?=P=\T; MZ7ZCV>_7Z2RC8K$0P($.+;88R&?MPG>9&O*LXC?-GLOA$Z0(' M,W6)/LQD)8*!&5IL,YC)V(\(#O5A[=[(R,2"0-7ZU$=/^2D8F`P%,<-#R<>F MC^JRXW^-DLWN4J'"MH"$?5`("(.!B$I(,\`(N%IZ%?/@JQMN`[_$25*OX*X9 MZ_0IYBLXUTN=5M/VK=H]+JE<_!B5K?/FZ)5U-N3K=M[1)+FBV9-3H"'F7^HJ:L^0)KS19L='%?1%GA>GZJQ7G( MHC1/=GVS^.QO+//]C$[.V7VRR M.'V:E2B')@`):=_>"TE]AP]"0"WPB/F%F\%*,:?\X[M@9Y5!T\WF%8,5SVY> MN4S%!L&!IO3)U+35@)(R-T9GY-^X=J"-ZUPYHU\DII\YA<#F!%0E%?*Q51A(@;M:BCT2.L(MP%U"XFG63W M=%DP-Y;TU`#=4L:7V=], M.,*TR:U$+P`/%T,1Z-KK=$FS52G`?I4IZV9\@28<0UW`O^[7%E,!!0P_\^6: M;)?UD-I$&5\JMV(]1]#9](;XV\HZ@DWTE4B_`V08D2G MB'I?]\:#U""2YGTF!1"OI%=(K8A.(1]5\2FCN086.N1J\2MR'Y>FHNZ4KWQ$ MLJ.7H:WJ%$N=JIIPUS<2V4[G\\UJD_`8EM,5?XSCSU)S>/PI&*@1"3(X#HSB M]#,!:L&*@P]VDJM':_[0FC>.!9*JVP%6X->^.A!J0G$M%TRI[?&J)`=H% M*&V82>F=C&--W5%_D M[KB65-)^R4S"/'P?D8]V);*4='N_$*+S'4E8$;40)&$:N%>HA(R"JNTZA`@7 MG'A:8`%9NO`P@6T*M7L@-2#X5!PU-W]N]D]"[>Y>BV[;3+(O2IUT<[?:!52[*.Z%51JP#J(R'>N"M M$USFP1=0:F!?P%/QA;=]=(J@5##!W:#*,MV3["6>DW.:EL--?%\;1UPOOA3$ MSJ8SK5ZAFE)W)S-,5>5"3%&%5S>.JD;RQ!89:W^%&"NLM991Z5]YI1-6G M5GSH61-@Z6Z`*XT:)92+C1L/+C3^3%_*MERGO78*DF=6*M`I4ND`5\07&,B[ M7-Z]#FV(5K\,38C47F!X"\S%D>0W[P_AQ2+F:E'9ACX98!#V9*%"!Y+4"H9: MS,,][>I+7/\SIT]I_"?IFU@LN1A1`O)0D:62W`K"!)4$_WBJUI0V2#9^-).: M(HWZV&DMY/3J.IXL-?+ZL$N.F_9]'UP]1[/D`-Y?EQ*)!ZG[(VQ-1*&$-,(0 MQ#GPB[`]L92W.D`Z,8"\B+H=AR%D)*X9C`31N59?DO1"R]K;3="VA_7]IIO! M'4-;ZP!WBI??*S2);Y"J77R-$%F-I2G709#/H_.'W%A6$Z($5+J`&%)Q()0VX@`J$\SD-JVHT!GV-1D0E%F^:!E7O" MYEFRN-\\,IL3IWPY/6/6,\YS_IXO+0APTJU5JCGW1I9R.&4H.H::RMZ?*\3U M[,Z^D?P#3RTJ&=D4/41D:MV?9T*L0C[#A.W\0'N($\H!MZ'B0C]_K.X$S:*L MV)8/>[*YG&]UGVW;7P13D'[!2LDZ!;U0BW"R@@D$8DXP0<6O%W%&YHP>B+H" M">II1T#@;.!*M$D1LG3'[9!9.8$(F'@4;UFW[31=-,V\7]--+G8UL.2USZ0D M][3K->7$`$'-5I^S MAL;%533GM[U$[@=,4`>."@@\$4?H4,A(A"*-<"KL",6W0V^7NT8))RF8H!)( M1.!L5$L[@"*DZ0Y?$3L^?D5LPC6%DF%(49B6*:V>/<1LPE6:8OY0FC;4/"'B M$FZ*GU^C+.:2W;$93C`;0)\KA0T_>R&([,K(/$$XSU^W@]THE@N\^=[1*''0/ M"QA-$8#G;/HK?4B2%WQB+]^/7,Q(-N>J>9('TV`*"B=)>4&?066L`#3:=&J8 MXMV),1:FO;]5[S[\'+W&J\WJC&89_1*G3^?1FGTIMF=D23-R1]9)-"_#_20; MB,:\!'N-!KQ\!J1-->&=HW&55K#]B]U7E!WM?JOD'P'K$2@^'M`>`J,-)'\( M?2E[%N5Q?L\DB!:W:7O%_E$ZDZN+">=Q63&?\6ZOX>&NO>ZI M`C2Y#O)ZS$G6E#)RP=I23.XSOC2%-5IKBOE6>/KW0,-7M((XH0TY@TC.%BMS MY\2'/6#5E1[578BA[J!;.P).H=[1.=OD?!3Q)Y0>>7@YX^KZRHZ@2=`+$1C2 MJG?EI,ZFDOU+DQ@F=V@A M5)U&M<7M&P:@AG(64W(.UVEMAN_BGYN\X`-:BB6(K(>A(5D8V%&(9X"9(<=P M%^SR>8'BC6M/CR*V;1T*V'V=W@YF8A[O\`"UA'N;3B#Z#7#_`4,*[ZVW2)T+ MVSKP.F==';/.*_^GO$2_Z[Q^@(Q)4?B835+4IRW'8??249I0;D$V%;:WP7`5 MA>MFS*(MMRCY`ZVV66O!2?XIHWE_&&+)Z]`9);GWB-.46`]E:N;F3HDO\:G' M>`$,"Q[M6V`JP$BO@AEX`)Z`1&!M6QJH$LJ!`MZ#S-C+8R> M$\%JG%T'L7C&DN>;*.7/XPYQ!WYOGZITOWN/(I5,>F`1<#,/9_0"$_7#ECTH M]']N\B[6/WO?\8`$>OV]9V)^?\&+;OY,BNMT3E?D9NC^"K_M8Z3:W[SO=9DL M>EW?XV1^C\"+_A?,_F)'>;HN$QO1R>0$/'2K\CG+.0($%DVF5,:%,+%9R9P1WQ;/).M\/Y0- MQ[9C:MNN;L>;`3ED1X=N6_1$#_RUNLDT5^KJ4*:H4]G4]J:J[,VH6.^R8[(< ME7R!9T"RJ9Y91MJQC3JNG<#[-6O=D<=R`(W"J-4D3@)VK3 MZK&.E>`GD0OM,+$U=V%K&S5/J6KZ.\7683@IG M!E(+%GBRP!&1FI,&>XP.\+3=.O-^=GU30J"\64:O:+:*KM,E_Z?$F3S(1Z\P M?*%)6M@G%>5U2ZOX0+5>H!*P,H8E?+(#F'X6Y_=1:$(YMB4U`YE^AC6&>[-) M)IXLQE.['`*8'L>&6H#GJ$C2$2`5QYV&>U5*HIW+*$OC]"F?D>S^F74OS^,] MQ\\QTN+J608H?APPUM'1!&A65'\D9]L(@2_B9%/L4R7K@[K'0!_6#8/C!K98 M3P>$=M.`*2Z)>;SH,W+^S59PV*JJ'OB/KRM=AT8RB4D2:K8JLQQYX'9#3;@7 M-C(ENG*3J[,_I5]9J`\%5-=M6?\4VS(9!=,`E]'U:P%5NV;]=@$;(UCRYE:E MBMR#EP.@1IYM.U^DSP<8\!B\(:#%P^&U6DPK!=D0]0LJ0"0JZ(5:A`D380*! MF/9S^M8OD%Y$+_'B)B:/A#D7J3!''8:TOC MEF8ML+*`'Z5H=,$ORQ7,`RV>Z>(Z92.W3)T^_)40_O:)Z.T*"ZP&.UPFK)PI M$VJ6<#K$$5<*41$[$_F<9FN:L:'R7S1.BU]9WVPR\>8`@K(25DKIS%0A^XOJ M2-JU2_(:N`&2+4J8HN?V2LHJ?XW4M#&[`(AC(A["4 M01#('*T9?52:5!G\?9RO]FTL'3".>A\+`SWT&UFAWI$YRA>R=""D_4H6!C;2 ME[)"?9:(+3[GA"SR*Z9C"5Q49+4%`LF"@`U22@.+`S(VS[Q"=KY)+O]<%'`//@75#GJ+DB@R2>0Y^KZ>0_>]!8`"2 MPV"RV',R3T/E>D/D=#[/-N4&Y9)Y1Z57SD6J$K'T,(`CKA2J(@X"+5H2ZT-( MQ7Z*!$>'/$W9$.:`+Y=Q$C-5B#$EI:G/4<0T02`((Y\^<`"NEF_F'A8JW'-J MR1Y#5@A#N@>.A#04_&"E-8*1A'F%IA_#0],^PPL73WPBWW=PM,I4&D>6"0)H M)O+K(PY92[T-:/G&6D@'?)IG3]/>HFC5:KZ<=7WFBKXV3NU4+S34:`]`1&99M`5:VR M%N.(HH3D=Z0S')\R0LI3?[&<.D7J"")4$7M27:=Q$4<)W].]7O.04#7YMOI]>FJM'_:8-,N5^^PX,L%`S9379B! M3:.V*>[1'[`?S.8D:F3DNWVA57/I!*%JM#GX'>1AXK$YR?8ZSS=D4;W=P]0R MRVC*_IR7LCKW@3Z3+U#3>$\^1ZP?\^NT31.S?EWS-UG%'H-%CLT560L_.+(S-OJ5JT;M&QD+E3;!KMU)G3H:MG;!=9!73 M`A?N\G5-TKQ_]"\G:EQ;,=&Q``ZEA$E0!]5LT^6`I[CJ"__/8Y03]LO_!U!+ M`P04````"`!5@&U'O*F>N]P-``"1C0``$0`<`'9A'-D M550)``/R3T96\D]&5G5X"P`!!"4.```$.0$``.U=W7/;-A)_OYG['WAZN72F MLNPX22M/W`XMT0[G%$E'RDU[+QV(A"1<*$`!*=OJ7W\+D)3X)7[)3I@Y/HDB M=L%=_!;`8A<$W__ZM':4!\Q=PNAUY^+LO*-@:C&;T.5U9^MVD6L1TOGUE[__ M[?T_NMT[3#%''K:5^4[1AG>JL2`.D+K*U)C`)58NS]Z=G9^=*P.VV7&R7'G* M1;__5NDJK\\OWBKF=KTFGG)+**(608XRY81Z4,&/RF@T.%-4QU$DEZMP[&+^ M@.VS;E<\_,F]#+'S=67G>YJK7>T`N6V.;6,@YL]BZ M)QYXWK\4"CEXC:EWR_AZB!=HZWC7G2];Y)`%P79'@1:@[M63NZ_I\?'Q[/'R MC/$E5')^T?O]X\B4SPYIQ:-*/-@`.CM+;WIXA M2ORVYQ>&I(0^8#=!ZF+K;,D>>GZ9T/0RKBG=KK.EL3W>$\W3`PK,B;5G8+0$ M#Z/=!)^-2;9H4"#D>A/(!=:F*,+>$*7,0QYT#'DKN+G9$+I@P1VX)]KV*L3# MP`M%MO:5D.*ZXY+UQA%-*>^M.%Y<=X2]=$,C^7/#\1G(%Y)PYN`<<$1Q;R.Z M!O4E&QT>'%:!N)6J)64-4`G;8.X1L+Z#,?6>32W1&2JJ!2S6UFFT5C9>5-4* M6`@E35;*0?.J2@$+=EY6'U'/##10Q,6]H1\=;J5`0V9MQ1"O4EN#^<3;Z=!' M^5H:4TX<<`9R)'E.>,6Z4V7S!W1"'D^`9,&IC"O7#A153H#6D4H:T;W)WLIALQ'H#Y'%AX!ZP-;3)"AC(`]9A ME;+&(^:6&COJUYEK):_+#R_F#'X^:F.PD,FM,IEJACK3@4!1QX+RX]30/@"; M_INFZ&/XKRFO1A/3_*$=B$ZQ']-CUN<5.RKFV8 ML\G@7Q\FHZ%FF/]4M'_?Z[,_6BLXQ0H&R%W=.NRQ\E"1P9B+^9NZF`]4\X-R M.YI\:AV//*0G?(DH^4M*"H/W%'R&Z'CNHUI$E(O@N]#;)Z[E,'?+,?R9&'?J M6/^/'+#E>#V%&3\^C+=0):"Z02Z!'C2-:"JF6TZD*Z1:%MO*R-\4^IT%:T$? MN\I)KXJ48X`R\85P@(GTI\."I%^N,Q60%"%ZF$32U.S%P*H8VG1@2)=^'`B=\ M/&O[8S9>&N)41.J%=SO%'/S>-:/F"M8G/E`YY04(O4DCI*G&&'`Q0Q\6ADGA MXWZ$CF9^4`VM12>!3C"RB17)!):+W,`6)@]H[F!WC#T?H0*:`I3>IE$*ACE_ M"3*9?0"0#&V@Z;^I-R/-_%$9:[,6J`10.GT`#1DG$6`2]PJ`>)<&0A__!B/7 MQ-#;5L]N]3O&[$?B.*'IZZ`N71)A^CX$>00%>/R4QN-N,AE^TD>C2,?0P5$8 MW^FB8[3H)+URT>*JZV(O],`C-PI:_^<,;ULVN&J:VJQMZXR)@F^QK3UMQ,)U M/Q>,")H3AWA[1[H$70$R_3-?#0NSM-H#+5;S3``#D.#Z>.^=:K2[3[WPL:>%\W+%QGK M_J%VT\[%J87]UB44NRZL$.:$1E*L604%;9ZU/+\W];%FFF*]<*./Y6JNQ2"! M@8$=$:K<(.[M9AQ1%UF1-??1T@(T,I;:AC82T-ADX]H,<(MR!Z2&VE4=0@$S&$ELLI_69'T`.PA\B%**-VVA59H<1(2=G MI[LN>$61.")G%"XM/^`?=I]2M`609:RWQ>)Z/!O]H>BF*=RH:)C1F(SA>N!G M!%KX3@PFGQ94S@PN)S<\"62-(78U\O]M/"72P)%X M*8IB,5D>I/G9HT*`*^>C6KA+)*:B\*9OY\$934<5@E>0SFJAJI_72LRJY:@+ M9M82V:Q"R&OGR5IC*)DPBR*?790'G*T.#=`DI$3 M*H2Q9&ZIA;+F9NLA]A!QRNVY#FESY]GB3=8%F/=K[MU67@7RM39P:J0T9A1U MF;]ZK+1__OK\]7/%2EM;JALLC1E/:>H7#I?VZX=+6TNH:PFQ?P9Q/U:V0>PSW0SR[Z!GC[OURA>+/3>KQ-Z;Q$OCKW'(P7I M^\\4?>\71]];M&J'WY,S;$GR%P_`]T\)P+?V4"X"'P/_2-DSQN#[Y6+P+7HY M+[XD()N7\HK$"R^%V!QY4:;%HTI2)!XH/5[^S&F1?OFT2(MFQ9=O8I`6$>7A M>OREFT)T*[W"TV)&,PEZ/*0SGV)IQ#LJF\%M7B?^'Y0HH=78.OJ_L([WO<09WOZ-^$G?XIQOLA;)!86FCIF/GMZ^1&@3.[S=/Z)^ MQ"Q96?RX\4S&'G8\-[S3/51U]N3:X:'(N>+DG62>*TZ21UQT#\SU!,@XY;V, M#!&VX+I[J**>)+(W\EUE4:)\X9_3A=G">HE:N\K@Q!CW_TZ&"3]9J])VFV*2 M5R?;*D7$DE\^N*@BQ('+O^P>*J@GADNLRD*$/.*BC@#)4]7[_AQ$\1+)HRF/ MR!!CAM>'8F025X]!Q;1#V"4:0/) M(OYU0S[1$I>B)4Z0XDV/BU/U2PH@J<5C85#XN7MQ7@V`U,<\2CXU9!`/?EM/ MT^S/=91Y?I1S[#.>W`/2'QRI)DE],?*_"%/?J9!UU1FITR-#\&D'$-7RNOAI MXR"*/,9WM_"__&@1K44[5)+39L&W>Z2,8KGE>I.%7'2YXHM%;NQ('>'9_WF< MQ/\@AOS^S=6:P9B%^$[W\%JXAZ#"=NYZQ-L*!>XXVVY"4@(D'842QQ$9Y.N. MQT5E"*@Y:''=62!'?HA'$F_`!)@]DT^RMSPX'<4OF_M'W$,!GA,O3\FD[/N3 MY@(-,\L;HY[%8765HQ_TUSGFD\6G%7.218ML$Z8A-$-^_LR\U+:2,ZDRH MAY>8OZ3*_A"?HYK<7.*.F>U#HF/RPH,0P?4DL8VV3S?T1/9+U=WS#.V2.L\`<(!DNX?X,7 MC&,#PSCFK_8CNIY8S]?&>V_9%>$.H52IO4?5W#!8BW_$`NQ(BQ23^DK[W_>Z MLMD:$?H,.OO_Z]B"29[VDJ;4R2ILG`(8EHQRS&3<%HD%;$\Y$Y,'3+HPZ*1! M*LW1/%7Y`[&PRCFB2S_TEJ'<49JFJ:,]>9C:`(0OL@@LBRK3.A41-DVQ@_,2 M^"YIE8Z3-$T9G88F1>T9!VE@4$^IDT?4/(7V^^ADTLI/],_8U/]DVTY\/>W+ MEFSDE]0\CY/YUA,RS%CPK@]=CC!R(VLC7JL7\W MC8-V4N(94RTP?8[O,'W$C@-2N;%6R*=KC+I%?4%\22?0P+X%CT)>NS*',UD$ M.D7G@%+DC=&^`.R,_1T&MMB2DK^PK=M`2!9$R.+OBPP5!RN/[*B#LNT:A@:9 M!/"B!4&G`%.1=02;\=*$D?9MC$3?RT+G!1K,IXR\G)!HI^B)ZB\%6ED9F@)3 M04<+1@90`CR%1^8\9+B7.31-<\=`P$]2P-%HD-(CJ[!I"A3O$P[L+*)7!9ZF M6&5AE"38,6LBZ&$'QV7,J)52OP1M4]0NZ(R1+R+/L+6BS&'+7?#N9L8JJ9BX M:=8M(3)P=`/,,?6*29NFW'Y!=DRE8P1-4^0.?\#(\586+*XR)H-T8=,4",., M0_1`8";'(.0:T:/QU6RRIBHUQ1XX&\CUG.,1XPR:IJD3;/>=)K;[JK8MURS( M$@#':C0WX=YJ`!0'L05&Q$_*9YKTAL7T[6MVA-G%U>"B"#K&F8 M3@$4/]9PF)%2*N41-4VA(;.V,L1&;0W6"MXN,NFJ0?U1M$J11YT1N$?H\AOG M;&`YM"`6F.N1@]UW,_SDW3C,^AS+YE1ABP'KA?>_;>(R^["=>Q=/%AH(`[#E MZ5^+NXG-D.%HJ4N.)4F&C9&UL550%``/R M3T96=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`58!M1W,,4V4T$@``\OT` M`!4`&````````0```*2!><0``'9A`Q0````(`%6`;4`L``00E#@``!#D!``!02P$"'@,4````"`!5@&U'>BPW0ZJ%```4 M;`<`%0`8```````!````I(&L]P``=F%S;RTR,#$U,#DS,%]L86(N>&UL550% M``/R3T96=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`58!M1VI65>1G00`` M;&\$`!4`&````````0```*2!I7T!`'9A`Q0````(`%6`;4>\J9Z[W`T` M`)&-```1`!@```````$```"D@5N_`0!V87-O+3(P,34P.3,P+GAS9%54!0`# I\D]&5G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``""S0$````` ` end XML 23 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814

DEFERRED REVENUE (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Changes in deferred revenue [Roll Forward]

Deferred revenue at beginning of period $ 19,614 $ 17,712 $ 22,532 $ 18,019

Deferred revenue at end of period 19,750 18,236 19,750 18,236

Less: current portion 11,174 9,158 11,174 9,158 $ 9,882

Long-term deferred revenue at end of period 8,576 9,078 8,576 9,078 $ 12,650

Extended Service Contracts [Member]

Changes in deferred revenue [Roll Forward]

Additions: 160 244 465 791

Recognized as revenue: (209) (207) (654) (654)

In-Service and Training [Member]

Changes in deferred revenue [Roll Forward]

Additions: 5 13 10 28

Recognized as revenue: 0 (10) (10) (25)

Service Arrangements [Member]

Changes in deferred revenue [Roll Forward]

Additions: 10 28 25 58

Recognized as revenue: (15) (26) (58) (72)

Commission Revenues [Member]

Changes in deferred revenue [Roll Forward]

Additions: 3,516 3,457 6,847 8,840

Recognized as revenue: $ (3,331) $ (2,975) $ (9,407) $ (8,749)

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_MovementInDeferredRevenueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=vaso_ExtendedServiceContractsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=vaso_InServiceAndTrainingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=vaso_ServiceArrangementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=vaso_CommissionRevenuesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814

OTHER ASSETS (Tables)
9 Months Ended

Sep. 30, 2015

OTHER ASSETS [Abstract]

Schedule of Other Assets
Other assets consist of the following at September 30, 2015 and December 31, 2014:

(in thousands)

September 30, 2015

December 31, 2014

(unaudited)

Deferred commission expense - noncurrent
$ 1,845 $ 2,988
Trade receivables - noncurrent
1,026 2,171
Other
633 458
$ 3,504 $ 5,617

X

- References
No definition available.
+ Details

Name: us-gaap_OtherAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfOtherAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

GOODWILL AND OTHER INTANGIBLES (Tables)
9 Months Ended

Sep. 30, 2015

GOODWILL AND OTHER INTANGIBLES [Abstract]

Schedule of Changes in Carrying Amount of Goodwill
The components of the change in goodwill are as follows:

(in thousands)

Carrying Amount

Balance at December 31, 2014
$ 3,288
Foreign currency translation
(112 )
Acquisition of Netwolves
19,406
Balance at September 30, 2015 (unaudited)
$ 22,582

Schedule of Other Intangible Assets
The Company’s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:

(in thousands)

September 30, 2015

December 31, 2014

(unaudited)

Patents and Technology

Costs
$ 2,441 $ 2,489
Accumulated amortization
(742 ) (549 )
1,699 1,940

Customer lists

Costs
800 800
Accumulated amortization
(467 ) (381 )
333 419

Software

Costs
1,133 962
Accumulated amortization
(718 ) (495 )
415 467

$ 2,447 $ 2,826

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_ScheduleOfGoodwillTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R44.htm IDEA: XBRL DOCUMENT v3.3.0.814

DEBT (Details)
3 Months Ended 9 Months Ended

Jul. 31, 2015

USD ($)

May. 29, 2015

USD ($)

Director

Jun. 30, 2015

USD ($)

Sep. 30, 2015

USD ($)

Sep. 30, 2014

USD ($)

Dec. 31, 2014

USD ($)

Debt Instrument [Line Items]

Secured subordinated promissory note $ 5,007,000 $ 0

Aggregate amount used to acquire note 4,800,000 $ 0

Line of Credit [Member]

Debt Instrument [Line Items]

Line of credit facility, maximum borrowing capacity before replacement $ 2,000,000

Line of credit facility, maximum borrowing capacity amount $ 3,000,000

Amount of line of credit drawn $ 1,200,000

Line of Credit [Member] | LIBOR [Member]

Debt Instrument [Line Items]

Interest rate percentage 2.25%

Note [Member]

Debt Instrument [Line Items]

Secured subordinated promissory note $ 250,000 $ 3,800,000 $ 750,000

Debt instrument, interest rate 9.00%

Note [Member] | Six Directors [Member]

Debt Instrument [Line Items]

Aggregate amount used to acquire note $ 1,950,000

Number of directors | Director 6

Note [Member] | Director and Director's Relative [Member]

Debt Instrument [Line Items]

Aggregate amount used to acquire note $ 250,000

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromSecuredLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
No definition available.
+ Details

Name: vaso_LineOfCreditFacilityMaximumBorrowingCapacityBeforeReplacement

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of directors for the company.
+ References
No definition available.
+ Details

Name: vaso_NumberOfDirectors

Namespace Prefix: vaso_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=vaso_SecuredSubordinatedPromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vaso_SixDirectorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vaso_DirectorAndDirectorsSpouseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814

ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)
9 Months Ended

Sep. 30, 2015

ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]

Schedule of Accrued Liabilities
Accrued expenses and other liabilities consist of the following at September 30, 2015 and December 31, 2014:
(in thousands)

September 30, 2015

December 31, 2014

(unaudited)

Accrued compensation
$ 1,344 $ 2,917
Accrued expenses - other
1,292 1,098
Other liabilities
1,623 1,612
$ 4,259 $ 5,627

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814

DEFERRED REVENUE (Tables)
9 Months Ended

Sep. 30, 2015

DEFERRED REVENUE [Abstract]

Changes in Deferred Revenues
The changes in the Company’s deferred revenues are as follows:

(in thousands)
For the three months ended For the nine months ended

September 30, 2015

September 30, 2014

September 30, 2015

September 30, 2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Deferred revenue at beginning of period
$ 19,614 $ 17,712 $ 22,532 $ 18,019
Additions:

Deferred extended service contracts
160 244 465 791
Deferred in-service and training
5 13 10 28
Deferred service arrangements
10 28 25 58
Deferred commission revenues
3,516 3,457 6,847 8,840
Recognized as revenue:

Deferred extended service contracts
(209 ) (207 ) (654 ) (654 )
Deferred in-service and training
- (10 ) (10 ) (25 )
Deferred service arrangements
(15 ) (26 ) (58 ) (72 )
Deferred commission revenues
(3,331 ) (2,975 ) (9,407 ) (8,749 )
Deferred revenue at end of period
19,750 18,236 19,750 18,236
Less: current portion
11,174 9,158 11,174 9,158
Long-term deferred revenue at end of period
$ 8,576 $ 9,078 $ 8,576 $ 9,078

X

- Definition
Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueByArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
9 Months Ended

Sep. 30, 2015

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract]

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in connection with:

1)
The audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC on March 30, 2015.

2)
The audited consolidated financial statements of NetWolves, LLC and related notes thereto included in the Form 8-K/A filed with the SEC on August 12, 2015.  The operating results of NetWolves from May 29, 2015 to September 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and nine month periods ended September 30, 2015.

These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended December 31, 2014, and Note B of the Notes to Consolidated Financial Statements for the year ended December 31, 2014, included on Form 8-K/A, include a summary of the significant accounting policies used in the preparation of the condensed consolidated financial statements.

Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured.

Revenue and Expense Recognition for the Sales Representation Segment

The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured.  These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.  Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the condensed consolidated balance sheets.  Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded.  Commission expense is recognized when the corresponding commission revenue is recognized.

Variable Interest Entities

The Company follows the guidance of accounting for variable interest entities, which requires certain variable interest entities to be consolidated by the primary beneficiary of the entities.  Biox is a Variable Interest Entity (VIE).

Liabilities recognized as a result of consolidating this VIE do not represent additional claims on the Company’s general assets. The financial information of Biox, which is included in the accompanying condensed consolidated financial statements, is presented as follows:


(in thousands)

As of
September 30, 2015

As of
December 31, 2014

(unaudited)
Cash and cash equivalents
$ 119 $ 159
Total assets
$ 1,037 $ 1,047
Total liabilities
$ 1,040 $ 878


(in thousands)

Three months ended
September 30,

Nine months ended
September 30,

2015

2014

2015

2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Total net revenue
$ 358 $ 368 $ 1,183 $ 1,126

Net income (loss)
$ 24 $ (152 ) $ (199 ) $ (382 )

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814

BUSINESS COMBINATION (Tables)
9 Months Ended

Sep. 30, 2015

BUSINESS COMBINATION [Abstract]

Estimated Fair Values of the Net Assets Acquired
The following table summarizes the current allocation of the assets acquired and liabilities assumed based on their preliminary estimated fair values and current measurement period adjustments as follows:

(in thousands)

As initially reported

Measurement period adjustments

As adjusted

Cash and cash equivalents
$ 733 $ - $ 733
Accounts receivable and other current assets
1,638 (103 ) 1,535
Other assets
50 - 50
Property and equipment
2,359 - 2,359
Accounts payable and other current liabilities
(4,382 ) - (4,382 )
Long term debt
(1,701 ) - (1,701 )
Goodwill and other intangibles
19,303 103 19,406
Total
$ 18,000 $ - $ 18,000

Business Acquisition Proforma Information
The following unaudited supplemental pro forma information presents the financial results as if the acquisitions of Genwell and NetWolves had occurred January 1, 2013, and January 1, 2014, respectively.

(in thousands)
Three months ended Nine months ended

September 30, 2015

September 30, 2014

September 30, 2015

September 30, 2014

Revenue
$ 17,401 $ 15,101 $ 48,850 $ 44,532

Net income (loss)
1,353 (2 ) 1,584 (1,397 )

Basic earnings (loss) per share
$ 0.01 $ (0.00 ) $ 0.01 $ (0.01 )

Diluted earnings (loss) per share
$ 0.01 $ (0.00 ) $ 0.01 $ (0.01 )

X

- Definition
Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814

GOODWILL AND OTHER INTANGIBLES (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Dec. 31, 2014

Change in carrying amount of goodwill [Roll Forward]

Goodwill, Beginning Balance $ 3,288,000

Foreign currency translation (112,000)

Acquisition of Netwolves 19,406,000

Goodwill, Ending Balance $ 22,582,000 22,582,000

Other intangible assets, net [Abstract]

Intangible assets, net $ 2,447,000 $ 2,826,000

Goodwill 22,582,000 22,582,000 22,582,000 3,288,000

Amortization expense 167,000 $ 50,000 502,000 $ 146,000

Equipment Segment [Member]

Change in carrying amount of goodwill [Roll Forward]

Goodwill, Ending Balance 3,176,000 3,176,000

Other intangible assets, net [Abstract]

Goodwill 3,176,000 3,176,000 3,176,000

IT Segment [Member]

Change in carrying amount of goodwill [Roll Forward]

Goodwill, Ending Balance 19,406,000 19,406,000

Other intangible assets, net [Abstract]

Goodwill $ 19,406,000 $ 19,406,000 19,406,000

Patents and Technology [Member]

Other intangible assets, net [Abstract]

Costs 2,441,000 2,489,000

Accumulated amortization (742,000) (549,000)

Intangible assets, net 1,699,000 1,940,000

Patents [Member]

Other intangible assets, net [Abstract]

Useful life of intangible assets 10 years

Customer Lists [Member]

Other intangible assets, net [Abstract]

Costs 800,000 800,000

Accumulated amortization (467,000) (381,000)

Intangible assets, net 333,000 419,000

Useful life of intangible assets 7 years

Software [Member]

Other intangible assets, net [Abstract]

Costs 1,133,000 962,000

Accumulated amortization (718,000) (495,000)

Intangible assets, net $ 415,000 $ 467,000

Useful life of intangible assets 5 years

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillAcquiredDuringPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) from foreign currency translation adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillTranslationAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=vaso_EquipmentSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=vaso_InformationTechnologySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vaso_PatentsAndTechnologyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

CURRENT ASSETS

Cash and cash equivalents $ 1,928 $ 9,128

Short-term investments 109 111

Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $4,265 at September 30, 2015 and $4,571 at December 31, 2014 8,817 15,273

Receivables due from related parties 21 21

Inventories, net 1,950 1,898

Deferred commission expense 2,583 2,200

Prepaid expenses and other current assets 515 363

Total current assets 15,923 28,994

PROPERTY AND EQUIPMENT, net of accumulated depreciation of $2,745 at September 30, 2015 and $1,397 at December 31, 2014 2,928 266

GOODWILL 22,582 3,288

INTANGIBLES, net 2,447 2,826

OTHER ASSETS 3,504 5,617

Total Assets 47,384 40,991

CURRENT LIABILITIES

Accounts payable 3,604 462

Accrued commissions 1,746 2,247

Accrued expenses and other liabilities 4,259 5,627

Sales tax payable 612 247

Deferred revenue - current portion 11,174 9,882

Notes payable - current portion 1,654 163

Deferred tax liability, net 112 112

Notes payable due to related party 997 1,039

Total current liabilities 24,158 19,779

LONG-TERM LIABILITIES

Notes payable 5,007 0

Deferred revenue 8,576 12,650

Other long-term liabilities 539 811

Total long-term liabilities $ 14,122 $ 13,461

COMMITMENTS AND CONTINGENCIES (NOTE N)

STOCKHOLDERS' EQUITY

Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at September 30, 2015, and December 31, 2014 $ 0 $ 0

Common stock, $.001 par value; 250,000,000 shares authorized; 168,720,370 and 166,435,370 shares issued at September 30, 2015 and December 31, 2014, respectively; 158,412,283 and 156,127,283 shares outstanding at September 30, 2015 and December 31, 2014, respectively 169 166

Additional paid-in capital 62,222 61,924

Accumulated deficit (51,267) (52,433)

Accumulated other comprehensive income (20) 94

Treasury stock, at cost, 10,308,087 shares at September 30, 2015 and December 31, 2014 (2,000) (2,000)

Total stockholders' equity 9,104 7,751

Total liabilities and stockholders' equity $ 47,384 $ 40,991

X

- Definition
Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For an unclassified balance sheet, amount of receivables arising from transactions with related parties.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),3)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsReceivableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedSalesCommissionCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DeferredCostsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

+ Details

Name: us-gaap_DeferredTaxLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

+ Details

Name: us-gaap_SalesAndExciseTaxPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568447-111683

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of expenses as of balance sheet date incurred and payable, pertaining to costs that are statutory in nature, incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include, but not limited to, taxes, interest, rent and utilities. Also includes the aggregate carrying amount of liabilities not separately disclosed.
+ References
No definition available.
+ Details

Name: vaso_AccruedExpensesAndOtherLiabilitiesCurrent

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 33 R45.htm IDEA: XBRL DOCUMENT v3.3.0.814

BUSINESS COMBINATION (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

May. 29, 2015

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Jul. 31, 2015

Jun. 30, 2015

Business Acquisition [Line Items]

Business combination, cash paid $ 18,000,000 $ 0

Business combination, issue of notes $ 5,007,000 5,007,000 $ 0

Debt issuance costs 60,000

Revenue attributed to Netwolves, LLC 17,401,000 $ 7,643,000 35,698,000 22,599,000

Net income (loss) 1,230,000 (123,000) 1,166,000 (1,343,000) 1,128,000

Estimated fair values of the net assets acquired [Abstract]

Goodwill and other intangibles 22,582,000 22,582,000 $ 3,288,000

Note [Member]

Business Acquisition [Line Items]

Business combination, issue of notes $ 3,800,000 $ 250,000 $ 750,000

NetWolves, LLC [Member]

Business Acquisition [Line Items]

Consideration for acquisition 18,000,000

Business combination, cash paid 14,200,000 14,200,000

Acquisition-related legal costs 100,000

Debt issuance costs 60,000

Revenue attributed to Netwolves, LLC 11,470,000 8,707,000

Net income (loss) 377,000 227,000

Estimated fair values of the net assets acquired [Abstract]

Cash and cash equivalents 733,000

Accounts receivable and other current assets 1,535,000

Other assets 50,000

Property and equipment 2,359,000

Accounts payable and other current liabilities (4,382,000)

Long term debt (1,701,000)

Goodwill and other intangibles 19,406,000

Total 18,000,000

NetWolves, LLC [Member] | As initially reported [Member]

Estimated fair values of the net assets acquired [Abstract]

Cash and cash equivalents 733,000

Accounts receivable and other current assets 1,638,000

Other assets 50,000

Property and equipment 2,359,000

Accounts payable and other current liabilities (4,382,000)

Long term debt (1,701,000)

Goodwill and other intangibles 19,303,000

Total 18,000,000

NetWolves, LLC [Member] | Measurement period adjustments [Member]

Estimated fair values of the net assets acquired [Abstract]

Cash and cash equivalents 0

Accounts receivable and other current assets (103,000)

Other assets 0

Property and equipment 0

Accounts payable and other current liabilities 0

Long term debt 0

Goodwill and other intangibles 103,000

Total 0

NetWolves, LLC [Member] | Note [Member]

Business Acquisition [Line Items]

Business combination, issue of notes $ 3,800,000 3,800,000 3,800,000

Genwell and Netwolves [Member]

Business acquisition proforma information [Abstract]

Revenue 17,401,000 15,101,000 48,850,000 44,532,000

Net income (loss) $ 1,353,000 $ (2,000) $ 1,584,000 $ (1,397,000)

Basic earnings (loss) per share (in dollars per share) $ 0.01 $ 0 $ 0.01 $ (0.01)

Diluted earnings (loss) per share (in dollars per share) $ 0.01 $ 0 $ 0.01 $ (0.01)

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionsProFormaRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 25

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e1043-128460

+ Details

Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).
+ References
No definition available.
+ Details

Name: us-gaap_DebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle and also includes other assets, if longer, acquired at the acquisition date.
+ References
No definition available.
+ Details

Name: vaso_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesAndOtherCurrentAssets

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date and also other current liabilities
+ References
No definition available.
+ Details

Name: vaso_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=vaso_SecuredSubordinatedPromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=vaso_NetWolvesLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=vaso_GenwellAndNetwolvesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Cash flows from operating activities

Net income (loss) $ 1,166 $ (1,343)

Adjustments to reconcile net income (loss) to net cash provided by operating activities

Depreciation and amortization 783 290

Loss on disposal of fixed assets 0 39

Provision for doubtful accounts and commission adjustments 109 (1)

Share-based compensation and arrangements 301 320

Changes in operating assets and liabilities:

Accounts and other receivables 7,775 6,396

Inventories, net (221) (332)

Deferred commission expense (382) (75)

Other current assets (53) (123)

Other assets 2,274 (1,639)

Accounts payable (5) (72)

Accrued commissions (548) (55)

Accrued expenses and other liabilities (2,129) (1,203)

Sales tax payable (68) (48)

Deferred revenue (2,782) 218

Notes payable due to related party (42) 0

Other long-term liabilities (299) 214

Net cash provided by operating activities 5,879 2,586

Cash flows from investing activities

Purchases of equipment and software (619) (227)

Purchases of short-term investments (38) (40)

Redemption of short-term investments 40 40

Acquisition of Genwell 0 (1,136)

Cash acquired through purchase of Genwell 0 113

Acquisition of Netwolves (18,000) 0

Cash acquired through purchase of Netwolves 733 0

Investment in VSK (100) 0

Net cash used in investing activities (17,984) (1,250)

Cash flows from financing activities

Net borrowings on revolving line of credit 136 0

Repurchase of common stock 0 (244)

Repayment of notes payable (83) 0

Proceeds from note payable 4,800 0

Net cash provided by (used in) financing activities 4,853 (244)

Effect of exchange rate differences on cash and cash equivalents 52 1

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (7,200) 1,093

Cash and cash equivalents - beginning of period 9,128 7,961

Cash and cash equivalents - end of period 1,928 9,054

SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION

Interest paid 66 0

Income taxes paid 130 48

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES

Inventories transferred to property and equipment, attributable to operating leases, net 138 5

Note issued for acquisition $ 0 $ 1,017

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_CashAcquiredFromAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2443-110228

+ Details

Name: us-gaap_GainLossOnDispositionOfAssets1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount owed by the reporting entry in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInNotesPayableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change in carrying value during the period of obligations incurred through and payable within one year (or in the operating cycle if longer) for employer-related costs not otherwise specified in the taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The fair value of notes issued in noncash investing and financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

+ Details

Name: us-gaap_NotesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireInterestInJointVenture

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ProceedsFromLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the acquisition of Genwell during the period (for example, cash that was held by the acquired business).
+ References
No definition available.
+ Details

Name: vaso_CashAcquiredFromAcquisitionOfGenwell

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of inventories transferred to property and equipment, attributable to operating leases in noncash financing and investing activities.
+ References
No definition available.
+ Details

Name: vaso_InventoriesTransferredToPropertyAndEquipmentAttributableToOperatingLeasesNet

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of Genwell during the period. The cash portion only of the acquisition price.
+ References
No definition available.
+ Details

Name: vaso_PaymentsToAcquireGenwellGross

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts and commission adjustments for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).
+ References
No definition available.
+ Details

Name: vaso_ProvisionForDoubtfulAccountsAndCommissionAdjustments

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based Employee and Non Employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
No definition available.
+ Details

Name: vaso_ShareBasedCompensationAndArrangements

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 35 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814

SEGMENT REPORTING AND CONCENTRATIONS (Details)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

USD ($)

Sep. 30, 2014

USD ($)

Sep. 30, 2015

USD ($)

Segment

Sep. 30, 2014

USD ($)

Dec. 31, 2014

USD ($)

SEGMENT REPORTING AND CONCENTRATIONS [Abstract]

Number of segments | Segment 3

Segment Reporting Information [Line Items]

Revenues from external customers $ 17,401 $ 7,643 $ 35,698 $ 22,599

Operating income (loss) 1,337 (149) 1,257 (1,443)

Total assets 47,384 32,319 47,384 32,319 $ 40,991

Accounts and other receivables, net 8,817 7,167 8,817 7,167 15,273

Deferred commission expense 2,583 2,388 2,583 2,388

Other assets 3,504 7,585 3,504 7,585 $ 5,617

Corporate [Member]

Segment Reporting Information [Line Items]

Revenues from external customers 0 0 0 0

Operating income (loss) (480) (385) (1,408) (1,267)

Total assets 2,041 9,067 2,041 9,067

Accounts and other receivables, net 0 0 0 0

Deferred commission expense 0 0 0 0

Other assets 110 13 110 13

Sales Representation Segment [Member] | Operating Segments [Member]

Segment Reporting Information [Line Items]

Revenues from external customers 7,584 6,409 21,010 19,335

Operating income (loss) 2,586 723 5,466 2,267

Total assets 11,408 13,341 11,408 13,341

Accounts and other receivables, net 5,663 6,376 5,663 6,376

Deferred commission expense 2,533 2,388 2,533 2,388

Other assets 2,720 4,402 2,720 4,402

IT Segment [Member] | Operating Segments [Member]

Segment Reporting Information [Line Items]

Revenues from external customers 8,800 0 11,611 0

Operating income (loss) (187) (82) (908) (82)

Total assets 24,642 2 24,642 2

Accounts and other receivables, net 2,253 0 2,253 0

Deferred commission expense 50 0 50 0

Other assets 51 0 51 0

Equipment Segment [Member] | Operating Segments [Member]

Segment Reporting Information [Line Items]

Revenues from external customers 1,017 1,234 3,077 3,264

Operating income (loss) (582) (405) (1,893) (2,361)

Total assets 9,293 9,909 9,293 9,909

Accounts and other receivables, net 901 791 901 791

Deferred commission expense 0 0 0 0

Other assets $ 623 $ 3,170 $ 623 $ 3,170

GE Healthcare [Member] | Sales Revenue, Net [Member]

Revenue, Major Customer [Line Items]

Percentage of revenue 44.00% 84.00% 59.00% 86.00%

X

- Definition
Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount of advanced commission payments.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredSalesCommission

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EntityWideRevenueMajorCustomerLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=vaso_SalesRepresentationSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=vaso_InformationTechnologySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=vaso_EquipmentSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=vaso_GeHealthcareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Policies)
9 Months Ended

Sep. 30, 2015

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract]

Basis of Presentation and Use of Estimates
Basis of Presentation and Use of Estimates

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in connection with:

1)
The audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC on March 30, 2015.

2)
The audited consolidated financial statements of NetWolves, LLC and related notes thereto included in the Form 8-K/A filed with the SEC on August 12, 2015.  The operating results of NetWolves from May 29, 2015 to September 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and nine month periods ended September 30, 2015.

These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

Significant Accounting Policies
Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended December 31, 2014, and Note B of the Notes to Consolidated Financial Statements for the year ended December 31, 2014, included on Form 8-K/A, include a summary of the significant accounting policies used in the preparation of the condensed consolidated financial statements.

Revenue Recognition
Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured.

Revenue and Expense Recognition for the Sales Representation Segment
Revenue and Expense Recognition for the Sales Representation Segment

The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured.  These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.  Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the condensed consolidated balance sheets.  Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded.  Commission expense is recognized when the corresponding commission revenue is recognized.

Variable Interest Entity
Variable Interest Entities

The Company follows the guidance of accounting for variable interest entities, which requires certain variable interest entities to be consolidated by the primary beneficiary of the entities.  Biox is a Variable Interest Entity (VIE).

Liabilities recognized as a result of consolidating this VIE do not represent additional claims on the Company’s general assets. The financial information of Biox, which is included in the accompanying condensed consolidated financial statements, is presented as follows:


(in thousands)

As of
September 30, 2015

As of
December 31, 2014

(unaudited)
Cash and cash equivalents
$ 119 $ 159
Total assets
$ 1,037 $ 1,047
Total liabilities
$ 1,040 $ 878


(in thousands)

Three months ended
September 30,

Nine months ended
September 30,

2015

2014

2015

2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Total net revenue
$ 358 $ 368 $ 1,183 $ 1,126

Net income (loss)
$ 24 $ (152 ) $ (199 ) $ (382 )

Reclassifications
Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 5A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6759159-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 4

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=52262685&loc=d3e5728-111685

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 2AA

-Subparagraph a

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6759068-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 2A

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6225816-111685

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_ConsolidationVariableInterestEntityPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition for commission revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 20

-Section 25

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=51667699&loc=d3e48393-111629

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

-Paragraph a

-Subparagraph Question 2

-Subsection 4

+ Details

Name: us-gaap_RevenueRecognitionServicesCommissions

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). and for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
No definition available.
+ Details

Name: vaso_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock

Namespace Prefix: vaso_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for all significant accounting policies of the reporting entity.
+ References
No definition available.
+ Details

Name: vaso_SignificantAccountingPoliciesPolicyTextBlock

Namespace Prefix: vaso_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814

SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Sep. 30, 2014

Concentration Risk [Line Items]

Accounts and other receivables $ 8,817 $ 15,273 $ 7,167

Accounts and Other Receivables [Member] | Credit Concentration Risk [Member] | GE Healthcare [Member]

Concentration Risk [Line Items]

Accounts and other receivables $ 5,500 $ 14,200

Percentage of accounts and other receivables 62.00% 93.00%

X

- Definition
Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=vaso_GeHealthcareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

SEGMENT REPORTING AND CONCENTRATIONS (Tables)
9 Months Ended

Sep. 30, 2015

SEGMENT REPORTING AND CONCENTRATIONS [Abstract]

Summary Financial Information for Segments
Summary financial information for the segments is set forth below:


(in thousands)
As of or for the three months ended September 30, 2015 (unaudited)

Sales Representation Segment

IT Segment

Equipment Segment

Corporate

Consolidated

Revenues from external customers
$ 7,584 $ 8,800 $ 1,017 $ - $ 17,401
Operating income (loss)
$ 2,586 $ (187 ) $ (582 ) $ (480 ) $ 1,337
Total assets
$ 11,408 $ 24,642 $ 9,293 $ 2,041 $ 47,384
Accounts and other receivables, net
$ 5,663 $ 2,253 $ 901 $ - $ 8,817
Deferred commission expense
$ 2,533 $ 50 $ - $ - $ 2,583
Other assets
$ 2,720 $ 51 $ 623 $ 110 $ 3,504

As of or for the three months ended September 30, 2014 (unaudited)

Sales Representation Segment

IT Segment

Equipment Segment

Corporate

Consolidated

Revenues from external customers
$ 6,409 $ - $ 1,234 $ - $ 7,643
Operating income (loss)
$ 723 $ (82 ) $ (405 ) $ (385 ) $ (149 )
Total assets
$ 13,341 $ 2 $ 9,909 $ 9,067 $ 32,319
Accounts and other receivables, net
$ 6,376 $ - $ 791 $ - $ 7,167
Deferred commission expense
$ 2,388 $ - $ - $ - $ 2,388
Other assets
$ 4,402 $ - $ 3,170 $ 13 $ 7,585

As of or for the nine months ended September 30, 2015 (unaudited)

Sales Representation Segment

IT Segment

Equipment Segment

Corporate

Consolidated

Revenues from external customers
$ 21,010 $ 11,611 $ 3,077 $ - $ 35,698
Operating income (loss)
$ 5,466 $ (908 ) $ (1,893 ) $ (1,408 ) $ 1,257
Total assets
$ 11,408 $ 24,642 $ 9,293 $ 2,041 $ 47,384
Accounts and other receivables, net
$ 5,663 $ 2,253 $ 901 $ - $ 8,817
Deferred commission expense
$ 2,533 $ 50 $ - $ - $ 2,583
Other assets
$ 2,720 $ 51 $ 623 $ 110 $ 3,504

As of or for the nine months ended September 30, 2014 (unaudited)

Sales Representation Segment

IT Segment

Equipment Segment

Corporate

Consolidated

Revenues from external customers
$ 19,335 $ - $ 3,264 $ - $ 22,599
Operating income (loss)
$ 2,267 $ (82 ) $ (2,361 ) $ (1,267 ) $ (1,443 )
Total assets
$ 13,341 $ 2 $ 9,909 $ 9,067 $ 32,319
Accounts and other receivables, net
$ 6,376 $ - $ 791 $ - $ 7,167
Deferred commission expense
$ 2,388 $ - $ - $ - $ 2,388
Other assets
$ 4,402 $ - $ 3,170 $ 13 $ 7,585

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8736-108599

+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 40 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

ORGANIZATION AND PLAN OF OPERATIONS
9 Months Ended

Sep. 30, 2015

ORGANIZATION AND PLAN OF OPERATIONS [Abstract]

ORGANIZATION AND PLAN OF OPERATIONS
NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987.  Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries.  Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP®) systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets. Beginning in July 2010 the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. (Vaso Diagnostics), began its sales representation business via its agreement (the “GEHC Agreement”) with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia.   In June 2012, the GEHC Agreement was amended and extended through June 30, 2015 and again, in December 2014, the GEHC Agreement was further amended and extended through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns or controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd. (Biox), respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and started to operate through three wholly-owned subsidiaries.  Vaso Diagnostics continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

In April 2014, the Company entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (PSK) of Chongqing, China, the leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited (VSK), for the global marketing, sale and advancement of ECP therapy technology.  The Company owns 49.9% of the joint venture, which began operations in January 2015.

In June 2014, the Company entered into a Value Added Reseller Agreement (VAR Agreement) with GEHC to become a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support.  This multiyear VAR Agreement focuses primarily on existing customer segments currently served by Vaso Diagnostics on behalf of GEHC.  A new wholly owned subsidiary, VasoHealthcare IT Corp., was formed to conduct the healthcare IT business.

In August 2014, the Company, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone), acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China.  Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCareTM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system.

In May 2015, the Company entered into an agreement for, and completed its purchase of, all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC  (collectively, “NetWolves”). The purchase of NetWolves was accomplished pursuant to an Asset Purchase Agreement.  As a result, the Company effectively purchased all rights, titles and ownership of all assets held by NetWolves.  NetWolves designs and delivers efficient and cost-effective multi-network and multi-technology solutions as a managed network provider, and provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution.  The Company believes there are significant operational synergies between NetWolves’ capabilities and VasoHealthcare IT’s requirements under its VAR Agreement with GEHC, as well as the opportunity to expand NetWolves’ existing services to the healthcare IT market.

We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment.  Vaso Diagnostics activities are included under our Sales Representation segment.  VasoHealthcare IT and NetWolves operations report under the IT segment.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6003-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2A

-URI http://asc.fasb.org/extlink&oid=51801978&loc=SL51803626-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

CURRENT ASSETS

Accounts and other receivables, allowance for doubtful accounts and commission adjustments $ 4,265 $ 4,571

PROPERTY AND EQUIPMENT, accumulated depreciation $ 2,745 $ 1,397

STOCKHOLDERS' EQUITY

Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01

Preferred stock, shares authorized (in shares) 1,000,000 1,000,000

Preferred stock, shares issued (in shares) 0 0

Preferred stock, shares outstanding (in shares) 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized (in shares) 250,000,000 250,000,000

Common stock, shares issued (in shares) 168,720,370 166,435,370

Common stock, shares outstanding (in shares) 158,412,283 156,127,283

Treasury stock, at cost (in shares) 10,308,087 10,308,087

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 42 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

DEBT
9 Months Ended

Sep. 30, 2015

DEBT [Abstract]

DEBT
NOTE K – DEBT

On May 29, 2015, the Company entered into a Note Purchase Agreement with MedTechnology Investments, LLC (“MedTech”) pursuant to which it issued MedTech a secured subordinated promissory note (“Note”) for $3,800,000 for the purchase of NetWolves. MedTech was formed to acquire the Note, and $1,950,000 of the aggregate funds used to acquire the Note was provided by six of our directors.  In June 2015, a second Note for $750,000 was issued to MedTech for working capital purposes, $250,000 of which was provided by a director and a director’s relative.  In July 2015, an additional $250,000 was borrowed under the Note Purchase Agreement.

The Notes bear interest at an annual rate of 9%, mature on May 29, 2019, may be prepaid without penalty, and are subordinated to any current or future Senior Debt as defined in the Subordinated Security Agreement. The Subordinated Security Agreement secures payment and performance of the Company’s obligations under the Notes and as a result, MedTech was granted a subordinated security interest in the Company’s assets.

In July 2015, NetWolves' lending institution extended its $2.0 million line of credit and increased the maximum borrowings to $3.0 million.  Advances under the line, which expires on August 26, 2016, bear interest at a rate of LIBOR plus 2.25% and are secured by substantially all of the assets of NetWolves Network Services, LLC and guaranteed by Vasomedical, Inc.  At September 30, 2015, the Company had drawn approximately $1.2 million against the line.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2015

Nov. 08, 2015

Document and Entity Information [Abstract]

Entity Registrant Name VASOMEDICAL, INC

Entity Central Index Key 0000839087

Current Fiscal Year End Date --12-31

Entity Well-known Seasoned Issuer No

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 158,412,283

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2015

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: vaso_DocumentAndEntityInformationAbstract

Namespace Prefix: vaso_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

BUSINESS COMBINATION
9 Months Ended

Sep. 30, 2015

BUSINESS COMBINATION [Abstract]

BUSINESS COMBINATION
NOTE L – BUSINESS COMBINATION

On May 29, 2015, the Company entered into an agreement for, and completed its purchase of, all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC  (collectively, “NetWolves”) for $18,000,000 (the “Purchase Price”). The purchase of NetWolves was accomplished pursuant to an Asset Purchase Agreement (the "Purchase Agreement").  As a result, the Company effectively purchased all rights, titles and ownership of all assets held by NetWolves.   The Purchase Price was paid using $14,200,000 in cash on hand and $3,800,000 raised through the issuance of the Note to MedTech (see Note K).  The Company believes there are significant operational synergies between NetWolves’ capabilities and VasoHealthcare IT’s requirements under its VAR contract with GEHC, as well as the opportunity to expand NetWolves’ existing services to the healthcare IT market.

The operating results of NetWolves from May 29, 2015 to September 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and nine month periods ended September 30, 2015.  The accompanying condensed consolidated balance sheet at September 30, 2015 reflects the acquisition of NetWolves effective May 29, 2015.

In accordance with Accounting Standards Codification 805, Business Combinations, the total purchase consideration is allocated to the net tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at May 29, 2015 (the acquisition date).  The purchase price was initially allocated based on the information then available, and certain amounts were adjusted after revisions of certain preliminary estimates.  The Company expects additional measurement period adjustments will be recorded after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.  The following table summarizes the current allocation of the assets acquired and liabilities assumed based on their preliminary estimated fair values and current measurement period adjustments as follows:

(in thousands)

As initially reported

Measurement period adjustments

As adjusted

Cash and cash equivalents
$ 733 $ - $ 733
Accounts receivable and other current assets
1,638 (103 ) 1,535
Other assets
50 - 50
Property and equipment
2,359 - 2,359
Accounts payable and other current liabilities
(4,382 ) - (4,382 )
Long term debt
(1,701 ) - (1,701 )
Goodwill and other intangibles
19,303 103 19,406
Total
$ 18,000 $ - $ 18,000

During the nine months ended September 30, 2015, the Company expensed $100,000 of acquisition-related legal costs and incurred $60,000 in debt issue costs.  The legal costs are included in the line item Selling, General & Administrative costs in the accompanying condensed consolidated statements of operations and comprehensive income (loss).  The debt issue costs are recorded as a reduction to long term notes payable in the accompanying condensed consolidated balance sheet at September 30, 2015.  The amounts of revenue and net income of NetWolves included in the Company’s condensed consolidated statements of operations and comprehensive income (loss) was $8,707,000 and $227,000, respectively, for the three months ended September 30, 2015, and $11,470,000 and $377,000, respectively, for the nine months ended September 30, 2015.  The goodwill is expected to be deductible for tax purposes.

The following unaudited supplemental pro forma information presents the financial results as if the acquisitions of Genwell and NetWolves had occurred January 1, 2013, and January 1, 2014, respectively.

(in thousands)
Three months ended Nine months ended

September 30, 2015

September 30, 2014

September 30, 2015

September 30, 2014

Revenue
$ 17,401 $ 15,101 $ 48,850 $ 44,532

Net income (loss)
1,353 (2 ) 1,584 (1,397 )

Basic earnings (loss) per share
$ 0.01 $ (0.00 ) $ 0.01 $ (0.01 )

Diluted earnings (loss) per share
$ 0.01 $ (0.00 ) $ 0.01 $ (0.01 )

X

- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Revenues

Professional sales services $ 7,584 $ 6,409 $ 21,010 $ 19,335

Managed IT systems and services 8,800 0 11,611 0

Equipment sales and services 1,017 1,234 3,077 3,264

Total revenues 17,401 7,643 35,698 22,599

Cost of revenues

Cost of professional sales services 1,701 1,828 4,748 5,282

Cost of managed IT systems and services 5,308 0 6,921 0

Cost of equipment sales and services 542 440 1,283 1,294

Total cost of revenues 7,551 2,268 12,952 6,576

Gross profit 9,850 5,375 22,746 16,023

Operating expenses

Selling, general and administrative 8,355 5,344 21,059 16,867

Research and development 158 180 430 599

Total operating expenses 8,513 5,524 21,489 17,466

Operating income (loss) 1,337 (149) 1,257 (1,443)

Other income (expense)

Interest and financing costs (148) 0 (265) (1)

Interest and other income, net 79 52 225 151

Total other income (expense), net (69) 52 (40) 150

Income (loss) before income taxes 1,268 (97) 1,217 (1,293)

Income tax expense (38) (26) (51) (50)

Net income (loss) 1,230 (123) 1,166 (1,343)

Other comprehensive income

Foreign currency translation (loss) gain (145) 2 (114) (28)

Comprehensive income (loss) $ 1,085 $ (121) $ 1,052 $ (1,371)

Income (loss) per common share

basic (in dollars per share) $ 0.01 $ 0 $ 0.01 $ (0.01)

diluted (in dollars per share) $ 0.01 $ 0 $ 0.01 $ (0.01)

Weighted average common shares outstanding

basic (in shares) 157,288 155,186 156,502 155,319

diluted (in shares) 157,782 155,186 156,868 155,319

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a),(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostOfGoodsAndServicesSoldAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents interest incurred for borrowed money which was used to produce goods or render services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_FinancingInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51673353&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).
+ References
No definition available.
+ Details

Name: us-gaap_InterestAndOtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SalesRevenueNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51677171&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Costs incurred in providing technology services. The services may include training, installation, engineering or consulting. Consulting services often include implementation support, software design or development, or the customization or modification of the licensed software.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 605

-Section 25

-Paragraph 76

-URI http://asc.fasb.org/extlink&oid=51674016&loc=d3e132428-111767

+ Details

Name: us-gaap_TechnologyServicesCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue from providing technology services. The services may include training, installation, engineering or consulting. Consulting services often include implementation support, software design or development, or the customization or modification of the licensed software.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 605

-Section 25

-Paragraph 76

-URI http://asc.fasb.org/extlink&oid=51674016&loc=d3e132428-111767

+ Details

Name: us-gaap_TechnologyServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue during the period from commissions earned from the sales representative agreement with GE Healthcare.
+ References
No definition available.
+ Details

Name: vaso_CommissionsRevenueNet

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total costs related to commissions earned under the sales representative agreement with GE Healthcare.
+ References
No definition available.
+ Details

Name: vaso_CostOfCommissionsRevenue

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 46 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

INVENTORIES, NET
9 Months Ended

Sep. 30, 2015

INVENTORIES, NET [Abstract]

INVENTORIES, NET
NOTE F – INVENTORIES, NET

Inventories, net of reserves, consist of the following:

(in thousands)

September 30, 2015

December 31, 2014

(unaudited)

Raw materials
$ 475 $ 583
Work in process
626 679
Finished goods
849 636
$ 1,950 $ 1,898

At September 30, 2015 and December 31, 2014, the Company maintained reserves for excess and obsolete inventory of $673,000 and $815,000, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

ACCOUNTS AND OTHER RECEIVABLES, NET
9 Months Ended

Sep. 30, 2015

ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]

ACCOUNTS AND OTHER RECEIVABLES, NET
NOTE E – ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company’s accounts and other receivables as of September 30, 2015 and December 31, 2014:

(in thousands)

September 30, 2015

December 31, 2014

(unaudited)

Trade receivables
$ 12,877 $ 19,734
Due from employees
205 110
Allowance for doubtful accounts and

commission adjustments
(4,265 ) (4,571 )
Accounts and other receivables, net
$ 8,817 $ 15,273

Trade receivables include amounts due for shipped products and services rendered. Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement. Due from employees is primarily commission advances made to sales personnel.

X

- Definition
The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5066-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5162-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 9

+ Details

Name: us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Tables)
9 Months Ended

Sep. 30, 2015

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract]

Schedule of Variable Interest Entities
The financial information of Biox, which is included in the accompanying condensed consolidated financial statements, is presented as follows:


(in thousands)

As of
September 30, 2015

As of
December 31, 2014

(unaudited)
Cash and cash equivalents
$ 119 $ 159
Total assets
$ 1,037 $ 1,047
Total liabilities
$ 1,040 $ 878


(in thousands)

Three months ended
September 30,

Nine months ended
September 30,

2015

2014

2015

2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Total net revenue
$ 358 $ 368 $ 1,183 $ 1,126

Net income (loss)
$ 24 $ (152 ) $ (199 ) $ (382 )

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=52262685&loc=d3e5747-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6228884-111685

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=52262685&loc=d3e5728-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Variable Interest Entity

-URI http://asc.fasb.org/extlink&oid=6528138

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 5A

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6759159-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=52262685&loc=d3e5710-111685

+ Details

Name: us-gaap_ScheduleOfVariableInterestEntitiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

RELATED-PARTY TRANSACTIONS
9 Months Ended

Sep. 30, 2015

RELATED-PARTY TRANSACTIONS [Abstract]

RELATED-PARTY TRANSACTIONS
NOTE M – RELATED-PARTY TRANSACTIONS

One of the Company’s directors, Peter Castle, was the Chief Executive Officer and President of NetWolves, LLC.  Another of the Company’s directors, David Lieberman, was a director of NetWolves Network Services, LLC. Mr. Castle and Mr. Lieberman owned of record approximately 10.4% and 5.7%, respectively of the membership interests of NetWolves LLC.  Mr. Lieberman may also be deemed to have owned beneficially up to an additional 13.5% of such membership interests.  The Company’s board of directors negotiated the Purchase Price on an arm’s length basis, and both Mr. Castle and Mr. Lieberman abstained from the vote approving the Purchase Agreement.

The Company obtained an opinion regarding the fairness of the Purchase Price for the NetWolves entities from a reputable, independent third-party investment banking firm.  $14,200,000 of the Purchase Price was paid for by cash on hand, and the remaining $3,800,000 was raised from the sale of a Subordinated Secured Note sold to MedTech.  Of the $4,800,000 borrowed from MedTech at September 30, 2015, $2,200,000 was provided by six of our directors or members of their families.

David Lieberman, the Vice Chairman of the Company’s Board of Directors, is a practicing attorney in the State of New York and a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which performs certain legal services for the Company.  Fees of approximately $85,000 and $213,000 were billed by the firm for the three and nine month periods ended September 30, 2015, respectively, at which date no amounts were outstanding. Fees of approximately $60,000 and $180,000 were billed by the firm for the three and nine month periods ended September 30, 2014, respectively, at which date no amounts were outstanding.

In January 2015, operations began under the VSK joint venture.  The Company accounts for its investment in VSK using the equity method.  At September 30, 2015, the Company had contributed $100,000 to VSK, and $1,000 was due from VSK for equipment the Company sold to it. VSK earned approximately $97,000 and $143,000 for the three and nine months ended September 30, 2015, respectively.  Under the terms of the agreement, the Company’s accrues no interest in VSK’s income in the years ending December 31, 2015, 2016 and 2017 unless certain performance targets are achieved.  For the nine months ended September 30, 2015 such targets had not been achieved.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

ACCRUED EXPENSES AND OTHER LIABILITIES
9 Months Ended

Sep. 30, 2015

ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]

ACCRUED EXPENSES AND OTHER LIABILITIES
NOTE I – ACCRUED EXPENSES AND OTHER LIABILITIES

Accrued expenses and other liabilities consist of the following at September 30, 2015 and December 31, 2014:
(in thousands)

September 30, 2015

December 31, 2014

(unaudited)

Accrued compensation
$ 1,344 $ 2,917
Accrued expenses - other
1,292 1,098
Other liabilities
1,623 1,612
$ 4,259 $ 5,627

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

GOODWILL AND OTHER INTANGIBLES
9 Months Ended

Sep. 30, 2015

GOODWILL AND OTHER INTANGIBLES [Abstract]

GOODWILL AND OTHER INTANGIBLES
NOTE G – GOODWILL AND OTHER INTANGIBLES

Goodwill aggregating $22,582,000 and $3,288,000 was recorded on the Company’s condensed consolidated balance sheets at September 30, 2015 and December 31, 2014, respectively, of which $19,406,000, allocated to the IT segment, resulted from the acquisition of NetWolves in May 2015.  The remaining $3,176,000 of goodwill is allocated to the Company’s Equipment segment.  The components of the change in goodwill are as follows:

(in thousands)

Carrying Amount

Balance at December 31, 2014
$ 3,288
Foreign currency translation
(112 )
Acquisition of Netwolves
19,406
Balance at September 30, 2015 (unaudited)
$ 22,582

The Company’s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:

(in thousands)

September 30, 2015

December 31, 2014

(unaudited)

Patents and Technology

Costs
$ 2,441 $ 2,489
Accumulated amortization
(742 ) (549 )
1,699 1,940

Customer lists

Costs
800 800
Accumulated amortization
(467 ) (381 )
333 419

Software

Costs
1,133 962
Accumulated amortization
(718 ) (495 )
415 467

$ 2,447 $ 2,826

Patents, customer lists, and software are included in other assets in the accompanying condensed consolidated balance sheets and are amortized on a straight line basis over their estimated useful lives of ten, seven, and five years, respectively.  Amortization expense amounted to $167,000 and $502,000 for the three and nine months ended September 30, 2015, respectively, and $50,000 and $146,000 for the three and nine months ended September 30, 2014, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

OTHER ASSETS
9 Months Ended

Sep. 30, 2015

OTHER ASSETS [Abstract]

OTHER ASSETS
NOTE H – OTHER ASSETS

Other assets consist of the following at September 30, 2015 and December 31, 2014:

(in thousands)

September 30, 2015

December 31, 2014

(unaudited)

Deferred commission expense - noncurrent
$ 1,845 $ 2,988
Trade receivables - noncurrent
1,026 2,171
Other
633 458
$ 3,504 $ 5,617

X

- References
No definition available.
+ Details

Name: us-gaap_OtherAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
No definition available.
+ Details

Name: us-gaap_OtherAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

DEFERRED REVENUE
9 Months Ended

Sep. 30, 2015

DEFERRED REVENUE [Abstract]

DEFERRED REVENUE
NOTE J – DEFERRED REVENUE

The changes in the Company’s deferred revenues are as follows:

(in thousands)
For the three months ended For the nine months ended

September 30, 2015

September 30, 2014

September 30, 2015

September 30, 2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Deferred revenue at beginning of period
$ 19,614 $ 17,712 $ 22,532 $ 18,019
Additions:

Deferred extended service contracts
160 244 465 791
Deferred in-service and training
5 13 10 28
Deferred service arrangements
10 28 25 58
Deferred commission revenues
3,516 3,457 6,847 8,840
Recognized as revenue:

Deferred extended service contracts
(209 ) (207 ) (654 ) (654 )
Deferred in-service and training
- (10 ) (10 ) (25 )
Deferred service arrangements
(15 ) (26 ) (58 ) (72 )
Deferred commission revenues
(3,331 ) (2,975 ) (9,407 ) (8,749 )
Deferred revenue at end of period
19,750 18,236 19,750 18,236
Less: current portion
11,174 9,158 11,174 9,158
Long-term deferred revenue at end of period
$ 8,576 $ 9,078 $ 8,576 $ 9,078

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.3(b).Q1(c),(b).Q2,(c).Q3)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Dec. 31, 2013

Variable Interest Entity [Line Items]

Cash and cash equivalents $ 1,928 $ 9,054 $ 1,928 $ 9,054 $ 9,128 $ 7,961

Total net revenue 17,401 7,643 35,698 22,599

Net income (loss) 1,230 (123) 1,166 (1,343) 1,128

Biox [Member]

Variable Interest Entity [Line Items]

Cash and cash equivalents 119 119 159

Total assets 1,037 1,037 1,047

Total liabilities 1,040 1,040 $ 878

Total net revenue 358 368 1,183 1,126

Net income (loss) $ 24 $ (152) $ (199) $ (382)

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The carrying amount of the consolidated Variable Interest Entity's assets included in the reporting entity's statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (bb)

-URI http://asc.fasb.org/extlink&oid=52262685&loc=d3e5710-111685

+ Details

Name: us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amount of the consolidated Variable Interest Entity's liabilities included in the reporting entity's statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (bb)

-URI http://asc.fasb.org/extlink&oid=52262685&loc=d3e5710-111685

+ Details

Name: us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_VariableInterestEntityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
9 Months Ended

Sep. 30, 2015

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract]

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers”, a comprehensive new revenue recognition standard which will supersede previous existing revenue recognition guidance. The standard creates a five-step model for revenue recognition that requires companies to exercise judgment when considering contract terms and relevant facts and circumstances. The five-step model includes (1) identifying the contract, (2) identifying the separate performance obligations in the contract, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations and (5) recognizing revenue when each performance obligation has been satisfied. The standard also requires expanded disclosures surrounding revenue recognition. The standard is effective for fiscal periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption. In August 2015, FASB issued ASU 2015-14, “Revenue from Contracts with Customers – Deferral of the Effective Date” (Topic 606). The amendments in this ASU defer the effective date of ASU 2014-09, “Revenue from Contracts with Customers,” for all entities by one year. Public business entities should apply the guidance in ASU 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company is currently evaluating the impact of the adoption of this standard on its Consolidated Financial Statements.

In April 2015, the FASB issued ASU 2015-03 “Simplifying the Presentation of Debt Issuance Costs”, which changes the presentation of debt issuance costs in financial statements. An entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense.  The standard is effective for fiscal periods beginning after December 31, 2015 and allows for early adoption.  The Company has early adopted this statement for the nine months ended September 30, 2015, resulting in $60,000 in debt issue costs initially deducted from the MedTech debt and $5,000 amortized to interest expense.

In September 2015, the FASB issued ASU 2015-16 “Simplifying the Accounting for Measurement-period Adjustments”, which require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined.  The standard is effective for fiscal periods beginning after December 15, 2015 and allows for early adoption.  The Company is currently evaluating the impact of the adoption of this standard on its Consolidated Financial Statements.

X

- Definition
The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section S99

-Paragraph 5

-Subparagraph (SAB TOPIC 11.M)

-URI http://asc.fasb.org/extlink&oid=26874127&loc=d3e31137-122693

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 11

-Section M

+ Details

Name: us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 56 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

ACCOUNTS AND OTHER RECEIVABLES, NET (Tables)
9 Months Ended

Sep. 30, 2015

ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]

Accounts and Other Receivables
The following table presents information regarding the Company’s accounts and other receivables as of September 30, 2015 and December 31, 2014:

(in thousands)

September 30, 2015

December 31, 2014

(unaudited)

Trade receivables
$ 12,877 $ 19,734
Due from employees
205 110
Allowance for doubtful accounts and

commission adjustments
(4,265 ) (4,571 )
Accounts and other receivables, net
$ 8,817 $ 15,273

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814

OTHER ASSETS (Details) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Sep. 30, 2014

OTHER ASSETS [Abstract]

Deferred commission expense - noncurrent $ 1,845 $ 2,988

Trade receivables - noncurrent 1,026 2,171

Other 633 458

Total $ 3,504 $ 5,617 $ 7,585

X

- Definition
Amount due from customers or clients, more than one year from the balance sheet date, for goods or services that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 7

+ Details

Name: us-gaap_OtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OtherAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Noncurrent carrying amount of advanced commission payments.
+ References
No definition available.
+ Details

Name: vaso_DeferredSalesCommissionNoncurrent

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 58 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
shares in Thousands, $ in Thousands

Common Stock [Member]

Treasury Stock [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Accumulated Other Comprehensive Income [Member]

Total

Balance at Dec. 31, 2013 $ 165 $ (1,755) $ 61,508 $ (53,561) $ 108 $ 6,465

Balance (in shares) at Dec. 31, 2013 164,705 (9,481)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Repurchase of shares $ 0 $ (245) 0 0 0 (245)

Repurchase of shares (in shares) 0 (827)

Share-based compensation $ 1 389 0 0 390

Share-based compensation (in shares) 1,280

Shares not issued for employee tax liability $ 0 (9) 0 0 (9)

Exercise of stock options $ 0 36 0 0 36

Exercise of stock options (in shares) 450

Foreign currency translation (loss) gain $ 0 0 0 (14) (14)

Net income 0 0 1,128 0 1,128

Balance at Dec. 31, 2014 $ 166 $ (2,000) 61,924 (52,433) 94 7,751

Balance (in shares) at Dec. 31, 2014 166,435 (10,308)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation $ 3 298 0 0 301

Share-based compensation (in shares) 2,285

Foreign currency translation (loss) gain $ 0 0 0 (114) (114)

Net income 0 0 1,166 0 1,166

Balance at Sep. 30, 2015 $ 169 $ (2,000) $ 62,222 $ (51,267) $ (20) $ 9,104

Balance (in shares) at Sep. 30, 2015 168,720 (10,308)

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockRepurchasedDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_StockRepurchasedDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568447-111683

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Refers to amount of increase (decrease) in additional paid in capital (APIC) resulting from common stock that is not issued for employee tax liability.
+ References
No definition available.
+ Details

Name: vaso_SharesNotIssuedForEmployeeTaxLiability

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

EARNINGS (LOSS) PER COMMON SHARE
9 Months Ended

Sep. 30, 2015

EARNINGS (LOSS) PER COMMON SHARE [Abstract]

EARNINGS (LOSS) PER COMMON SHARE
NOTE D – EARNINGS (LOSS) PER COMMON SHARE

Basic earnings (loss) per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.  Diluted earnings (loss) per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

Diluted earnings (loss) per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares.  A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

(in thousands)
Three months ended September 30, Nine months ended September 30,

2015

2014

2015

2014

Basic weighted average shares outstanding
157,288 155,186 156,502 155,319
Dilutive effect of share-based compensation
494 - 366 -
Diluted weighted average shares outstanding
157,782 155,186 156,868 155,319

The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2015 and 2014, because the effect of their inclusion would be anti-dilutive.

(in thousands)
For the three months ended For the nine months ended

September 30, 2015

September 30, 2014

September 30, 2015

September 30, 2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Stock options
300 1,402 300 1,402
Common stock grants
- 490 - 490
300 1,892 300 1,892

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

INVENTORIES, NET (Tables)
9 Months Ended

Sep. 30, 2015

INVENTORIES, NET [Abstract]

Inventories, Net of Reserves
Inventories, net of reserves, consist of the following:

(in thousands)

September 30, 2015

December 31, 2014

(unaudited)

Raw materials
$ 475 $ 583
Work in process
626 679
Finished goods
849 636
$ 1,950 $ 1,898

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 142 226 1 false 38 0 false 9 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://vasomedical.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://vasomedical.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://vasomedical.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) Sheet http://vasomedical.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) Statements 4 false false R5.htm 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://vasomedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://vasomedical.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperations ORGANIZATION AND PLAN OF OPERATIONS Notes 7 false false R8.htm 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPolicies BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Notes 8 false false R9.htm 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS Sheet http://vasomedical.com/role/SegmentReportingAndConcentrations SEGMENT REPORTING AND CONCENTRATIONS Notes 9 false false R10.htm 060400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE Sheet http://vasomedical.com/role/EarningsLossPerCommonShare EARNINGS (LOSS) PER COMMON SHARE Notes 10 false false R11.htm 060500 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNet ACCOUNTS AND OTHER RECEIVABLES, NET Notes 11 false false R12.htm 060600 - Disclosure - INVENTORIES, NET Sheet http://vasomedical.com/role/InventoriesNet INVENTORIES, NET Notes 12 false false R13.htm 060700 - Disclosure - GOODWILL AND OTHER INTANGIBLES Sheet http://vasomedical.com/role/GoodwillAndOtherIntangibles GOODWILL AND OTHER INTANGIBLES Notes 13 false false R14.htm 060800 - Disclosure - OTHER ASSETS Sheet http://vasomedical.com/role/OtherAssets OTHER ASSETS Notes 14 false false R15.htm 060900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES Sheet http://vasomedical.com/role/AccruedExpensesAndOtherLiabilities ACCRUED EXPENSES AND OTHER LIABILITIES Notes 15 false false R16.htm 061000 - Disclosure - DEFERRED REVENUE Sheet http://vasomedical.com/role/DeferredRevenue DEFERRED REVENUE Notes 16 false false R17.htm 061100 - Disclosure - DEBT Sheet http://vasomedical.com/role/Debt DEBT Notes 17 false false R18.htm 061200 - Disclosure - BUSINESS COMBINATION Sheet http://vasomedical.com/role/BusinessCombination BUSINESS COMBINATION Notes 18 false false R19.htm 061300 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://vasomedical.com/role/RelatedpartyTransactions RELATED-PARTY TRANSACTIONS Notes 19 false false R20.htm 061400 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://vasomedical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 061500 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Sheet http://vasomedical.com/role/RecentlyIssuedAccountingPronouncements RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Notes 21 false false R22.htm 070200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Policies) Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPoliciesPolicies BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Policies) Policies 22 false false R23.htm 080200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Tables) Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPoliciesTables BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Tables) Tables http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPolicies 23 false false R24.htm 080300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Tables) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsTables SEGMENT REPORTING AND CONCENTRATIONS (Tables) Tables http://vasomedical.com/role/SegmentReportingAndConcentrations 24 false false R25.htm 080400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Tables) Sheet http://vasomedical.com/role/EarningsLossPerCommonShareTables EARNINGS (LOSS) PER COMMON SHARE (Tables) Tables http://vasomedical.com/role/EarningsLossPerCommonShare 25 false false R26.htm 080500 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNetTables ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) Tables http://vasomedical.com/role/AccountsAndOtherReceivablesNet 26 false false R27.htm 080600 - Disclosure - INVENTORIES, NET (Tables) Sheet http://vasomedical.com/role/InventoriesNetTables INVENTORIES, NET (Tables) Tables http://vasomedical.com/role/InventoriesNet 27 false false R28.htm 080700 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Tables) Sheet http://vasomedical.com/role/GoodwillAndOtherIntangiblesTables GOODWILL AND OTHER INTANGIBLES (Tables) Tables http://vasomedical.com/role/GoodwillAndOtherIntangibles 28 false false R29.htm 080800 - Disclosure - OTHER ASSETS (Tables) Sheet http://vasomedical.com/role/OtherAssetsTables OTHER ASSETS (Tables) Tables http://vasomedical.com/role/OtherAssets 29 false false R30.htm 080900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables) Sheet http://vasomedical.com/role/AccruedExpensesAndOtherLiabilitiesTables ACCRUED EXPENSES AND OTHER LIABILITIES (Tables) Tables http://vasomedical.com/role/AccruedExpensesAndOtherLiabilities 30 false false R31.htm 081000 - Disclosure - DEFERRED REVENUE (Tables) Sheet http://vasomedical.com/role/DeferredRevenueTables DEFERRED REVENUE (Tables) Tables http://vasomedical.com/role/DeferredRevenue 31 false false R32.htm 081200 - Disclosure - BUSINESS COMBINATION (Tables) Sheet http://vasomedical.com/role/BusinessCombinationTables BUSINESS COMBINATION (Tables) Tables http://vasomedical.com/role/BusinessCombination 32 false false R33.htm 090100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS (Details) Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperationsDetails ORGANIZATION AND PLAN OF OPERATIONS (Details) Details http://vasomedical.com/role/OrganizationAndPlanOfOperations 33 false false R34.htm 090202 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Details) Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPoliciesDetails BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Details) Details http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPoliciesTables 34 false false R35.htm 090300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Details) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsDetails SEGMENT REPORTING AND CONCENTRATIONS (Details) Details http://vasomedical.com/role/SegmentReportingAndConcentrationsTables 35 false false R36.htm 090302 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsConcentrationRiskDetails SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) Details 36 false false R37.htm 090400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Details) Sheet http://vasomedical.com/role/EarningsLossPerCommonShareDetails EARNINGS (LOSS) PER COMMON SHARE (Details) Details http://vasomedical.com/role/EarningsLossPerCommonShareTables 37 false false R38.htm 090500 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Details) Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNetDetails ACCOUNTS AND OTHER RECEIVABLES, NET (Details) Details http://vasomedical.com/role/AccountsAndOtherReceivablesNetTables 38 false false R39.htm 090600 - Disclosure - INVENTORIES, NET (Details) Sheet http://vasomedical.com/role/InventoriesNetDetails INVENTORIES, NET (Details) Details http://vasomedical.com/role/InventoriesNetTables 39 false false R40.htm 090700 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details) Sheet http://vasomedical.com/role/GoodwillAndOtherIntangiblesDetails GOODWILL AND OTHER INTANGIBLES (Details) Details http://vasomedical.com/role/GoodwillAndOtherIntangiblesTables 40 false false R41.htm 090800 - Disclosure - OTHER ASSETS (Details) Sheet http://vasomedical.com/role/OtherAssetsDetails OTHER ASSETS (Details) Details http://vasomedical.com/role/OtherAssetsTables 41 false false R42.htm 090900 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Details) Sheet http://vasomedical.com/role/AccruedExpensesAndOtherLiabilitiesDetails ACCRUED EXPENSES AND OTHER LIABILITIES (Details) Details http://vasomedical.com/role/AccruedExpensesAndOtherLiabilitiesTables 42 false false R43.htm 091000 - Disclosure - DEFERRED REVENUE (Details) Sheet http://vasomedical.com/role/DeferredRevenueDetails DEFERRED REVENUE (Details) Details http://vasomedical.com/role/DeferredRevenueTables 43 false false R44.htm 091100 - Disclosure - DEBT (Details) Sheet http://vasomedical.com/role/DebtDetails DEBT (Details) Details http://vasomedical.com/role/Debt 44 false false R45.htm 091200 - Disclosure - BUSINESS COMBINATION (Details) Sheet http://vasomedical.com/role/BusinessCombinationDetails BUSINESS COMBINATION (Details) Details http://vasomedical.com/role/BusinessCombinationTables 45 false false R46.htm 091300 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) Sheet http://vasomedical.com/role/RelatedpartyTransactionsDetails RELATED-PARTY TRANSACTIONS (Details) Details http://vasomedical.com/role/RelatedpartyTransactions 46 false false R47.htm 091400 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://vasomedical.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://vasomedical.com/role/CommitmentsAndContingencies 47 false false R48.htm 091500 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) Sheet http://vasomedical.com/role/RecentlyIssuedAccountingPronouncementsDetails RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) Details http://vasomedical.com/role/RecentlyIssuedAccountingPronouncements 48 false false All Reports Book All Reports In ''CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited)'', column(s) 13 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)'', column(s) 1, 2, 5 are contained in other reports, so were removed by flow through suppression. vaso-20150930.xml vaso-20150930_cal.xml vaso-20150930_def.xml vaso-20150930_lab.xml vaso-20150930_pre.xml vaso-20150930.xsd true true XML 62 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814

ACCOUNTS AND OTHER RECEIVABLES, NET (Details) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Sep. 30, 2014

ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]

Trade receivables $ 12,877 $ 19,734

Due from employees 205 110

Allowance for doubtful accounts and commission adjustments (4,265) (4,571)

Accounts and other receivables, net $ 8,817 $ 15,273 $ 7,167

X

- Definition
Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amounts due from an Entity employee, not to include stockholders or officers, which are usually due within 1 year (or 1 business cycle).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_DueFromEmployeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 63 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

COMMITMENTS AND CONTINGENCIES
9 Months Ended

Sep. 30, 2015

COMMITMENTS AND CONTINGENCIES [Abstract]

COMMITMENTS AND CONTINGENCIES
NOTE N – COMMITMENTS AND CONTINGENCIES

Sales representation agreement

In June 2012, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010.  The amendment, effective July 1, 2012, extended the initial term of three years commencing July 1, 2010 to five years through June 30, 2015.  In December 2014, the Company concluded an additional amendment, effective January 1, 2015, extending the term through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017.  These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements.  Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

RELATED-PARTY TRANSACTIONS (Details)		3 Months Ended		9 Months Ended
RELATED-PARTY TRANSACTIONS (Details)	May. 29, 2015 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) Director	Sep. 30, 2014 USD ($)	Jul. 31, 2015 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2014 USD ($)
Related Party Transaction [Line Items]
Related party transaction, amount of purchase price				$ 18,000,000	$ 0
Secured subordinated promissory note		$ 5,007,000		5,007,000				$ 0
Related party transaction, amount borrowed				4,800,000	0
Note [Member]
Related Party Transaction [Line Items]
Secured subordinated promissory note	$ 3,800,000					$ 250,000	$ 750,000
VSK Medical Limited [Member]
Related Party Transaction [Line Items]
Contribution to related parties		100,000		100,000
Receivables due from related parties		1,000		1,000
Gain from joint venture		97,000		143,000
NetWolves, LLC [Member]
Related Party Transaction [Line Items]
Related party transaction, amount of purchase price	14,200,000			14,200,000
NetWolves, LLC [Member] \| Note [Member]
Related Party Transaction [Line Items]
Secured subordinated promissory note	$ 3,800,000	3,800,000		3,800,000
Related party transaction, amount borrowed				4,800,000
Director - David Lieberman [Member]
Related Party Transaction [Line Items]
Fees for legal services		$ 85,000	$ 60,000	$ 213,000	180,000
Outstanding legal fees amount			$ 0		$ 0
Director - David Lieberman [Member] \| NetWolves, LLC [Member]
Related Party Transaction [Line Items]
Related party transaction, ownership interest		5.70%		5.70%
Related party transaction, additional ownership interest		13.50%		13.50%
Director - Peter Castle [Member] \| NetWolves, LLC [Member]
Related Party Transaction [Line Items]
Related party transaction, ownership interest		10.40%		10.40%
Directors or Members of Their Family [Member] \| NetWolves, LLC [Member]
Related Party Transaction [Line Items]
Related party transaction, amount borrowed				$ 2,200,000
Number of directors \| Director				6

ORGANIZATION AND PLAN OF OPERATIONS (Details)	9 Months Ended
ORGANIZATION AND PLAN OF OPERATIONS (Details)	Sep. 30, 2015 State Company Subsidiary
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]
Number of contiguous states in which VasoHealthcare has been appointed exclusive representative for GE Healthcare Diagnostic Imaging products \| State	48
Number of Chinese operating companies acquired	2
Number of wholly-owned subsidiaries \| Subsidiary	3
Noncontrolling interest	49.90%

ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]
Accrued compensation	$ 1,344	$ 2,917
Accrued expenses - other	1,292	1,098
Other liabilities	1,623	1,612
Accrued expenses and other liabilities	$ 4,259	$ 5,627

EARNINGS (LOSS) PER COMMON SHARE (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Reconciliation of basic to diluted shares used in the earnings per share calculation [Abstract]
Basic weighted average shares outstanding (in shares)	157,288	155,186	156,502	155,319
Dilutive effect of share-based compensation (in shares)	494	0	366	0
Diluted weighted average shares outstanding (in shares)	157,782	155,186	156,868	155,319
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share (in shares)	300	1,892	300	1,892
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share (in shares)	300	1,402	300	1,402
Common Stock Grants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share (in shares)	0	490	0	490

COMMITMENTS AND CONTINGENCIES (Details)	9 Months Ended
COMMITMENTS AND CONTINGENCIES (Details)	Sep. 30, 2015
Sales Representation Agreement [Abstract]
Initial term of sales representation agreement	3 years
Amended term of sales representation agreement	5 years

DEFERRED REVENUE (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
DEFERRED REVENUE (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Changes in deferred revenue [Roll Forward]
Deferred revenue at beginning of period	$ 19,614	$ 17,712	$ 22,532	$ 18,019
Deferred revenue at end of period	19,750	18,236	19,750	18,236
Less: current portion	11,174	9,158	11,174	9,158	$ 9,882
Long-term deferred revenue at end of period	8,576	9,078	8,576	9,078	$ 12,650
Extended Service Contracts [Member]
Changes in deferred revenue [Roll Forward]
Additions:	160	244	465	791
Recognized as revenue:	(209)	(207)	(654)	(654)
In-Service and Training [Member]
Changes in deferred revenue [Roll Forward]
Additions:	5	13	10	28
Recognized as revenue:	0	(10)	(10)	(25)
Service Arrangements [Member]
Changes in deferred revenue [Roll Forward]
Additions:	10	28	25	58
Recognized as revenue:	(15)	(26)	(58)	(72)
Commission Revenues [Member]
Changes in deferred revenue [Roll Forward]
Additions:	3,516	3,457	6,847	8,840
Recognized as revenue:	$ (3,331)	$ (2,975)	$ (9,407)	$ (8,749)

DEBT (Details)			3 Months Ended	9 Months Ended
DEBT (Details)	Jul. 31, 2015 USD ($)	May. 29, 2015 USD ($) Director	Jun. 30, 2015 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Dec. 31, 2014 USD ($)
Debt Instrument [Line Items]
Secured subordinated promissory note				$ 5,007,000		$ 0
Aggregate amount used to acquire note				4,800,000	$ 0
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity before replacement	$ 2,000,000
Line of credit facility, maximum borrowing capacity amount	$ 3,000,000
Amount of line of credit drawn				$ 1,200,000
Line of Credit [Member] \| LIBOR [Member]
Debt Instrument [Line Items]
Interest rate percentage	2.25%
Note [Member]
Debt Instrument [Line Items]
Secured subordinated promissory note	$ 250,000	$ 3,800,000	$ 750,000
Debt instrument, interest rate				9.00%
Note [Member] \| Six Directors [Member]
Debt Instrument [Line Items]
Aggregate amount used to acquire note		$ 1,950,000
Number of directors \| Director		6
Note [Member] \| Director and Director's Relative [Member]
Debt Instrument [Line Items]
Aggregate amount used to acquire note			$ 250,000

GOODWILL AND OTHER INTANGIBLES (Details) - USD ($)	3 Months Ended		9 Months Ended
GOODWILL AND OTHER INTANGIBLES (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Dec. 31, 2014
Change in carrying amount of goodwill [Roll Forward]
Goodwill, Beginning Balance			$ 3,288,000
Foreign currency translation			(112,000)
Acquisition of Netwolves			19,406,000
Goodwill, Ending Balance	$ 22,582,000		22,582,000
Other intangible assets, net [Abstract]
Intangible assets, net					$ 2,447,000	$ 2,826,000
Goodwill	22,582,000		22,582,000		22,582,000	3,288,000
Amortization expense	167,000	$ 50,000	502,000	$ 146,000
Equipment Segment [Member]
Change in carrying amount of goodwill [Roll Forward]
Goodwill, Ending Balance	3,176,000		3,176,000
Other intangible assets, net [Abstract]
Goodwill	3,176,000		3,176,000		3,176,000
IT Segment [Member]
Change in carrying amount of goodwill [Roll Forward]
Goodwill, Ending Balance	19,406,000		19,406,000
Other intangible assets, net [Abstract]
Goodwill	$ 19,406,000		$ 19,406,000		19,406,000
Patents and Technology [Member]
Other intangible assets, net [Abstract]
Costs					2,441,000	2,489,000
Accumulated amortization					(742,000)	(549,000)
Intangible assets, net					1,699,000	1,940,000
Patents [Member]
Other intangible assets, net [Abstract]
Useful life of intangible assets			10 years
Customer Lists [Member]
Other intangible assets, net [Abstract]
Costs					800,000	800,000
Accumulated amortization					(467,000)	(381,000)
Intangible assets, net					333,000	419,000
Useful life of intangible assets			7 years
Software [Member]
Other intangible assets, net [Abstract]
Costs					1,133,000	962,000
Accumulated amortization					(718,000)	(495,000)
Intangible assets, net					$ 415,000	$ 467,000
Useful life of intangible assets			5 years

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 1,928	$ 9,128
Short-term investments	109	111
Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $4,265 at September 30, 2015 and $4,571 at December 31, 2014	8,817	15,273
Receivables due from related parties	21	21
Inventories, net	1,950	1,898
Deferred commission expense	2,583	2,200
Prepaid expenses and other current assets	515	363
Total current assets	15,923	28,994
PROPERTY AND EQUIPMENT, net of accumulated depreciation of $2,745 at September 30, 2015 and $1,397 at December 31, 2014	2,928	266
GOODWILL	22,582	3,288
INTANGIBLES, net	2,447	2,826
OTHER ASSETS	3,504	5,617
Total Assets	47,384	40,991
CURRENT LIABILITIES
Accounts payable	3,604	462
Accrued commissions	1,746	2,247
Accrued expenses and other liabilities	4,259	5,627
Sales tax payable	612	247
Deferred revenue - current portion	11,174	9,882
Notes payable - current portion	1,654	163
Deferred tax liability, net	112	112
Notes payable due to related party	997	1,039
Total current liabilities	24,158	19,779
LONG-TERM LIABILITIES
Notes payable	5,007	0
Deferred revenue	8,576	12,650
Other long-term liabilities	539	811
Total long-term liabilities	$ 14,122	$ 13,461
COMMITMENTS AND CONTINGENCIES (NOTE N)
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at September 30, 2015, and December 31, 2014	$ 0	$ 0
Common stock, $.001 par value; 250,000,000 shares authorized; 168,720,370 and 166,435,370 shares issued at September 30, 2015 and December 31, 2014, respectively; 158,412,283 and 156,127,283 shares outstanding at September 30, 2015 and December 31, 2014, respectively	169	166
Additional paid-in capital	62,222	61,924
Accumulated deficit	(51,267)	(52,433)
Accumulated other comprehensive income	(20)	94
Treasury stock, at cost, 10,308,087 shares at September 30, 2015 and December 31, 2014	(2,000)	(2,000)
Total stockholders' equity	9,104	7,751
Total liabilities and stockholders' equity	$ 47,384	$ 40,991

BUSINESS COMBINATION (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
BUSINESS COMBINATION (Details) - USD ($)	May. 29, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Jul. 31, 2015	Jun. 30, 2015
Business Acquisition [Line Items]
Business combination, cash paid				$ 18,000,000	$ 0
Business combination, issue of notes		$ 5,007,000		5,007,000		$ 0
Debt issuance costs				60,000
Revenue attributed to Netwolves, LLC		17,401,000	$ 7,643,000	35,698,000	22,599,000
Net income (loss)		1,230,000	(123,000)	1,166,000	(1,343,000)	1,128,000
Estimated fair values of the net assets acquired [Abstract]
Goodwill and other intangibles		22,582,000		22,582,000		$ 3,288,000
Note [Member]
Business Acquisition [Line Items]
Business combination, issue of notes	$ 3,800,000						$ 250,000	$ 750,000
NetWolves, LLC [Member]
Business Acquisition [Line Items]
Consideration for acquisition	18,000,000
Business combination, cash paid	14,200,000			14,200,000
Acquisition-related legal costs		100,000
Debt issuance costs		60,000
Revenue attributed to Netwolves, LLC		11,470,000		8,707,000
Net income (loss)		377,000		227,000
Estimated fair values of the net assets acquired [Abstract]
Cash and cash equivalents	733,000
Accounts receivable and other current assets	1,535,000
Other assets	50,000
Property and equipment	2,359,000
Accounts payable and other current liabilities	(4,382,000)
Long term debt	(1,701,000)
Goodwill and other intangibles	19,406,000
Total	18,000,000
NetWolves, LLC [Member] \| As initially reported [Member]
Estimated fair values of the net assets acquired [Abstract]
Cash and cash equivalents	733,000
Accounts receivable and other current assets	1,638,000
Other assets	50,000
Property and equipment	2,359,000
Accounts payable and other current liabilities	(4,382,000)
Long term debt	(1,701,000)
Goodwill and other intangibles	19,303,000
Total	18,000,000
NetWolves, LLC [Member] \| Measurement period adjustments [Member]
Estimated fair values of the net assets acquired [Abstract]
Cash and cash equivalents	0
Accounts receivable and other current assets	(103,000)
Other assets	0
Property and equipment	0
Accounts payable and other current liabilities	0
Long term debt	0
Goodwill and other intangibles	103,000
Total	0
NetWolves, LLC [Member] \| Note [Member]
Business Acquisition [Line Items]
Business combination, issue of notes	$ 3,800,000	3,800,000		3,800,000
Genwell and Netwolves [Member]
Business acquisition proforma information [Abstract]
Revenue		17,401,000	15,101,000	48,850,000	44,532,000
Net income (loss)		$ 1,353,000	$ (2,000)	$ 1,584,000	$ (1,397,000)
Basic earnings (loss) per share (in dollars per share)		$ 0.01	$ 0	$ 0.01	$ (0.01)
Diluted earnings (loss) per share (in dollars per share)		$ 0.01	$ 0	$ 0.01	$ (0.01)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities
Net income (loss)	$ 1,166	$ (1,343)
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Depreciation and amortization	783	290
Loss on disposal of fixed assets	0	39
Provision for doubtful accounts and commission adjustments	109	(1)
Share-based compensation and arrangements	301	320
Changes in operating assets and liabilities:
Accounts and other receivables	7,775	6,396
Inventories, net	(221)	(332)
Deferred commission expense	(382)	(75)
Other current assets	(53)	(123)
Other assets	2,274	(1,639)
Accounts payable	(5)	(72)
Accrued commissions	(548)	(55)
Accrued expenses and other liabilities	(2,129)	(1,203)
Sales tax payable	(68)	(48)
Deferred revenue	(2,782)	218
Notes payable due to related party	(42)	0
Other long-term liabilities	(299)	214
Net cash provided by operating activities	5,879	2,586
Cash flows from investing activities
Purchases of equipment and software	(619)	(227)
Purchases of short-term investments	(38)	(40)
Redemption of short-term investments	40	40
Acquisition of Genwell	0	(1,136)
Cash acquired through purchase of Genwell	0	113
Acquisition of Netwolves	(18,000)	0
Cash acquired through purchase of Netwolves	733	0
Investment in VSK	(100)	0
Net cash used in investing activities	(17,984)	(1,250)
Cash flows from financing activities
Net borrowings on revolving line of credit	136	0
Repurchase of common stock	0	(244)
Repayment of notes payable	(83)	0
Proceeds from note payable	4,800	0
Net cash provided by (used in) financing activities	4,853	(244)
Effect of exchange rate differences on cash and cash equivalents	52	1
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(7,200)	1,093
Cash and cash equivalents - beginning of period	9,128	7,961
Cash and cash equivalents - end of period	1,928	9,054
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
Interest paid	66	0
Income taxes paid	130	48
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Inventories transferred to property and equipment, attributable to operating leases, net	138	5
Note issued for acquisition	$ 0	$ 1,017

SEGMENT REPORTING AND CONCENTRATIONS (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) Segment	Sep. 30, 2014 USD ($)	Dec. 31, 2014 USD ($)
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]
Number of segments \| Segment			3
Segment Reporting Information [Line Items]
Revenues from external customers	$ 17,401	$ 7,643	$ 35,698	$ 22,599
Operating income (loss)	1,337	(149)	1,257	(1,443)
Total assets	47,384	32,319	47,384	32,319	$ 40,991
Accounts and other receivables, net	8,817	7,167	8,817	7,167	15,273
Deferred commission expense	2,583	2,388	2,583	2,388
Other assets	3,504	7,585	3,504	7,585	$ 5,617
Corporate [Member]
Segment Reporting Information [Line Items]
Revenues from external customers	0	0	0	0
Operating income (loss)	(480)	(385)	(1,408)	(1,267)
Total assets	2,041	9,067	2,041	9,067
Accounts and other receivables, net	0	0	0	0
Deferred commission expense	0	0	0	0
Other assets	110	13	110	13
Sales Representation Segment [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues from external customers	7,584	6,409	21,010	19,335
Operating income (loss)	2,586	723	5,466	2,267
Total assets	11,408	13,341	11,408	13,341
Accounts and other receivables, net	5,663	6,376	5,663	6,376
Deferred commission expense	2,533	2,388	2,533	2,388
Other assets	2,720	4,402	2,720	4,402
IT Segment [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues from external customers	8,800	0	11,611	0
Operating income (loss)	(187)	(82)	(908)	(82)
Total assets	24,642	2	24,642	2
Accounts and other receivables, net	2,253	0	2,253	0
Deferred commission expense	50	0	50	0
Other assets	51	0	51	0
Equipment Segment [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues from external customers	1,017	1,234	3,077	3,264
Operating income (loss)	(582)	(405)	(1,893)	(2,361)
Total assets	9,293	9,909	9,293	9,909
Accounts and other receivables, net	901	791	901	791
Deferred commission expense	0	0	0	0
Other assets	$ 623	$ 3,170	$ 623	$ 3,170
GE Healthcare [Member] \| Sales Revenue, Net [Member]
Revenue, Major Customer [Line Items]
Percentage of revenue	44.00%	84.00%	59.00%	86.00%

ORGANIZATION AND PLAN OF OPERATIONS	9 Months Ended
ORGANIZATION AND PLAN OF OPERATIONS	Sep. 30, 2015
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]
ORGANIZATION AND PLAN OF OPERATIONS	NOTE A - ORGANIZATION AND PLAN OF OPERATIONS Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP®) systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets. Beginning in July 2010 the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. (Vaso Diagnostics), began its sales representation business via its agreement (the “GEHC Agreement”) with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia. In June 2012, the GEHC Agreement was amended and extended through June 30, 2015 and again, in December 2014, the GEHC Agreement was further amended and extended through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017. In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns or controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd. (Biox), respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and started to operate through three wholly-owned subsidiaries. Vaso Diagnostics continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations. In April 2014, the Company entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (PSK) of Chongqing, China, the leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited (VSK), for the global marketing, sale and advancement of ECP therapy technology. The Company owns 49.9% of the joint venture, which began operations in January 2015. In June 2014, the Company entered into a Value Added Reseller Agreement (VAR Agreement) with GEHC to become a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. This multiyear VAR Agreement focuses primarily on existing customer segments currently served by Vaso Diagnostics on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp., was formed to conduct the healthcare IT business. In August 2014, the Company, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone), acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China. Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCareTM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system. In May 2015, the Company entered into an agreement for, and completed its purchase of, all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC (collectively, “NetWolves”). The purchase of NetWolves was accomplished pursuant to an Asset Purchase Agreement. As a result, the Company effectively purchased all rights, titles and ownership of all assets held by NetWolves. NetWolves designs and delivers efficient and cost-effective multi-network and multi-technology solutions as a managed network provider, and provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution. The Company believes there are significant operational synergies between NetWolves’ capabilities and VasoHealthcare IT’s requirements under its VAR Agreement with GEHC, as well as the opportunity to expand NetWolves’ existing services to the healthcare IT market. We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment. Vaso Diagnostics activities are included under our Sales Representation segment. VasoHealthcare IT and NetWolves operations report under the IT segment.

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Accounts and other receivables, allowance for doubtful accounts and commission adjustments	$ 4,265	$ 4,571
PROPERTY AND EQUIPMENT, accumulated depreciation	$ 2,745	$ 1,397
STOCKHOLDERS' EQUITY
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	168,720,370	166,435,370
Common stock, shares outstanding (in shares)	158,412,283	156,127,283
Treasury stock, at cost (in shares)	10,308,087	10,308,087

DEBT	9 Months Ended
DEBT	Sep. 30, 2015
DEBT [Abstract]
DEBT	NOTE K – DEBT On May 29, 2015, the Company entered into a Note Purchase Agreement with MedTechnology Investments, LLC (“MedTech”) pursuant to which it issued MedTech a secured subordinated promissory note (“Note”) for $3,800,000 for the purchase of NetWolves. MedTech was formed to acquire the Note, and $1,950,000 of the aggregate funds used to acquire the Note was provided by six of our directors. In June 2015, a second Note for $750,000 was issued to MedTech for working capital purposes, $250,000 of which was provided by a director and a director’s relative. In July 2015, an additional $250,000 was borrowed under the Note Purchase Agreement. The Notes bear interest at an annual rate of 9%, mature on May 29, 2019, may be prepaid without penalty, and are subordinated to any current or future Senior Debt as defined in the Subordinated Security Agreement. The Subordinated Security Agreement secures payment and performance of the Company’s obligations under the Notes and as a result, MedTech was granted a subordinated security interest in the Company’s assets. In July 2015, NetWolves' lending institution extended its $2.0 million line of credit and increased the maximum borrowings to $3.0 million. Advances under the line, which expires on August 26, 2016, bear interest at a rate of LIBOR plus 2.25% and are secured by substantially all of the assets of NetWolves Network Services, LLC and guaranteed by Vasomedical, Inc. At September 30, 2015, the Company had drawn approximately $1.2 million against the line.

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Nov. 08, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	VASOMEDICAL, INC
Entity Central Index Key	0000839087
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		158,412,283
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015

RELATED-PARTY TRANSACTIONS	9 Months Ended
RELATED-PARTY TRANSACTIONS	Sep. 30, 2015
RELATED-PARTY TRANSACTIONS [Abstract]
RELATED-PARTY TRANSACTIONS	NOTE M – RELATED-PARTY TRANSACTIONS One of the Company’s directors, Peter Castle, was the Chief Executive Officer and President of NetWolves, LLC. Another of the Company’s directors, David Lieberman, was a director of NetWolves Network Services, LLC. Mr. Castle and Mr. Lieberman owned of record approximately 10.4% and 5.7%, respectively of the membership interests of NetWolves LLC. Mr. Lieberman may also be deemed to have owned beneficially up to an additional 13.5% of such membership interests. The Company’s board of directors negotiated the Purchase Price on an arm’s length basis, and both Mr. Castle and Mr. Lieberman abstained from the vote approving the Purchase Agreement. The Company obtained an opinion regarding the fairness of the Purchase Price for the NetWolves entities from a reputable, independent third-party investment banking firm. $14,200,000 of the Purchase Price was paid for by cash on hand, and the remaining $3,800,000 was raised from the sale of a Subordinated Secured Note sold to MedTech. Of the $4,800,000 borrowed from MedTech at September 30, 2015, $2,200,000 was provided by six of our directors or members of their families. David Lieberman, the Vice Chairman of the Company’s Board of Directors, is a practicing attorney in the State of New York and a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which performs certain legal services for the Company. Fees of approximately $85,000 and $213,000 were billed by the firm for the three and nine month periods ended September 30, 2015, respectively, at which date no amounts were outstanding. Fees of approximately $60,000 and $180,000 were billed by the firm for the three and nine month periods ended September 30, 2014, respectively, at which date no amounts were outstanding. In January 2015, operations began under the VSK joint venture. The Company accounts for its investment in VSK using the equity method. At September 30, 2015, the Company had contributed $100,000 to VSK, and $1,000 was due from VSK for equipment the Company sold to it. VSK earned approximately $97,000 and $143,000 for the three and nine months ended September 30, 2015, respectively. Under the terms of the agreement, the Company’s accrues no interest in VSK’s income in the years ending December 31, 2015, 2016 and 2017 unless certain performance targets are achieved. For the nine months ended September 30, 2015 such targets had not been achieved.

OTHER ASSETS (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014
OTHER ASSETS [Abstract]
Deferred commission expense - noncurrent	$ 1,845	$ 2,988
Trade receivables - noncurrent	1,026	2,171
Other	633	458
Total	$ 3,504	$ 5,617	$ 7,585

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Total
Balance at Dec. 31, 2013	$ 165	$ (1,755)	$ 61,508	$ (53,561)	$ 108	$ 6,465
Balance (in shares) at Dec. 31, 2013	164,705	(9,481)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Repurchase of shares	$ 0	$ (245)	0	0	0	(245)
Repurchase of shares (in shares)	0	(827)
Share-based compensation	$ 1		389	0	0	390
Share-based compensation (in shares)	1,280
Shares not issued for employee tax liability	$ 0		(9)	0	0	(9)
Exercise of stock options	$ 0		36	0	0	36
Exercise of stock options (in shares)	450
Foreign currency translation (loss) gain	$ 0		0	0	(14)	(14)
Net income	0		0	1,128	0	1,128
Balance at Dec. 31, 2014	$ 166	$ (2,000)	61,924	(52,433)	94	7,751
Balance (in shares) at Dec. 31, 2014	166,435	(10,308)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	$ 3		298	0	0	301
Share-based compensation (in shares)	2,285
Foreign currency translation (loss) gain	$ 0		0	0	(114)	(114)
Net income	0		0	1,166	0	1,166
Balance at Sep. 30, 2015	$ 169	$ (2,000)	$ 62,222	$ (51,267)	$ (20)	$ 9,104
Balance (in shares) at Sep. 30, 2015	168,720	(10,308)

ACCOUNTS AND OTHER RECEIVABLES, NET (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014
ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]
Trade receivables	$ 12,877	$ 19,734
Due from employees	205	110
Allowance for doubtful accounts and commission adjustments	(4,265)	(4,571)
Accounts and other receivables, net	$ 8,817	$ 15,273	$ 7,167

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2015
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE N – COMMITMENTS AND CONTINGENCIES Sales representation agreement In June 2012, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010. The amendment, effective July 1, 2012, extended the initial term of three years commencing July 1, 2010 to five years through June 30, 2015. In December 2014, the Company concluded an additional amendment, effective January 1, 2015, extending the term through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017. These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements. Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.